US20210087256A1

US20210087256A1 - Novel methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries

Info

Publication number: US20210087256A1
Application number: US16/984,655
Authority: US
Inventors: Robert Charles Ladner; Edward H. Cohen; Horacio G. Nastri; Kristin L. Rookey; Rene Hoet; Hendricus Renerus Jacobus Mattheus Hoogenboom
Original assignee: Dyax Corp
Current assignee: Takeda Pharmaceutical Co Ltd
Priority date: 2000-04-17
Filing date: 2020-08-04
Publication date: 2021-03-25
Also published as: US20130040861A1; CA2458462A1; EP1578903B1; US20090162835A9; US20150158932A1; US20030232333A1; EP1578903A2; US8288322B2; AU2009200092A1; EP1578903B2; AU2009200092B2; AU2002307422B2; US20170369557A1; WO2002083872A2; WO2002083872A3; EP1578903B8; US8901045B2; CA2458462C; US9683028B2; EP1578903A4

Abstract

Methods useful in constructing libraries that collectively display and/or express members of diverse families of peptides, polypeptides or proteins and the libraries produced using those methods. Methods of screening those libraries and the peptides, polypeptides or proteins identified by such screens.

Description

This application is a divisional of U.S. patent application Ser. No. 14/557,171, filed Dec. 1, 2014, now U.S. Pat. No. 9,683,028, issued Jun. 20, 2017, which is a continuation of U.S. patent application Ser. No. 13/464,047, filed May 4, 2012, now U.S. Pat. No. 8,901,045, issued Dec. 2, 2014, which is a continuation of U.S. patent application Ser. No. 10/045,674, filed Oct. 25, 2001, now U.S. Pat. No. 8,288,322, issued Oct. 16, 2012, which is a continuation-in-part of U.S. patent application Ser. No. 10/000,516, filed Oct. 24, 2001 (now abandoned), which is a continuation-in-part of U.S. patent application Ser. No. 09/837,306, filed on Apr. 17, 2001 (abandoned), which claims the benefit from U.S. provisional application 60/198,069, filed Apr. 17, 2000. U.S. patent application Ser. No. 10/045,674, filed Oct. 25, 2001, now U.S. Pat. No. 8,288,322, issued Oct. 16, 2012, is also a continuation-in-part of U.S. patent application Ser. No. 09/837,306, filed on Apr. 17, 2001 (now abandoned). All of the earlier applications are specifically incorporated by reference herein.
The present invention relates to libraries of genetic packages that display and/or express a member of a diverse family of peptides, polypeptides or proteins and collectively display and/or express at least a portion of the diversity of the family. In an alternative embodiment, the invention relates to libraries that include a member of a diverse family of peptides, polypeptides or proteins and collectively comprise at least a portion of the diversity of the family. In a preferred embodiment, the displayed and/or expressed polypeptides are human Fab.
More specifically, the invention is directed to the methods of cleaving single-stranded nucleic acids at chosen locations, the cleaved nucleic acids comprise at least a portion of the diversity of the family. In a preferred embodiment, the displayed and/or expressed polypeptides are human Fabs.
More specifically, the invention is directed to the methods of cleaving single-stranded nucleic acids at chosen locations, the cleaved nucleic acids encoding, at least in part, the peptides, polypeptides or proteins displayed on the genetic packages of, and/or expressed in, the libraries of the invention. In a preferred embodiment, the genetic packages are filamentous phage or phagemids or yeast.
The present invention further relates to vectors for displaying and/or expressing a diverse family of peptides, polypeptides or proteins.
The present invention further relates to methods of screening the libraries of the invention and to the peptides, polypeptides and proteins identified by such screening.

BACKGROUND OF THE INVENTION

It is now common practice in the art to prepare libraries of genetic packages that display, express or comprise a member of a diverse family of peptides, polypeptides or proteins and collectively display, express or comprise at least a portion of the diversity of the family. In many common libraries, the peptides, polypeptides or proteins are related to antibodies. Often, they are Fabs or single chain antibodies.
In general, the DNAs that encode members of the families to be displayed and/or expressed must be amplified before they are cloned and used to display and/or express the desired member. Such amplification typically makes use of forward and backward primers.
Such primers can be complementary to sequences native to the DNA to be amplified or complementary to oligonucleotides attached at the 5′ or 3′ ends of that DNA. Primers that are complementary to sequences native to the DNA to be amplified are disadvantaged in that they bias the members of the families to be displayed. Only those members that contain a sequence in the native DNA that is substantially complementary to the primer will be amplified. Those that do not will be absent from the family. For those members that are amplified, any diversity within the primer region will be suppressed.
For example, in European patent 368,684 B1, the primer that is used is at the 5′ end of the V_Hregion of an antibody gene. It anneals to a sequence region in the native DNA that is said to be “sufficiently well conserved” within a single species. Such primer will bias the members amplified to those having this “conserved” region. Any diversity within this region is extinguished.
It is generally accepted that human antibody genes arise through a process that involves a combinatorial selection of V and J or V, D, and J followed by somatic mutations. Although most diversity occurs in the Complementary Determining Regions (CDRs), diversity also occurs in the more conserved Framework Regions (FRs) and at least some of this diversity confers or enhances specific binding to antigens (Ag). As a consequence, libraries should contain as much of the CDR and FR diversity as possible.
To clone the amplified DNAs of the peptides, polypeptides or proteins that they encode for display on a genetic package and/or for expression, the DNAs must be cleaved to produce appropriate ends for ligation to a vector. Such cleavage is generally effected using restriction endonuclease recognition sites carried on the primers. When the primers are at the 5′ end of DNA produced from reverse transcription of RNA, such restriction leaves deleterious 5′ untranslated regions in the amplified DNA. These regions interfere with expression of the cloned genes and thus the display of the peptides, polypeptides and proteins coded for by them.

SUMMARY OF THE INVENTION

It is an object of this invention to provide novel methods for constructing libraries that display, express or comprise a member of a diverse family of peptides, polypeptides or proteins and collectively display, express or comprise at least a portion of the diversity of the family. These methods are not biased toward DNAs that contain native sequences that are complementary to the primers used for amplification. They also enable any sequences that may be deleterious to expression to be removed from the amplified DNA before cloning and displaying and/or expressing.
It is another object of this invention to provide a method for cleaving single-stranded nucleic acid sequences at a desired location, the method comprising the steps of:

- (i) contacting the nucleic acid with a single-stranded oligonucleotide, the oligonucleotide being functionally complementary to the nucleic acid in the region in which cleavage is desired and including a sequence that with its complement in the nucleic acid forms a restriction endonuclease recognition site that on restriction results in cleavage of the nucleic acid at the desired location; and
- (ii) cleaving the nucleic acid solely at the recognition site formed by the complementation of the nucleic acid and the oligonucleotide;
  the contacting and the cleaving steps being performed at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur at the chosen temperature and at the desired location, and the cleavage being carried out using a restriction endonuclease that is active at the chosen temperature.

It is a further object of this invention to provide an alternative method for cleaving single-stranded nucleic acid sequences at a desired location, the method comprising the steps of:

- (i) contacting the nucleic acid with a partially double-stranded oligonucleotide, the single-stranded region of the oligonucleotide being functionally complementary to the nucleic acid in the region in which cleavage is desired, and the double-stranded region of the oligonucleotide having a restriction endonuclease recognition site; and
- (ii) cleaving the nucleic acid solely at the cleavage site formed by the complementation of the nucleic acid and the single-stranded region of the oligonucleotide;
  the contacting and the cleaving steps being performed at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur at the chosen temperature and at the desired location, and the cleavage being carried out using a restriction endonuclease that is active at the chosen temperature.

In an alternative embodiment of this object of the invention, the restriction endonuclease recognition site is not initially located in the double-stranded part of the oligonucleotide. Instead, it is part of an amplification primer, which primer is complementary to the double-stranded region of the oligonucleotide. On amplification of the DNA-partially double-stranded combination, the restriction endonuclease recognition site carried on the primer becomes part of the DNA. It can then be used to cleave the DNA.
Preferably, the restriction endonuclease recognition site is that of a Type II-S restriction endonuclease whose cleavage site is located at a known distance from its recognition site.
It is another object of the present invention to provide a method of capturing DNA molecules that comprise a member of a diverse family of DNAs and collectively comprise at least a portion of the diversity of the family. These DNA molecules in single-stranded form have been cleaved by one of the methods of this invention. This method involves ligating the individual single-stranded DNA members of the family to a partially duplex DNA complex. The method comprises the steps of:

- (i) contacting a single-stranded nucleic acid sequence that has been cleaved with a restriction endonuclease with a partially double-stranded oligonucleotide, the single-stranded region of the oligonucleotide being functionally complementary to the nucleic acid in the region that remains after cleavage, the double-stranded region of the oligonucleotide including any sequences necessary to return the sequences that remain after cleavage into proper reading frame for expression and containing a restriction endonuclease recognition site 5′ of those sequences; and
- (ii) cleaving the partially double-stranded oligonucleotide sequence solely at the restriction endonuclease cleavage site contained within the double-stranded region of the partially double-stranded oligonucleotide.

As before, in this object of the invention, the restriction endonuclease recognition site need not be located in the double-stranded portion of the oligonucleotide. Instead, it can be introduced on amplification with an amplification primer that is used to amplify the DNA-partially double-stranded oligonucleotide combination.
It is another object of this invention to prepare libraries, that display, express or comprise a diverse family of peptides, polypeptides or proteins and collectively display, express or comprise at least part of the diversity of the family, using the methods and DNAs described above.
It is an object of this invention to screen those libraries to identify useful peptides, polypeptides and proteins and to use those substances in human therapy.
Additional objects of the invention are reflected in the original claims. Each of these claims is specifically incorporated by reference in this specification.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic of various methods that may be employed to amplify VH genes without using primers specific for VH sequences. The T15 oligonucleotide is shown in SEQ ID NO: 622.

FIG. 2 is a schematic of various methods that may be employed to amplify VL genes without using primers specific for VL sequences.

FIG. 3 is a schematic of RACE amplification of antibody heavy and light chains.

FIG. 4 depicts gel analysis of amplification products obtained after the primary PCR reaction from 4 different patient samples.

FIG. 5 depicts gel analysis of cleaved kappa DNA from Example 2.

FIG. 6 depicts gel analysis of extender-cleaved kappa DNA from Example 2.

FIG. 7 depicts gel analysis of the PCR product from the extender-kappa amplification from Example 2.

FIG. 8 depicts gel analysis of purified PCR product from the extender-kappa amplification from Example 2.

FIG. 9 depicts gel analysis of cleaved and ligated kappa light chains from Example 2.

FIG. 10 is a schematic of the design for CDR1 and CDR2 synthetic diversity (SEQ ID NOs: 636 and 637, respectively). The YADSVKG peptide is shown as SEQ ID NO: 604.

FIG. 11 is a schematic of the cloning schedule for construction of the heavy chain repertoire.

FIG. 12 is a schematic of the cleavage and ligation of the antibody light chains. A: cleavage of the antibody light chains; B: ligation of the cleaved antibody light chains FIG. 13 depicts gel analysis of cleaved and ligated lambda light chains from Example 4.

FIG. 14 is a schematic of the cleavage and ligation of the antibody heavy chain. A:CJ cleavage of heavy chains; B: ligation of heavy chain CDR3 diversity.

FIG. 15 depicts gel analysis of cleaved and ligated lambda light chains from Example 5.

FIG. 16 is a schematic of a phage display vector.

FIG. 17 is a schematic of a Fab cassette.

FIG. 18 is a schematic of a process for incorporating fixed FR1 residues in an antibody lambda sequence. The PCRpr oligonucleotide is shown in SEQ ID NO: 605 while the Bridge oligonucleotide and encoded peptide are shown in SEQ ID NOs: 606-607, respectively.

FIG. 19 is a schematic of a process for incorporating fixed FR1 residues in an antibody kappa sequence (see SEQ ID NOs: 608-611, respectively, in order of appearance).

FIG. 20 is a schematic of a process for incorporating fixed FR1 residues in an antibody heavy chain sequence. The PCRpr oligonucleotide is shown in SEQ ID NO: 612. The Bridge oligonucleotides are shown in SEQ ID NOs: 613 and 615, respectively, in order of appearance, while the encoded peptides are shown in SEQ ID NOs: 614 and 615, respectively, in order of appearance.

TERMS

In this application, the following terms and abbreviations are used:


Sense strand	The upper strand of ds DNA as usually written.
	In the sense strand, 5′-ATG-3′ codes for Met.
Antisense strand	The lower strand of ds DNA as usually written.
	In the antisense strand, 3′-TAC-5′ would
	correspond to a Met codon in the sense strand.
Forward primer	A “forward” primer is complementary to a part
	of the sense strand and primes for synthesis of a
	new antisense-strand molecule.
	“Forward primer” and “lower-strand primer”
	are equivalent.
Backward primer	A “backward” primer is complementary to a
	part of the antisense strand and primes for
	synthesis of a new sense-strand molecule.
	“Backward primer” and “top-strand primer”
	are equivalent.
Bases	Bases are specified either by their position in a
	vector or gene as their position within a gene by
	codon and base. For example, “89.1” is the first
	base of codon 89, 89.2 is the second base of
	codon 89.
Sv	Streptavidin
Ap	Ampicillin
ap^R	A gene conferring ampicillin resistance.
RERS	Restriction endonuclease recognition site
RE	Restriction endonuclease - cleaves preferentially
	at RERS
URE	Universal restriction endonuclease
Functionally	Two sequences are sufficiently complementary so
complementary	as to anneal under the chosen conditions.
AA	Amino acid
PCR	Polymerization chain reaction
GLGs	Germline genes
Ab	Antibody: an immunoglobin.
	The term also covers any protein having a binding
	domain which is homologous to an immunoglobin
	binding domain. A few examples of antibodies
	within this definition are, inter alia, immunoglobin
	isotypes and the Fab, F(ab¹)₂, scfv, Fv, dAb and Fd
	fragments.
Fab	Two chain molecule comprising an Ab light chain
	and part of a heavy-chain.
scFv	A single-chain Ab comprising either VH::linker::VL
	or VL::linker::VH
w.t.	Wild type
HC	Heavy chain
LC	Light chain
VK	A variable domain of a Kappa light chain.
VH	A variable domain of a heavy chain.
VL	A variable domain of a lambda light chain.

In this application when it is said that nucleic acids are cleaved solely at the cleavage site of a restriction endonuclease, it should be understood that minor cleavage may occur at random, e.g., at non-specific sites other than the specific cleavage site that is characteristic of the restriction endonuclease. The skilled worker will recognize that such non-specific, random cleavage is the usual occurrence. Accordingly, “solely at the cleavage site” of a restriction endonuclease means that cleavage occurs preferentially at the site characteristic of that endonuclease.
As used in this application and claims, the term “cleavage site formed by the complementation of the nucleic acid and the single-stranded region of the oligonucleotide” includes cleavage sites formed by the single-stranded portion of the partially double-stranded oligonucleotide duplexing with the single-stranded DNA, cleavage sites in the double-stranded portion of the partially double-stranded oligonucleotide, and cleavage sites introduced by the amplification primer used to amplify the single-stranded DNA-partially double-stranded oligonucleotide combination.
In the two methods of this invention for preparing single-stranded nucleic acid sequences, the first of those cleavage sites is preferred. In the methods of this invention for capturing diversity and cloning a family of diverse nucleic acid sequences, the latter two cleavage sites are preferred.
In this application, all references referred to are specifically incorporated by reference.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The nucleic acid sequences that are useful in the methods of this invention, i.e., those that encode at least in part the individual peptides, polypeptides and proteins displayed, or expressed in or comprising the libraries of this invention, may be native, synthetic or a combination thereof. They may be mRNA, DNA or cDNA. In the preferred embodiment, the nucleic acids encode antibodies. Most preferably, they encode Fabs.
The nucleic acids useful in this invention may be naturally diverse, synthetic diversity may be introduced into those naturally diverse members, or the diversity may be entirely synthetic. For example, synthetic diversity can be introduced into one or more CDRs of antibody genes. Preferably, it is introduced into CDR1 and CDR2 of immunoglobulins. Preferably, natural diversity is captured in the CDR3 regions of the immunoglobin genes of this invention from B cells. Most preferably, the nucleic acids of this invention comprise a population of immunoglobin genes that comprise synthetic diversity in at least one, and more preferably both of the CDR1 and CDR2 and diversity in CDR3 captured from B cells.
Synthetic diversity may be created, for example, through the use of TRIM technology (U.S. Pat. No. 5,869,644). TRIM technology allows control over exactly which amino-acid types are allowed at variegated positions and in what proportions. In TRIM technology, codons to be diversified are synthesized using mixtures of trinucleotides. This allows any set of amino acid types to be included in any proportion.
Another alternative that may be used to generate diversified DNA is mixed oligonucleotide synthesis. With TRIM technology, one could allow Ala and Trp. With mixed oligonucleotide synthesis, a mixture that included Ala and Trp would also necessarily include Ser and Gly. The amino-acid types allowed at the variegated positions are picked with reference to the structure of antibodies, or other peptides, polypeptides or proteins of the family, the observed diversity in germline genes, the observed somatic mutations frequently observed, and the desired areas and types of variegation.
In a preferred embodiment of this invention, the nucleic acid sequences for at least one CDR or other region of the peptides, polypeptides or proteins of the family are cDNAs produced by reverse transcription from mRNA. More preferably, the mRNAs are obtained from peripheral blood cells, bone marrow cells, spleen cells or lymph node cells (such as B-lymphocytes or plasma cells) that express members of naturally diverse sets of related genes. More preferable, the mRNAs encode a diverse family of antibodies. Most preferably, the mRNAs are obtained from patients suffering from at least one autoimmune disorder or cancer. Preferably, mRNAs containing a high diversity of autoimmune diseases, such as systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, antiphospholipid syndrome and vasculitis are used.
In a preferred embodiment of this invention, the cDNAs are produced from the mRNAs using reverse transcription. In this preferred embodiment, the mRNAs are separated from the cell and degraded using standard methods, such that only the full length (i.e., capped) mRNAs remain. The cap is then removed and reverse transcription used to produce the cDNAs.
The reverse transcription of the first (antisense) strand can be done in any manner with any suitable primer. See, e.g., HJ de Haard et al., Journal of Biological Chemistry, 274(26):18218-30 (1999). In the preferred embodiment of this invention where the mRNAs encode antibodies, primers that are complementary to the constant regions of antibody genes may be used. Those primers are useful because they do not generate bias toward subclasses of antibodies. In another embodiment, poly-dT primers may be used (and may be preferred for the heavy-chain genes). Alternatively, sequences complementary to the primer may be attached to the termini of the antisense strand.
In one preferred embodiment of this invention, the reverse transcriptase primer may be biotinylated, thus allowing the cDNA product to be immobilized on streptavidin (Sv) beads. Immobilization can also be effected using a primer labeled at the 5′ end with one of a) free amine group, b) thiol, c) carboxylic acid, or d) another group not found in DNA that can react to form a strong bond to a known partner on an insoluble medium. If, for example, a free amine (preferably primary amine) is provided at the 5′ end of a DNA primer, this amine can be reacted with carboxylic acid groups on a polymer bead using standard amide-forming chemistry. If such preferred immobilization is used during reverse transcription, the top strand RNA is degraded using well-known enzymes, such as a combination of RNAseH and RNAseA, either before or after immobilization.
The nucleic acid sequences useful in the methods of this invention are generally amplified before being used to display and/or express the peptides, polypeptides or proteins that they encode. Prior to amplification, the single-stranded DNAs may be cleaved using either of the methods described before. Alternatively, the single-stranded DNAs may be amplified and then cleaved using one of those methods.
Any of the well known methods for amplifying nucleic acid sequences may be used for such amplification. Methods that maximize, and do not bias, diversity are preferred. In a preferred embodiment of this invention where the nucleic acid sequences are derived from antibody genes, the present invention preferably utilizes primers in the constant regions of the heavy and light chain genes and primers to a synthetic sequence that are attached at the 5′ end of the sense strand. Priming at such synthetic sequence avoids the use of sequences within the variable regions of the antibody genes. Those variable region priming sites generate bias against V genes that are either of rare subclasses or that have been mutated at the priming sites. This bias is partly due to suppression of diversity within the primer region and partly due to lack of priming when many mutations are present in the region complementary to the primer. The methods disclosed in this invention have the advantage of not biasing the population of amplified antibody genes for particular V gene types.
The synthetic sequences may be attached to the 5′ end of the DNA strand by various methods well known for ligating DNA sequences together. RT CapExtention is one preferred method.
In RT CapExtention (derived from Smart PCR™), a short overlap (5′- . . . GGG-3′ in the upper-strand primer (USP-GGG) complements 3′-CCC . . . 5′ in the lower strand) and reverse transcriptases are used so that the reverse complement of the upper-strand primer is attached to the lower strand.
FIGS. 1 and 2 show schematics to amplify VH and VL genes using RT CapExtention. FIG. 1 shows a schematic of the amplification of VH genes. FIG. 1, Panel A shows a primer specific to the poly-dT region of the 3′ UTR priming synthesis of the first, lower strand. Primers that bind in the constant region are also suitable. Panel B shows the lower strand extended at its 3′ end by three Cs that are not complementary to the mRNA. Panel C shows the result of annealing a synthetic top-strand primer ending in three GGGs that hybridize to the 3′ terminal CCCs and extending the reverse transcription extending the lower strand by the reverse complement of the synthetic primer sequence. Panel D shows the result of PCR amplification using a 5′ biotinylated synthetic top-strand primer that replicates the 5′ end of the synthetic primer of panel C and a bottom-strand primer complementary to part of the constant domain. Panel E shows immobilized double-stranded (ds) cDNA obtained by using a 5′-biotinylated top-strand primer.
FIG. 2 shows a similar schematic for amplification of VL genes. FIG. 2, Panel A shows a primer specific to the constant region at or near the 3′ end priming synthesis of the first, lower strand. Primers that bind in the poly-dT region are also suitable. Panel B shows the lower strand extended at its 3′ end by three Cs that are not complementary to the mRNA. Panel C shows the result of annealing a synthetic top-strand primer ending in three GGGs that hybridize to the 3′ terminal CCCs and extending the reverse transcription extending the lower strand by the reverse complement of the synthetic primer sequence. Panel D shows the result of PCR amplification using a 5′ biotinylated synthetic top-strand primer that replicates the 5′ end of the synthetic primer of panel C and a bottom-strand primer complementary to part of the constant domain. The bottom-strand primer also contains a useful restriction endonuclease site, such as AscI. Panel E shows immobilized ds cDNA obtained by using a 5′-biotinylated top-strand primer.
In FIGS. 1 and 2, each V gene consists of a 5′ untranslated region (UTR) and a secretion signal, followed by the variable region, followed by a constant region, followed by a 3′ untranslated region (which typically ends in poly-A). An initial primer for reverse transcription may be complementary to the constant region or to the poly A segment of the 3′-UTR. For human heavy-chain genes, a primer of 15 T is preferred. Reverse transcriptases attach several C residues to the 3′ end of the newly synthesized DNA. RT CapExtention exploits this feature. The reverse transcription reaction is first run with only a lower-strand primer. After about 1 hour, a primer ending in GGG (USP-GGG) and more RTase are added. This causes the lower-strand cDNA to be extended by the reverse complement of the USP-GGG up to the final GGG. Using one primer identical to part of the attached synthetic sequence and a second primer complementary to a region of known sequence at the 3′ end of the sense strand, all the V genes are amplified irrespective of their V gene subclass.
In another preferred embodiment, synthetic sequences may be added by Rapid Amplification of cDNA Ends (RACE) (see Frohman, M. A., Dush, M. K., & Martin, G. R. (1988) Proc. Natl. Acad. Sci. USA (85): 8998-900?).
FIG. 1 shows a schematic of RACE amplification of antibody heavy and light chains. First, mRNA is selected by treating total or poly(A+) RNA with calf intestinal phosphatase (CIP) to remove the 5′-phosphate from all molecules that have them such as ribosomal RNA, fragmented mRNA, tRNA and genomic DNA. Full length mRNA (containing a protective 7-methyl cap structure) is uneffected. The RNA is then treated with tobacco acid pyrophosphatase (TAP) to remove the cap structure from full length mRNAs leaving a 5′-monophosphate group. Next, a synthetic RNA adaptor is ligated to the RNA population, only molecules which have a 5-phosphate (uncapped, full length mRNAs) will accept the adaptor. Reverse trascriptase reactions using an oligodT primer, and nested PCR (using one adaptor primer (located in the 5′ synthetic adaptor) and one primer for the gene) are then used to amplify the desired transcript.
In a preferred embodiment of this invention, the upper strand or lower strand primer may be also biotinylated or labeled at the 5′ end with one of a) free amino group, b) thiol, c) carboxylic acid and d) another group not found in DNA that can react to form a strong bond to a known partner as an insoluble medium. These can then be used to immobilize the labeled strand after amplification. The immobilized DNA can be either single or double-stranded.
After amplification (using e.g., RT CapExtension or RACE), the DNAs of this invention are rendered single-stranded. For example, the strands can be separated by using a biotinylated primer, capturing the biotinylated product on streptavidin beads, denaturing the DNA, and washing away the complementary strand. Depending on which end of the captured DNA is wanted, one will choose to immobilize either the upper (sense) strand or the lower (antisense) strand.
To prepare the single-stranded amplified DNAs for cloning into genetic packages so as to effect display of, or for expression of, the peptides, polypeptides or proteins encoded, at least in part, by those DNAs, they must be manipulated to provide ends suitable for cloning and display and/or expression. In particular, any 5′ untranslated regions and mammalian signal sequences must be removed and replaced, in frame, by a suitable signal sequence that functions in the display or expression host. Additionally, parts of the variable domains (in antibody genes) may be removed and replaced by synthetic segments containing synthetic diversity. The diversity of other gene families may likewise be expanded with synthetic diversity.
According to the methods of this invention, there are two ways to manipulate the single-stranded DNAs for display and/or expression. The first method comprises the steps of:

In this first method, short oligonucleotides are annealed to the single-stranded DNA so that restriction endonuclease recognition sites formed within the now locally double-stranded regions of the DNA can be cleaved. In particular, a recognition site that occurs at the same position in a substantial fraction of the single-stranded DNAs is identical.
For antibody genes, this can be done using a catalog of germline sequences. See, e.g., “www.mrc-cpe.cam.ac.uk/imt-doc/restricted/ok.html.” Updates can be obtained from this site under the heading “Amino acid and nucleotide sequence alignments.” For other families, similar comparisons exist and may be used to select appropriate regions for cleavage and to maintain diversity.
For example, Table 1 depicts the DNA sequences of the FR3 regions of the 51 known human VH germline genes. In this region, the genes contain restriction endonuclease recognition sites shown in Table 2. Restriction endonucleases that cleave a large fraction of germline genes at the same site are preferred over endonucleases that cut at a variety of sites. Furthermore, it is preferred that there be only one site for the restriction endonucleases within the region to which the short oligonucleotide binds on the single-stranded DNA, e.g., about 10 bases on either side of the restriction endonuclease recognition site.
An enzyme that cleaves downstream in FR3 is also more preferable because it captures fewer mutations in the framework. This may be advantageous is some cases. However, it is well known that framework mutations exist and confer and enhance antibody binding. The present invention, by choice of appropriate restriction site, allows all or part of FR3 diversity to be captured. Hence, the method also allows extensive diversity to be captured.
Finally, in the methods of this invention restriction endonucleases that are active between about 37° C. and about 75° C. are used. Preferably, restriction endonucleases that are active between about 45° C. and about 75° C. may be used. More preferably, enzymes that are active above 50° C., and most preferably active about 55° C., are used. Such temperatures maintain the nucleic acid sequence to be cleaved in substantially single-stranded form.
Enzymes shown in Table 2 that cut many of the heavy chain FR3 germline genes at a single position include: MaeIII(24@4), Tsp45I(21@4), HphI(44@5), BsaJI(23@65), AluI(23@47), BlpI(21@48), DdeI(29@58), BglII(10@61), MslI(44@72), BsiEI(23@74), EaeI(23@74), EagI(23@74), HaeIII(25@75), Bst4CI(51@86), HpyCH4III(51@86), HinfI(38@2), MlyI(18@2), PleI(18@2), MnlI(31@67), HpyCH4V(21@44), BsmAI(16@11), BpmI(19@12), XmnI(12@30), and SacI(11@51). (The notation used means, for example, that BsmAI cuts 16 of the FR3 germline genes with a restriction endonuclease recognition site beginning at base 11 of FR3.)
For cleavage of human heavy chains in FR3, the preferred restriction endonucleases are: Bst4CI (or TaaI or HpyCH4III), BipI, HpyCH4V, and MslI. Because ACNGT (the restriction endonuclease recognition site for Bst4CI, TaaI, and HpyCH4III) is found at a consistent site in all the human FR3 germline genes, one of those enzymes is the most preferred for capture of heavy chain CDR3 diversity. BlpI and HpyCH4V are complementary. BlpI cuts most members of the VH1 and VH4 families while HpyCH4V cuts most members of the VH3, VH5, VH6, and VH7 families. Neither enzyme cuts VH2s, but this is a very small family, containing only three members. Thus, these enzymes may also be used in preferred embodiments of the methods of this invention.
The restriction endonucleases HpyCH4III, Bst4CI, and TaaI all recognize 5′-ACnGT-3′ and cut upper strand DNA after n and lower strand DNA before the base complementary to n. This is the most preferred restriction endonuclease recognition site for this method on human heavy chains because it is found in all germline genes. Furthermore, the restriction endonuclease recognition region (ACnGT) matches the second and third bases of a tyrosine codon (tay) and the following cysteine codon (tgy) as shown in Table 3. These codons are highly conserved, especially the cysteine in mature antibody genes.
Table 4 E shows the distinct oligonucleotides of length 22 (except the last one which is of length 20) bases. Table 5 C shows the analysis of 1617 actual heavy chain antibody genes. Of these, 1511 have the site and match one of the candidate oligonucleotides to within 4 mismatches. Eight oligonucleotides account for most of the matches and are given in Table 4 F.1. The 8 oligonucleotides are very similar so that it is likely that satisfactory cleavage will be achieved with only one oligonucleotide (such as H43.77.97.1-02#1) by adjusting temperature, pH, salinity, and the like. One or two oligonucleotides may likewise suffice whenever the germline gene sequences differ very little and especially if they differ very little close to the restriction endonuclease recognition region to be cleaved. Table 5 D shows a repeat analysis of 1617 actual heavy chain antibody genes using only the 8 chosen oligonucleotides. This shows that 1463 of the sequences match at least one of the oligonucleotides to within 4 mismatches and have the site as expected. Only 7 sequences have a second HpyCH4III restriction endonuclease recognition region in this region.
Another illustration of choosing an appropriate restriction endonuclease recognition site involves cleavage in FR1 of human heavy chains. Cleavage in FR1 allows capture of the entire CDR diversity of the heavy chain.
The germline genes for human heavy chain FR1 are shown in Table 6. Table 7 shows the restriction endonuclease recognition sites found in human germline genes FR1s. The preferred sites are BsgI(GTGCAG;39@4), BsoFI(GCngc;43@6,11@9,2@3,1@12), TseI(Gcwgc;43@6,11@9,2@3,1@12), MspAlI(CMGckg;46@7,2@1), PvuII(CAGctg;46@7,2@1), AluI(AGct;48@82@2), DdcI(Ctnag;22@52,9@48), HphI(tcacc;22@80), BssKI(Nccngg;35@39,2@40), BsaJI(Ccnngg;32@40,2@41), BstNI(CCwgg;33@40), ScrFI(CCngg;35@40,2@41), EcoO109I(RGgnccy;22@46, 11@43), Sau96I(Ggncc;23@47,11@44), AvaII(Ggwcc;23@47,4@44), PpuMI(RGgwccy;22@46,4@43), BsmFI(gtccc;20@48), HinfI(Gantc;34@16,21@56,21@77), TriI(21@77), MlyI(GAGTC;34@16), MlyI(gactc;21@5b6), and AlwNI(CAGnnnctg;22@68). The more preferred sites are MspAI and PvuII. MspAI and PvuII have 46 sites at 7-12 and 2 at 1-6. To avoid cleavage at both sites, oligonucleotides are used that do not fully cover the site at 1-6. Thus, the DNA will not be cleaved at that site. We have shown that DNA that extends 3, 4, or 5 bases beyond a PvuII-site can be cleaved efficiently.
Another illustration of choosing an appropriate restriction endonuclease recognition site involves cleavage in FR1 of human kappa light chains. Table 8 shows the human kappa FR1 germline genes and Table 9 shows restriction endonuclease recognition sites that are found in a substantial number of human kappa FR1 germline genes at consistent locations. Of the restriction endonuclease recognition sites listed, BsmAI and PflFI are the most preferred enzymes. BsmAI sites are found at base 18 in 35 of 40 germline genes. PflFI sites are found in 35 of 40 germline genes at base 12.
Another example of choosing an appropriate restriction endonuclease recognition site involves cleavage in FR1 of the human lambda light chain. Table 10 shows the 31 known human lambda FR1 germline gene sequences. Table 11 shows restriction endonuclease recognition sites found in human lambda FR1 germline genes. HinfI and DdeI are the most preferred restriction endonucleases for cutting human lambda chains in FR1.
After the appropriate site or sites for cleavage are chosen, one or more short oligonucleotides are prepared so as to functionally complement, alone or in combination, the chosen recognition site. The oligonucleotides also include sequences that flank the recognition site in the majority of the amplified genes. This flanking region allows the sequence to anneal to the single-stranded DNA sufficiently to allow cleavage by the restriction endonuclease specific for the site chosen.
The actual length and sequence of the oligonucleotide depends on the recognition site and the conditions to be used for contacting and cleavage. The length must be sufficient so that the oligonucleotide is functionally complementary to the single-stranded DNA over a large enough region to allow the two strands to associate such that cleavage may occur at the chosen temperature and at the desired location.
Typically, the oligonucleotides of this preferred method of the invention are about 17 to about 30 nucleotides in length. Below about 17 bases, annealing is too weak and above 30 bases there can be a loss of specificity. A preferred length is 18 to 24 bases.
Oligonucleotides of this length need not be identical complements of the germline genes. Rather, a few mismatches taken may be tolerated. Preferably, however, no more than 1-3 mismatches are allowed. Such mismatches do not adversely affect annealing of the oligonucleotide to the single-stranded DNA. Hence, the two DNAs are said to be functionally complementary.
The second method to manipulate the single-stranded DNAs of this invention for display and/or expression comprises the steps of:

As explained above, the cleavage site may be formed by the single-stranded portion of the partially double-stranded oligonucleotide duplexing with the single-stranded DNA, the cleavage site may be carried in the double-stranded portion of the partially double-stranded oligonucleotide, or the cleavage site may be introduced by the amplification primer used to amplify the single-stranded DNA-partially double-stranded oligonucleotide combination. In this embodiment, the first is preferred. And, the restriction endonuclease recognition site may be located in either the double-stranded portion of the oligonucleotide or introduced by the amplification primer, which is complementary to that double-stranded region, as used to amplify the combination.
Preferably, the restriction endonuclease site is that of a Type II-S restriction endonuclease, whose cleavage site is located at a known distance from its recognition site.
This second method, preferably, employs Universal Restriction Endonucleases (“URE”). UREs are partially double-stranded oligonucleotides. The single-stranded portion or overlap of the URE consists of a DNA adapter that is functionally complementary to the sequence to be cleaved in the single-stranded DNA. The double-stranded portion consists of a restriction endonuclease recognition site, preferably type II-S.
The URE method of this invention is specific and precise and can tolerate some (e.g., 1-3) mismatches in the complementary regions, i.e., it is functionally complementary to that region. Further, conditions under which the URE is used can be adjusted so that most of the genes that are amplified can be cut, reducing bias in the library produced from those genes.
The sequence of the single-stranded DNA adapter or overlap portion of the URE typically consists of about 14-22 bases. However, longer or shorter adapters may be used. The size depends on the ability of the adapter to associate with its functional complement in the single-stranded DNA and the temperature used for contacting the URE and the single-stranded DNA at the temperature used for cleaving the DNA with the restriction enzyme. The adapter must be functionally complementary to the single-stranded DNA over a large enough region to allow the two strands to associate such that the cleavage may occur at the chosen temperature and at the desired location. We prefer singe-stranded or overlap portions of 14-17 bases in length, and more preferably 18-20 bases in length.
The site chosen for cleavage using the URE is preferably one that is substantially conserved in the family of amplified DNAs. As compared to the first cleavage method of this invention, these sites do not need to be endonuclease recognition sites. However, like the first method, the sites chosen can be synthetic rather than existing in the native DNA. Such sites may be chosen by references to the sequences of known antibodies or other families of genes. For example, the sequences of many germline genes are reported at www.mrc-cpe.cam.ac.uk/imt-doc/restricted/ok.html. For example, one preferred site occurs near the end of FR3—codon 89 through the second base of codon 93. CDR3 begins at codon 95.
The sequences of 79 human heavy-chain genes are also available at www.ncbi.nlm.nih.gov/entre2/nucleotide.html. This site can be used to identify appropriate sequences for URE cleavage according to the methods of this invention. See, e.g., Table 12B.
Most preferably, one or more sequences are identified using these sites or other available sequence information. These sequences together are present in a substantial fraction of the amplified DNAs. For example, multiple sequences could be used to allow for known diversity in germline genes or for frequent somatic mutations. Synthetic degenerate sequences could also be used. Preferably, a sequence(s) that occurs in at least 65% of genes examined with no more than 2-3 mismatches is chosen
URE single-stranded adapters or overlaps are then made to be complementary to the chosen regions. Conditions for using the UREs are determined empirically. These conditions should allow cleavage of DNA that contains the functionally complementary sequences with no more than 2 or 3 mismatches but that do not allow cleavage of DNA lacking such sequences.
As described above, the double-stranded portion of the URE includes an endonuclease recognition site, preferably a Type II-S recognition site. Any enzyme that is active at a temperature necessary to maintain the single-stranded DNA substantially in that form and to allow the single-stranded DNA adapter portion of the URE to anneal long enough to the single-stranded DNA to permit cleavage at the desired site may be used.
The preferred Type II-S enzymes for use in the URE methods of this invention provide asymmetrical cleavage of the single-stranded DNA. Among these are the enzymes listed in Table 13. The most preferred Type II-S enzyme is FokI.
When the preferred FokI containing URE is used, several conditions are preferably used to effect cleavage:

- 1) Excess of the URE over target DNA should be present to activate the enzyme. URE present only in equimolar amounts to the target DNA would yield poor cleavage of ssDNA because the amount of active enzyme available would be limiting.
- 2) An activator may be used to activate part of the FokI enzyme to dimerize without causing cleavage. Examples of appropriate activators are shown in Table 14.
- 3) The cleavage reaction is performed at a temperature between 45°−75° C., preferably above 50° C. and most preferably above 55° C.

The UREs used in the prior art contained a 14-base single-stranded segment, a 10-base stem (containing a FokI site), followed by the palindrome of the 10-base stem. While such UREs may be used in the methods of this invention, the preferred UREs of this invention also include a segment of three to eight bases (a loop) between the FokI restriction endonuclease recognition site containing segments. In the preferred embodiment, the stem (containing the FokI site) and its palindrome are also longer than 10 bases. Preferably, they are 10-14 bases in length. Examples of these “lollipop” URE adapters are shown in Table 15.
One example of using a URE to cleave an single-stranded DNA involves the FR3 region of human heavy chain. Table 16 shows an analysis of 840 full-length mature human heavy chains with the URE recognition sequences shown. The vast majority (718/840=0.85) will be recognized with 2 or fewer mismatches using five UREs (VHS881-1.1, VHS881-1.2, VH3081-2.1, VHS861-4.1, and VHS601-9.1). Each has a 20-base adaptor sequence to complement the germline gene, a ten-base stem segment containing a FokI site, a five base loop, and the reverse complement of the first stem segment. Annealing those adapters, alone or in combination, to single-stranded antisense heavy chain DNA and treating with FokI in the presence of, e.g., the activator FOKIact, will lead to cleavage of the antisense strand at the position indicated.
Another example of using a URE(s) to cleave a single-stranded DNA involves the FR1 region of the human Kappa light chains. Table 17 shows an analysis of 182 full-length human kappa chains for matching by the four 19-base probe sequences shown. Ninety-six percent of the sequences match one of the probes with 2 or fewer mismatches. The URE adapters shown in Table 17 are for cleavage of the sense strand of kappa chains. Thus, the adaptor sequences are the reverse complement of the germline gene sequences. The URE consists of a ten-base stem, a five base loop, the reverse complement of the stem and the complementation sequence. The loop shown here is TTCTT, but other sequences could be used. Its function is to interrupt the palindrome of the stems so that formation of a lollypop monomer is favored over dimerization. Table 17 also shows where the sense strand is cleaved.
Another example of using a URE to cleave a single-stranded DNA involves the human lambda light chain. Table 18 shows analysis of 128 human lambda light chains for matching the four 19-base probes shown. With three or fewer mismatches, 88 of 128 (69%) of the chains match one of the probes. Table 18 also shows URE adapters corresponding to these probes. Annealing these adapters to upper-strand ssDNA of lambda chains and treatment with FokI in the presence of FOKIact at a temperature at or above 45° C. will lead to specific and precise cleavage of the chains.
The conditions under which the short oligonucleotide sequences of the first method and the UREs of the second method are contacted with the single-stranded DNAs may be empirically determined. The conditions must be such that the single-stranded DNA remains in substantially single-stranded form. More particularly, the conditions must be such that the single-stranded DNA does not form loops that may interfere with its association with the oligonucleotide sequence or the URE or that may themselves provide sites for cleavage by the chosen restriction endonuclease.
The effectiveness and specificity of short oligonucleotides (first method) and UREs (second method) can be adjusted by controlling the concentrations of the URE adapters/oligonucleotides and substrate DNA, the temperature, the pH, the concentration of metal ions, the ionic strength, the concentration of chaotropes (such as urea and formamide), the concentration of the restriction endonuclease (e.g., FokI), and the time of the digestion. These conditions can be optimized with synthetic oligonucleotides having: 1) target germline gene sequences, 2) mutated target gene sequences, or 3) somewhat related non-target sequences. The goal is to cleave most of the target sequences and minimal amounts of non-targets.
In accordance with this invention, the single-stranded DNA is maintained in substantially that form using a temperature between about 37° C. and about 75° C. Preferably, a temperature between about 45° C. and about 75° C. is used. More preferably, a temperature between 50° C. and 60° C., most preferably between 55° C. and 60° C., is used. These temperatures are employed both when contacting the DNA with the oligonucleotide or URE and when cleaving the DNA using the methods of this invention.
The two cleavage methods of this invention have several advantages. The first method allows the individual members of the family of single-stranded DNAs to be cleaved preferentially at one substantially conserved endonuclease recognition site. The method also does not require an endonuclease recognition site to be built into the reverse transcription or amplification primers. Any native or synthetic site in the family can be used.
The second method has both of these advantages. In addition, the preferred URE method allows the single-stranded DNAs to be cleaved at positions where no endonuclease recognition site naturally occurs or has been synthetically constructed.
Most importantly, both cleavage methods permit the use of 5′ and 3′ primers so as to maximize diversity and then cleavage to remove unwanted or deleterious sequences before cloning, display and/or expression.
After cleavage of the amplified DNAs using one of the methods of this invention, the DNA is prepared for cloning, display and/or expression. This is done by using a partially duplexed synthetic DNA adapter, whose terminal sequence is based on the specific cleavage site at which the amplified DNA has been cleaved.
The synthetic DNA is designed such that when it is ligated to the cleaved single-stranded DNA in proper reading frame so that the desired peptide, polypeptide or protein can be displayed on the surface of the genetic package and/or expressed. Preferably, the double-stranded portion of the adapter comprises the sequence of several codons that encode the amino acid sequence characteristic of the family of peptides, polypeptides or proteins up to the cleavage site. For human heavy chains, the amino acids of the 3-23 framework are preferably used to provide the sequences required for expression of the cleaved DNA.
Preferably, the double-stranded portion of the adapter is about 12 to 100 bases in length. More preferably, about 20 to 100 bases are used. The double-standard region of the adapter also preferably contains at least one endonuclease recognition site useful for cloning the DNA into a suitable display and/or expression vector (or a recipient vector used to archive the diversity). This endonuclease restriction site may be native to the germline gene sequences used to extend the DNA sequence. It may be also constructed using degenerate sequences to the native germline gene sequences. Or, it may be wholly synthetic.
The single-stranded portion of the adapter is complementary to the region of the cleavage in the single-stranded DNA. The overlap can be from about 2 bases up to about 15 bases. The longer the overlap, the more efficient the ligation is likely to be. A preferred length for the overlap is 7 to 10. This allows some mismatches in the region so that diversity in this region may be captured.
The single-stranded region or overlap of the partially duplexed adapter is advantageous because it allows DNA cleaved at the chosen site, but not other fragments to be captured. Such fragments would contaminate the library with genes encoding sequences that will not fold into proper antibodies and are likely to be non-specifically sticky.
One illustration of the use of a partially duplexed adaptor in the methods of this invention involves ligating such adaptor to a human FR3 region that has been cleaved, as described above, at 5′-ACnGT-3′ using HpyCH4III, Bst4CI or TaaI.
Table 4 F.2 shows the bottom strand of the double-stranded portion of the adaptor for ligation to the cleaved bottom-strand DNA. Since the HpyCH4III-Site is so far to the right (as shown in Table 3), a sequence that includes the AflI-site as well as the XbaI site can be added. This bottom strand portion of the partially-duplexed adaptor, H43.XAExt, incorporates both XbaI and AMl-sites. The top strand of the double-stranded portion of the adaptor has neither site (due to planned mismatches in the segments opposite the XbaI and AfII-Sites of H43.XAExt), but will anneal very tightly to H43.XAExt. H43AExt contains only the AflII-site and is to be used with the top strands H43.ABr1 and H43.ABr2 (which have intentional alterations to destroy the AflII-site).
After ligation, the desired, captured DNA can be PCR amplified again, if desired, using in the preferred embodiment a primer to the downstream constant region of the antibody gene and a primer to part of the double-standard region of the adapter. The primers may also carry restriction endonuclease sites for use in cloning the amplified DNA.
After ligation, and perhaps amplification, of the partially double-stranded adapter to the single-stranded amplified DNA, the composite DNA is cleaved at chosen 5′ and 3′ endonuclease recognition sites.
The cleavage sites useful for cloning depend on the phage or phagemid or other vectors into which the cassette will be inserted and the available sites in the antibody genes. Table 19 provides restriction endonuclease data for 75 human light chains. Table 20 shows corresponding data for 79 human heavy chains. In each Table, the endonucleases are ordered by increasing frequency of cutting. In these Tables, Nch is the number of chains cut by the enzyme and Ns is the number of sites (some chains have more than one site).
From this analysis, SfiI, NotI, AflII, ApaLI, and AscI are very suitable. SfiI and NotI are preferably used in pCES1 to insert the heavy-chain display segment. ApaLI and AscI are preferably used in pCES1 to insert the light-chain display segment.
BstEII-sites occur in 97% of germ-line JH genes. In rearranged V genes, only 54/79 (68%) of heavy-chain genes contain a BstEII-Site and 7/61 of these contain two sites. Thus, 47/79 (59%) contain a single BstEII-Site. An alternative to using BstEII is to cleave via UREs at the end of JH and ligate to a synthetic oligonucleotide that encodes part of CH1.
One example of preparing a family of DNA sequences using the methods of this invention involves capturing human CDR 3 diversity. As described above, mRNAs from various autoimmune patients are reverse transcribed into lower strand cDNA. After the top strand RNA is degraded, the lower strand is immobilized and a short oligonucleotide used to cleave the cDNA upstream of CDR3. A partially duplexed synthetic DNA adapter is then annealed to the DNA and the DNA is amplified using a primer to the adapter and a primer to the constant region (after FR4). The DNA is then cleaved using BstEII (in FR4) and a restriction endonuclease appropriate to the partially double-stranded adapter (e.g., XbaI and AflII (in FR3)). The DNA is then ligated into a synthetic VH skeleton such as 3-23.
One example of preparing a single-stranded DNA that was cleaved using the URE method involves the human Kappa chain. The cleavage site in the sense strand of this chain is depicted in Table 17. The oligonucleotide kapextURE is annealed to the oligonucleotides (kaBRO1UR, kaBR02UR, kaBRO3UR, and kaBRO4UR) to form a partially duplex DNA. This DNA is then ligated to the cleaved soluble kappa chains. The ligation product is then amplified using primers kapextUREPCR and CKForeAsc (which inserts a AscI site after the end of C kappa). This product is then cleaved with ApaLI and AscI and ligated to similarly cut recipient vector.
Another example involves the cleavage of lambda light chains, illustrated in Table 18. After cleavage, an extender (ON_LamEx133) and four bridge oligonucleotides (ON_LamB1-133, ON_LamB2-133, ON_LamB3-133, and ON_LamB4-133) are annealed to form a partially duplex DNA. That DNA is ligated to the cleaved lambda-chain sense strands. After ligation, the DNA is amplified with ON_Lam133PCR and a forward primer specific to the lambda constant domain, such as CL2ForeAsc or CL7ForeAsc (Table 130).
In human heavy chains, one can cleave almost all genes in FR4 (downstream, i.e., toward the 3′ end of the sense strand, of CDR3) at a BstEII-Site that occurs at a constant position in a very large fraction of human heavy-chain V genes. One then needs a site in FR3, if only CDR3 diversity is to be captured, in FR2, if CDR2 and CDR3 diversity is wanted, or in FR1, if all the CDR diversity is wanted. These sites are preferably inserted as part of the partially double-stranded adaptor.
The preferred process of this invention is to provide recipient vectors (e.g., for display and/or expression) having sites that allow cloning of either light or heavy chains. Such vectors are well known and widely used in the art. A preferred phage display vector in accordance with this invention is phage MALIA3. This displays in gene III. The sequence of the phage MALIA3 is shown in Table 21A (annotated) and Table 21B (condensed).
The DNA encoding the selected regions of the light or heavy chains can be transferred to the vectors using endonucleases that cut either light or heavy chains only very rarely. For example, light chains may be captured with ApaLI and AscI. Heavy-chain genes are preferably cloned into a recipient vector having SfiI, NcoI, XbaI, AflII, BstEII, ApaI, and NotI sites. The light chains are preferably moved into the library as ApaLI-AscI fragments. The heavy chains are preferably moved into the library as SfiI-NotI fragments.
Most preferably, the display is had on the surface of a derivative of M13 phage. The most preferred vector contains all the genes of M13, an antibiotic resistance gene, and the display cassette. The preferred vector is provided with restriction sites that allow introduction and excision of members of the diverse family of genes, as cassettes. The preferred vector is stable against rearrangement under the growth conditions used to amplify phage.
In another embodiment of this invention, the diversity captured by the methods of the present invention may be displayed and/or expressed in a phagemid vector (e.g., pCES1) that displays and/or expresses the peptide, polypeptide or protein. Such vectors may also be used to store the diversity for subsequent display and/or expression using other vectors or phage.
In another embodiment of this invention, the diversity captured by the methods of the present invention may be displayed and/or expressed in a yeast vector.
In another embodiment, the mode of display may be through a short linker to anchor domains—one possible anchor comprising the final portion of M13 III (“IIIstump”) and a second possible anchor being the full length III mature protein.
The IIIstump fragment contains enough of M13 III to assemble into phage but not the domains involved in mediating infectivity. Because the w.t. III proteins are present the phage is unlikely to delete the antibody genes and phage that do delete these segments receive only a very small growth advantage. For each of the anchor domains, the DNA encodes the w.t. AA sequence, but differs from the w.t. DNA sequence to a very high extent. This will greatly reduce the potential for homologous recombination between the anchor and the w.t. gene that is also present (see Example 6).
Most preferably, the present invention uses a complete phage carrying an antibiotic-resistance gene (such as an ampicillin-resistance gene) and the display cassette. Because the w.t. iii and possibly viii genes are present, the w.t. proteins are also present. The display cassette is transcribed from a regulatable promoter (e.g., P_LacZ). Use of a regulatable promoter allows control of the ratio of the fusion display gene to the corresponding w.t. coat protein. This ratio determines the average number of copies of the display fusion per phage (or phagemid) particle.
Another aspect of the invention is a method of displaying peptides, polypeptides or proteins (and particularly Fabs) on filamentous phage. In the most preferred embodiment this method displays FABs and comprises:

a) obtaining a cassette capturing a diversity of segments of DNA encoding the elements:
P_reg::RBS1::SS1::VL::CL::stop::RBS2::SS2::VH::CH1::linker::anchor::stop::,
where P_regis a regulatable promoter, RBS1 is a first ribosome binding site, SS1 is a signal sequence operable in the host strain, VL is a member of a diverse set of light-chain variable regions, CL is a light-chain constant region, stop is one or more stop codons, RBS2 is a second ribosome binding site, SS2 is a second signal sequence operable in the host strain, VH is a member of a diverse set of heavy-chain variable regions, CH1 is an antibody heavy-chain first constant domain, linker is a sequence of amino acids of one to about 50 residues, anchor is a protein that will assemble into the filamentous phage particle and stop is a second example of one or more stop codons; and
b) positioning that cassette within the phage genome to maximize the viability of the phage and to minimize the potential for deletion of the cassette or parts thereof.

The DNA encoding the anchor protein in the above preferred cassette should be designed to encode the same (or a closely related) amino acid sequence as is found in one of the coat proteins of the phage, but with a distinct DNA sequence. This is to prevent unwanted homologous recombination with the w.t. gene. In addition, the cassette should be placed in the intergenic region. The positioning and orientation of the display cassette can influence the behavior of the phage.
In one embodiment of the invention, a transcription terminator may be placed after the second stop of the display cassette above (e.g., Trp). This will reduce interaction between the display cassette and other genes in the phage antibody display vector.
In another embodiment of the methods of this invention, the phage or phagemid can display and/or express proteins other than Fab, by replacing the Fab portions indicated above, with other protein genes.
Various hosts can be used the display and/or expression aspect of this invention. Such hosts are well known in the art. In the preferred embodiment, where Fabs are being displayed and/or expressed, the preferred host should grow at 30° C. and be RecA⁻ (to reduce unwanted genetic recombination) and EndA⁻ (to make recovery of RF DNA easier). It is also preferred that the host strain be easily transformed by electroporation.
XL1-Blue MRF′ satisfies most of these preferences, but does not grow well at 30° C. XL1-Blue MRF′ does gLow slowly at 38° C. and thus is an acceptable host. TG-1 is also an acceptable host although it is RecA′ and EndA⁺. XL1-Blue MRF′ is more preferred for the intermediate host used to accumulate diversity prior to final construction of the library.
After display and/or expression, the libraries of this invention may be screened using well known and conventionally used techniques. The selected peptides, polypeptides or proteins may then be used to treat disease. Generally, the peptides, polypeptides or proteins for use in therapy or in pharmaceutical compositions are produced by isolating the DNA encoding the desired peptide, polypeptide or protein from the member of the library selected. That DNA is then used in conventional methods to produce the peptide, polypeptides or protein it encodes in appropriate host cells, preferably mammalian host cells, e.g., CHO cells. After isolation, the peptide, polypeptide or protein is used alone or with pharmaceutically acceptable compositions in therapy to treat disease.

EXAMPLES

Example 1: RACE Amplification of Heavy and Light Chain Antibody Repertoires from Autoimmune Patients

Total RNA was isolated from individual blood samples (50 ml) of 11 patients using a RNAzol™ kit (CINNA/Biotecx), as described by the manufacturer. The patients were diagnosed as follows:

1. SLE and phospholipid syndrome
2. limited systemic sclerosis
3. SLE and Sjogren syndrome
4. Limited Systemic sclerosis
5. Reumatoid Arthritis with active vasculitis
6. Limited systemic sclerosis and Sjogren Syndrome
7. Reumatoid Artritis and (not active) vasculitis
8. SLE and Sjogren syndrome
9. SLE
10. SLE and (active) glomerulonephritis
11. Polyarthritis/Raynauds Phenomen

From these 11 samples of total RNA, Poly-A+ RNA was isolated using Promega PolyATtractO mRNA Isolation kit (Promega).
250 ng of each poly-A+ RNA sample was used to amplify antibody heavy and light chains with the GeneRAacer™ kit (Invitrogen cat no. L1500-01). A schematic overview of the RACE procedure is shown in FIG. 3.
Using the general protocol of the GeneRAacer™ kit, an RNA adaptor was ligated to the 5′end of all mRNAs. Next, a reverse transcriptase reaction was performed in the presence of oligo(dT15) specific primer under conditions described by the manufacturer in the GeneRAacer™ kit.
1/5 of the cDNA from the reverse transcriptase reaction was used in a 20 ul PCR reaction. For amplification of the heavy chain IgM repertoire, a forward primer based on the CH1 chain of IgM [HuCmFOR] and a backward primer based on the ligated synthetic adaptor sequence [5′A] were used. (See Table 22)
For amplification of the kappa and lambda light chains, a forward primer that contains the 3′ coding-end of the cDNA [HuCkFor and HuCLFor2+HuCLfor7] and a backward primer based on the ligated synthetic adapter sequence [5′A] was used (See Table 22). Specific amplification products after 30 cycles of primary PCR were obtained.
FIG. 4 shows the amplification products obtained after the primary PCR reaction from 4 different patient samples. 8 ul primary PCR product from 4 different patients was analyzed on a agarose gel [labeled 1, 2, 3 and 4]. For the heavy chain, a product of approximately 950 nt is obtained while for the kappa and lambda light chains the product is approximately 850 nt. M1-2 are molecular weight markers.
PCR products were also analyzed by DNA sequencing [10 clones from the lambda, kappa or heavy chain repertoires]. All sequenced antibody genes recovered contained the full coding sequence as well as the 5′ leader sequence and the V gene diversity was the expected diversity (compared to literature data).
50 ng of all samples from all 11 individual amplified samples were mixed for heavy, lambda light or kappa light chains and used in secondary PCR reactions.
In all secondary PCRs approximately 1 ng template DNA from the primary PCR mixture was used in multiple 50 ul PCR reactions [25 cycles].
For the heavy chain, a nested biotinylated forward primer [HuCm-Nested] was used, and a nested 5′end backward primer located in the synthetic adapter-sequence [5′NA] was used. The 5′end lower-strand of the heavy chain was biotinylated.
For the light chains, a 5′end biotinylated nested primer in the synthetic adapter was used [5′NA] in combination with a 3′end primer in the constant region of Ckappa and Clambda, extended with a sequence coding for the AscI restriction site [kappa: HuCkForAscI, Lambda: HuCL2-FOR-ASC+HuCL7-FOR-ASC]. [5′end Top strand DNA was biotinylated]. After gel-analysis the secondary PCR products were pooled and purified with Promega Wizzard PCR cleanup.
Approximately 25 ug biotinylated heavy chain, lambda and kappa light chain DNA was isolated from the 11 patients.

Example 2: Capturing Kappa Chains with BamAI

A repertoire of human-kappa chain mRNAs was prepared using the RACE method of Example 1 from a collection of patients having various autoimmune diseases.
This Example followed the protocol of Example 1. Approximately 2 micrograms (ug) of human kappa-chain (Igkappa) gene RACE material with biotin attached to 5′-end of upper strand was immobilized as in Example 1 on 200 microliters (μL) of Seradyn magnetic beads. The lower strand was removed by washing the DNA with 2 aliquots 200 μL of 0.1 M NaOH (pH 13) for 3 minutes for the first aliquot followed by 30 seconds for the second aliquot. The beads were neutralized with 200 μL of 10 mM Tris (pH 7.5) 100 mM NaCl. The short oligonucleotides shown in Table 23 were added in 40 fold molar excess in 100 μL of NEB buffer 2 (50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl₂, 1 mM dithiothreitol pH 7.9) to the dry beads. The mixture was incubated at 95° C. for 5 minutes then cooled down to 55° C. over 30 minutes. Excess oligonucleotide was washed away with 2 washes of NEB buffer 3 (100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl₂, 1 mM dithiothreitol pH 7.9). Ten units of BsmAI (NEB) were added in NEB buffer 3 and incubated for 1 h at 55° C. The cleaved downstream DNA was collected and purified over a Qiagen PCR purification column (FIGS. 5 and 6).
FIG. 5 shows an analysis of digested kappa single-stranded DNA. Approximately 151.5 pmol of adapter was annealed to 3.79 pmol of immobilized kappa single-stranded DNA followed by digestion with 15 U of BsmAI. The supernatant containing the desired DNA was removed and analyzed by 5% polyacrylamide gel along with the remaining beads which contained uncleaved full length kappa DNA. 189 pmol of cleaved single-stranded DNA was purified for further analysis. Five percent of the original full length ssDNA remained on the beads.
FIG. 6 shows an analysis of the extender-cleaved kappa ligation. 180 pmol of pre-annealed bridge/extender was ligated to 1.8 pmol of BsmAI digested single-stranded DNA. The ligated DNA was purified by Qiagen PCR purification column and analyzed on a 5% polyacrylamide gel. Results indicated that the ligation of extender to single-stranded DNA was 95% efficient.
A partially double-stranded adaptor was prepared using the oligonucleotide shown in Table 23. The adaptor was added to the single-stranded DNA in 100 fold molar excess along with 1000 units of T4 DNA ligase and incubated overnight at 16° C. The excess oligonucleotide was removed with a Qiagen PCR purification column. The ligated material was amplified by PCR using the primers kapPCRt1 and kapfor shown in Table 23 for 10 cycles with the program shown in Table 24.
The soluble PCR product was run on a gel and showed a band of approximately 700 n, as expected (FIGS. 7 and 8). The DNA was cleaved with enzymes ApaLI and AscI, gel purified, and ligated to similarly cleaved vector pCES1.
FIG. 7 shows an analysis of the PCR product from the extender-kappa amplification. Ligated extender-kappa single-stranded DNA was amplified with primers specific to the extender and to the constant region of the light chain. Two different template concentrations, 10 ng versus 50 ng, were used as template and 13 cycles were used to generate approximately 1.5 ug of dsDNA as shown by 0.8% agarose gel analysis.
FIG. 8 shows an analysis of the purified PCR product from the extender-kappa amplification. Approximately 5 ug of PCR amplified extender-kappa double-stranded DNA was run out on a 0.8% agarose gel, cut out, and extracted with a GFX gel purification column. By gel analysis, 3.5 ug of double-stranded DNA was prepared.
The assay for capturing kappa chains with BsmAl was repeated and produced similar results. FIG. 9A shows the DNA after it was cleaved and collected and purified over a Qiagen PCR purification column. FIG. 9B shows the partially double-stranded adaptor ligated to the single-stranded DNA. This ligated material was then amplified (FIG. 9C). The gel showed a band of approximately 700 n.
Table 25 shows the DNA sequence of a kappa light chain captured by this procedure. Table 26 shows a second sequence captured by this procedure. The closest bridge sequence was complementary to the sequence 5′-agccacc-3′, but the sequence captured reads 5′-Tgccacc-3′, showing that some mismatch in the overlapped region is tolerated.

Example 3: Construction of Synthetic CDR1 and CDR2 Diversity in V-3-23 VH Framework

Synthetic diversity in Complementary Determinant Region (CDR) 1 and 2 was created in the 3-23 VH framework in a two step process: first, a vector containing the 3-23 VH framework was constructed; and then, a synthetic CDR 1 and 2 was assembled and cloned into this vector.
For construction of the 3-23 VH framework, 8 oligonucleotides and two PCR primers (long oligonucleotides—TOPFR1A, BOTFR1B, BOTFR2, BOTFR3, F06, BOTFR4, ON-vgC1, and ON-vgC2 and primers—SFPRMET and BOTPCRPRIM, shown in Table 27) that overlap were designed based on the Genebank sequence of 3-23 VH framework region. The design incorporated at least one useful restriction site in each framework region, as shown in Table 27. In Table 27, the segments that were synthesized are shown as bold, the overlapping regions are underscored, and the PCR priming regions at each end are underscored.
A mixture of these 8 oligos was combined at a final concentration of 2.5 uM in a 20 ul PCR reaction. The PCR mixture contained 200 uM dNTPs, 2.5 mM MgCl₂, 0.02 U Pfu Turbo™ DNA Polymerase, 1 U Qiagen HotStart Taq DNA Polymerase, and 1× Qiagen PCR buffer. The PCR program consisted of 10 cycles of 94_C for 30 s, 55_C for 30 s, and 72_C for 30 s.
The assembled 3-23 VH DNA sequence was then amplified, using 2.5 ul of a 10-fold dilution from the initial PCR in 100 ul PCR reaction. The PCR reaction contained 200 uM dNTPs, 2.5 mM MgCl₂, 0.02 U Pfu Turbo™ DNA Polymerase, 1 U Qiagen HotStart Taq DNA Polymerase, 1× Qiagen PCR Buffer and 2 outside primers (SFPRMET and BOTPCRPRIM) at a concentration of luM. The PCR program consisted of 23 cycles at 94_C for 30 s, 55_C for 30 s, and 72_C for 60 s. The 3-23 VH DNA sequence was digested and cloned into pCES1 (phagemid vector) using the SfiI and BstEII restriction endonuclease sites. All restriction enzymes mentioned herein were supplied by New England BioLabs, Beverly, Mass. and used as per the manufacturer's instructions.
Stuffer sequences (shown in Table 28 and Table 29) were introduced into pCES1 to replace CDR1/CDR2 sequences (900 bases between BspEI and XbaI RE sites) and CDR3 sequences (358 bases between AflII and BstEII) prior to cloning the CDR1/CDR2 diversity. This new vector was termed pCES5 and its sequence is given in Table 29.
Having stuffers in place of the CDRs avoids the risk that a parental sequence would be over-represented in the library. The stuffer sequences are fragments from the penicillase gene of E. coli. The CDR1-2 stuffer contains restriction sites for BglII, Bsu36I, BclI, XcmI, MluI, PvuII, HpaI, and HincII, the underscored sites being unique within the vector pCES5. The stuffer that replaces CDR3 contains the unique restriction endonuclease site RsrII.
A schematic representation of the design for CDR1 and CDR2 synthetic diversity is shown FIG. 10. The design was based on the presence of mutations in DP47/3-23 and related germline genes. Diversity was designed to be introduced at the positions within CDR1 and CDR2 indicated by the numbers in FIG. 10. The diversity at each position was chosen to be one of the three following schemes: 1=ADEFGHIKLMNPQRSTVWY; 2=YRWVGS; 3=PS, in which letters encode equimolar mixes of the indicated amino acids.
For the construction of the CDR1 and CDR2 diversity, 4 overlapping oligonucleotides (ON-vgCl, ON_Br12, ON_CD2Xba, and ON-vgC2, shown in Table 27 and Table 30) encoding CDR1/2, plus flanking regions, were designed. A mixture of these 4 oligos was combined at a final concentration of 2.5 uM in a 40 ul PCR reaction. Two of the 4 oligos contained variegated sequences positioned at the CDR1 and the CDR2. The PCR mixture contained 200 uM dNTPs, 2.5 U Pwo DNA Polymerase (Roche), and 1× Pwo PCR buffer with 2 mM MgSO₄. The PCR program consisted of 10 cycles at 94_C for 30 s, 60_C for 30 s, and 72_C for 60 s. This assembled CDR1/2 DNA sequence was amplified, using 2.5 ul of the mixture in 100 ul PCR reaction. The PCR reaction contained 200 uM dNTPs, 2.5 U Pwo DNA Polymerase, 1× Pwo PCR Buffer with 2 mM MgSO₄and 2 outside primers at a concentration of luM. The PCR program consisted of 10 cycles at 94_C for 30 s, 60_C for 30 s, and 72_C for 60 s. These variegated sequences were digested and cloned into the 3-23 VH framework in place of the CDR1/2 stuffer.
We obtained approximately 7×107 independent transformants. CDR3 diversity either from donor populations or from synthetic DNA can be cloned into the vector containing synthetic CDR1 and CDR 2 diversity.
A schematic representation of this procedure is shown in FIG. 11. A sequence encoding the FR-regions of the human V3-23 gene segment and CDR regions with synthetic diversity was made by oligonucleotide assembly and cloning via BspE1 and Xba1 sites into a vector that complements the FR1 and FR3 regions. Into this library of synthetic VH segments, the complementary VH-CDR3 sequence (top right) was cloned via Xbal an BstEll sites. The resulting cloned CH genes contain a combination of designed synthetic diversity and natural diversity (see FIG. 11).

Example 4: Cleavage and Ligation of the Lambda Light Chains with HinfI

A schematic of the cleavage and ligation of antibody light chains is shown in FIGS. 12A and 12B. Approximately 2 ug of biotinylated human Lambda DNA prepared as described in Example 1 was immobilized on 200 ul Seradyn magnetic beads. The lower strand was removed by incubation of the DNA with 200 ul of 0.1 M NaOH (pH=13) for 3 minutes, the supernatant was removed and an additional washing of 30 seconds with 200 ul of 0.1 M NaOH was performed. Supernatant was removed and the beads were neutralized with 200 ul of 10 mM Tris (pH=7.5), 100 mM NaCl. 2 additional washes with 200 ul NEB2 buffer 2, containing 10 mM Tris (pH=7.9), 50 mM NaCl, 10 mM MgCl2 and 1 mM dithiothreitol, were performed. After immobilization, the amount of ssDNA was estimated on a 5% PAGE-UREA gel.
About 0.8 ug ssDNA was recovered and incubated in 100 ul NEB2 buffer 2 containing 80 molar fold excess of an equimolar mix of ON_Lam1aB7, ON_Lam2aB7, ON_Lam31B7 and ON_Lam3rB7 [each oligo in 20 fold molar excess] (see Table 31).
The mixture was incubated at 95° C. for 5 minutes and then slowly cooled down to 50° C. over a period of 30 minutes. Excess of oligonucleotide was washed away with 2 washes of 200 ul of NEB buffer 2. 4 U/ug of Hinf I was added and incubated for 1 hour at 50° C. Beads were mixed every 10 minutes.
After incubation the sample was purified over a Qiagen PCR purification column and was subsequently analysed on a 5% PAGE-urea gel (see FIG. 13A, cleavage was more than 70% efficient).
A schematic of the ligation of the cleaved liqht chains is shown in FIG. 12B. A mix of bridge/extender pairs was prepared from the Brg/Ext oligo's listed in Table 31 (total molar excess 100 fold) in 1000 U of T4 DNA Ligase (NEB) and incubated overnight at 16° C. After ligation of the DNA, the excess oligonucleotide was removed with a Qiagen PCR purification column and ligation was checked on a Urea-PAGE gel (see FIG. 13B; ligation was more than 95% efficient).
Multiple PCRs were performed containing 10 ng of the ligated material in an 50 ul PCR reaction using 25 pMol ON lamPlePCR and 25 pmol of an equimolar mix of Hu-CL2AscI/HuCL7AscI primer (see Example 1). PCR was performed at 60° C. for 15 cycles using Pfu polymerase. About 1 ug of dsDNA was recovered per PCR (see FIG. 13C) and cleaved with ApaL1 and AscI for cloning the lambda light chains in pCES2.

Example 5: Capture of Human Heavy-Chain CDR3 Population

A schematic of the cleavage and ligation of antibody light chains is shown in FIGS. 14A and 14B.
Approximately 3 ug of human heavy-chain (IgM) gene RACE material with biotin attached to 5′-end of lower strand was immobilized on 300 uL of Seradyn magnetic beads. The upper strand was removed by washing the DNA with 2 aliquots 300 uL of 0.1 M NaOH (pH 13) for 3 minutes for the first aliquot followed by 30 seconds for the second aliquot. The beads were neutralized with 300 uL of 10 mM Tris (pH 7.5) 100 mM NaCl. The REdaptors (oligonucleotides used to make single-stranded DNA locally double-stranded) shown in Table 32 were added in 30 fold molar excess in 200 uL of NEB buffer 4 (50 mM Potasium Acetate, 20 mM Tris-Acetate, 10 mM Magnesuim Acetate, 1 mM dithiothreitol pH 7.9) to the dry beads. The REadaptors were incubated with the single-stranded DNA at 80° C. for 5 minutes then cooled down to 55° C. over 30 minutes. Excess REdaptors were washed away with 2 washes of NEB buffer 4. Fifteen units of HpyCH4III (NEB) were added in NEB buffer 4 and incubated for 1 hour at 55° C. The cleaved downstream DNA remaining on the beads was removed from the beads using a Qiagen Nucleotide removal column (see FIG. 15).
The Bridge/Extender pairs shown in Table 33 were added in 25 molar excess along with 1200 units of T4 DNA ligase and incubated overnight at 16° C. Excess Bridge/Extender was removed with a Qiagen PCR purification column. The ligated material was amplified by PCR using primers H43.XAExtPCR2 and Hucumnest shown in Table 34 for 10 cycles with the program shown in Table 35.
The soluble PCR product was run on a gel and showed a band of approximately 500 n, as expected (see FIG. 15B). The DNA was cleaved with enzymes SfiI and NotI, gel purified, and ligated to similarly cleaved vector PCES1.

Example 6: Description of Phage Display Vector CJRA05, a Member of the Library Built in Vector DY3F7

Table 36 contains an annotated DNA sequence of a member of the library, CJRA05, see FIG. 16. Table 36 is to be read as follows: on each line everything that follows an exclamation mark “!” is a comment. All occurrences of A, C, G, and T before “!” are the DNA sequence. Case is used only to show that certain bases constitute special features, such as restriction sites, ribosome binding sites, and the like, which are labeled below the DNA. CJRA05 is a derivative of phage DY3F7, obtained by cloning an ApaLI to NotI fragment into these sites in DY3F31. DY3F31 is like DY3F7 except that the light chain and heavy chain genes have been replaced by “stuffer” DNA that does not code for any antibody. DY3F7 contains an antibody that binds streptavidin, but did not come from the present library.
The phage genes start with gene ii and continue with genes x, v, vii, ix, viii, iii, vi, i, and iv. Gene iii has been slightly modified in that eight codons have been inserted between the signal sequence and the mature protein and the final amino acids of the signal sequence have been altered. This allows restriction enzyme recognition sites EagI and XbaI to be present. Following gene iv is the phage origin of replication (ori). After on is bla which confers resistance to ampicillin (ApR). The phage genes and bla are transcribed in the same sense.
After bla, is the Fab cassette (illustrated in FIG. 17) comprising:

- a) PlacZ promoter,
- b) A first Ribosome Binding Site (RBS1),
- c) The signal sequence form M13 iii,
- d) An ApaLI RERS,
- e) A light chain (a kappa L20::JK1 shortened by one codon at the V-J boundary in this case),
- f) An AscI RERS,
- g) A second Ribosome Binding Site (RBS2),
- h) A signal sequence, preferably PelB, which contains,
- i) An SfiI RERS,
- j) A synthetic 3-23 V region with diversity in CDR1 and CDR2,
- k) A captured CDR3,
- l) A partially synthetic J region (FR4 after BstEII),
- m) CH1,
- n) A NotI RERS,
- o) A His6 tag (SEQ ID NO: 12),
- p) A cMyc tag,
- q) An amber codon,
- r) An anchor DNA that encodes the same amino-acid sequence as codons 273 to 424 of M13 iii (as shown in Table 37).
- s) Two stop codons,
- t) An AvrII RERS, and
- u) A trp terminator.

The anchor (item r) encodes the same amino-acid sequence as do codons 273 to 424 of M13 iii but the DNA is approximately as different as possible from the wild-type DNA sequence. In Table 36, the III′ stump runs from base 8997 to base 9455. Below the DNA, as comments, are the differences with wild-type iii for the comparable codons with “!W.T” at the ends of these lines. Note that Met and Trp have only a single codon and must be left as is. These AA types are rare. Ser codons can be changed at all three base, while Leu and Arg codons can be changed at two.
In most cases, one base change can be introduced per codon. This has three advantages: 1) recombination with the wild-type gene carried elsewhere on the phage is less likely, 2) new restriction sites can be introduced, facilitating construction; and 3) sequencing primers that bind in only one of the two regions can be designed.
The fragment of M13 III shown in CJRA05 is the preferred length for the anchor segment. Alternative longer or shorter anchor segments defined by reference to whole mature III protein may also be utilized.
The sequence of M13 III consists of the following elements: Signal Sequence::Domain 1 (D1)::Linker 1 (L1)::Domain 2 (D2)::Linker 2 (L2)::Domain 3 (D3)::Transmembrane Segment (TM)::Intracellular anchor (IC) (see Table 38).
The pIII anchor (also known as trpIII) preferably consists of D2::L2::D3::TM::IC. Another embodiment for the pIII anchor consists of D2′::L2::D3::TM::IC (where D2′ comprises the last 21 residues of D2 with the first 109 residues deleted). A further embodiment of the pIII anchor consists of D2′(C>S)::L2::D3::TM::IC (where D2′(C>S) is D2′ with the single C converted to S), and d) D3::TM::IC.
Table 38 shows a gene fragment comprising the NotI site, His6 tag (SEQ ID NO: 12), cMyc tag, an amber codon, a recombinant enterokinase cleavage site, and the whole of mature M13 III protein. The DNA used to encode this sequence is intentionally very different from the DNA of wild-type gene iii as shown by the lines denoted “W.T.” containing the w.t. bases where these differ from this gene. III is divided into domains denoted “domain 1”, “linker 1”, “domain 2”, “linker 2”, “domain 3”, “transmembrane segment”, and “intracellular anchor”.
Alternative preferred anchor segments (defined by reference to the sequence of Table 38) include:
codons 1-29 joined to codons 104-435, deleting domain 1 and retaining linker 1 to the end;
codons 1-38 joined to codons 104-435, deleting domain land retaining the rEK cleavage site plus linker 1 to the end from III;
codons 1-29 joined to codons 236-435, deleting domain 1, linker 1, and most of domain 2 and retaining linker 2 to the end;
codons 1-38 joined to codons 236-435, deleting domain 1, linker 1, and most of domain 2 and retaining linker ? to the end and the rEK cleavage site;
codons 1-29 joined to codons 236-435 and changing codon 240 to Ser (e.g., agc), deleting domain 1, linker 1, and most of domain 2 and retaining linker 2 to the end; and codons 1-38 joined to codons 236-435 and changing codon 240 to Ser (e.g., agc), deleting domain 1, linker 1, and most of domain 2 and retaining linker 2 to the end and the rEK cleavage site.
The constructs would most readily be made by methods similar to those of Wang and Wilkinson (Biotechniques 2001: 31(4)722-724) in which PCR is used to copy the vector except the part to be deleted and matching restriction sites are introduced or retained at either end of the part to be kept. Table 39 shows the oligonucleotides to be used in deleting parts of the III anchor segment. The DNA shown in Table 38 has an NheI site before the DINDDRMA (residues 29-36 of SEQ ID NO: 594)_recombinant enterokinase cleavage site (rEKCS). If NheI is used in the deletion process with this DNA, the rEKCS site would be lost. This site could be quite useful in cleaving Fabs from the phage and might facilitate capture of very high-affinity antibodies. One could mutagenize this sequence so that the NheI site would follow the rEKCS site, an Ala Ser amino-acid sequence is already present. Alternatively, one could use SphI for the deletions. This would involve a slight change in amino acid sequence but would be of no consequence.

Example 7: Selection of Antigen Binders from an Enriched Library of Human Antibodies Using Phage Vector DY3F31

In this example the human antibody library used is described in de Haard et al., (Journal of Biological Chemistry, 274 (26): 18218-30 (1999). This library, consisting of a large non-immune human Fab phagemid library, was first enriched on antigen, either on streptavidin or on phenyl-oxazolone (phOx). The methods for this are well known in the art. Two preselected Fab libraries, the first one selected once on immobilized phOx-BSA (R1-ox) and the second one selected twice on streptavidin (R2-strep), were chosen for recloning.
These enriched repertoires of phage antibodies, in which only a very low percentage have binding activity to the antigen used in selection, were confirmed by screening clones in an ELISA for antigen binding. The selected Fab genes were transferred from the phagemid vector of this library to the DY3F31 vector via ApaL1-Not1 restriction sites.
DNA from the DY3F31 phage vector was pretreated with ATP dependent DNAse to remove chromosomal DNA and then digested with ApaL1 and Not1. An extra digestion with AscI was performed in between to prevent self-ligation of the vector. The ApaL1/NotI Fab fragment from the preselected libraries was subsequently ligated to the vector DNA and transformed into competent XL1-blue MRF′ cells.
Libraries were made using vector:insert ratios of 1:2 for phOx-library and 1:3 for STREP library, and using 100 ng ligated DNA per 50 μl of electroporation-competent cells (electroporation conditions: one shock of 1700 V, 1 hour recovery of cells in rich SOC medium, plating on amplicillin-containing agar plates).
This transformation resulted in a library size of 1.6×10⁶for R1-ox in DY3F31 and 2.1×10⁶for R2-strep in DY3F31. Sixteen colonies from each library were screened for insert, and all showed the correct size insert (±1400 bp) (for both libraries).
Phage was prepared from these Fab libraries as follows. A representative sample of the library was inoculated in medium with ampicillin and glucose, and at OD 0.5, the medium exchanged for ampicillin and 1 mM IPTG. After overnight growth at 37° C., phage was harvested from the supernatant by PEG-NaCl precipitation. Phage was used for selection on antigen. R1-ox was selected on phOx-BSA coated by passive adsorption onto immunotubes and R2-strep on streptavidin coated paramagnetic beads (Dynal, Norway), in procedures described in de Haard et. al. and Marks et. al., Journal of Molecular Biology, 222(3): 581-97 (1991). Phage titers and enrichments are given in Table 40.
Clones from these selected libraries, dubbed R2-ox and R3-strep respectively, were screened for binding to their antigens in ELISA. 44 clones from each selection were picked randomly and screened as phage or soluble Fab for binding in ELISA. For the libraries in DY3F31, clones were first grown in 2TY-2% glucose-50 μg/ml AMP to an OD600 of approximately 0.5, and then grown overnight in 2TY-50 μg/ml AMP+/−1 mM IPTG. Induction with IPTG may result in the production of both phage-Fab and soluble Fab. Therefore the (same) clones were also grown without IPTG. Table 41 shows the results of an ELISA screening of the resulting supernatant, either for the detection of phage particles with antigen binding (Anti-M13 HRP=anti-phage antibody), or for the detection of human Fabs, be it on phage or as soluble fragments, either with using the anti-myc antibody 9E10 which detects the myc-tag that every Fab carries at the C-terminal end of the heavy chain followed by a HRP-labeled rabbit-anti-Mouse serum (column 9E10/RAM-HRP), or with anti-light chain reagent followed by a HRP-labeled goat-anti-rabbit antiserum (anti-CK/CL Gar-HRP).
The results shows that in both cases antigen-binders are identified in the library, with as Fabs on phage or with the anti-Fab reagents (Table 41). IPTG induction yields an increase in the number of positives. Also it can be seen that for the phOx-clones, the phage ELISA yields more positives than the soluble Fab ELISA, most likely due to the avid binding of phage. Twenty four of the ELISA-positive clones were screened using PCR of the Fab-insert from the vector, followed by digestion with BstNI. This yielded 17 different patterns for the phOx-binding Fab's in 23 samples that were correctly analyzed, and 6 out of 24 for the streptavidin binding clones. Thus, the data from the selection and screening from this pre-enriched non-immune Fab library show that the DY3F31 vector is suitable for display and selection of Fab fragments, and provides both soluble Fab and Fab on phage for screening experiments after selection.

Example 8: Selection of Phage-Antibody Libraries on Streptavidin Magnetic Beads

The following example describes a selection in which one first depletes a sample of the library of binders to streptavidin and optionally of binders to a non-target (i.e., a molecule other than the target that one does not want the selected Fab to bind). It is hypothesized that one has a molecule, termed a “competitive ligand”, which binds the target and that an antibody which binds at the same site would be especially useful.
For this procedure Streptavidin Magnetic Beads (Dynal) were blocked once with blocking solution (2% Marvel Milk, PBS (pH 7.4), 0.01% Tween-20 (“2% MPBST”)) for 60 minutes at room temperature and then washed five times with 2% MPBST. 450 μL of beads were blocked for each depletion and subsequent selection set.
Per selection, 6.25 μL of biotinylated depletion target (1 mg/mL stock in PBST) was added to 0.250 mL of washed, blocked beads (from step 1). The target was allowed to bind overnight, with tumbling, at 4° C. The next day, the beads are washed 5 times with PBST.
Per selection, 0.010 mL of biotinylated target antigen (1 mg/mL stock in PBST) was added to 0.100 mL of blocked and washed beads (from step 1). The antigen was allowed to bind overnight, with tumbling, at 4° C. The next day, the beads were washed 5 times with PBST.
In round 1, 2×10¹²up to 10¹³plaque forming units (pfu) per selection were blocked against non-specific binding by adding to 0.500 mL of 2% MPBS (=2% MPBST without Tween) for 1 hr at RT (tumble). In later rounds, 1011 pfu per selection were blocked as done in round 1.
Each phage pool was incubated with 50 μL of depletion target beads (final wash supernatant removed just before use) on a Labquake rotator for 10 min at room temperature. After incubation, the phage supernatant was removed and incubated with another 50 μL of depletion target beads. This was repeated 3 more times using depletion target beads and twice using blocked streptavidin beads for a total of 7 rounds of depletion, so each phage pool required 350 μL of depletion beads.
A small sample of each depleted library pool was taken for titering. Each library pool was added to 0.100 mL of target beads (final wash supernatant was removed just before use) and allowed to incubate for 2 hours at room temperature (tumble).
Beads were then washed as rapidly as possible (e.g., 3 minutes total) with 5×0.500 mL PBST and then 2× with PBS. Phage still bound to beads after the washing were eluted once with 0.250 mL of competitive ligand (˜1 μμM) in PBST for 1 hour at room temperature on a Labquake rotator. The eluate was removed, mixed with 0.500 mL Minimal A salts solution and saved. For a second selection, 0.500 mL 100 mM TEA was used for elution for 10 min at RT, then neutralized in a mix of 0.250 mL of 1 M Tris, pH 7.4+0.500 mL Min A salts.
After the first selection elution, the beads can be eluted again with 0.300 mL of non-biotinylated target (1 mg/mL) for 1 hr at RT on a Labquake rotator. Eluted phage are added to 0.450 mL Minimal A salts.
Three eluates (competitor from 1st selection, target from 1st selection and neutralized TEA elution from 2nd selection) were kept separate and a small aliquot taken from each for titering. 0.500 mL Minimal A salts were added to the remaining bead aliquots after competitor and target elution and after TEA elution. Take a small aliquot from each was taken for tittering.
Each elution and each set of eluted beads was mixed with 2×YT and an aliquot (e.g., 1 mL with 1. E 10/mL) of XL1-Blue MRF′ E. coli cells (or other F′ cell line) which had been chilled on ice after having been grown to mid-logarithmic phase, starved and concentrated (see procedure below—“Mid-Log prep of XL-1 blue MRF′ cells for infection”).
After approximately 30 minutes at room temperature, the phage/cell mixtures were spread onto Bio-Assay Dishes (243×243×18 mm, Nalge Nunc) containing 2XYT, 1 mM IPTG agar. The plates were incubated overnight at 30° C. The next day, each amplified phage culture was harvested from its respective plate. The plate was flooded with 35 mL TBS or LB, and cells were scraped from the plate. The resuspended cells were transferred to a centrifuge bottle. An additional 20 mL TBS or LB was used to remove any cells from the plate and pooled with the cells in the centrifuge bottle. The cells were centrifuged out, and phage in the supernatant was recovered by PEG precipitation. Over the next day, the amplified phage preps were titered.
In the first round, two selections yielded five amplified eluates. These amplified eluates were panned for 2-3 more additional rounds of selection using ˜1. E 12 input phage/round. For each additional round, the depletion and target beads were prepared the night before the round was initiated.
For the elution steps in subsequent rounds, all elutions up to the elution step from which the amplified elution came from were done, and the previous elutions were treated as washes. For the bead infection amplified phage, for example, the competitive ligand and target elutions were done and then tossed as washes (see below). Then the beads were used to infect E. coli. Two pools, therefore, yielded a total of 5 final elutions at the end of the selection.
1st Selection Set

- A. Ligand amplified elution: elute w/ ligand for 1 hr, keep as elution
- B. Target amplified elution w/ ligand for 1 hr, toss as wash elute w/ target for 1 hr, keep as elution
- C. Bead infect. amp. elution: elute w/ligand for 1 hr, toss as wash elute w/ target for 1 hr, toss as wash elute w/ cell infection, keep as elution

2nd Selection Let

- A. TEA amplified elution; elute w/ TEA 10 min, keep as elution
- B. Bead infect. amp. elution; elute w/ TEA 10 min, toss as wash elute w/ cell infection, keep as elution

Mid-Log Prep of XL1 Blue MRF′ Cells for Infection
(based on Barbas et al. Phage Display manual procedure)
Culture XL1 blue MRF′ in NZCYM (12.5 mg/mL tet) at 37° C. and 250 rpm overnight. Started a 500 mL culture in 2 liter flask by diluting cells 1/50 in NZCYM/tet (10 mL overnight culture added) and incubated at 37° C. at 250 rpm until OD600 of 0.45 (1.5-2 hrs) was reached. Shaking was reduced to 100 rpm for 10 min. When OD600 reached between 0.55-0.65, cells were transferred to 2×250 mL centrifuge bottles, centrifuged at 600 g for 15 min at 4° C. Supernatant was poured off. Residual liquid was removed with a pipette.
The pellets were gently resuspended (not pipetting up and down) in the original volume of 1×Minimal A salts at room temp. The resuspended cells were transferred back into 2-liter flask, shaken at 100 rpm for 45 min at 37° C. This process was performed in order to starve the cells and restore pili. The cells were transferred to 2×250 mL centrifuge bottles, and centrifuged as earlier.
The cells were gently resuspended in ice cold Minimal A salts (5 mL per 500 mL original culture). The cells were put on ice for use in infections as soon as possible.
The phage eluates were brought up to 7.5 mL with 2XYT medium and 2.5 mL of cells were added. Beads were brought up to 3 mL with 2XYT and 1 mL of cells were added. Incubated at 37° C. for 30 min. The cells were plated on 2XYT, 1 mM IPTG agar large NUNC plates and incubated for 18 hr at 30° C.

Example 9: Incorporation of Synthetic Region in FR1/3 Region

Described below are examples for incorporating of fixed residues in antibody sequences for light chain kappa and lambda genes, and for heavy chains. The experimental conditions and oligonucleotides used for the examples below have been described in previous examples (e.g., Examples 3 & 4).
The process for incorporating fixed FR1 residues in an antibody lambda sequence consists of 3 steps (see FIG. 18): (1) annealing of single-stranded DNA material encoding VL genes to a partially complementary oligonucleotide mix (indicated with Ext and Bridge), to anneal in this example to the region encoding residues 5-7 of the FR1 of the lambda genes (indicated with X . . . X; within the lambda genes the overlap may sometimes not be perfect); (2) ligation of this complex; (3) PCR of the ligated material with the indicated primer (‘PCRpr’) and for example one primer based within the VL gene. In this process the first few residues of all lambda genes will be encoded by the sequences present in the oligonucleotides (Ext., Bridge or PCRpr). After the PCR, the lambda genes can be cloned using the indicated restriction site for ApaLI.
The process for incorporating fixed FR1 residues in an antibody kappa sequence (FIG. 19) consists of 3 steps: (1) annealing of single-stranded DNA material encoding VK genes to a partially complementary oligonucleotide mix (indicated with Ext and Bri), to anneal in this example to the region encoding residues 8-10 of the FR1 of the kappa genes (indicated with X . . . X; within the kappa genes the overlap may sometimes not be perfect); (2) ligation of this complex; (3) PCR of the ligated material with the indicated primer (‘PCRpr’) and for example one primer based within the VK gene. In this process the first few (8) residues of all kappa genes will be encode by the sequences present in the oligonucleotides (Ext., Bridge or PCRpr.). After the PCR, the kappa genes can be cloned using the indicated restriction site for ApaLI.
The process of incorporating fixed FR3 residues in a antibody heavy chain sequence (FIG. 20) consists of 3 steps: (1) annealing of single-stranded DNA material encoding part of the VH genes (for example encoding FR3, CDR3 and FR4 regions) to a partially complementary oligonucleotide mix (indicated with Ext and Bridge), to anneal in this example to the region encoding residues 92-94 (within the FR3 region) of VH genes (indicated with X . . . X; within the VH genes the overlap may sometimes not be perfect); (2) ligation of this complex; (3) PCR of the ligated material with the indicated primer (‘PCRpr’) and for example one primer based within the VH gene (such as in the FR4 region). In this process certain residues of all VH genes will be encoded by the sequences present in the oligonucleotides used here, in particular from PCRpr (for residues 70-73), or from Ext/Bridge oligonucleotides (residues 74-91). After the PCR, the partial VH genes can be cloned using the indicated restriction site for XbaI.
It will be understood that the foregoing is only illustrative of the principles of this invention and that various modifications can be made by those skilled in the art without departing from the scope of and sprit of the invention.

TABLE 1

Human GLG FR3 sequences

!	VH1
!	66 67 68 69 70 71 72 73 74 75 76 77 78 79 80
	agg gtc acc atg acc agg gac acg tcc atc agc aca gcc tac atg
!	81 82 82a 82b 82c 83 84 85 86 87 88 89 90 91 92
	gag ctg agc agg ctg aga tct gac gac acg gcc gtg tat tac tgt
!	93 94 95
	gcg aga ga ! 1-02# 1 (SEQ ID NO: 34)

	aga gtc acc att acc agg gac aca tcc gcg agc aca gcc tac atg
	gag ctg agc agc ctg aga tct gaa gac acg gct gtg tat tac tgt
	gcg aga ga ! 1-03# 2 (SEQ ID NO: 35)

	aga gtc acc atg acc agg aac acc tcc ata agc aca gcc tac atg
	gag ctg agc agc ctg aga tct gag gac acg gcc gtg tat tac tgt
	gcg aga gg ! 1-08# 3 (SEQ ID NO: 36)

	aga gtc acc atg acc aca gac aca tcc acg agc aca gcc tac atg
	gag ctg agg agc ctg aga tct gac gac acg gcc gtg tat tac tgt
	gcg aga ga ! 1-18# 4 (SEQ ID NO: 37)

	aga gtc acc atg acc gag gac aca tct aca gac aca gcc tac atg
	gag ctg agc agc ctg aga tct gag gac acg gcc gtg tat tac tgt
	gca aca ga ! 1-24# 5 (SEQ ID NO: 38)

	aga gtc acc att acc agg gac agg tct atg agc aca gcc tac atg
	gag ctg agc agc ctg aga tct gag gac aca gcc atg tat tac tgt
	gca aga ta ! 1-45# 6 (SEQ ID NO: 39)

	aga gtc acc atg acc agg gac acg tcc acg agc aca gtc tac atg
	gag ctg agc agc ctg aga tct gag gac acg gcc gtg tat tac tgt
	gcg aga ga ! 1-46# 7 (SEQ ID NO: 40)

	aga gtc acc att acc agg gac atg tcc aca agc aca gcc tac atg
	gag ctg agc agc ctg aga tcc gag gac acg gcc gtg tat tac tgt
	gcg gca ga ! 1-58# 8 (SEQ ID NO: 41)

	aga gtc acg att acc gcg gac gaa tcc acg agc aca gcc tac atg
	gag ctg agc agc ctg aga tct gag gac acg gcc gtg tat tac tgt
	gcg aga ga ! 1-69# 9 (SEQ ID NO: 42)

	aga gtc acg att acc gcg gac aaa tcc acg agc aca gcc tac atg
	gag ctg agc agc ctg aga tct gag gac acg gcc gtg tat tac tgt
	gcg aga ga ! 1-e# 10 (SEQ ID NO: 43)

	aga gtc acc ata acc gcg gac acg tct aca gac aca gcc tac atg
	gag ctg agc agc ctg aga tct gag gac acg gcc gtg tat tac tgt
	gca aca ga ! 1-f# 11 (SEQ ID NO: 44)

!	VH2
	agg ctc acc atc acc aag gac acc tcc aaa aac cag gtg gtc ctt
	aca atg acc aac atg gac cct gtg gac aca gcc aca tat tac tgt
	gca cac aga c! 2-05# 12 (SEQ ID NO: 45)

	agg ctc acc atc tcc aag gac acc tcc aaa agc cag gtg gtc ctt
	acc atg acc aac atg gac cct gtg gac aca gcc aca tat tac tgt
	gca cgg ata c! 2-26# 13 (SEQ ID NO: 46)

	agg ctc acc atc tcc aag gac acc tcc aaa aac cag gtg gtc ctt
	aca atg acc aac atg gac cct gtg gac aca gcc acg tat tac tgt
	gca cgg ata c! 2-70# 14 (SEQ ID NO: 47)

!	VH3
	cga ttc acc atc tcc aga gac aac gcc aag aac tca ctg tat ctg
	caa atg aac agc ctg aga gcc gag gac acg gct gtg tat tac tgt
	gcg aga ga ! 3-07* 15 (SEQ ID NO: 48)

	cga ttc acc atc tcc aga gac aac gcc aag aac tcc ctg tat ctg
	caa atg aac agt ctg aga gct gag gac acg gcc ttg tat tac tgt
	gca aaa gat e! 3-09#16 (SEQ ID NO: 49)

	cga ttc acc atc tcc agg gac aac gcc aag aac tca ctg tat ctg
	caa atg aac agc ctg aga gcc gag gac acg gcc gtg tat tac tgt
	gcg aga ga ! 3-11# 17 (SEQ ID NO: 50)

	cga ttc acc atc tcc aga gaa aat gcc aag aac tcc ttg tat ctt
	caa atg aac agc ctg aga gcc ggg gac acg gct gtg tat tac tgt
	gca aga ga ! 3-13# 18 (SEQ ID NO: 51)

	aga ttc acc atc tca aga gat gat tca aaa aac acg ctg tat ctg
	caa atg aac agc ctg aaa acc gag gac aca gcc gtg tat tac tgt
	acc aca ga ! 3-15# 19 (SEQ ID NO: 52)

	cga ttc acc atc tcc aga gac aac gcc aag aac tcc ctg tat ctg
	caa atg aac agt ctg aga gcc gag gac acg gcc ttg tat cac tgt
	gcg aga ga ! 3-20# 20 (SEQ ID NO: 53)

	cga ttc acc atc tcc aga gac aac gcc aag aac tca ctg tat ctg
	caa atg acc agc ctg aga gcc gag gac acg gct gtg tat tac tgt
	gcg aga ga ! 3-21# 21 (SEQ ID NO: 54)

	cgg ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctg
	caa atg aac agc ctg aga gcc gag gac acg gcc gta tat tac tgt
	gcg aaa ga ! 3-23* 22 (SEQ ID NO: 55)

	cga ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctg
	caa atg aac agc ctg aga gct gag gac acg gct gtg tat tac tgt
	gcg aaa ga ! 3 30# 23 (SEQ ID NO: 56)

	cga ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctg
	caa atg aac agc ctg aga gct gag gac acg gct gtg tat tac tgt
	gcg aga ga ! 3303# 24 (SEQ ID NO: 57)

	cga ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctg
	caa atg aac agc ctg aga gct gag gac acg gct gtg tat tac tgt
	gcg aaa ga ! 3305# 25 (SEQ ID NO: 58)

	cga ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctg
	caa atg aac agc ctg aga gcc gag gac acg gct gtg tat tac tgt
	gcg aga ga ! 3-33# 26 (SEQ ID NO: 59)

	cga ttc acc atc tcc aga gac aac agc aaa aac tcc ctg tat ctg
	caa atg aac agt ctg aga act gag gac acc gcc ttg tat tac tgt
	gca aaa gat a! 3-43#27 (SEQ ID NO: 60)

	cga ttc acc atc tcc aga gac aat gcc aag aac tca ctg tat ctg
	caa atg aac agc ctg aga gac gag gac acg gct gtg tat tac tgt
	gcg aga ga ! 3-48# 28 (SEQ ID NO: 61)

	aga ttc acc atc tca aga gat ggt tcc aaa agc atc gcc tat ctg
	caa atg aac agc ctg aaa acc gag gac aca gcc gtg tat tac tgt
	act aga ga ! 3-49# 29 (SEQ ID NO: 62)

	cga ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctt
	caa atg aac agc ctg aga gcc gag gac acg gcc gtg tat tac tgt
	gcg aga ga ! 3-53# 30 (SEQ ID NO: 63)

	aga ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctt
	caa atg ggc agc ctg aga gct gag gac atg gct gtg tat tac tgt
	gcg aga ga ! 3-64# 31 (SEQ ID NO: 64)

	aga ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat ctt
	caa atg aac agc ctg aga gct gag gac acg gct gtg tat tac tgt
	gcg aga ga ! 3-66# 32 (SEQ ID NO: 65)

	aga ttc acc atc tca aga gat gat tca aag aac tca ctg tat ctg
	caa atg aac agc ctg aaa acc gag gac acg gcc gtg tat tac tgt
	gct aga ga ! 3-72# 33 (SEQ ID NO: 66)

	agg ttc acc atc tcc aga gat gat tca aag aac acg gcg tat ctg
	caa atg aac agc ctg aaa acc gag gac acg gcc gtg tat tac tgt
	act aga ca ! 3 73# 34 (SEQ ID NO: 67)

	cga ttc acc atc tcc aga gac aac gcc aag aac acg ctg tat ctg
	caa atg aac agt ctg aga gcc gag gac acg gct gtg tat tac tgt
	gca aga ga ! 3-74# 35 (SEQ ID NO: 68)

	aga ttc acc atc tcc aga gac aat tcc aag aac acg ctg cat ctt
	caa atg aac agc ctg aga gct gag gac acg gct gtg tat tac tgt
	aag aaa ga ! 3-d# 36 (SEQ ID NO: 69)

!	VH4
	cga gtc acc ata tca gta gac aag tcc aag aac cag ttc tcc ctg
	aag ctg agc tct gtg acc gcc gcg gac acg gcc gtg tat tac tgt
	gcg aga ga ! 4-04# 37 (SEQ ID NO: 70)

	cga gtc acc atg tca gta gac acg tcc aag aac cag ttc tcc ctg
	aag ctg agc tct gtg acc gcc gtg gac acg gcc gtg tat tac tgt
	gcg aga aa ! 4-28# 38 (SEQ ID NO: 71)

	cga gtt acc ata tca gta aac acg tct aag aac cag ttc tcc ctg
	aag ctg agc tct gtg act gcc gcg gac acg gcc gtg tat tac tgt
	gcg aga ga ! 4301# 39 (SEQ ID NO: 72)

	cga gtc acc ata tca gta gac agg tcc aag aac cag ttc tcc ctg
	aag ctg agc tct gtg acc gcc gcg gac acg gcc gtg tat tac tgt
	gcc aga ga ! 4302# 40 (SEQ ID NO: 73)

	cga gtt acc ata tca gta gac acg tcc aag aac cag ttc tcc ctg
	aag ctg agc tct gtg act gcc gca gac acg gcc gtg tat tac tgt
	gcc aga ga ! 4304# 41 (SEQ ID NO: 74)

	cga gtt acc ata tca gta gac acg tct aag aac cag ttc tcc ctg
	aag ctg agc tct gtg act gcc gcg gac acg gcc gtg tat tac tgt
	gcg aga ga ! 4-31# 42 (SEQ ID NO: 75)

	cga gtc acc ata tca gta gac acg tcc aag aac cag ttc tcc ctg
	aag ctg agc tct gtg acc gcc gcg gac acg gct gtg tat tac tgt
	gcg aga ga ! 4-34# 43 (SEQ ID NO: 76)

	cga gtc acc ata tcc gta gac acg tcc aag aac cag ttc tcc ctg
	aag ctg agc tct gtg acc gcc gca gac acg gct gtg tat tac tgt
	gcg aga ca ! 4-39# 44 (SEQ ID NO: 77)

	cga gtc acc ata tca gta gac acg tcc aag aac cag ttc tcc ctg
	aag ctg agc tct gtg acc gct gcg gac acg gcc gtg tat tac tgt
	gcg aga ga ! 4-59# 45 (SEQ ID NO: 78)

	cga gtc acc ata tca gta gac acg tcc aag aac cag ttc tcc ctg
	aag ctg agc tct gtg acc gct gcg gac acg gcc gtg tat tac tgt
	gcg aga ga ! 4-61# 46 (SEQ ID NO: 79)

	cga gtc acc ata tca gta gac acg tcc aag aac cag ttc tcc ctg
	aag ctg agc tct gtg acc gcc gca gac acg gcc gtg tat tac tgt
	gcg aga ga ! 4-b# 47 (SEQ ID NO: 80)

!	VH5
	cag gtc acc atc tca gcc gac aag tcc atc agc acc gcc tac ctg
	cag tgg agc agc ctg aag gcc tcg gac acc gcc atg tat tac tgt
	gcg aga ca ! 5-51# 48 (SEQ ID NO: 81)

	cac gtc acc atc tca gct gac aag tcc atc agc act gcc tac ctg
	cag tgg agc agc ctg aag gcc tcg gac acc gcc atg tat tac tgt
	gcg aga ! 5-a# 49 (SEQ ID NO: 82)

!	VH6
	cga ata acc atc aac cca gac aca tcc aag aac cag ttc tcc ctg
	cag ctg aac tct gtg act ccc gag gac acg gct gtg tat tac tgt
	gca aga ga ! 6-1# 50 (SEQ ID NO: 83)

!	VH7
	cgg ttt gtc ttc tcc ttg gac acc tct gtc agc acg gca tat ctg
	cag atc tgc agc cta aag gct gag gac act gcc gtg tat tac tgt
	gcg aga ga ! 74.1# 51 (SEQ ID NO: 84)

TABLE 2

Enzymes that either cut 15 or more human GLGs or
have 5+-base recognition in FR3

Typical entry:

REname Recognition #sites

GLGid#: base# GLGid#: base# GLGid#: base# . . .

BstEii Ggtnacc 2

1: 3

48: 3

There are 2 hits at base# 3

MaeIII gtnac 36

1: 4	2: 4	3: 4	4: 4	5: 4	6: 4
7: 4	8: 4	9: 4	10: 4	11: 4	37: 4
37: 58	38: 4	38: 58	39: 4	39: 58	40: 4
40: 58	41: 4	41: 58	42: 4	42: 53	43: 4
43: 58	44: 4	44: 58	45: 4	45: 58	46: 4
46: 58	47: 4	47: 58	48: 4	49: 4	50: 58

There are 24 hits at base# 4

Tsp45I atsac 33

1: 4	2: 4	3: 4	4: 4	5: 4	6: 4
7: 4	8: 4	9: 4	10: 4	11: 4	37: 4
37: 58	38: 4	38: 58	39: 58	40: 4	40: 58
41: 58	42: 58	43: 4	43: 58	44: 4	44: 58
45: 4	45: 58	46: 4	46: 58	47: 4	47: 58
48: 4	49: 4	50: 58

There are 21 hits at base# 4

HpftI tcacc 45

1: 5	2: 5	3: 5	4: 5	5: 5	6: 5
7: 5	8: 5	11: 5	12: 5	12: 11	13: 5
14: 5	15: 5	16: 5	17: 5	18: 5	19: 5
20: 5	21: 5	22: 5	23: 5	24: 5	25: 5
26: 5	27: 5	28: 5	29: 5	30: 5	31: 5
32: 5	33: 5	34: 5	35: 5	36: 5	37: 5
33: 5	40: 5	43: 5	44: 5	45: 5	46: 5
47: 5	48: 5	49: 5

There are 44 hits at base# 5

NlaIII CATG 26

1: 9	1: 42	2: 42	3: 9	3: 42	4: 9
4: 42	5: 9	5: 42	6: 42	6: 78	7: 9
7: 42	8: 21	8: 42	9: 42	10: 42	11: 42
12: 57	13: 48	13: 57	14: 57	31: 72	38: 9
48: 78	49: 78

There are 11 hits at base# 42

There are 1 hits at base# 48 Could cause

raggedness.

BsaJI Ccnngg 37

1: 14	2: 14	5: 14	6: 14	7: 14	8: 14
8: 65	9: 14	10: 14	11: 14	12: 14	13: 14
14: 14	15: 65	17: 14	17: 65	18: 65	19: 65
20: 65	21: 65	22: 65	26: 65	29: 65	30: 65
33: 65	34: 65	35: 65	37: 65	38: 65	39: 65
40: 65	42: 65	43: 65	48: 65	49: 65	50: 65
51: 14

There are 23 hits at base# 65

There are 14 hits at base# 14

AluI AGct 42

1: 47	2: 47	3: 47	4: 47	5: 47	6: 47
7: 47	8: 47	9: 47	10: 47	11: 47	16: 63
23: 63	24: 63	25: 63	31: 63	32: 63	36: 63
37: 47	37: 52	38: 47	38: 52	39: 47	39: 52
40: 47	40: 52	41: 47	41: 52	42: 47	42: 52
43: 47	43: 52	44: 47	44: 52	45: 47	45: 52
46: 47	46: 52	47: 47	47: 52	49: 15	50: 47

There are 23 hits at base# 47

There are 11 hits at base# 52 Only 5 bases from 47

BlpI GCtnagc 21

1: 48	2: 48	3: 48	5: 48	6: 48	7: 48
8: 48	9: 48	10: 48	11: 48	37: 48	38: 48
39: 48	40: 48	41: 48	42: 48	43: 48	44: 48
45: 48	46: 48	47: 48

There are 21 hits at base# 48

MwoI GCNNNNNnngc (SEQ ID NO: 85) 19

1: 48	2: 28	19: 36	22: 36	23: 36	24: 36
25: 36	26: 36	35: 36	37: 67	39: 67	40: 67
41: 67	42: 67	43: 67	44: 67	45: 67	46: 67
47: 67

There are 10 hits at base# 67

There are 7 hits at base# 36

DdeI Ctnag 7

1: 49	1: 58	2: 49	2: 58	3: 49	3: 58
3: 65	4: 49	4: 50	5: 49	5: 50	5: 65
6: 49	6: 58	6: 65	7: 49	7: 58	7: 65
8: 49	8: 58	9: 49	9: 58	9: 65	10: 49
10: 58	10: 65	11: 49	11: 58	11: 65	15: 58
16: 58	16: 65	17: 58	18: 58	20: 58	21: 58
22: 58	23: 58	23: 65	24: 58	24: 65	25: 58
25: 65	26: 58	27: 58	27: 65	28: 58	30: 58
31: 58	31: 65	32: 58	32: 65	35: 58	36: 58
36: 65	37: 49	38: 49	39: 26	39: 49	40: 49
41: 49	42: 26	42: 49	43: 49	44: 49	45: 49
46: 49	47: 49	48: 12	49: 12	51: 65

There are 29 hits at base# 58

There are 22 hits at base# 49 Only nine base from

58

There are 16 hits at base# 65 Only seven bases

from 58

BglII Agatct 11

1: 61	2: 61	3: 61	4: 61	5: 61	6: 61
7: 61	9: 61	10: 61	11: 61	51: 47

There are 10 hits at base# 61

BstYI Rgatcy 12

1: 61	2: 61	3: 61	4: 61	5: 61	6: 61
7: 61	8: 61	9: 61	10: 61	11: 61	51: 47

There are 11 hits at base# 61

Hpy188I TCNga 17

1: 64	2: 64	3: 64	4: 64	5: 64	6: 64
7: 64	8: 64	9: 64	10: 64	11: 64	16: 57
20: 57	27: 57	35: 57	43: 67	49: 67

There are 11 hits at base# 64

There are 4 hits at base# 57

There are 2 hits at base# 67 Could be ragged.

MslI CAYNNnnRTG (SEQ ID NO: 86) 44

1: 72	2: 72	3: 72	4: 72	5: 72	6: 72
7: 72	8: 72	9: 72	10: 72	11: 72	15: 72
17: 72	18: 72	19: 72	21: 72	23: 72	24: 72
25: 72	26: 72	28: 72	29: 72	30: 72	31: 72
32: 72	33: 72	34: 72	35: 72	36: 72	37: 72
38: 72	39: 72	40: 72	41: 72	42: 72	43: 72
44: 72	45: 72	46: 72	47: 72	48: 72	49: 72
50: 72	51: 72

There are 44 hits at base# 72

BsiEI CGRYcg 23

1: 74	3: 74	4: 74	5: 74	7: 74	8: 74
9: 74	10: 74	11: 74	17: 74	22: 74	30: 74
33: 74	34: 74	37: 74	38: 74	39: 74	40: 74
41: 74	42: 74	45: 74	46: 74	47: 74

There are 23 hits at base# 74

EaeI Yggccr 23

There are 23 hits at base# 74

EagI Cggccg 23

There are 23 hits at base# 74

HaeIII GGcc 97

1: 75	3: 75	4: 75	5: 75	7: 75	8: 75
9: 75	10: 75	11: 75	16: 75	17: 75	20: 75
22: 75	30: 75	33: 75	34: 75	37: 75	38: 75
39: 75	40: 75	41: 75	42: 75	45: 75	46: 75
47: 75	48: 63	49: 63

There are 25 hits at base# 75

Bst4CI ACNgt 65° C. 63 Sites There is a third

isoschismer

1: 86	2: 86	3: 86	4: 86	5: 86	6: 86
7: 34	7: 86	8: 86	9: 86	10: 86	11: 86
12: 86	13: 86	14: 86	15: 36	15: 86	16: 53
16: 86	17: 36	17: 86	18: 86	19: 86	20: 53
20: 86	21: 36	21: 86	22: 0	22: 86	23: 86
24: 86	25: 86	26: 86	27: 53	27: 86	28: 36
28: 86	29: 86	30: 86	31: 86	32: 86	33: 36
33: 86	34: 86	35: 53	35: 86	36: 86	37: 86
38: 86	39: 86	40: 86	41: 86	42: 86	43: 86
44: 86	45: 86	46: 86	47: 86	48: 86	49: 86
50: 86	51: 0	51: 86

There are 51 hits at base# 86 All the other sites

are well away

HpyCH4III ACNgt 63

There are 51 hits at base# 86

HinfI Gantc 43

2: 2	3: 2	4: 2	5: 2	6: 2	7: 2
8: 2	9: 2	9: 22	10: 2	11: 2	15: 2
16: 2	17: 2	18: 2	19: 2	19: 22	20: 2
21: 2	23: 2	24: 2	25: 2	26: 2	27: 2
28: 2	29: 2	30: 2	31: 2	32: 2	33: 2
33: 22	34: 22	35: 2	36: 2	37: 2	38: 2
40: 2	43: 2	44: 2	45: 2	46: 2	47: 2
50: 60

There are 38 hits at base# 2

MlyI GAGTCNNNNNn (SEQ ID NO: 87) 18

2: 2	3: 2	4: 2	5: 2	6: 2	7: 2
8: 2	9: 2	10: 2	11: 2	37: 2	38: 2
40: 2	43: 2	44: 2	45: 2	46: 2	47: 2

There are 18 hits at base# 2

PleI gagtc 18

There are 18 hits at base# 2

AciI Ccgc 24

2: 26	9: 14	10: 14	11: 14	27: 74	37: 62
37: 65	33: 62	39: 65	40: 62	40: 65	41: 65
42: 65	43: 62	43: 65	44: 62	44: 65	45: 62
46: 62	47: 62	47: 65	48: 35	43: 74	49: 74

There are 8 hits at base# 62

There are 8 hits at base# 65

There are 3 hits at basa# 14

There are 3 hits at basa# 74

There are 1 hits at basa# 26

There are 1 hits at base# 35

-″- Gcgg 11

8: 91	9: 16	10: 16	11: 16	37: 67	39: 67
40: 67	42: 67	43: 67	45: 67	46: 67

There are 7 hits at base# 67

There are 3 hits at base# 16

There are 1 hits at base# 91

BsiHKAI GWGCWc 20

2: 30	4: 30	6: 30	7: 30	9: 30	10: 30
12: 89	13: 89	14: 89	37: 51	38: 51	39: 51
40: 51	41: 51	42: 51	43: 51	44: 51	45: 51
46: 51	47: 51

There are 11 hits at base# 51

Bsp1206I GDGCHc 20

There are 11 hits at base# 51

HgiAi GWGCWc 20

There are 11 hits at base# 51

BsoFI Gangc 26

2: 53	3: 53	5: 53	6: 53	7: 53	8: 53
8: 91	9: 53	10: 53	11: 53	31: 53	36: 36
37: 64	39: 64	40: 64	41: 64	42: 64	43: 64
44: 64	45: 64	46: 64	47: 64	48: 53	49: 53
50: 45	51: 53

There are 13 hits at base# 53

There are 10 hits at base# 64

TseI Gcwgc 17

2: 53	3: 53	5: 53	6: 53	7: 53	8: 53
9: 53	10: 53	11: 53	31: 53	36: 36	45: 64
46: 64	48: 53	49: 53	50: 45	51: 53

There are 13 hits at base# 53

MnlI gagg 34

3: 67	3: 95	4: 51	5: 16	5: 67	6: 67
7: 67	8: 67	9: 67	10: 67	11: 67	15: 67
16: 67	17: 67	19: 67	20: 67	21: 67	22: 67
23: 67	24: 67	25: 67	26: 67	27: 67	28: 67
29: 67	30: 67	31: 67	32: 67	33: 67	34: 67
35: 67	36: 67	50: 67	51: 67

There are 31 hits at base# 67

HpyCH4V TGca 34

5: 90	6: 90	11: 90	12: 90	13: 90	14: 90
15: 44	16: 44	16: 90	17: 44	18: 90	19: 44
20: 44	21: 44	22: 44	23: 44	24: 44	25: 44
26: 44	27: 44	27: 90	28: 44	29: 44	33: 44
34: 44	35: 44	35: 90	36: 38	48: 44	49: 44
50: 44	50: 90	51: 44	51: 52

There are 21 hits at base# 44

There are 1 hits at base# 52

AccI GTmkac 13 5-base recognition

7: 37	11: 24	37: 16	38: 16	39: 16	40: 16
41: 16	42: 16	43: 16	44: 16	45: 16	46: 16
47: 16

There are 11 hits at base# 15

SacII CCGCgg 8 6-base recognition

9: 14	10: 14	11: 14	37: 65	39: 65	40: 65
42: 65	43: 65

There are 5 hits at base# 65

There are 3 hits at base# 14

TfiI Gawtc 24

9: 22	15: 2	16: 2	17: 2	18: 2	19: 2
19: 22	20: 2	21: 2	23: 2	24: 2	25: 2
26: 2	27: 2	28: 2	29: 2	30: 2	31: 2
32: 2	33: 2	33: 22	34: 22	35: 2	35: 2

There are 20 hits at base# 2

BsmAI Nnnnnngagac (SEQ ID NO: 88) 19

15: 11	16: 11	20: 11	21: 11	22: 11	23: 11
24: 11	25: 11	26: 11	27: 11	28: 11	28: 56
30: 11	31: 11	32: 11	35: 11	36: 11	44: 87
48: 87

There are 16 hits at base# 11

BpmI ctccag 19

15: 12	16: 12	17: 12	18: 12	20: 12	21: 12
22: 12	23: 12	24: 12	25: 12	26: 12	27: 12
28: 12	30: 12	31: 12	32: 12	34: 12	35: 12
36: 12

There are 19 hits at base# 12

XmnI GAANNnnttc (SEQ ID NO: 89) 12

37: 30	39: 30	39: 30	40: 30	41: 30	42: 30
43: 30	44: 30	45: 30	46: 30	47: 30	50: 30

There are 12 hits at base# 30

BsrI NCcagt 12

37: 32	33: 32	39: 32	40: 32	41: 32	42: 32
43: 32	44: 32	45: 32	46: 32	47: 32	50: 32

There are 12 hits at base# 32

BanII GRGCYc 11

37: 51	38: 51	39: 51	40: 51	41: 51	42: 51
43: 51	44: 51	45: 51	46: 51	47: 51

There are 11 hits at base# 51

Ecl136I GAGctc 11

37: 51	38: 51	39: 51	40: 51	41: 51	42: 51
43: 51	44: 51	45: 51	46: 51	47: 51

There are 11 hits at base# 51

SacI GAGCTc 11

37: 51	38: 51	39: 51	40: 51	41: 51	42: 51
43: 51	44: 51	45: 51	46: 51	47: 51

There are 11 hits at base# 51

TABLE 3

Synthetic 3-23 FR3 of human heavy chains showning
positions of possible cleavage sites

! Sites engineered into the synthetic gene are shown in upper case

DNA

! with the RE name between vertical bars (as in | XbaI |).

! RERSs frequently found in GLGs are shown below the synthetic

sequence

! with the name to the right (as in gtn ac = MaeIII(24), indicating

that

! 24 of the 51 GLGs contain the site).

!

! |---FR3---

! 89 90 (codon #

in

! R F

synthetic 3-23

|cgc|ttc| 6

! Allowed DNA |cgn|tty|

! |agr|

! ga ntc =

HinfI(38)

! ga gtc =

PieI(18)

! ga wtc =

TfiI(20)

! gtn ac =

MaeIII(24)

! gts ac =

Tsp45I(21)

! tc acc =

HphI(44)

!

! --------FR3--------------------------------------------------

! 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105

! T I S R D N S K N T L Y L Q M

(SEQ ID NO: 91)

|act|atc|TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg| 51

!allowed|acn|ath|tcn|cgn|gay|aay|tcn|aar|aay|acn|ttr|tay|ttr|car|atg|

(SEQ ID NO: 90)

! |agy|agr| |agy| |ctn| |ctn|

! | ga|gac = BsmAI(16) ag ct =

AluI(23)

! c|tcc ag = BpmI(19) g ctn agc =

BlpI(21)

! | | g aan nnn ttc = XmnI(12)

! | XbaI | tg ca = HpyCH4v(21)

!

! ---FR3----------------------------------------------------->|

! 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120

! N S L R A E D T A V Y Y C A K

|aac|agC|TTA|AGg|gct|gag|gac|aCT|GCA|Gtc|tac|tat|tgc|gct|aaa| 96

!allowed|aay|tcn|ttr|cgn|gcn|gar|gay|acn|gcn|gtn|tay|tay|tgy|gcn|aar|

! |agy|ctn|agr| | |

! | | cc nnq q = BsaJI(23) ac ngt = Bst4CI(51)

! | aga tct = BglII(10) | ac ngt = HpyCH4III(51)

! | Rga tcY = BstYI(11) | ac ngt = TaaI(51)

! | | c ayn nnn rtc = MslI(44)

! | | cg ryc g = BsiEI(23)

! | | yg gcc r = EaeI(23)

! | | cg gcc g = EagI(23)

! | | |g gcc = HaeIII(25)

! | | gag g = MnlI(31)|

! |AflII | | PstI |

TABLE 4

REdaptors, Extenders, and Bridges used for Cleavage and
Capture of Human Heavy Chains in FR3

A: HpyCH4V Probes of actual human BC genes (SEQ ID NOs: 92-100,
respectively, in order of appearance)

!HpyCH4V in FR3 of human HC, bases 35-56; only those with TGca site
TGca; 10,
RE recognition: tgca of length 4 is expected at
10

1	6-1	agttctccctgcagctgaactc

2	3-11, 3-07, 3-21, 3-72, 3-48	cactgtatctgcaaatgaacag

3	3-09, 3-43, 3-20	ccctgtatctgcaaatgaacag

4	5-51	ccgcctacctgcagtggagcag

5	3-15, 3-30, 3-30.5, 3-30.3, 3-74, 3-23, 3-33	cgctgtatctgcaaatgaacag

6	7-4.1	cggcatatctgcagatctgcag

7	3-73	cggcgtatctgcaaatgaacag

8	5-a	ctgcctacctgcagtggagcag

9	3-49	tcgoctatctqcaaatgaacag

B: HpyCH4V REdaptors, Extenders, and Bridges

B.1 REdaptors

! Cutting HC lower strand:

! TmKeller for 100 mM NaCl, zero formamide

! Edapters for cleavage

				SEQ
		T_m ^W	T_m ^K	ID NO:

(ON_HCFR36-1)	5′-agttctcccTGCAgctgaactc-3′	68.0	64.5	92
(ON_HCFR36-1A	5′-ttctcccTGCAgctgaactc-3	62.0	62.5	residues
				3-22 of 92

(ON_HCFR36-1B)	5′-ttctcccTGCAgctgaac-3′	56.0	59.9	residues
				3-20 of 92

(ON_HCFR33-15)	5′-cgctgtatcTGCAaatgaacag-3′	64.0	60.8	96
(ON_HCFR33-15A)	5′-ctgtatcTGCAaatgaacaa-3′	56.0	56.3	residues
				3-22 of 96

(ON_HCFR33-15B)	5′-ctgtatcTGCAaatgaac-3′	50.0	53.1	residues
				3-20 of 96

(ON_HCFR33-11)	5′-cactgtatcTGCAaatgaacag-3′	62.0	58.9	93
(ON_HCFR35-51)	5′-ccgcctaccTGCAgtggagcag-3′	74.0	70.1	95
!

B.2 Segment of synthetic 3-23 gene into which captured CDR3 is to

be cloned

! XbaI... (SEQ ID NO: 101)

!D323* cgCttcacTaag tcT aga gac aaC tcT aag aaT acT ctC taC

! scab... designed gene 3-23 gene...

!

! HpyCH4V

! .. .. AflII...

! Ttg caG atg aac agc TtA agG . . .

! ........................... . . .

!

B.3 Extender and Bridges

! Extender (bottom strand):

! (SEQ ID NO: 102)

(ON_HCHpyEx01) 5′-cAAgTAgAgAgTATTcTTAgAgTTgTcTcTAgAcTTAgTgAgcg-3′

! ON_HCApyEx01 is the reverse complement of

! 5′-cgCttcacTaag tcT aga gac aaC tcT aag aaT acT ctC tat Ttg -3′

!

! Bridges (top strand, 9-base cverlao):

!(SEQ ID NO: 103)

(ON_HCHpyBr016-1) 5′-cgCttcacTaag tcT aga gac aaC tcT aag-

aaT acT ctC taC Ttg CAgctgaac-3′ (3′-term C is

blocked)

!

! 3-15 at al. + 3-11 (SEQ ID NO: 104)

(ON HCHpyBr023-15) 5′-cgCttcacTaag tcT aga gac aaC tcT aag-

aaT acT ctC taC Ttg CAaatgaac-3′ (3′-term C is

blocked)

!

! 5-51 (SEQ ID NO: 105)

(ON_HCHpyBr045-51) 5′-cgCttcacTaag tcT aga gac aaC tcT aag-

aaT acT ctC taC Ttg CAgtggagc-3′ (3′-term C is

blocked)

!

! PCR primer (top strand)

!

(ON_HCHpyPCR) 5′-cgCttcacTaag tcT aga gac-3′ (SEQ ID NO: 106)

!

C: BlpI Probes from human HC GLGs

1 1-58, 1-03, 1-08, 1-69, 1-24, 1-45, 1-46, 1-f, 1-e

acatggaGCTGAGCagcctgag (SEQ ID NO: 107)

2 1-02

acatggaGCTGAGCaggctgag (SEQ ID NO: 108)

3 1-18

acatggagctgaggagcctgag (SEQ ID NO: 109)

4 5-51, 5-a

acctgcagtggagcagcctgaa (SEQ ID NO: 110)

5 3-15,3-73,3-49,3-72

atctgcaaatgaacagcctgaa (SEQ ID NO: 111)

6 3303, 3-33, 3-01,3-11,3-30,3-21,3-23,3305,3-48

atctgcaaatgaacagcctgag (SEQ ID NO: 112)

7 3-20,3-74,3-09,3-43

atctgcaaatgaacagtctgag (SEQ ID NO: 113)

8 74.1

atctgcagatctgcagcctaaa (SEQ ID NO: 114)

9 3-66,3-13,3-53,3-0

atcttcaaatgaacagcctgag (SEQ ID NO: 115)

10 3-64

atcttcaaatgggcagcctgag (SEQ ID NO: 116)

11 4301,4-28,4302,4-04,4304,4-31,4-34,4-39,4-59,4-61,4-h

ccctgaaGCTGAGCtctgtgac (SEQ ID NO: 117)

12 6-1

ccctgcagctgaactctgtgac (SEQ ID NO: 118)

13 2-70,2-05

tccttacaatgaccaacatgga (SEQ ID NO: 119)

14 2-26

tccttaccatgaccaacatgga (SEQ ID NO: 120)

D: BlpI REdaptors, Extenders, and Bridges

D.1 REdaptors

		T_m ^W	T_m ^K

(BlpF3HC1-58)	5′-ac atg gaG CTG AGC agc ctg ag-3′	70	66.4
	(SEQ ID NO: 12)

(BlpF3HC6-1)	5′-cc ctg aag ctg agc tct gtg ac-3′	70	66.4
	(SEQ ID NO: 122)

! BlpF3HC6-1 matches 4-30.1, not 6-1.

D.2 Segment of synthetic 3-23 gene into which captured CDR3 is to

be cloned

!

BlpI

! XbaI...

... ...

!D323* cgCttcacTaag TCT AGA gac aaC tcT aag aaT acT ctC taC Ttg

caG atg aac (SEQ ID NO: 123)

!

! AflII...

! agC TTA AGG

D.3 Extender and Bridges

! Bridges

(BlpF3Br1) 5′-cgCttcacTcag tcT aga gaT aaC AGT aaA aaT acT TtG-

taC Ttg caG Ctg a|GC agc ctg-3′ (SEQ ID NO: 124)

(BlpF3Br2) 5′-cgCttcacTcag tcT aga gaT aaC AGT aaA aaT acT TtG-

taC Ttg caG Ctg a|gc tct gtg-3′ (SEQ ID NO: 125)

! | lower strand is cut here

! Extender

(BlpF3Ext) 5′-TcAgcTgcAAgTAcAAAgTATTTTTAcTgTTATcTcTAgAcTgAgTgAAgog-

3′ (SEQ ID NO: 126)

! BlpF3Ext is the reverse complement of:

! 5′-cgCttcacTcag tcT aga gaT aaC AGT aaA aaT acT TtG taC Ttg caG

Ctg a-3′ (SEQ ID NO: 127)

!

(BlpF3PCR) 5′-cgCttcacTcag tcT aga gaT aaC-3′

E: HpyCH4III Distinct GLG sequences surrounding site, bases

77-98

1

102#1, 118#4, 146#7, 169#9, 1e#10, 311#17, 353#30,404#37, 4301

ccgtgtattactgtgcgagaga (SEQ ID NO: 128)

2

103#2, 307#15, 321#21, 3303#24, 333#26, 348#28, 364#31, 366#32

ctgtgtattactgtgcgagaga (SEQ ID NO: 129)

3

108#3 ccgtgtattactgtgcgagagg (SEQ ID NO: 130)

4

124#5, 1f#11 ccgtatattactgtgcaacaga (SEQ ID NO: 131)

5

145#6 ccatgtattactgtgcaagata (SEQ ID NO: 132)

6

158#8 ccgtgtattactgtgcggcaga (SEQ ID NO: 133)

7

205#12 ccacatattactgtgcacacag (SEQ ID NO: 134)

8

226#13 ccacatattactgtgcacggat (SEQ ID NO: 135)

9

270#14 ccacgtattactgtgcacagat (SEQ ID NO: 136)

10

309#16, 343#27 ccttgtattactgtgcaaaaga (SEQ ID NO: 137)

11

313#18, 374#35, 61#50 ctgtgtattactgtgcaagaga (SEQ ID NO: 138)

12

315#19 ccgtgtattactgtaccacaga (SEQ ID NO: 139)

13

320#20 ccttgtatcactgtgcgagaga (SEQ ID NO: 140)

14

323#22 ccgtatattactgtgcgaaaga (SEQ ID NO: 141)

15

330#23, 3305#25 ctgtgtattactgtgcgaaaga (SEQ ID NO: 142)

16

349#29 ccgtgtattactgtactagaga (SEQ ID NO: 143)

17

372#33 ccgtgtattactgtgctagaga (SEQ ID NO: 144)

18

373#34 ccgtgtattactgtactagaca (SEQ ID NO: 145)

19

3d#36 ctctgtattactgtaagaaaga (SEQ ID NO: 146)

20

428#38 ccatgtattactgtgcgagaaa (SEQ ID NO: 147)

21

4302#40, 4304#41 ccgtgtattactgtgccagaga (SEQ ID NO: 148)

22

439#44 ctgtgtattactgtgcgagaca (SEQ ID NO: 149)

23

551#48 ccatgtattactgtgcgagaca (SEQ ID NO: 150)

24

5a#49 ccatgtattcctgtgcgaga (SEQ ID NO: 151)

F: hpyCH4III REdaptors, Extenders, and Bridges

F.1 REdaptors

(SEQ ID NOs: 152 159, respectively, in order of appearance)

! ONS for cleavaGe of HC(lower) in FR3(bases 77-97)

! For cleavage with HpyCH4III, Bst4CI, or TaaI

! cleavage id in lower chain before base 88.

!	77 788 888 888 889 999 999 9
T_m ^K	78 901 234 567 890 123 456 7	T_m ^W

(H43.77.97.1-02#1)	5′-cc gtg tat tAC TGT gcg aga g-3′	6462.6

(H43.77.97.1-03#2)	5′-ct gtg tat tAC TGT gcg aga g-3′	6260.6

(H43.77.97.108#3)	5′-cc gtg tat tAC TGT gcg aga g-3′	6462.6

(H43.77.97.323#22)	5′-cc gta tat tac tgt gcg aaa g-3′	6058.7

(H4377.97.330#23)	5′-ct gtg tat tac tgt grg aaa g-3′	6058.7

(H43.77.97.439#44)	5′-ct gtg tat tac tgt gcg aga c-3′	6260.6

(H43.77.97.551#48)	5′-cc atg tat tac tgt gcg aga c-3′	6760.6

(H43.77.97.5a#49)	5′-cc atg tat tAC TGT gcg aga -3′	5858.3

F.2 Extender and Bridges

! XbaI and AflII sites in bridges are bunged

(H43.XABr1) 5′-ggtgtagtga-

|TCT|AGt|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|-

|aac|

aCT|GCA|Gtc|tac|tat tgt gcg aga-3′

(SEQ ID NO: 160)

(H43.XABr2) 5′-ggtgtagtga-

|TCT|AGt|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|-

|aac|

aCT|GCA|Gtc|tac|tat tgt gcg aaa-3′

(SEQ ID NO: 161)

(H43.XAExt) 5′-ATAgTAgAcT gcAgTgTccT cAgcccTTAA gcTgTTcATc

TgcAAgTAgA-

gAgTATTcTT AgAgTTgTcT cTAgATcAcT AcAcc-3′(SEQ ID NO: 162)

!H43.XAExt is the reverse complement of

! 5′-ggtgtagtga-

! |TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|-

! |aac|

aCT|GCA|Gtc|tac|tat -3′ (SEQ ID NO:

638)

(H43.XAPCR) 5′-ggtgtagtga |TCT|AGA|gac|aac-3′ (SEQ ID NO: 163)

! XbaI and AflII sites in bridges are bunged

(H43.ABr1) 5′-ggtgtagtga-

|aac|

aCT|GCA|Gtc|tac|tat tgt gcg aga-3′

(SEQ ID NO: 164)

(H43.ABr2) 5′-ggtgtagtga-

|aac|

aCT|GCA|Gtc|tac|tat tgt gct aaa-3′

(SEQ ID NO: 165)

(H43.AExt) 5′-ATAgTAgAcTgcAgTgTgTccTcAgcccTTAAgcTgTTTcAcTAcAcc-3′

(SEQ ID NO: 166)

!(H43.AExt) is the reverse complement of 5′-ggtgtagtga-

! |aac|

aCT|GCA|Gtc|tac|tat -3′(SEQ ID NO:

167)

(H43.APCR) 5′-ggtgtagtga |aac|

(SEQ ID NO: 168)

TABLE 5

Analysis of frequency of matching REdaptors in actual V genes

A: HpyCH4V in HC at bases 35-56

Number of mismatches . . .

Number

Id	Ntot	0	1	2	3	4	5	6	7	8	9	10	Cut	Id	Probe

1	510	5	11	274	92	61	25	22	11	1	3	5	443	6-1	agttctcccTGCAgctgaactc

2	192	54	42	32	24	15	2	3	10	3	1	6	167	3-11	cactgtatcTGCAaatgaacag

3	58	19	7	17	6	5	1	0	1	0	2	0	54	3-09	ccctgtatcTGCAaatgaacag

4	267	42	33	9	8	8	82	43	22	8	11	1	100	5-51	ccgcctaccTGCAgtggagcag

5	250	111	59	41	24	7	5	1	0	0	2	0	242	3-15	cgctgtatcTGCAaatgaacag

6	7	0	2	0	1	0	0	0	0	0	4	0	3	7-4.1	cggcatatcTGCAgatctgcsg

7	7	0	2	2	0	0	2	1	0	0	0	0	4	3-73	cggcgtatcTGCAastgaacag

8	26	10	4	1	3	1	2	1	3	1	0	0	19	5-a	ctgcctaccTGCAgtggagcag

9	21	8	2	3	1	6	1	0	0	0	0	0	20	3-49	tcgcctatcTGCAaatgaacsg
	1338	249	162	379	149	103	120	71	47	13	23	12	1052		(SEQ ID NO: 169-177,
		249	411	790	939	1042	1162	1233	1280	1293	1316	1338			respectively, in order of
															appearance)

Id	Probe	dotted probe

6-1	agttctcccTGCAgctgaactc	agttctcccTGCAgctgaactc

3-11	cactgtatcTGCAaatgaacag	cac.g.at.....aa.....ag

3-09	ccctgtatcTGCAaatgaacag	ccc.g.at.....aa.....ag

5-51	ccgcctaccTGCAgtggagcag	ccgc..a.......tg..g.ag

3-15	cgctgtatcTGCAaatgaacag	c.c.g.at.....aa.....ag

7-4.1	cggcatatcTGCAgatctgcag	c.gca.at......a.ctg.ag

3-73	cggcgtatcTGCAaatgaacag	c.gcg.at.....aa.....ag

5-a	ctgcctaccTGCAgtggagcag	ctgc..a.......tg..g.ag

3-49	tcgcctatcTGCAaatgaacag	tcgc..at.....aa.....ag

(SEQ ID NO: 169-177, respectively, in order of appearance)

Seqs with the expected RE site only . . . 1004

(Counts only cases with 4 or fewer mismatches)

Seqs with only an unexpected site . . . 0

Seqs with both expected and unexpected . . . 48

(Counts only cases with 4 or fewer mismatches)

Seqs with no sites . . . 0

B: BlpI in HC

Id	Ntot	0	1	2	3	4	5	6	7	8	Ncut	Name

1	133	73	16	11	13	6	9	1	4	0	119	1-58	acatggaGCTGAGCagcctgag

2	14	11	1	0	0	0	0	1	0	1	12	1-02	acatggagctgagcaggctgag

3	34	17	8	2	6	1	0	0	0	0	0	1-18	acatggagctgaggagcctgag

4	120	50	32	16	10	9	1	1	1	0	2	5-51	acctgcagtggagcagcctgaa

5	55	13	11	10	17	3	1	0	0	0	0	3-15	atctgcaaatgaacagcctgaa

6	340	186	88	41	15	6	3	0	1	0	0	3303	atctgcaaatgaacagcctgag

7	82	25	16	25	12	1	3	0	0	0	0	3-20	atctgcaaatgaacagtctgag

8	3	0	2	0	1	0	0	0	0	0	0	74.1	atctgcagatctgcagcctaaa

9	23	18	2	2	1	0	0	0	0	0	0	3-66	atcttcaaatgaacagcctgag

10	2	1	0	1	0	0	0	0	0	0	0	3-64	atcttcaaatgggcagcctgag

11	486	249	78	81	38	21	10	4	4	1	467	4301	ccctgaagctgagctctgtgac

12	16	6	3	1	0	1	1	3	1	0	1	6-1	ccctgcagctgaactctgtgac

13	28	15	6	2	2	1	0	0	0	0	0	2-70	tccttacaatgaccaacatgga

14	2	0	2	0	0	0	0	0	0	0	0	2-26	tccttaccatgaccaacatgga
											601		(SEQ ID NO: 178-191,
													respectively in order of appearance)

Name	Full sequence	Dot mode

1-58	acatggaGCTGAGCagcctgag	acatggaGCTGAGCagcctgag

1-02	acatggagctgagcaagctgag	................g.....

1-18	acatggagctgaggagcctgag	.............g........

5-51	acctgcagtggagcagcctgaa	..c..c..tg...........a

3-15	atctgcaaatgaacagcctgaa	.tc..c.aa...a........a

3-30.3	atctgcaaatgaacagcctgag	.tc..c.aa...a.........

3-20	atctgcaaatgaacagtctgag	.tc..c.aa...a...t.....

7-4.1	atctgcagatctgcagcctaaa	.tc..c..a.ct.......a.a

3-66	atcttcaaatgaacagcctgag	.tc.tc.aa...a.........

3-64	atcttcaaatgggcagcctgag	.tc.tc.aa..g..........

4-30.1	ccctgaagctgagctctgtgac	c.c..a........tctg...c

6-1	ccctgcagctgaactctgtgac	c.c..c......a.tctg...c

2-70	tccttacaatgaccaacatgga	t.c.tacaa...c..a.a..ga

2-26	tccttaccatgaccaacatgga	t.c.tacca...c..a.a..ga

(SEQ ID NO: 178-191, respectively, in order of appearance)

Seqs with the expected RE site only . . . 597 (counting sequences with 4 or fewer mismatches)

Seqs with only an unexpected site . . . 2

Seqs with both expected and unexpected . . . 2

Seqs with no sites . . . 686

C: HpyCH4III, Bst4CI, or TaaI in HC

In scoring whether the RE site of interest is present, only ONs that have 4 or fewer mismatches are counted.

Number of sequences . . . 1617

Id	Ntot	0	1	2	3	4	5	6	7	8	Ncut		acngt	acngt

1	244	78	92	43	18	10	1	2	0	0	241	102#1,1	ccgtgtattACTGTgcgagaga	ccgtgtattactgtgcgagaga

2	457	69	150	115	66	34	11	8	3	1	434	103#2,3	ctgtgtattactgtgcgagaga	.t....................

3	173	52	45	36	22	14	3	0	0	1	169	108#3	ccgtgtattactgtgcgagagg	.....................g

4	16	0	3	2	2	1	6	0	1	1	8	124#5,1	ccgtgtattactgtgcaacaga	................a.c...

5	4	0	0	1	0	1	1	0	1	0	2	145#6	ccatgtattactgtgcaagata	..a.............a...t.

6	15	1	0	1	0	6	4	1	1	1	3	15840	ccgtgtattactgtgcggcaga	.................gc...

7	23	4	8	5	2	2	1	1	0	0	21	205#12	ccacatattactgtgcacacag	..aca...........acacag

8	9	1	1	1	0	3	2	1	0	0	6	226#13	ccacatattactgtgcacggat	..aca...........ac.gat

9	7	1	3	1	1	0	0	1	0	0	6	270#14	ccacgtattactgtgaacggat	..ac............ac.gat

10	23	7	3	5	5	2	1	0	0	0	22	309#16,	ccttgtattactgtgcaaaaga	..t.............a.a...

11	35	5	10	7	6	3	3	0	2	0	31	313#18,	ctgtgtattactgtgcaagaga	.t..............a.....

12	18	2	3	2	2	6	1	0	2	0	15	315#19	ccgtgtattactgtaccacaga	..............a.c.c...

13	3	1	2	0	0	0	0	0	0	0	3	320#20	ccttgtatcactgtgcgagaga	..t.....c.............

14	117	29	23	28	22	8	4	2	1	0	110	323#22	ccgtatattactgtgcgaaaga	....a.............a...

15	75	21	25	13	9	1	4	2	0	0	69	330#23,	ctgtgtattactgtgcgaaaga	.t................a...

16	14	2	2	2	3	0	3	1	1	0	9	349#29	ccgtgtattactgtactagaga	..............a.t.....

17	2	0	0	1	0	0	1	0	0	0	1	372#33	ccgtgtattactgtgctagaga	................t.....

18	1	0	0	1	0	0	0	0	0	0	1	373#34	ccgtgtattactgtactagaca	..............a.t...c.

19	2	0	0	0	0	0	0	0	0	2	0	3d#36	ctgtgtattactgtaagaaaga	.t............aa..a...

20	34	4	9	9	4	5	3	0	0	0	31	428#38	ccgtgtattactgtgcgagaaa	....................a.

21	17	5	4	2	2	3	1	0	0	0	16	4302#40	ccgtgtattactgtgccagaga	................c.....

22	75	15	17	24	7	10	1	1	0	0	73	439#44	ctgtgtattactgtgcgagaca	.t..................c.

23	40	14	15	4	5	1	0	1	0	0	39	551#48	ccatgtattactgtgcgagaca	..a.................c.

24	213	26	56	60	42	20	7	2	0	0	204	5a#49

ccatgtattactgtgcgagaAA ..a.................AA

Group	337	471	363	218	130	58	23	11	6	(SEQ ID NO: 192-215,
Cumulative	337	808	1171	1389	1519	1577	1600	1611	1617	respectively, in order of appearance

Seqs with the expected RE site only 1511

Seqs with only an unexpected site 0

Seqs with both expected and unexpected 8

Seqs with no sites 0

TABLE 5D

Analysis repeated using only 8 best REdaptors

Id Ntot 0 1 2 3 4 5 6 7 8+

1 301 78 101 54 32 16 9 10 1 0 281 102#1

ccgtgtattactgtggagaga (SEQ ID NO: 267)

2 493 69 155 125 73 37 14 11 3 6 459 103#2

ctgtgtattactgtgcgagaga (SEQ ID NO: 263)

3 189 52 45 38 23 13 5 4 1 3 176 108#3

ccgtgtattactgtgcgagagg (SEQ ID NO: 269)

4 127 29 23 28 24 10 6 5 2 0 114 323#22

ccgtatattactgtgcgaaaga (SEQ ID NO: 270)

5 78 21 25 14 11 1 4 2 0 0 72 330#23

ctgtgtattactgtgcgaaaga (SEQ ID NO: 639)

6 79 15 17 25 8 11 1 2 0 0 76 439#44

ctgtgtattactgtgcgaaaca (SEQ ID NO: 272)

7 43 14 15 5 5 3 0 1 0 0 42 551#48

ccatgtattactgtgcgagaca (SEQ ID NO: 273)

8 307 26 63 72 51 38 24 14 13 6 250 5a#49

ccatgtattactgtgcgaaa (residues 1-20 of SEQ ID No: 274)

1	102#1	ccgtgtattactgtgcgagaga	ccgtgtattactgtgcgagaga

2	103#2	ctgtgtattactgtqcgagaga	.t....................

3	108#3	ccgtgtattactgtgcgagagg	.....................g

4	323#22	ccgtatattactgtgcgaaaga	...a..............a...

5	330#23	ctgtgtattactgtgcgaaaga	.t................a...

6	439#44	ctgtgtattactgtqcqagaca	.t..................c.

	551#48	ccatgtattactgtgcgagaca	..a.................c.

8	5a#49	ccatatattactgtgcgagaAA	..a.................AA

(SEQ ID NOs: 267-274, respectively, in order of appearance)

Seqs with the expected RE site only . . .	1463 / 1617
Seqs with only an unexpected site . . .	0
Seqs with both expected and unexpected . . .	7
Seqs with no sites . . .	0

TABLE 6

Human HC GLG FR1 Sequences
VH Exon - Nucleotide sequence alignment

VH1

1-02	CAG GTG CAG CTG GTG CAG TCT GGG GCT GAG GTG AAG AAG CCT GGG GCC TCA GTG AAG GTC
	TCC TGC AAG GCT TCT GGA TAC ACC TTC ACC (SEQ ID NO: 215)

1-03	cag gtC cag ctT gtg cag tct ggg gct gag gtg aag aag cct ggg gcc tca gtg aag gtT
	tcc tgc aag gct tct gga tac acc ttc acT (SEQ ID NO: 217)

1-08	cag gtg cag ctg gtg cag tct ggg gct gag gtg aag aag cct ggg gcc tca gtg aag gtc
	tcc tgc aag gct tct gga tac acc ttc acc (SEQ ID NO: 218)

1-18	cag gtT cag ctg gtg cag tct ggA gct gag gtg aag aag cct ggg gcc tca gtg aag gtc
	tcc tgc aag gct tct ggT tac acc ttT acc (SEQ ID NO: 219)

1-24	cag gtC cag ctg gtA cag tct ggg gct gag gtg aag aag cct ggg gcc tca gtg aag gtc
	tcc tgc aag gTt tcC gga tac acc Ctc acT (SEQ ID NO: 220)

1-45	cag Atg cag ctg gtg cag tct ggg gct gag gtg aag aag Act ggg Tcc tca gtg aag gtT
	tcc tgc aag gct tcC gga tac acc ttc acc (SEQ ID NO: 221)

1-46	cag gtg cag ctg gtg cag tct ggg gct gag gtg aag aag cct ggg gcc tca gtg aag gtT
	tcc tgc aag gcA tct gga tac acc ttc acc (SEQ ID NO: 222)

1-58	caA Atg cag ctg gtg cag tct ggg Cct gag gtg aag aag cct ggg Acc tca gtg aag gtc
	tcc tgc aag gct tct gga tTc acc ttT acT (SEQ ID NO: 223)

1-69	cag gtg cag ctg gtg cag tct ggg gct gag gtg aag aag cct ggg Tcc tcG gtg aag gtc
	tcc tgc aag gct tct gga GGc acc ttc aGc (SEQ ID NO: 224)

1-e	cag gtg cag ctg gtg cag tct ggg gct gag gtg aag aag cct ggg Tcc tcG gtg aag gtc
	tcc tgc aag gct tct gga GGc acc ttc aGc (SEQ ID NO: 225)

1-f	Gag gtC cag ctg gtA cag tct ggg gct gag gtg aag aag cct ggg gcT Aca gtg aaA Atc
	tcc tgc aag gTt tct gga tac acc ttc acc (SEQ ID NO: 225)

VH2

2-05	CAG ATC ACC TTG AAG GAG TCT GGT CCT ACG GTG GTG AAA CCC ACA CAG ACC CTC ACG CTG
	ACC TGC ACC TTC TCT GGG TTC TCA CTC AGC (SEQ ID NO: 227)

2-25	cag Gtc acc ttg aag gag tct ggt cct GTg ctg gtg aaa ccc aca Gag acc ctc acg ctg
	acc tgc acc Gtc tct ggg ttc tca ctc agc (SEQ ID NO: 228)

2-70	cag Gtc acc ttg aag gag tct ggt cct Gcg ctg gtg aaa ccc aca cag acc ctc acA ctg
	acc tgc acc ttc tct ggg ttc tca ctc agc (SEQ ID NO: 229)

VH3

3-07	GAG GTG CAG CTG GTG GAG TCT GGG GGA GGC TTG GTC CAG CCT GGG GGG TCC CTG AGA CTC
	TCC TGT GCA GCC TCT GGA TTC ACC TTT AGT (SEQ ID NO: 230)

3-09	gaA gtg cag ctg gtg gag tct ggg gga ggc ttg gtA cag cct ggC Agg tcc ctg aga ctc
	tcc tgt gca gcc tct gga ttc acc ttt Gat (SEQ ID NO: 231)

3-11	Cag gtg cag ctg gtg gag tct ggg gga ggc ttg gtc Aag cct ggA ggg tcc ctg aga ctc
	tcc tgt gca gcc tct gga ttc acc ttC agt (SEQ ID NO: 232)

3-13	gag gtg cag ctg gtg gag tct ggg gga ggc ttg gtA cag cct ggg ggg tcc ctg aga ctc
	tcc tgt gca gcc tct gga ttc acc ttC agt (SEQ ID NO: 233)

3-15	gag gtg cag ctg gtg gag tct ggg gga ggc ttg gtA Aag cct ggg gag tcc ctT aga ctc
	tcc tgt gca gcc tct gga ttc acT ttC agt (SEQ ID NO: 234)

3-20	gag ttg cat ctg gtg gag tct ggg gga ggT Gtg gtA cGG cct ggg ggg tcc ctg aga ctc
	tcc tgt gca gcc tct gga ttc acc ttt Gat (SEQ ID NO: 235)

3-21	gag gtg cag ctg gtg gag tct ggg gga ggc Ctg gtc Aag cct ggg ggg tcc ctg aga ctc
	tcc tgt gca gcc tct gga ttc aca ttC agt (SEQ ID NO: 236)

3-23	gag gtg cag ctg Ttg gag tct ggg gga ggc ttg gtA cag cct ggg ggg tcc ctg aga ctc
	tcc tgt gca gcc tct gga ttc acc ttt agC (SEQ ID NO: 237)

3-30	Cag gtg cag ctg gtg tag tct ggg gga ggc Gtg gtc cag cct ggg Agg tcc ctg aga ctc
	tcc tgt gca gcc tct gga ttc acc ttC agt (SEQ ID NO: 238)

3-30.3	Cag gtg cag ctg gtg gag tct ggg gga ggc Gtg gtc cag cct ggg Agg tcc ctg aga ctc
	tcc tgt gca gcc tct gga ttc aca ttC agt (SEQ ID NO: 239)

3-30.5	Cag gtg cag ctg gtg gag tct ggg gga ggc Gtg gtc cag cct ggg Agg tcc ctg aga ctc
	tcc tgt gca gcc tct gga ttc acc ttC agt (SEQ ID NO: 240)

3-33	Cag gtg cag ctg gtg gag tct ggg gga ggc Gtg gtc cag cct ggg Agg tcc ctg aga ctc
	tcc tgt gca gcG tct gga ttc acc ttC agt (SEQ ID NO: 241)

3-43	gaA gtg cag ctg gtg gag tct ggg gga gTc Gtg gtA cag cct ggg ggg tcc ctg aga ctc
	tcc tgt gca gcc tct gga ttc acc ttt Gat (SEQ ID NO: 242)

3-48	gag gtg cag ctg gtg gag tct ggg gga ggc ttg gtA cag cct ggg ggg tcc ctg aga ctc
	tcc tgt gca gcc tct gga ttc acc ttC agt (SEQ ID NO: 243)

3-49	gag gtg cag ctg gtg gag tct ggg gga ggc ttg gtA cag ccA ggg Cgg tcc ctg aga ctc
	tcc tgt Aca gcT tct gga ttc act ttt Ggt (SEQ ID NO: 244)

3-53	gag gtg cag ctg gtg gag Act ggA gga ggc ttg Atc cag cct ggg ggg tcc ctg aga ctc
	tcc tgt gca gcc tct ggG ttc acc GtC agt (SEQ ID NO: 245)

3-64	gag gtg cag ctg gtg gag tct ggg gga ggc ttg gtc cag cct ggg ggg tcc ctg aga ctc
	tcc tgt gca gcc tct gga ttc acc ttC agt (SEQ ID NO: 246)

3-66	gag gtg cag ctg gtg gag tct ggg gga ggc ttg gtc cag cct ggg ggg tcc ctg aga ctc
	tcc tgt gca gcc tct gga ttc acc GtC agt (SEQ ID NO: 247)

3-72	gag gtg cag ctg gtg gag tct ggg gga ggc ttg gtc cag cct ggA ggg tcc ctg aga ctc
	tcc tgt gca gcc tct gga ttc acc ttC agt (SEQ ID NO: 248)

3-73	gag gtg cag ctg gtg gag tct ggg gga ggc ttg gtc cag cct ggg ggg tcc ctg aAa ctc
	tcc tgt gca gcc tct ggG ttc acc ttC agt (SEQ ID NO: 249)

3-74	gag gtg cag ctg gtg gag tcC ggg gga ggc ttA gtT cag cct ggg ggg tcc ctg aga ctc
	tcc tgt gca gcc tct gga ttc acc ttC agt (SEQ ID NO: 250)

3-d	gag gtg cag ctg gtg gag tct Cgg gga gTc ttg gtA cag cct ggg ggg tcc ctg aga ctc
	tcc tgt gca gcc tct gga ttc acc GtC agt (SEQ ID NO: 251)

VH4

4-04	CAG GTG CAG CTG CAG GAG TCG GGC CCA GGA CTG GTG AAG CCT TCG GGG ACC CTG TCC CTC
	ACC TGC GCT GTC TCT GGT GGC TCC ATC AGC (SEQ ID NO: 252)

4-28	cag gtg cag ctg cag gag tcg ggc cca gga ctg gtg aag cct tcg gAC acc ctg tcc ctc
	aac tgc gct gtc tct ggt TAc tcc atc agc (SEQ ID NO: 253)

4-30.1	cag gtg cag ctg cag gag tcg ggc cca gga ctg gtg aag cct tcA CAg acc ctg tcc ctc
	acc tgc Act gtc tct ggt ggc tcc atc agc (SEQ ID NO: 254)

4-30.2	cag Ctg cag ctg cag gag tcC ggc Tca gga ctg gtg aag cct tcA CAg acc ctg tcc ctc
	acc tgc gct gtc tct ggt ggc tcc atc agc (SEQ ID NO: 255)

4-30.4	cag gtg cag ctg cag gag tcg ggc cca gga ctg gtg aag cct tcA CAg acc ctg tcc ctc
	acc tgc Act gtc tct ggt ggc tcc atc agc (SEQ ID NO: 256)

4-31	cag gtg cag ctg cag gag tcg ggc cca gga ctg gtg aag cct tcA CAg acc ctg tcc ctc
	acc tgc Act gtc tct ggt ggc tcc atc agc (SEQ ID NO: 257)

4-34	cag gtg cag ctA cag Cag tGg ggc Gca gga ctg Ttg aag cct tcg gAg acc ctg tcc ctc
	acc tgc gct gtc tAt ggt ggG tcc Ttc agT (SEQ ID NO: 258)

4-39	cag Ctg cag ctg cag gag tcg ggc cca gga ctg gtg aag cct tcg gAg acc ctg tcc ctc
	acc tgc Act gtc tct ggt atc tcc atc agc (SEQ ID NO: 259)

4-59	cag gtg cag ctg cag gag tcg ggc cca gga ctg gtg aag cct tcg gAg acc ctg tcc ctc
	acc tgc Act gtc tct ggt ggc tcc atc agT (SEQ ID NO: 260)

4-61	cag gtg cag ctg cag gag tcg ggc cca gga ctg gtg aag cct tcg gAg acc ctg tcc ctc
	acc tgc Act gtc tct ggt ggc tcc Gtc agc (SEQ ID NO: 261)

4-b	cag gtg cag ctg cag gag tcg ggc cca gga ctg gtg aag cct tcg gAg acc ctg tcc ctc
	acc tgc gct gtc tct ggt TAc tcc atc agc (SEQ ID NO: 262)

VH5

5-51	GAG GTG CAG CTG GTG CAG TCT GGA GCA GAG GTG AAA AAG CCC GGG GAG TCT CTG AAG ATC
	TCC TGT AAG GGT TCT GGA TAC AGC TTT ACC (SEQ ID NO: 263)

5-a	gaA gtg cag ctg gtg cag tct gga gca gag gtg aaa aag ccc ggg gag tct ctg aGg atc
	tcc tgt aag ggt tct gga tac agc ttt acc (SEQ ID NO: 264)

VP6

6-1	CAG GTA CAG CTG CAG CAG TCA GGT CCA GGA CTG GTG AAG CCC TCG CAG ACC CTC TCA CTC
	ACC TGT GCC ATC TCC GGG GAC AGT GTC TCT (SEQ ID NO: 265)

VH7

7-4.1	CAG GTG CAG CTG GTG CAA TCT GGG TCT GAG TTG AAG AAG CCT GGG GCC TCA GTG AAG GTT
	TCC TGC AAG GCT TCT GGA TAC ACC TTC ACT (SEQ ID NO: 266)

TABLE 7

RERS sites in Human HC GLG FR1s where there are at least 20 GLGs cut

BsgI GTGCAG	71 (cuts 16/14 bases to right)

1: 4	1: 13	2: 13	3: 4	3: 13	4: 13
6: 13	7: 4	7: 13	8: 13	9: 4	9: 13
10: 4	10: 13	15: 4	15: 65	16: 4	16: 65
17: 4	17: 65	18: 4	18: 65	19: 4	19: 65
20: 4	20: 65	21: 4	21: 65	22: 4	22: 65
23: 4	23: 65	24: 4	24: 65	25: 4	25: 65
26: 4	26: 65	27: 4	27: 65	28: 4	28: 65
29: 4	30: 4	30: 65	31: 4	31: 65	32: 4
32: 65	33: 4	33: 65	34: 4	34: 65	35: 4
35: 65	36: 4	36: 65	37: 4	38: 4	39: 4
41: 4	42: 4	43: 4	45: 4	46: 4	47: 4
48: 4	48: 13	49: 4	49: 13	51: 4

There are 39 hits at base# 4

There are 21 hits at base# 65

-″- ctqcac	9

12: 63	13: 63	14: 63	39: 63	41: 63	42: 63
44: 63	45: 63	46: 63

BbvI GCAGC	65

1: 6	3: 6	6: 6	7: 6	8: 6	9: 6
10: 6	15: 6	15: 67	16: 6	16: 67	17: 6
17: 67	18: 6	18: 67	19: 6	19: 67	20: 6
20: 67	21: 6	21: 67	22: 6	22: 67	23: 6
23: 67	24: 6	24: 67	25: 6	25: 67	26: 6
26: 67	27: 6	27: 67	28: 6	28: 67	29: 6
30: 6	30: 67	31: 6	31: 67	32: 6	32: 67
33: 6	33: 67	34: 6	34: 67	35: 6	35: 67
36: 6	36: 67	37: 6	38: 6	39: 6	40: 6
41: 6	42: 6	43: 6	44: 6	45: 6	46: 6
47: 6	48: 6	49: 6	50: 12	51: 6

There are 43 hits at base# 6 Bolded sites very near sites

listed below

There are 21 hits at base# 67

-″- gctgc	13

37: 9	38: 9	39: 9	40: 3	40: 9	41: 9
42: 9	44: 3	44: 9	45: 9	46: 9	47: 9
50: 9

There are 11 hits at base # 9

BsoFI GCngc	78

1: 6	3: 6	6: 6	7: 6	8: 6	9: 6
10: 6	15: 6	15: 67	16: 6	16: 67	17: 6
17: 67	18: 6	18: 67	19: 6	19: 67	20: 6
20: 67	21: 6	21: 67	22: 6	22: 67	23: 6
23: 67	24: 6	24: 67	25: 6	25: 67	26: 6
26: 67	27: 6	27: 67	28: 6	28: 67	29: 6
30: 6	30: 67	31: 6	31: 67	32: 6	32: 67
33: 6	33: 67	34: 6	34: 67	35: 6	35: 67
36: 6	36: 67	37: 6	37: 9	38: 6	38: 9
39: 6	39: 9	40: 3	40: 6	40: 9	41: 6
41: 9	42: 6	42: 9	43: 6	44: 3	44: 6
44: 9	45: 6	45: 9	46: 6	46: 9	47: 6
47: 9	48: 6	49: 6	50: 9	50: 12	51: 6

There are 43 hits at base# 6 These often occur together.

There are 11 hits at base# 9

There are 2 hits at base# 3

There are 21 hits at base# 67

TseI Gcwgc	78

There are 43 hits at base# 6 Often together.

There are 11 hits at base# 9

There are 2 hits at base# 3

There are 1 hits at base# 12

There are 21 hits at base# 67

MspA1I CMGckg	48

1: 7	3: 7	4: 7	5: 7	6: 7	7: 7
8: 7	9: 7	10: 7	11: 7	15: 7	16: 7
17: 7	18: 7	19: 7	20: 7	21: 7	22: 7
23: 7	24: 7	25: 7	26: 7	27: 7	28: 7
29: 7	30: 7	31: 7	32: 7	33: 7	34: 7
35: 7	36: 7	37: 7	38: 7	39: 7	40: 1
40: 7	41: 7	42: 7	44: 1	44: 7	45: 7
46: 7	47: 7	48: 7	49: 7	50: 7	51: 7

There are 46 hits at base# 7

PvuII CAGctg	48

There are 46 hits at base# 7

There are 2 hits at base# 1

AluI AGct	54

1: 8	2: 8	3: 8	4: 8	4: 24	5: 8
6: 8	7: 8	8: 8	9: 8	10: 8	11: 8
15: 8	16: 8	17: 8	18: 8	19: 8	20: 8
21: 8	22: 8	23: 8	24: 8	25: 8	26: 8
27: 8	28: 8	29: 8	29: 69	30: 8	31: 8
32: 8	33: 8	34: 8	35: 8	36: 8	37: 8
38: 8	39: 8	40: 2	40: 8	41: 8	42: 8
43: 8	44: 2	44: 8	45: 8	46: 8	47: 8
48: 8	48: 82	49: 8	49: 82	50: 8	51: 8

There are 48 hits at base# 8

There are 2 hits at base# 2

DdeI Ctnag	48

1: 26	1: 48	2: 26	2: 48	3: 26	3: 48
4: 26	4: 48	5: 26	5: 48	6: 26	6: 48
7: 26	7: 48	8: 26	8: 48	9: 26	10: 26
11: 26	12: 85	13: 85	14: 85	15: 52	16: 52
17: 52	18: 52	19: 52	20: 52	21: 52	22: 52
23: 52	24: 52	25: 52	26: 52	27: 52	28: 52
29: 52	30: 52	31: 52	32: 52	33: 52	35: 30
35: 52	36: 52	40: 24	49: 52	51: 26	51: 48

There are 22 hits at base# 52 52 and 48 never together.

There are 9 hits at base# 48

There are 12 hits at base# 26 26 and 24 never together.

HphI tcacc	42

1: 86	3: 86	6: 86	7: 86	8: 80	11: 86
12: 5	13: 5	14: 5	15: 80	16: 80	17: 80
18: 80	20: 80	21: 80	22: 80	23: 80	24: 80
25: 80	26: 80	27: 80	28: 80	29: 80	30: 80
31: 80	32: 80	33: 80	34: 80	35: 80	36: 80
37: 59	38: 59	39: 59	40: 59	41: 59	42: 59
43: 59	44: 59	45: 59	46: 59	47: 59	50: 59

There are 22 hits at base# 80 80 and 86 never together

There are 5 hits at base# 86

There are 12 hits at base# 59

BssKI Nccngg	50

1: 39	2: 39	3: 39	4: 39	5: 39	7: 39
8: 39	9: 39	10: 39	11: 39	15: 39	16: 39
17: 39	18: 39	19: 39	20: 39	21: 29	21: 39
22: 39	23: 39	24: 39	25: 39	25: 39	27: 39
28: 39	29: 39	30: 39	31: 39	32: 39	33: 39
34: 39	35: 19	35: 39	36: 39	37: 24	38: 24
39: 24	41: 24	42: 24	44: 24	45: 24	46: 24
47: 24	48: 39	48: 40	49: 39	49: 40	50: 24
50: 73	51: 39

There are 35 hits at base# 39 39 and 40 together twice.

There are 2 hits at base# 40

BsaJI Ccnngg	47

1: 40	2: 40	3: 40	4: 40	5: 40	7: 40
8: 40	9: 40	9: 47	10: 40	10: 47	11: 40
15: 40	18: 40	19: 40	20: 40	21: 40	22: 40
23: 40	24: 40	25: 40	26: 40	27: 40	28: 40
29: 40	30: 40	31: 40	32: 40	34: 40	35: 20
35: 40	36: 40	37: 24	38: 24	39: 24	41: 24
42: 24	44: 24	45: 24	46: 24	47: 24	40: 40
48: 41	49: 40	49: 41	50: 74	51: 40

There are 32 hits at base# 40 40 and 41 together twice

There are 2 hits at base# 41

There are 9 hits at base# 24

There are 2 hits at base# 47

BstNI CCwgg	44
PspGI ccwgg
ScrFI ($M.HpaII) CCwgg

CCwqg

1: 40	2: 40	3: 40	4: 40	5: 40	7: 40
8: 40	9: 40	10: 40	11: 40	15: 40	16: 40
17: 40	18: 40	19: 40	20: 40	21: 30	21: 40
22: 40	23: 40	24: 40	25: 40	26: 40	27: 40
28: 40	29: 40	30: 40	31: 40	32: 40	33: 40
34: 40	35: 40	36: 40	37: 25	36: 25	39: 25
41: 25	42: 25	44: 25	45: 25	46: 25	47: 25
50: 25	51: 40

There are 33 hits at base# 40

ScrFi CCngg	50

1: 40	2: 40	3: 40	4: 40	5: 40	7: 40
8: 40	9: 40	10: 40	11: 40	15: 40	16: 40
17: 40	18: 40	19: 40	20: 40	21: 30	21: 40
22: 40	23: 40	24: 40	25: 40	25: 40	27: 40
28: 40	29: 40	30: 40	31: 40	32: 40	33: 40
34: 40	35: 20	35: 40	36: 40	37: 25	38: 25
39: 25	41: 25	42: 25	44: 25	45: 25	46: 25
47: 25	48: 40	43: 41	49: 40	49: 41	50: 25
50: 74	51: 40

There are 35 hits at base# 40

There are 2 hits at base# 41

EcoO109I RGgnccy	34

1: 43	2: 43	3: 43	4: 43	5: 43	6: 43
7: 43	8: 43	9: 43	10: 43	15: 46	16: 46
17: 46	18: 46	19: 46	20: 46	21: 46	22: 46
23: 46	24: 46	25: 46	26: 46	27: 46	28: 46
30: 46	31: 46	32: 46	33: 46	34: 46	35: 46
36: 46	37: 46	43: 79	51: 43

There are 22 hits at base# 46 46 and 43 never together

There are 11 hits at base# 43

NlaTIV GGNncc	71

1: 43	2: 43	3: 43	4: 43	5: 43	6: 43
7: 43	8: 43	9: 43	9: 79	10: 43	10: 79
15: 46	15: 47	16: 47	17: 46	17: 47	18: 46
18: 47	19: 46	19: 47	20: 46	20: 47	21: 46
21: 47	22: 46	22: 47	23: 47	24: 47	25: 47
26: 47	27: 46	27: 47	28: 46	28: 47	29: 47
30: 46	30: 47	31: 46	31: 47	32: 46	32: 47
33: 46	33: 47	34: 46	34: 47	35: 46	35: 47
36: 46	36: 47	37: 21	37: 46	37: 47	37: 79
38: 21	39: 21	39: 79	40: 79	41: 21	41: 79
42: 21	42: 79	43: 79	44: 21	44: 79	45: 21
45: 79	46: 21	46: 79	47: 21	51: 43

There are 23 hits at base# 47 46 & 47 often together

There are 17 hits at base# 46 There are 11 hits at base# 43

Sau96I Ggncc	70

1: 44	2: 3	2: 44	3: 44	4: 44	5: 3	5: 44	6: 44
7: 44	8: 22	8: 44	9: 44	10: 44	11: 3	12: 22	13: 22
14: 22	15: 33	15: 47	16: 47	17: 47	18: 47	19: 47	20: 47
21: 47	22: 47	23: 33	23: 47	24: 33	24: 47	25: 33	25: 47
26: 33	26: 47	27: 47	28: 47	29: 47	30: 47	31: 33	31: 47
32: 33	32: 47	33: 33	33: 47	34: 33	34: 47	35: 47	36: 47
37: 21	37: 22	37: 47	38: 21	38: 22	39: 21	39: 22	41: 21
41: 22	42: 21	42: 22	43: 80	44: 21	44: 22	45: 21	45: 22
46: 21	46: 22	47: 21	47: 22	50: 22	51: 44

There are 23 hits at base# 47 These do not occur together.

There are 11 hits at base # 44

There are 14 hits at base# 22 These do occur together.

There are 9 hits at base# 21

(SEQ ID NO: 13)

BsmAI GTCTCNnnnn	22

1: 58	3: 58	4: 58	5: 58	8: 58	9: 58
10: 58	13: 70	36: 18	37: 70	38: 70	39: 70
40: 70	41: 70	42: 70	44: 70	45: 70	46: 70
47: 70	48: 48	49: 48	50: 85

There are 11 hits at base# 70

(SEQ ID NO: 14)

-″- Nnnnnngagac	27

13: 40	15: 48	16: 48	17: 48	18: 48	20: 48
21: 48	22: 48	23: 48	24: 48	25: 48	26: 48
27: 48	28: 48	29: 48	30: 10	30: 48	31: 48
32: 48	33: 48	35: 48	36: 48	43: 40	44: 40
45: 40	46: 40	47: 40

There are 20 hits at base# 48

AvaII Gqwcc	44
Sau96I ($M.HaeIII) Ggwcc	44

2: 3	5: 3	6: 44	0: 44	9: 44	10: 44
11: 3	12: 22	13: 22	14: 22	15: 33	15: 47
16: 47	17: 47	18: 47	19: 47	20: 47	21: 47
22: 47	23: 33	23: 47	24: 33	24: 47	25: 33
25: 47	25: 33	26: 47	27: 47	28: 47	29: 47
30: 47	31: 33	31: 47	32: 33	32: 47	33: 33
33: 47	34: 33	34: 47	35: 47	36: 47	37: 47
43: 80	50: 22

There are 23 hits at base# 47 44 & 47 never together

There are 4 hits at base# 44

PpuMI RGgwccy	27

6: 43	8: 43	9: 43	10: 43	15: 46	15: 46
17: 46	18: 46	19: 46	20: 46	21: 46	22: 46
23: 46	24: 46	25: 46	26: 46	27: 46	28: 46
30: 46	31: 46	32: 46	33: 46	34: 46	35: 46
36: 46	37: 46	43: 79

There are 22 hits at base# 46 43 and 46 never occur together.

There are 4 hits at base# 43

BsmFI GGGAC	3

8: 43	37: 46	50: 77

-″- gtccc	33

15: 48	16: 48	17: 48	1: 0	1: 0	20: 48
21: 48	22: 48	23: 48	24: 48	25: 48	26: 48
27: 48	28: 48	29: 48	30: 48	31: 48	32: 48
33: 48	34: 48	35: 48	36: 48	37: 54	38: 54
39: 54	40: 54	41: 54	42: 54	43: 54	44: 54
45: 54	46: 54	47: 54

There are 20 hits at base# 48

There are 11 hits at base# 54

HinfI Gantc	80

8: 77	12: 16	13: 16	14: 16	15: 16	15: 56
15: 77	16: 16	16: 56	16: 77	17: 16	17: 56
17: 77	18: 16	18: 56	18: 77	19: 16	19: 56
19: 77	20: 16	20: 56	20: 77	21: 16	21: 56
21: 77	22: 16	22: 56	22: 77	23: 16	23: 56
23: 77	24: 16	24: 56	24: 77	25: 16	25: 56
25: 77	26: 16	26: 56	26: 77	27: 16	27: 26
27: 56	27: 77	28: 16	28: 56	28: 77	29: 16
29: 56	29: 77	30: 56	31: 16	31: 56	31: 77
32: 16	32: 56	32: 77	33: 16	33: 56	33: 77
34: 16	35: 16	35: 56	35: 77	36: 16	36: 26
36: 56	36: 77	37: 16	38: 16	39: 16	40: 16
41: 16	42: 16	44: 16	45: 16	46: 16	47: 16
48: 46	49: 46

There are 34 hits at base# 16

TfiI Gawtc	21

8: 77	15: 77	16: 77	17: 77	18: 77	19: 77
20: 77	21: 77	22: 77	23: 77	24: 77	25: 77
26: 77	27: 77	28: 77	29: 77	31: 77	32: 77
33: 77	35: 77	36: 77

There are 21 hits at base# 77

MlyI GAGTC	38

12: 16	13: 16	14: 16	15: 16	16: 16	17: 16
18: 16	19: 16	20: 16	21: 16	22: 16	23: 16
24: 16	25: 16	26: 16	27: 16	27: 26	28: 16
29: 16	31: 16	32: 16	33: 16	34: 16	35: 16
36: 16	36: 26	37: 16	38: 16	39: 16	40: 16
41: 16	42: 16	44: 16	45: 16	46: 16	47: 16
48: 46	49: 46

There are 34 hits at base# 16

-″- GACTC	21

15: 56	16: 56	17: 56	18: 56	19: 56	20: 56
21: 56	22: 56	23: 56	24: 56	25: 56	26: 56
27: 56	28: 56	29: 56	30: 56	31: 56	32: 56
33: 56	35: 56	36: 56

There are 21 hits at base# 56

PleI gagtc	38

There are 34 hits at base# 16

-″- gactc	21

There are 21 hits at base# 56

AlwNI CAGNNNctg	26

15: 68	16: 68	17: 68	18: 68	19: 68	20: 68
21: 68	22: 68	23: 68	24: 68	25: 68	26: 68
27: 68	28: 68	29: 68	30: 68	31: 68	32: 68
33: 68	34: 68	35: 68	36: 68	39: 46	40: 46
41: 46	42: 46

There are 22 hits at base# 68

TABLE 8

Kappa FR1 GLGs

!	1 2 3 4 5 6 7 8 9 10 11 12	O12	(SEQ ID NO: 275)
	GAC ATC CAG ATG ACC CAG TCT CCA TCC TCC CTG TCT

!	13 14 15 16 17 18 19 20 21 22 23
	GCA TCT CTA GGA GAC AGA GTC ACC ATC ACT TGC !

	GAC ATC CAG ATG ACC CAG TCT CCA TCC TCC CTG TCT	O2	(SEQ ID NO: 276)
	GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGC !

	GAC ATC CAG ATG ACC CAG TCT CCA TCC TCC CTG TCT	O18	(SEQ ID NO: 277)
	GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGC !

	GAC ATC CAG ATG ACC CAG TCT CCA TCC TCC CTG TCT	O8	(SEQ ID NO: 278)
	GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGC !

	GAC ATC CAG ATG ACC CAG TCT CCA TCC TCC CTG TCT	A20	(SEQ ID NO: 279)
	GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGC !

	GAC ATC CAG ATG ACC CAG TCT CCA TCC TCC CTG TCT	A30	(SEQ ID NO: 280)
	GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGC !

	AAC ATC CAG ATG ACC CAG TCT CCA TCT GCC ATG TCT	L14	(SEQ ID NO: 281)
	GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGT !

	GAC ATC CAG ATG ACC CAG TCT CCA TCC TCA CTG TCT	L1	(SEQ ID NO: 282)
	GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGT !

	GAC ATC CAG ATG ACC CAG TCT CCA TCC TCA CTG TCT	L15	(SEQ ID NO: 283)
	GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGT !

	GCC ATC CAG TTG ACC CAG TCT CCA TCC TCC CTG TCT	L4	(SEQ ID NO: 284)
	GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGC !

	GCC ATC CAG TTG ACC CAG TCT CCA TCC TCC CTG TCT	L18	(SEQ ID NO: 285)
	GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGC !

	GAC ATC CAG ATG ACC CAG TCT CCA TCT TCC GTG TCT	L5	(SEQ ID NO: 286)
	GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGT !

	GAC ATC CAG ATG ACC CAG TCT CCA TCT TCT GTG TCT	L19	(SEQ ID NO: 287)
	GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGT !

	GAC ATC CAG TTG ACC CAG TCT CCA TCC TTC CTG TCT	L8	(SEQ ID NO: 288)
	GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGC !

	GCC ATC CGG ATG ACC CAG TCT CCA TTC TCC CTG TCT	L23	(SEQ ID NO: 239)
	GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGC !

	GCC ATC CGG ATG ACC CAG TCT CCA TCC TCA TTC TCT	L9	(SEQ ID NO: 290)
	GCA TCT ACA GGA GAC AGA GTC ACC ATC ACT TGT !

	GTC ATC TGG ATG ACC CAG TCT CCA TCC TTA CTC TCT	L24	(SEQ ID NO; 291)
	GCA TCT ACA GGA GAC AGA GTC ACC ATC AGT TGT !

	GCC ATC CAG ATG ACC CAG TCT CCA TCC TCC CTG TCT	L11	(SEQ ID NO: 292)
	GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGC !

	GAC ATC CAG ATG ACC CAG TCT CCT TCC ACC CTG TCT	L12	(SEQ ID NO: 293)
	GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGC !

	GAT ATT GTG ATG ACC CAG ACT CCA CTC TCC CTG CCC	O11	(SEQ ID NO: 294)
	GTC ACC CCT GGA GAG CCG GCC TCC ATC TCC TGC !

	GAT ATT GTG ATG ACC CAG ACT CCA CTC TCC CTG CCC	O1	(SEQ ID NO: 295)
	GTC ACC CCT GGA GAG CCG GCC TCC ATC TCC TGC !

	GAT GTT GTG ATG ACT CAG TCT CCA CTC TCC CTG CCC	A17	(SEQ ID NO: 296)
	GTC ACC CTT GGA CAG CCG GCC TCC ATC TCC TGC !

	GAT GTT GTG ATG ACT CAG TCT CCA CTC TCC CTG CCC	A1	(SEQ ID NO: 297)
	GTC ACC CTT GGA CAG CCG GCC TCC ATC TCC TGC !

	GAT ATT GTG ATG ACC CAG ACT CCA CTC TCT CTG TCC	A18	(SEQ ID NO: 293)
	GTC ACC CCT GGA CAG CCG GCC TCC ATC TCC TGC !

	GAT ATT GTG ATG ACC CAG ACT CCA CTC TCT CTG TCC	A2	(SEQ ID NO: 299)
	GTC ACC CCT GGA CAG CCG GCC TCC ATC TCC TGC !

	GAT ATT GTG ATG ACT CAG TCT CCA CTC TCC CTG CCC	A19	(SEQ ID NO: 300)
	GTC ACC CCT GGA GAG CCG GCC TCC ATC TCC TGC !

	GAT ATT GTG ATG ACT CAG TCT CCA CTC TCC CTG CCC	A3	(SEQ ID NO: 301)
	GTC ACC CCT GGA GAG CCG GCC TCC ATC TCC TGC !

	GAT ATT GTG ATG ACC CAG ACT CCA CTC TCC TCA CCT	A23	(SEQ ID NO: 302)
	GTC ACC CTT GGA CAG CCG GCC TCC ATC TCC TGC !

	GAA ATT GTG TTG ACG CAG TCT CCA GGC ACC CTG TCT	A27	(SEQ ID NO: 303)
	TTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC !

	GAA ATT GTG TTG ACG CAG TCT CCA GCC ACC CTG TCT	A11	(SEQ ID NO: 3CA)
	TTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC !

	GAA ATA GTG ATG ACG CAG TCT CCA GCC ACC CTG TCT	L2	(SEQ ID NO: 305)
	GTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC !

	GAA ATA GTG ATG ACG CAG TCT CCA GCC ACC CTG TCT	L16	(SEQ ID NO: 306)
	GTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC !

	GAA ATT GTG TTG ACA CAG TCT CCA GCC ACC CTG TCT	L6	(SEQ ID NO: 307)
	TTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC !

	GAA ATT GTG TTG ACA CAG TCT CCA GCC ACC CTG TCT	L20	(SEQ ID NO: 303)
	TTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC !

	GAA ATT GTA ATG ACA CAG TCT CCA GCC ACC CTG TCT	L25	(SEQ ID NO: 30))
	TTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC !

	GAC ATC GTG ATG ACC CAG TCT CCA GAC TCC CTG GCT	B3	(SEQ ID NO: 310)
	GTG TCT CTG GGC GAG AGG GCC ACC ATC AAC TGC !

	GAA ACG ACA CTC ACG CAG TCT CCA GCA TTC ATG TCA	B2	(SEQ ID NO: 311)
	GCG ACT CCA GGA GAC AAA GTC AAC ATC TCC TGC !

	CAA ATT GTG CTG ACT CAG TCT CCA GAC TTT CAG TCT	A26	(SEQ ID NO: 312)
	GTG ACT CCA AAG GAG AAA GTC ACC ATC ACC TGC !

	GAA ATT GTG CTG ACT CAG TCT CCA GAC TTT CAG TCT	A10	(SEQ ID NO: 313)
	GTG ACT CCA AAG GAG AAA GTC ACC ATC ACC TGC !

	GAT GTT GTG ATG ACA CAG TCT CCA GCT TTC CTC TCT	A14	(SEQ ID NO: 314)
	GTG ACT CCA GGG GAG AAA GTC ACC ATC ACC TGC !

TABLE 9

RERS sites found in Human Kappa FR1 GLGs

		FokI					HpyC
	MsII	--> <-- -->	PflFI	BsrI	BsmAI	MnlI	H4V

VKI

O12 1-69	3	3	23	12	49	15	18	47	26	36
O2 101-169	103	103	123	112	149	115	118	147	126	136
O18 201-269	203	203	223	212	249	215	218	247	226	236
O8 301-369	303	303	323	312	349	315	318	347	326	336
A20 401-469	403	403	423	412	449	415	418	447	426	436
A30 501-569	503	503	523	512	549	515	518	547	526	536

L14 601-669

603

612

649

615

618

647

—

636

L1 701-769	703	703	723	712	749	715	718	747	726	736
L15 801-869	803	803	823	812	849	815	818	847	826	836

L4 901-969

—

903

923

912

949

906

915

918

947

926

936

L18 1001-1069

—

1003

1012

1049

1006

1015

1018

1047

1026

1036

L5 1101-1169

1103

—

1112

1149

1115

1118

1147

—

1136

L19 1201-1269

1203

1212

1249

1215

1218

1247

—

1236

L8 1301-1369

—

1303

1323

1312

1349

1306

1315

1318

1347

—

1336

L23 1401-1469

1403

1408

1412

1449

1415

1418

1447

—

1436

L9 1501-1569

1503

1508

1523

1512

1549

1515

1518

1547

1526

1536

L24 1601-1669	1603	1608	1623	1612	1649	1615	1618	1647	—	1636
L11 1701-1769	1703	1703	1723	1712	1749	1715	1718	1747	1726	1736

L12 1801-1869

1803

1812

1849

1815

1818

1847

—

1836

VKII
O11 1901-1969	—	—	—	—	—	1956	—
O1 2001-2069	—	—	—	—	—	2056	—
A17 2101-2169	—	—	2112	—	2118	2156	—
A1 2201-2269	—	—	2212	—	2218	2256	—
A18 2301-2369	—	—	—	—	—	2356	—
A2 2401-2469	—	—	—	—	—	2456	—
A19 2501-2569	—	—	2512	—	2518	2556	—
A3 2601-2669	—	—	2612	—	2618	2656	—
A23 2701-2769	—	—	—	—	—	2729	—
VKIII

A27 2801-2869	—	—	2812	—	2818	2839	2860	—
A11 2901-2969	—	—	2912	—	2918	2939	2960	—
L2 3001-3069	—	—	3012	—	3018	3039	3060	—
L16 3101-3169	—	—	3112	—	3118	3139	3160	—
L6 3201-3.269	—	—	3212	—	3218	3239	3260	—
L20 3301-3369	—	—	3312	—	3318	3339	3360	—
L25 3401-3469	—	—	3412	—	3418	3439	3460	—
VKIV

B3 3501-3569	3503	—	3512	3515	3518	3539	3551<	—
VKV

B2 3601-3669

—

3649

—

3618

3647

—

VKVI
A26 3701-3769	—	—	3712	—	3718	—
A10 3801-3869	—	—	3812	—	3818	—

A14 3901-3969	—	—	3912	—	3918	3930>	—

TABLE 9

RERS sites found in Human Kappa FR1 GLGs, continued

				MaeIII	HphI	HpaII
				Tsp45I	xx38	MspI
			MlyI	same	xx56	xx06
SfaNI	SfcI	HinfI	--> --> <--	sites	xx62	xx52

VKI
O12 1-69	37	41	53	53	55	56	—
O2 101-169	137	141	153	153	155	156	—
O18 201-269	237	241	253	253	255	256	—
O8 301-369	337	341	353	353	355	356	—
A20 401-469	437	441	453	453	455	456	—
A30 501-569	537	541	553	553	555	556	—
L14 601-669	637	641	653	653	655	656	—
L1 701-769	737	741	753	753	755	756	—
L15 801-869	837	841	853	853	855	856	—
L4 901-969	937	941	953	953	955	956	—
L18 1001-1069	1037	1041	1053	1053	1055	1056	—
L5 11014169	1137	1141	1153	1153	1155	1156	—
L19 1201-1269	1237	1241	1253	1253	1255	1256	—
L8 1301-1369	1337	1341	1353	1353	1355	1356	—
L23 1401-1469	1437	1441	11453	1453	1455	1456	1406
L9 1501-1569	1537	541	1553	1553	1555	1556	1506
L24 1601-1669	1637	1641	1653	1653	1655	1656
L11 1701-1769	1737	1741	1753	1753	1755	1756
L12 1801-1869	1837	1841	1853	1853	1855	1856
VKII
O11 1901-1969	—	—	1918	1918	1937	1938	1952
O1 2001-2069	—	—	2018	2018	2037	2038	2052
A17 2101-2169	—	—	2112	2112	2137	2138	2152
A1 2201-2268	—	—	2212	2212	2237	2238	2252
A18 2301-2369	—	—	2318	2318	2337	2338	2352
A2 2401-2469	—	—	2418	2418	2437	2438	2452
A19 2501-2569	—	—	2512	2512	2537	2538	2552
A3 2601-2669	—	—	2612	2612	2637	2638	2652
A23 2701-2769	—	—	2718	2718	2737	2731* 2738*	—
VKIII
A27 2801-2869	—	—	—	—			—
A11 2901-2969	—	—	—	—			—
L2 3001-3069	—	—	—	—			—
L16 3101-3169	—	—	—	—			—
L6 3201-3269	—	—	—	—			—
L20 3301-3369	—	—	—	—			—
L25 3401-3469	—	—	—	—			—
VKIV
B3 3501-3569	—	—	3525	3525			—
VKV
B2 3601-3669	—	—	3639	3639			—
VKVI
A26 3701-3769	—	—	3712 3739	3712 3739	3737 3755	3756 3762	—
A10 3801-3869	—	—	3812 3839	3812 3839	3837 3855	3856 3862	—
A14 3901-3969	—	—	3939	3939	3937 3955	3956 3962	—

TABLE 9

RERS sites found in Human Kappa FR1, continued

		BpmI	BsrFI
BsaJI	BssKI (NstNI)	xx20 xx41 xx44	Cac8I NaeI
xx29 xx42 xx43	xx22 xx30 xx43	--> --> <--	NgoMIV	HaeIII	Tsp509I

VKI
O12 1-69	—	—	—	—	—	—
O2 101-169	—	—	—	—	—	—
O18 201-269	—	—	—	—	—	—
O8 301-369	—	—	—	—	—	—
A20 401-469	—	—	—	—	—	—
A30 501-569	—	—	—	—	—	—
L14 601-669	—	—	—	—	—	—
L1 701-769	—	—	—	—	—	—
L15 801-869	—	—	—	—	—	—
L4 901-969	—	—	—	—	—	—
L18 1001-1069	—	—	—	—	—	—
L5 1101-1169	—	—	—	—	—	—
L19 1201-1269	—	—	—	—	—	—
L8 1301-1369	—	—	—	—	—	—
L23 1401-1469	—	—	—	—	—	—
L9 1501-1569	—	—	—	—	—	—
L24 1601-1669	—	—	—	—	—	—
L11 1701-1769	—	—	—	—	—	—
L12 1801-1869	—	—	—	—	—	—
VKII
O11 1901-1969	1942	1943	1944	1951	1954	—
O1 2001-2069	2042	2043	2044	2051	2054	—
A17 2101-2169	2142	—	—	2151	2154	—
A1 2201-2269	2242	—	—	2251	2254	—
A18 2301-2369	2342	2343	—	2351	2354	—
A2 2401-2469	2442	2443	—	2451	2454	—
A19 2501-2569	2542	2543	2544	2551	2554	—
A3 2601-2669	2642	2643	2644	2651	2654	—
A23 2701-2769	2742	—	—	2751	2754	—
VKIII
A27 2801-2869	2843	2822 2843	2820 2841	—	—	2803
A11 2901-2969	2943	2943	2920 2941	—	—	2903
L2 3001-3069	3043	3043	3041	—	—	—
L16 3101-3169	3143	3143	3120 3141	—	—	—
L6 3201-3269	3243	3243	3220 3241	—	—	3203
L20 3301-3369	3343	3343	3320 3341	—	—	3303
L25 3401-3469	3443	3443	3420 3441	—	—	3403
VKIV
B3 3501-3569	3529	3530	3520	—	3554
VKV
B2 3601-3669		3643	3620 3641	—	—
VKVI
A26 3701-3769		—	3720	—	—	3703
A10 3801-3869		—	3820	—	—	3803
A24 3901-3969	3943	3943	3920 3941	—	—	—

TABLE 10

Lambda FR1 GLG sequences

! VL1	CAG TCT GTG CTG ACT CAG CCA CCC TCG GTG TCT GAA
	GCC CCC AGG CAG AGG GTC ACC ATC TCC TGT ! 1a
	(SEQ ID No: 315)

	cag tct gtg ctg acG cag ccG ccc tcA gtg tct gGG
	gcc ccA Ggg cag agg gtc acc atc tcc tgC ! 1e
	(SEQ ID No: 316)

	cag tct gtg ctg act cag cca ccc tcA gCg tct gGG
	Acc ccc Ggg cag agg gtc acc atc tcT tgt ! 1c
	(SEQ ID NO: 317)

	cag tct gtg ctg act cag cca ccc tcA gCg tct gGG
	Acc ccc Ggg cag agg gtc acc atc tcT tgt ! 1g
	(SEQ ID NO: 318)

	cag tct gtg Ttg acG cag ccG ccc tcA gtg tct gCG
	gcc ccA GgA cag aAg gtc acc atc tcc tgC ! 1b
	(SEQ ID NO: 319)

! VL2	CAG TCT GCC CTG ACT CAG CCT CCC TCC GCG TCC GGG
	TCT CCT GGA CAG TCA GTC ACC ATC TCC TGC ! 2c
	(SEQ ID NO: 320)

	cag tct gcc ctg act cag cct cGc tcA gTg tcc ggg
	tct cct gga cag tca gtc acc atc tcc tgc! 2e
	(SEQ ID NO: 321)

	cag tct gcc ctg act cag cct Gcc tcc gTg tcT ggg
	tct cct gga cag tcG Atc acc atc tcc tgc ! 2a2
	(SEQ ID NO: 322)

	cag tct gcc ctg act cag cct ccc tcc gTg tcc ggg
	tct cct gga cag tca gtc acc atc tcc tgc ! 2d
	(SEQ ID NO: 323)

	cag tct gcc ctg act cag cct Gcc tcc gTg tcT ggg
	tct cct gga cag tcG Atc acc atc tcc tgc ! 2b2
	(SEQ ID NO: 324)

! VL3	TCC TAT GAG CTG ACT CAG CCA CCC TCA GTG TCC GTG
	TCC CCA GGA CAG ACA GCC AGC ATC ACC TGC ! 3r
	(SEQ ID NO: 325)

	tcc tat gag ctg act cag cca cTc tca gtg tcA gtg
	Gcc cTG gga cag acG gcc agG atT acc tgT ! 3j
	(SEQ ID NO: 326)

	tcc tat gag ctg acA cag cca ccc tcG gtg tcA gtg
	tcc cca gga caA acG gcc agG atc acc tgc! 3p
	(SEQ ID NO: 327)

	tcc tat gag ctg acA cag cca ccc tcG gtg tcA gtg
	tcc cTa gga cag aTG gcc agG atc acc tgc ! 3a
	(SEQ ID NO: 328)

	tcT tCt gag ctg act cag GAC ccT GcT gtg tcT gtg
	Gcc TTG gga cag aca gTc agG atc acA tgc ! 3l
	(SEQ ID NO: 329)

	tcc tat gTg ctg act cag cca ccc tca gtg tcA gtg
	Gcc cca gga Aag acG gcc agG atT acc tgT ! 3h
	(SEQ ID NO: 330)

	tcc tat gag ctg acA cag cTa ccc tcG gtg tcA gtg
	tcc cca gga cag aca gcc agG atc acc tgc ! 3e
	(SEQ ID NO: 331)

	tcc tat gag ctg aTG cag cca ccc tcG gtg tcA gtg
	tcc cca gga cag acG gcc agG atc acc tgc ! 3m
	(SEQ ID NO: 332)

	tcc tat gag ctg acA cag cca Tcc tca gtg tcA gtg
	tcT ccG gga cag aca gcc agG atc acc tgc ! V2-19
	(SEQ ID NO: 333)

! VL4	CTG CCT GTG CTG ACT CAG CCC CCG TCT GCA TCT GCC
	TTG CTG GGA GCC TCG ATC AAg CTC ACC TGC ! 4c
	(SEQ ID NO: 334)

	cAg cct gtg ctg act caA TcA TcC tct gcC tct gcT
	tCC ctg gga Tcc tcg Gtc aag ctc acc tgc ! 4a
	(SEQ ID NO: 335)

	cAg cTt gtg ctg act caA TcG ccC tct gcC tct gcc
	tCC ctg gga gcc tcg Gtc aag ctc acc tgc ! 4b
	(SEQ ID NO: 336)

! VL5	CAG CCT GTG CTG ACT CAG CCA CCT TCC TCC TCC GCA
	TCT CCT GGA GAA TCC GCC AGA CTC ACC TGC ! 5e
	(SEQ ID NO: 337)

	cag Gct gtg ctg act cag ccG Gct tcc CTc tcT gca
	tct cct gga gCa tcA gcc agT ctc acc tgc ! 5c
	(SEQ ID NO: 338)

	cag cct gtg ctg act cag cca Tct tcc CAT tcT gca
	tct Tct gga gCa tcA gTc aga ctc acc tgc ! 5b
	(SEQ ID NO: 339)

! VL6	AAT TTT ATG CTG ACT CAG CCC CAC TCT GTG TCG GAG
	TCT CCG GGG AAG ACG GTA ACC ATC TCC TGC ! 6a
	(SEQ ID NO: 340)

!VL7	CAG ACT GTG GTG ACT CAG GAG CCC TCA CTG ACT GTG
	TCC CCA GGA GGG ACA GTC ACT CTC ACC TGT ! 7a
	(SEQ ID NO: 341)

	cag Gct gtg gtg act cag gag ccc tca ctg act gtg
	tcc cca gga ggg aca gtc act ctc acc tgt ! 7b
	(SEQ ID NO: 342)

! VL8	CAG ACT GTG GTG ACC CAG GAG CCA TCG TTC TCA GTG
	TCC CCT GGA GGG ACA GTC ACA CTC ACT TGT ! 8a
	(SEQ ID NO: 343)

! VL9	CAG CCT GTG CTG ACT CAG CCA CCT TCT GCA TCA GCC
	TCC CTG GGA GCC TCG GTC ACA CTC ACC TGC ! 9a
	(SEQ ID NO: 344)

! VL10	CAG GCA GGG CTG ACT CAG CCA CCC TCG GTG TCC AAG
	GGC TTG AGA CAG ACC GCC ACA CTC ACC TGC ! 10a
	(SEQ ID NO: 345)

TABLE 11

RERSs found in human lambda FR1 GLGs

! There are 31 lambda GLGs

MlyI NnnnnnGACTC (SEQ ID NO: 346) 25

1: 6	2: 6	4: 6	6: 6	7: 6	8: 6
9: 6	10: 6	11: 6	12: 6	15: 6	16: 6
20: 6	21: 6	22: 6	23: 6	23: 50	24: 6
25: 6	25: 50	26: 6	27: 6	28: 6	30: 6
21: 6

There are 23 hits at base# 6

-″- GAGTCNNNNNn (SEQ ID NO: 347) 1

26: 34

MwoI GCNNNNNnngc (SEG ID NO: 348) 20

1: 9	2: 9	3: 9	4: 9	11: 9	11: 56
12: 9	13: 9	14: 9	16: 9	17: 9	18: 9
19: 9	20: 9	23: 9	24: 9	25: 9	26: 9
30: 9	31: 9

There are 19 hits at base# 9

HinfI Gantc 27

1: 12	3: 12	4: 12	6: 12	7: 12	8: 12
9: 12	10: 12	11: 12	12: 12	15: 12	16: 12
20: 12	21: 12	22: 12	23: 12	23: 46	23: 56
24: 12	25: 12	25: 56	26: 12	26: 34	27: 12
28: 12	30: 12	31: 12

There are 23 hits at base# 12

PleI gactc 2

1: 12	3: 12	4: 12	6: 12	7: 12	8: 12
9: 12	10: 12	11: 12	12: 12	15: 12	16: 12
20: 12	21: 12	22: 12	23: 12	23: 56	24: 12
25: 12	25: 56	26: 12	27: 12	28: 12	30: 12
31: 12

There are 23 hits at base# 12

-″- gagtc

26: 34

DdeI Ctnag 32

1: 14	2: 24	3: 14	3: 24	4: 14	4: 24
5: 24	6: 14	7: 14	7: 24	8: 14	9: 14
10: 14	11: 14	11: 24	12: 14	12: 24	15: 5
15: 14	16: 14	16: 24	19: 24	20: 14	23: 14
24: 14	25: 14	26: 14	27: 14	28: 14	29: 30
30: 14	31: 14

There are 21 hits at base# 14

B3aJI Ccnngg 38

1: 23	1: 40	2: 39	2: 40	3: 39	3: 40
4: 39	4: 40	5: 39	11: 39	12: 38	12: 39
13: 23	13: 39	14: 23	14: 39	15: 38	16: 39
17: 23	17: 39	18: 23	18: 39	21: 38	21: 39
21: 47	22: 38	22: 39	22: 47	26: 40	27: 39
28: 39	29: 14	29: 39	30: 38	30: 39	30: 47
31: 23	31: 32

There are 17 hits at base# 39

There are 5 hits at base# 38

There are 5 hits at base# 40 Makes cleavage

ragged.

MnlI cctc 3

1: 23	2: 23	3: 23	4: 23	5: 23	6: 19
6: 23	7: 19	8: 23	9: 19	9: 23	10: 23
11: 23	13: 23	14: 23	16: 23	17: 23	13: 23
19: 23	20: 47	21: 23	21: 29	21: 47	22: 23
22: 29	22: 35	22: 47	23: 26	23: 29	24: 27
27: 23	28: 23	30: 35	30: 47	31: 23

There are 21 hits at base# 23

There are 3 hits at base# 19

There are 3 hits at base# 29

There are 1 hits at base# 26

There are 1 hits at base# 27 These could make

cleavage ragged.

-″- gagg 7

1: 48	2: 48	3: 48	4: 48	27: 44	28: 44
29: 44

BssKI Nccngg 39

1: 40	2: 39	3: 39	3: 40	4: 39	4: 40
5: 39	6: 31	6: 39	7: 31	7: 39	8: 39
9: 31	9: 39	10: 39	11: 39	12: 38	12: 52
13: 39	13: 52	14: 52	16: 39	16: 52	17: 39
17: 52	18: 39	18: 52	19: 39	19: 52	21: 38
22: 38	23: 39	24: 39	26: 39	27: 39	28: 39
29: 14	29: 39	30: 38

There are 21 hits at base# 39

There are 4 hits at base# 38

There are 3 hits at base# 31

There are 3 hits at base# 40 Ragged

BstNI CCwgg 30

1: 41	2: 40	5: 40	6: 40	7: 40	8: 40
9: 40	10: 40	11: 40	12: 39	12: 53	13: 40
13: 53	14: 53	16: 40	16: 53	17: 40	17: 53
18: 40	18: 53	19: 53	21: 39	22: 39	23: 40
24: 40	27: 40	28: 40	29: 15	29: 40	30: 39

There are 17 hits at base# 40

There are 7 hits at base# 53

There are 4 hits at base# 39

There are 1 hits at base# 41 Ragged

PspGI ccwgg 30

1: 41	2: 40	5: 40	6: 40	7: 40	8 : 40
9: 40	10: 40	11: 40	12: 39	12: 53	13: 40
13: 53	14: 53	16: 40	16: 53	17: 40	17: 53
18: 40	18: 53	19: 53	21: 39	22: 39	23: 40
24: 40	27: 40	28: 40	29: 15	29: 40	30: 39

There are 17 hits at base# 40

There are 7 hits at base# 53

There are 4 hits at base# 39

There are 1 hits at base# 41

ScrFI CCngg 39

1: 41	2: 40	3: 40	3: 41	4: 40	4: 41
5: 40	6: 32	6: 40	7: 32	7: 40	8: 40
9: 32	9: 40	10: 40	11: 40	12: 39	12: 53
13: 40	13: 53	14: 53	16: 40	16: 53	17: 40
17: 53	18: 40	18: 53	19: 40	19: 53	21: 39
22: 39	23: 40	24: 40	26: 40	27: 40	28: 40
29: 15	29: 40	30: 39

There are 21 hits at basei 40

There are 4 hits at base# 39

There are 3 hits at base# 41

MaeIII gtnac 16

1: 52	2: 52	3: 52	4: 52	5: 52	6: 52
7: 2	9: 52	26: 52	27: 10	27: 52	28: 10
28: 52	29: 10	29: 52	30: 52

There are 13 hits at base# 52

Tsp45I gtsac 15

1: 52	2: 52	3: 52	4: 52	5: 52	6: 52
7: 52	9: 52	27: 10	27: 52	28: 10	28: 52
29: 10	29: 52	30: 52

There are 12 hits at base# 52

HphI tcacc 26

1: 53	2: 53	3: 53	4: 53	5: 53	6: 53
7: 53	8: 53	9: 53	10: 53	11: 59	13: 59
14: 59	17: 59	18: 59	19: 59	20: 59	21: 59
22: 59	23: 59	24: 59	25: 59	27: 59	28: 59
30: 59	31: 59

There are 16 hits at base# 59

There are 10 hits at base# 53

BspMI ACCTGCNNNNn (SEQ ID NO: 349) 14

11: 61	13: 61	14: 61	17: 61	18: 61	19: 61
20: 61	21: 61	22: 61	23: 61	24: 61	25: 61
30: 61	31: 61

There are 14 hits at base# 61 Goes into CDR1

TABLE 12

Matches to URE FR3 adapters in 79 human HC.

A. List of Heavy-chains genes sampled

AF008566	af103343	HSA235676	HSU94412	MCOMFRAA

AF035043	AF103367	HSA235675	HSU94415	MCOMFRVA

AF103026	AF103368	HSA235674	HSU94416	S32745

af103033	AF103369	HSA235673	HSU94417	382764

AF103061	AF103370	HSA240559	HSU94413	S83240

Af103072	af103371	HSCB201	HSU96389	SABVH369

af103078	AF103372	HSIGGVHC	HSU96391	SADEIGVH

AF103099	AF158381	HSU44791	HSU96392	SAH2TGVH

AF103102	E05213	HSU44793	HSU96395	SDA3IGVH

AF103103	E05886	HSU82771	HSZ93849	SIGVHTTD

AF103174	E05887	HSU82949	HSZ93850	SUK4IGVH

AF103186	HSA235661	HSU82950	HSZ93851

af103187	HSA235664	HSU82952	HS3Z93853

AF103195	HSA235660	HSU82961	HSZ93855

af103277	HSA235659	HSU36522	HS393357

af103286	HSA235678	HSU86523	HSZ93860

AF103309	HSA235677	HSU92452	HSZ93863

Table 12B. Testing all distinct GLGs from bases 89.1 to 93.2 of

the heavy variable domain

Id
NO:	Nb	0	1	2	3	4			SEQ ID

1	30	15	11	10	0	2	Seq1	gtgtattactgtgc	25

2	19	7	6	4	2	0	Seq2	gtAtattactgtgc	26

3	1	0	0	1	0	0	Seq3	utgtattactgtAA	27

4	7	1	5	1	0	0	Seq4	gtgtattactgtAc	28

5	0	0	0	0	0	0	Seq5	Ttgtattactatac	29

6	0	0	0	0	0	0	Seq6	TtgtatCactgtgc	30

7	3	1	0	1	1	0	Seq7	ACAtattactgtgc		31

8	2	0	2	0	0	0	Seq8	ACgtattactutac	32

9	9	2	2	4	1	0	Seq9	ATgtattactatac	33
Group		26	26	21	4	2
Cumulative		26	5	73	77	79

Table 12C Most important URE recognition secTs in FRS Heavy

1	VHSzy1	GTGtattactgtgc	(ON_SHC103)	(SEQ ID NO: 25)

2	VHSzy2	GTAtattactgtgc	(ON_SHC323)	(SEQ ID NO: 28)

3	VHSzy4	GTGtattactgtac	(ON_SHC349)	(SEQ ID NO: 28)

4	VHSzy9	ATGtattactgtgc	(ON_SHC5a)	(SEQ ID NO: 33)

Table 12D, testing 79 human HC V genes with four probes

Number of sequences . . . 79

Number of bases . . . 29143

Number of mismatches

Id	Best	0	1	2	3	4	5

1	39	15	11	10	1	2	0	Seq1	gtgtattactgtgc	(SEQ ID NO: 25)

2	22	7	6	5	3	0	1	Seq2	atAtattactgtgc	(SEQ ID NO: 26)
3	7	1	5	1	0	0	0	Seq4	gtgtattactgtAc	(SEQ ID NO: 28)
4	11	2	4	4	1	0	0	Seq9	ATgtattactgtgc	(SEQ ID NO: 33)
Group		25	26	20	5	2
Cumulative		25	51	71	76	78

One sequence has five mismatches with sequences 2, 4, and 9; it is scored as best for 2.
Id is the number of the adapter.
Best is the number of sequence for which the identified adapter was the best available.
The rest of the table shows how well the sequences match the adapters. For example, there are 10 sequences that match VHSzy1(Id = 1) with 2 mismatches and are worse for all other adapters. In this sample, 90% come within 2 bases of one of the four adapters.

TABLE 13

The following list of enzymes was taken from
rebase.neb.com/cgi-bin/asymmlist.
I have removed the enzymes that a) cut within the recognition, b) cut on
both sides of the recognition, or c) have fewer than 2 bases between
recognition and closest cut site.
REBASE Enzyme
Apr./13/2001
Type II restriction enzymes with asymmetric recognition sequences:

Enzymes	Recognition Sequence	Isoschizomers	Suppliers

AarI	CACCTGCNNNN{circumflex over ( )}NNNN_	—	y

AceIII	CAGCTCNNNNNNN{circumflex over ( )}NNNN_	—	—

BbrVI	GAAGACNNNNNNN{circumflex over ( )}NNNN_	—	—

BbvI	GCAGCNNNNNNNN{circumflex over ( )}NNNN_		y

BbvII	GAAGACNN{circumflex over ( )}NNNN_

Bce831	CTTGAGNNNNNNNNNNNNNN_NN{circumflex over ( )}	—	—

BceAI	ACGGCNNNNNNNNNNN{circumflex over ( )}NN_	—	y

BcefI	ACGGCNNNNNNNNNNN{circumflex over ( )}N_	—	—

BciVI	GTATCCNNNNN_N{circumflex over ( )}	BfuI	y

BfiI	ACTGGGNNNN_N{circumflex over ( )}	BmrI	y

BinI	GGATCNNNN{circumflex over ( )}N_

BscAI	GCATCNNNN{circumflex over ( )}NN_	—	—

BseRI	GAGGAGNNNNNNNN_NN{circumflex over ( )}	—	y

BsmFI	GGGACNNNNNNNNNN{circumflex over ( )}NNNN_	BspLU11III	y

BspMI	ACCTGCNNNN{circumflex over ( )}NNNN_	Acc36I	y

EciI	GGCGGANNNNNNNNN_NN{circumflex over ( )}	—	y

Eco57I	CTGAAGNNNNNNNNNNNNNN_NN{circumflex over ( )}	BspKT5I	y

FauI	CCCGCNNNN{circumflex over ( )}NN_	BstFZ438I	y

FokI	GGATGNNNNNNNNN{circumflex over ( )}NNNN_	Bstpz4181	y

GsuI	CTGGAGNNNNNNNNNNNNNN_NN{circumflex over ( )}	—	y

HgaI	GACGCNNNNN{circumflex over ( )}NNNNN_	—	y

HphI	GGTGANNNNNNN_N{circumflex over ( )}	AsuHPI	y

MboII	GAAGANNNNNNN_N{circumflex over ( )}	—	y

MlyI	GAGTCNNNNN{circumflex over ( )}	SchI	y

MmeI	TCCRACNNNNNNNNNNNNNNNNNN_NN{circumflex over ( )}	—	—

MnlI	CCTCNNNNNN_N{circumflex over ( )}	—

PleI	GAGTCNNNN{circumflex over ( )}N_	PpsI	y

RleAI	CCCACANNNNNNNNN_NNN{circumflex over ( )}	—	—

SfaNI	GCATCNNNN{circumflex over ( )}NNNN_	BspST5I	y

SspD5I	GGTGANNNNNNNN{circumflex over ( )}	—	—

Sth132I	CCCGNNNN{circumflex over ( )}NNNN_	—	—

StsI	GGATGNNNNNNNNNN{circumflex over ( )}NNNN_	—	—

TaqII	GACCGANNNNNNNNN_NN{circumflex over ( )}, CACCCANNNNNNNNN_NN{circumflex over ( )}	—	—

Tth111II	CAARCANNNNNNNNN_NN{circumflex over ( )}	—	—

UbaPI	CGAACG	—	—

(SEQ ID NOs: 356-390, respectively, in order of appearance) The notation is {circumflex over ( )} means cut the upper strand and _ means cut the lower strand. If the upper and lower strand are cut at the same place, then only {circumflex over ( )} appears.

TABLE 14

(FOKlact)	5′- TTgTT -3′ (SEQ ID NO: 350)

(VHEx881)	5′-AATAgTAgAc TgcAgTgTcc TcAgcccTTA AgcTgTTcAT cTgcAAgTAg-
	AgAgTATTcT TAgAgTTgTc TcTAgAcTTA gTgAAgcg-3′ (SEQ ID NO: 351)

! note that VHEx881 is the reverse complement cf the ON below

!	[RC] 5′-cgCttcacTaag-
!	Scab . . .
!	Synthetic 3-23 as in Table 206
!	\|TCT\|AGA\|gac\|aac\|tct\|aag\|aat\|act\|ctc\|tac\|ttg\|cag\|atg\|-
!	XbaI . . .
!	\|aac\|agC\|TTA\|AGg\|gct\|gag\|gac\|aCT\|GCA\|Gtc\|tac\|tat\|t-3′ (SEQ ID NO: 352)
!	AflII . . .

(VHBA881)	5′-cgCttcacTaag-
	\|TCT\|AGA\|gac\|aac\|tct\|aag\|aat\|act\|ctc\|tac\|ttg\|cag\|atg\|-
	\|aac\|agC\|TTA\|AGg\|gct\|gag\|gac\|aCT\|GCA\|Gtc\|tac\|tat\|tgt gcg ag-3′ (SEQ ID NO: 353)

(VHBB881)	5′-cgCttcacTaag-
	\|TCT\|AGA\|gac\|aac\|tct\|aag\|aat\|act\|ctc\|tac\|ttg\|cag\|atg\|-
	\|aac\|agC\|TTA\|AGg\|gct\|gag\|gac\|aCT\|GCA\|Gtc\|tac\|tat\|tgt Acg ag-3′ (SEQ ID NO: 354)

(VH881PCR)	5′-cgCttcacTaag\|TCT\|AGA\|gac\|aac -3′ (SEQ ID NO: 355)

TABLE 15

Use of FokI as “Universal Restriction Enzyme”

FokI - for dsDNA, | represents sites of cleavage

sites of cleavage

5′-cacGGATGtg--nnnnnnn|nnnnnnn-3′(SEQ ID NO: 15)

3′-gtgCCTACac--nnnnnnnnnnn|nnn-5′ (SEQ ID NO: 16)

RECOG

NITion of FokI

Case I

Case II

Case III (Case I rotated 180 degrees)

Case IV (Case II rotated 180 degrees)

Improved FokI adapters

FokI - for dsDNA, | represents sites of cleavage

Case I

Stem 11, loop 5, stem 11, recognition 17

Case II

Stem 10, loop 5, stem 10, recognition 18

Case III (Case I rotated 180 degrees)

Stem 11, loop 5, stem 11, recognition 20

Case IV (Case II rotated 180 degrees)

Stem 11, loop 4, stem 11, recognition 17

BseRI

(SEQ ID NO: 9) | sites of cleavage

5′-cacGAGGAGnnnnnnnnnn|nnnnn-3′

3′-gtgctctcctcnnnnnnnn|nnnnnnn-5′

RECOG

NITion of BseRI

Stem 11, loop 5, stem 11, recognition 19

TABLE 16

Human heavy chains bases 88.1 TO 94.2
Number of sequences . . . 840

Number of Mismatchers . . .

Probe

Id	Ntot	0	1	2	3	4	5	6	7	Name	Sequence . . .	Dot form . . .

1	364	152	97	76	26	7	4	2	0	VHS881-1.1	gctgtgtattactgtgcgag	gctgtgtattactgtgcgag

2	265	150	60	33	13	5	4	0	0	VES881-1.2	gccgtgLattactgtgogag	..c.................

3	96	14	34	16	10	5	7	9	1	VBS881-2.1	gccgtatattactgtgcgag	..c..a..............

20	0	3	4	9	2	2	0	0		V5S881-4.1	gccgtgtattactgtacgag	..c............a....

	95	25	36	18	11	2	2	0	1	VHS881-9.1	gccatgtattactqtgcgag	..ca................

840	341	230	147	69	21	19	11	2	(SEQ. ID NOs: 391-395, respectively in order of
	341	571	718	787	808	827	838	840	appearance)

88 89 90 91 92 93 94 95

Codon number as in Table 195

	Recognition . . .	Stem . . .	Loop . . .	Stem . . .

(VHS881-1.1)	5′-gctgtgtat\|tact-gtgcgag		TTgTT	-3′

(VHS881-1.2)	5′-gccgtgtat\|tact-gtgcgag		TTgTT	-3′

(VHS881-2.1)	5′-gccgtatat\|tact-gtgcgag		TTgTT	-3′

(VHS881-4.1)	5′-gcagtgtat\|tact-gtacgag		TTgTT	-3′

(VHS881-9.1)	5′-gccatgtat\|tact-gtgcgag		TTgTT	-3′

| site of substrate cleavage

(Sequences in the left column above are SEQ. ID NOs 391-395, respectively in oder of appearance;

Sequences in the right column above are all SEQ ID NO: 396)

(FOKlact)	5′- TTgTT -3′ (SEQ ID NO: 396)

(VHEx881)	5′-AATAgTAgAc TgcAgTgTcc TcAgcccTTA AgcTgTTcAT cTgcAAgTAg-
	AgAgTATTcT TAgAgTTgTc TcTAgAcTTA gTgAAgcg-3′ (SEQ ID NO: 397)

! note that VHEx881 is the reverse complement of the ON below

!	[RC] 5′-cgCttcacTaag-
!	Scab . . .
!	Synthetic 3-23 as in Table 206
!	\|TCT\|AGA\|gac\|aac\|tct\|aag\|aat\|act\|ctc\|tac\|ttg\|cag\|atg\|-
!	XbaI . . .
!	\|aac\|agC\|TTA\|AGg\|gcg\|gag\|gac\|aCT\|GCA\|Gtc\|tac\|tat\|t-3′
!	AflII . . .

(VHBA881)	5′-cgCttcacTaag-
	\|TCT\|AGA\|gac\|aac\|tct\|aag\|aat\|act\|ctc\|tac\|ttg\|cag\|atg\|-
	\|aac\|agC\|TTA\|AGg\|gct\|gag\|gac\|aCT\|GCA\|Gtc\|tac\|tat\|tgt gcg ag-3′ (SEQ ID NO: 398)

(VHBB881)	5′-cgCttcacTaag-
	\|TCT\|AGA\|gac\|aac\|tct\|aag\|aat\|act\|ctc\|tac\|ttg\|cag\|atg\|-
	\|aac\|agC\|TTA\|AGg\|gct\|gag\|gac\|aCT\|GCA\|Gtc\|tac\|tat\|tgt Acg ag-3′ (SEQ ID NO: 618)

(VH881PCR)	5′-cgCttcacTaag\|TCT\|AGA\|gac\|aac -3′ (SEQ ID NO: 399)

TABLE 17

Kappa, bases 12-30

!

! ID Ntot 0 1 2 3 4 5 6 Name Sequence........... Dot Form...........

! 1 84 40 21 20 1 2 0 0 SK12O12 gacccagtctccatcctcc gacccagtctccatcctcc (residues 26-44 of SEQ ID NO: 400)

! 2 32 19 3 6 2 1 0 1 SK12A17 gactcagtctccactctcc ...t.........ct.... (residues 26-44 of SEQ ID NO: 400)

! 3 26 17 8 1 0 0 0 0 SK12A27 gacgcagtctccaggcacc ...g.........gg..a.. (residues 26-44 of SEQ ID NO: 400)

! 4 40 21 18 1 0 0 0 0 SK12A11 gacgcagtctccagccacc ...g.........g..a.. (residues 26-44 of SEQ ID NO: 400)

! 182 97 50 28 3 3 0 1

! 97 147 175 178 181 181 182

!

URE adapters:

! Stem...... Loop. Stem...... Recognition.......

(SzKB1230-O12) 5′-cAcATccgTg TTgTT cAcggATgTg ggAggATggAgAcTgggTc-3′ (SEQ ID NO: 400)

! [RC] 5′-gacccagtctccatcctcc

AAcAA

-3′

! Recognition........ Stem...... loop. Stem......

! FokI. FokI.

!

! Stem...... Loop. Stem...... Recognition.......

(SzKB1230-A17) 5′-cAcATccgTg TTgTT cAcggATgTg ggAgAgTggAgAcTgAgTc-3′ (SEQ ID NO: 401)

! [RC] 5′-gactcagtctccactctcc

AAcAA

-3′

! Recognition........ Stem...... loop. Stem......

! FokI. FokI.

! Stem...... Loop. Stem...... Recognition.......

(SzKB1230-A27) 5′-cAcATccgTg TTgTT cAcggATgTg ggTggccTggAgAcTgcgTc-3′ (SEQ ID NO: 402)

! [RC] 5′-gacgcagtctccaggcacc

AAcAA

-3′

! Recognition........ Stem...... loop. Stem......

! FokI. FokI.

!

! Stem...... Loop. Stem...... Recognition.......

(SzKB1230-A11) 5′-cAcATccgTg TTgTT cAcggATgTg ggTggcTggAgAcTgcgTc-3′ (SEQ ID NO: 403)

! [RC] 5′-gacgcagtctccagccacc

AAcAA

-3′

! Recognition........ Stem...... loop. Stem......

! FokI. FokI.

What happens in the upper strand:

(SzKB1230-O12*)

!

(SzKB1230-A17*)

!

(SzKB1230-A27*)

!

(SzKB1230-A11*)

(kapextURE)

(kapextUREPCR)

(kaBR01UR) 5′-ggAggATggA cTggATgTct TgTgcAcTgT gAcAAgAgTA gAgg-3′ (SEQ ID NO: 406)

! [RC] 5′-ccTctactctTgTcAcAgTgcAcAA gAc ATc cAg tcc a-tc ctc c-3′ ON above is R.C. of this one

(kaBR02UR) 5′-ggAggATggA cTggATgTct TgTgcAcTgT gAcAAgAgTA gAgg-3′ (SEQ ID NO: 407)

! [RC] 5′-ggTctactctTgTcAcAgTgcAcAA gAc ATc cAg tcc a-ct ctc c-3′ ON above is R.C. of this one

(kaBR03UR) 5′-ggTgccTggA cTggATgTcT TgTgcAcTgT gAcAAgAgTA gAgg-3′ (SEQ ID NO: 408)

! [RC] 5′-ccTctactctTgTcAcAgTgcAcAA gAc ATc cAg tcc a-gg cac c-3′ ON above is R.C. of this one

(kaBR04UR) 5′-ggTggcTggA cTggATgTcT TgTgcAcTgT gAcAAgAgTA gAgg-3′ (SEQ ID NO: 409)

! [RC] 5′-ccTctactctTgTcAcAgTgcAcAA gAc ATc cAg tcc a-gc cac c-3′ ON above is R.C. of this one

Scab..............ApaLI.

TABLE 18

Lambda URE adgpters bases 13.3 to 19.3

!

! Number of sequences.......... 128

!

! Number of mismatches..............

! Id Ntot 0 1 2 3 4 5 6 7 8 Name Sequence........... Dot form...........

! 1 58 45 7 1 0 0 0 2 2 1 VL133-2a2 gtctcctggacagtcgatc gtctcctggacagtcgatc (residues 632-635 of SEQ ID NO: 410)

! 2 16 10 1 0 1 0 1 1 0 2 VL133-3l ggccttgggacagacagtc .g.cttg......a.ag.. (residues 632-635 of SEQ ID NO: 411)

! 3 17 6 0 0 0 4 1 1 5 0 VL133-2c gtctcctggacagtcagtc ...............ag.. (residues 632-635 of SEQ ID NO: 412)

! 4 37 3 0 10 4 4 3 7 4 2 VL133-1c ggccccagggcagagggtc .g.c..a..g...ag.g.. (residues 632-635 of SEQ ID NO: 413)

! 128 64 8 11 5 8 5 11 11 5

64 72 83 88 96 101 112 123 128

! Stem...... loop. Stem...... Recognition........

(VL133-2a2) 5′-cAcATccgTg TTgTT cAcggATgTg gATcgAcTgTccAggAgAc-3′ (SEQ ID NO: 410)

! [RC] 5′-gtctcctggacagtcgatc

AAcAA

-3′

! Recognition........ Stem...... loop. Stem......

!

! Stem...... loop. Stem...... Recognition........

(VL133-3l) 5′-cAcATccgTg TTgTT cAcggATgTg gAcTgTcTgTcccA Aggcc-3' (SEQ ID NO: 411)

! [RC] 5′-ggccttgggacagacagtc

AAcAA

-3′

! Recognition........ Stem...... loop. Stem......

!

! Stem...... loop. Stem...... Recognition........

(VL133-2c) 5′-cAcATccgTg TTgTT cAcggATgTg gAcTgAcTgTccAggAgAc-3′ (SEQ ID NO: 412)

! [RC] 5′-gtctcctggacagtcagtc

AAcAA

-3′

! Recognition........ Stem...... loop. Stem......

!

! Stem...... loop. Stem...... Recognition........

(VL133-1c) 5′-cAcATccgTg TTgTT cAcggATgTg gAcccTcTgcccTggggcc-3′ (SEQ ID NO: 413)

[RC] 5′-ggccccagggcagagggtc

AAcAA

-3'

What happens in the top strand:

! | site of cleavage in the upper strand

(VL133-2a2*) 5′-g tct cct g|ga cag tcg atc (residues 632-635 of SEQ ID NO: 410)

!

(VL133-3l*) 5′-g gcc ttg g|ga cag aca gtc (residues 632-635 of SEQ ID NO: 411)

!

(VL133-2c*) 5'-g tct cct g|ga cag tca gtc (residues 632-635 of SEQ ID NO: 412)

!

(VL133-1e) 5'-g gcc cca g|gg cag agg gtc (residues 632-635 of SEQ ID NO: 413)

!

! The following Extenders and Bridges all encode the AA sequence of 2a2 for codons 1-15

! 1

(ON_LamEx133) 5′-ccTcTgAcTgAgT gcA cAg-

!

! 2 3 4 5 6 7 8 9 10 11 12

AGt gcT TtA acC caA ccG gcT AGT gt-T AGC ggT-

!

! 13 14 15

tcC ccG g! 2a2 (SEQ ID NO: 414)

!

(ON_LamB1-133)[RC] 5′-ccTcTgAcTgAgT gcA cAg -

! 2 3 4 5 6 7 8 9 10 11 12

AGt gcT TtA acC caA ccG gcT AGT gsT AGC ggT-

!

! 13 14 15

tcC ccG g ga cag tcg at-3′ ! (SEQ ID NO: 415)_2a2

the actual seq is the

! reverse complement of the

! one shown.

!

(ON_LamB2-133)[RC] 5′-ccTcTgAcTgAgT gcA cAg-

!

! 2 3 4 5 6 7 8 9 10 11 12

AGt gcT TtA acC caA ccG gcT AGT grT AGC ggT-

!

! 13 14 15

tcC ccG g ga cag aca gt-3′! (SEQ ID NO: 416) 31 N.B. the actual seq is the

! reverse complement of the

! one shown.

!

(ON_LamB3 133)[RC] 5′ ccTcTgAcTgAgT gcA cAg

! 2 3 4 5 6 7 8 9 10 11 12

AGt gcT TtA acC caA ccG gcT AGT gtT AGC ggT-

!

! 13 14 15

tcC ccG g ga cag tca gt-3′! (SEQ ID NO: 417)_2c

the actual seq is the

reverse complement of the

one shown.

!

! (ON_LamB4-133) [RC] 5′-ccTcTgAcTgAgT gcA cAg-

!

! 2 3 4 5 6 7 8 9 10 11 12

AGt gcT TtA acC caA ccG gcT AGT gtT AGC ggT-s

!

13 14 15

tcC ccG g gg cag agg gt-3′ ! (SEQ ID NO: 413) 1c

the

actual seq is the

! reverse complement of the

! one shown.

!

(ON_Lam133PCR) 5′-ccTcTgAcTaAgT gcA cAg AGt gc-3′ (SEQ ID NO: 419)

TABLE 19

Cleavage of 75 human light chains.

Enzyme	Recognition*	Nch	Ns	Planned location of site

AfeI	AGCgct	0	0

AflII	Cttaag	0	0	HC FR3

AgeI	AccggL	0	0

AscI	GGcgcgcc	0	0	After LC

BglII	Aqatct	0	0

BsiWI	Cgtacg	0	0

BspDI	ATcgat	0	0

BssHII	Gcgcgc	0	0

BstBI	TTcgaa	0	0

DraIII	CACNNNgtg	0	0

EagI	Cqqccg	0	0

FseI	GGCCGGcc	0	0

FspI	TGCgca	0	0

HpaI	GTTaac	0	0

MfeI	Caattg	0	0	HC FR1

MluI	Acgcgt	0	0

NcoI	Ccatgg	0	0	Heavy chain signal

NheI	Gctagc	0	0	HC/anchor linker

NotI	GCggccgc	0	0	In linker after HC

NruI	TCGcga	0	0

PacI	TTAATtaa	0	0

PmeI	GTTTaaac	0	0

PmlI	CACgtg	0	0

PvuI	CGATcg	0	0

SacII	CCGCgg	0	0

SalI	Gtcgac	0	0

SfiI	GGCCNNNNnggcc	0	0	Heavy Chain signal
				(SEQ ID NO: 436)

SgfI	GCGATcgc	0	0

SnaBI	TACgta	0	0

StuI	AGGcct	0	0

XbaI	Tctaga	0	0	HC FR3

AatII	GACGTc	1	1

AclI	AAcgtt	1	1

AseI	ATtaat	1	1

BsmI	GAATGCN	1	1

BspEI	Tccgga	1	1	HC FR1 (SEQ ID NO: 437)

BstXI	CCANNNNNntgg	I	1	HC FR2 (SEQ ID NO: 438)

DrdI	GACNNNNnngtc	1	1

HindIII	Aagctt	1	1

PciI	Acatgt	1	1

SapI	gaagagc	1	1

ScaI	AGTact	1	1

SexAI	Accwggt	1	1

SpeI	Actagt	1	1

TliI	Ctcgag	1	1

XhoI	Ctcgag	1	1

BcgI	cgannnnnntgo	2	2	(SDQ ID NO: 439)

BlpI	GCtnagc	2	2

BssSI	Ctagtg	2	2

BstAPT	GCANNNNntgc	2	2	(SEQ ID NO: 440)

EspI	GCtnagc	2	2

KasI	Ggcgcc	2	2

PflMI	CCANNNNntgg	2	2	(SEQ ID NO: 441)

XmnI	GAANNnnttc	2	2	(SEQ ID NO: 442)

ApaLI	Gtgcac	3	3	LC signal seq

NaeI	GCCggc	3	3

NgoMI	Gccggc	3	3

PvuII	CAGctg	3	3

RsrII	CGgwocg	3	3

BsrBI	GAGcgg	4	4

BsrDI	GCAATGNNn	4	4

BstZ17I	GTAtac	4	4

EcoRI	Gaattc	4	4

SphI	GCATGc	4	4

SspI	AATatt	4	4

AccI	GTmkac	5	5

BclI	Tgatca	5	5

BsmBI	Nnnnnngagacg	5	5	(SEQ ID NO: 443)

BsrGI	Tgtaca	5	5

DraI	TTTaaa	6	6

NdeI	CAtatg	6	6	HC FR4

SwaI	ATTTaaat	6	t

BamHI	Ggatcc	7	7

SacI	GAGCTc	7	7

BciVI	GTATCCNNNNUN	8	8	(SEQ ID NO: 444)

BsaBI	GATNNnnatc	8	8	(SEQ ID NO: 619)

NsiI	ATGCAt	8	8

Bsp120I	Gggccc	9	9	CH1

ApaI	GGGCCc	9	9	CH1

PspOOMI	Gggccc	9	9

BspHI	Tcatga	9	11

EcoRV	GATatc	9	9

AhdI	GACNNNnngtc	11	11	(SEQ ID NO: 445)

BbsI	GAAGAC	11	14

PsiI	TTAtaa	12	12

BsaI	GGTCTCNnnnn	13	15	(SEQ ID NO: 446)

XmaI	Cccggg	13	14

AvaI	Cycgrg	14	16

BglI	GCCNNNNnggc	14	17	(SEQ ID NO: 447)

AlwNI	CAGNNNctg	16	16

BspMI	ACCTGC	17	19

XcmI	CCANNNNNnnnntgg	17	26	(SEQ ID NO: 448)

BstEII	Ggtnacc	19	22	HC FR4

Sse8387I	CCTGCAgg	20	20

AvrII	Cctagg	27	27

HincII	GTYrac	22	22

BsgI	GTGCAG	27	29

MscI	TGGcca	30	34

BseRI	NNnnnnnnnnctcctc	32	35	(SEQ ID NO: 449)

Bsu36I	CCtnagg	35	37

PstI	CTGCAg	35	40

EciI	nnnnnnnnntccgcc	38	40	(SEQ ID NO: 450)

PpuMI	RGgwccy	41	50

StyI	Ccwwgg	44	73

EcoO109I	RGgnccy	46	70

Acc65I	Ggtacc	50	51

KpnI	GGTACc	50	51

BpmI	ctccag	53	82

AvaII	Ggwcc	71	124

* cleavage occurs in the top strand after the last upper-case base. For EMs
that cut palindromic sequences, the lower strand is cut at the symmetrical
site.

TABLE 20

Cleavage of 79 human heavy chains

				Planned location
Enzyme	Recognition	Nch	Ns	of site

AfeI	AGCgct	0	0

AflII	Cttaag	0	0	NC FR3

AscI	GGcgcgcc	0	0	After LC

BsiWI	Cgtacg	0	0

BspDI	ATcgat	0	0

BssHII	Gcgcgc	0	0

FseI	GGCCGGcc	0	0

HpaI	GTTaac	0	0

NheI	Gctagc	0	0	HC Linker

NotI	GCggccgc	0	0	In linker, HC/anchor

NruI	TCGcga	0	0

NsiI	ATGCAt	0	0

PacI	TTAATtaa	0	0

PciI	Acatgt	0	0

PmeI	GTTTaaac	0	0

PvuI	CGATcg	0	0

RsrII	CGgwccg	0	0

SapI	aaagagc	0	0

SfiI	GGCCNNNNnggcc	0	0	HC signal seq
				(SEQ ID NO: 420)

SgfI	GCGATcgc	0	0

SwaI	ATTTaaat	0	0

Roil	kAcgtt	1	1

AgeI	Accggt	1	1

AseI	ATtaat	1	1

AvrII	Cctagg	1	1

BsmI	GAATGCN	1	1

BsrBI	GAGcqg	1	1

BsrDI	GCAATGNNn	1	1

Dual	TTTaaa	1	1

FspI	TGCgca	1	1

HindIII	Aagctt	1	1

MfeI	Caattg	1	1	HC FR1

NaeI	GCCggc	1	1

NgoMI	Gccggc	1	1

SpeI	Actagt	1	1

Acc65I	Ggtacc	2	2

BstBI	TTcgaa	2	2

KpnI	GGTACc	2	2

MluI	Acgcgt	2	2

NcoI	Ccatgg	2	2	In HC signal seq

NdeI	CAtatg	2	2	HC FR4

PmlI	CACgtg	2	2

XcmI	CCANNNNNnnnntgg	2	2	(SEQ ID NO: 421)

BcgI	cgannnnnntgc	3	3	(SEQ ID NO: 422)

BclI	Tgatca	3	3

BglI	GCCNNNNnggc	3	3	(SEQ ID NO: 423)

BsaBI	GATNNnnatc	3	3	(SEQ ID NO: 424)

BsrGI	Tgtaca	3	3

SnaBI	TACgta	3	3

Sse8387I	CCTGCAgg	3	3

ApaLI	Gtgcac	4	4	LC Signal/FR1

BspHI	Tcatga	4	4

BssSI	Ctcgtg	4	4

Pail	TTAtaa	4	5

SpnI	GCATGc	4	4

AhdI	GACNNNnngtc	5	5	(SEQ ID NO: 425)

BspEI	Tccgga	5	5	HC FR1

MscI	TGGcca	5	5

SacI	GAGCTc	5	5

ScaI	AGTact

SexAI	Accwggt	5	6

SspI	AATatt	5	5

TliI	Ctcgag	5	5

XhoI	Ctcgag	5	5

BbsI	GAAGAC	7	P

BstAPI	GCANNNNntgc	7	8	(SEQ ID NO: 426)

BstZ17I	GTAtac	7	7

BcoRV	GATatc	7	7

EcoRI	Gaattc	8	8

BlpI	GCtnagc	9	9

Bsu361	CCtnagg	9	9

DraIII	CACNNNgtg	9	9

EspI	GCtnagc	9	9

StuI	AGGcct	9	13

XbaI	Tctaga	9	9	HC FR3

Bsp120I	Gggccc	10	11	CH1

ApaI	GGGCCc	10	11	CH1

PspOOMI	Gggccc	10	ii

BciVI	GTATCCNNNNNN	11	11	(SEQ ID NO: 427)

SalI	Gtcgac	11	12

DrdI	GACNNNNnngtc	12	12	(SEQ ID NO: 428)

KasI	Ggcgcc	12	12

XmaI	Cccggg	12	14

BglII	Agatct	14	14

HincII	GTYrac	16	18

BamBI	Ggatcc	17	17

Pf1MI	CCANNNNntgg	17	18	(SEQ ID NO: 429)

BsmBI	Nnnnnngagag	18	21	(SEQ ID NO: 430)

BstXI	CCANNNNNntgg	18	19	HC FR2
				(SEQ ID NO: 431)

XmnI	GAANNnnttc	18	18	(SEQ ID NO: 432)

SacII	CCGCgg	19	19

PstI	CTGCAg	20	24

PvuII	CAGctg	20	22

AvaI	Cycgrg	21	24

EagI	Cggccg	21	22

AatII	GACGTc	22	22

BspMI	ACCTGC	27	33

AccI	GTmkac	30	43

StyI	Ccwwgg	36	49

AlwNI	CAGNNNctg	38	44

BsaI	GGTCTCNnnnn	38	44	(SEQ ID NO: 433)

PpuMI	RGgwccy	43	46

BsgI	GTGCAG	44	54

BseRI	NNnnnnnnnnctcctc	48	60	(SEQ ID NO: 434)

EciI	nnnnnnnnntccgcc	52	57	(SEQ ID NO: 435)

BstEII	Ggtnacc	54	61	HC Fr4, 47/79
				have one

EccO109I	RGgnccy	54	86

BpmI	ctccag	60	121

AvaII	Ggwcc	71	140

TABLE 21

MALIA3, annotated

! MALIA3 9532 bases

!

(SEQ ID NO: 451)

1 aat act act act att act aga att gat gcc acc ttt tca gct cgc gcc

! gene ii continued

49 cca aat gaa aat ata gct aaa cag gtt att gac cat ttg cga aat gta

97 tct aat ggt caa act aaa tct act cgt tcg cag aat tgg gaa tca act

145 gtt aca tgg aat gaa act tcc aga cag cgt act tta gtt gca tat tta

193 aaa cat gtt gag cta cag cac cag att cag caa tta agc tct aag cca

241 tcc gca aaa atg acc tct tat caa aaa gag caa tta aag gta ctc tct

289 aat cct gac ctg ttg gag ttt gct tcc ggt ctg gtt cgc ttt gaa gct

337 cga att aaa acg cga tat ttg aag tct ttc ggg ctt cct ctt aat ctt

385 ttt gat gca atc cgc ttt gct tct gac tat aat agt cag ggt aaa gac

433 ctg att ttt gat tta tgg tca ttc tcg ttt tct gaa ctg ttt aaa gca

481 ttt gag ggg gat tca ATG aat att tat gac gat tcc gca gta ttg gac

! RBS?...... Start gene x, ii continues

529 gct atc cag tct aaa cat ttt act att acc ccc tct ggc aaa act tct

577 ttt gca aaa acc tct cgc tat ttt ggt ttt tat cgt cgt ctg gta aac

625 gag ggt tat gat agt gtt gct ctt act atg cct cgt aat tcc ttt tgg

673 cgt tat gta tct gca tta gtt gaa tgt ggt att cct aaa tct caa ctg

721 atg cat ctt tct acc tat aat aat gtt gtt ccg tta gtt cat ttt att

769 aac gta gat ttt tct tcc caa cgt cct gac tgg tat aat gag cca gtt

817 ctt aaa atc gca TAA

! End X & II

832 ggtaattca ca

!

(SEQ ID NO: 623)

! M1 E5 Q10 T15

843 ATG att aaa gtt gaa att aaa cca tct caa gcc caa ttt act act cgt

! Start gene V

!

! S17 S20 P25 E30

891 tct ggt gtt tct cgt cag ggc aag cct tat tca ctg aat gag cap ctt

!

! V35 E40 V45

939 tgt tac gtt gat ttg ggt aat gaa tat ccg gtt ctt gtc aag att act

!

! D50 A55 L60

987 ctt gat gaa ggt cag cca gcc tat gcg cct ggt cTG TAC Acc gtt cgt

! BsrGI...

! L65 V70 575 R80

1035 ctg tcc tct ttc aaa gtt ggt cag ttc ggt tcc ott atg att gac cgt

!

! P85 K87 end of V

1083 ctg cgc ctc gtt ccg gct aag TAA C

!

1108 ATG gag cag gtc gcg gat ttc gac aca att tat cag gcg atg

! Start gene VII

!

1150 ata caa atc tcc gtt gta ctt tgt ttc gcg ctt ggt ata atc

!

! VII and IX overlap.

! ..... S2 V3 L4 V5 (SEQ ID NO: 624) S10

1192 gct ggg ggt caa agA TGA gt gtt tta atg tat tct ttc gcc tct ttc gtt

! End VII

! |start IX

! L13 W15 G20 T25 E29

1242 tta ggt tgg tgc ctt cgt agt ggc att acg tat ttt acc cgt tta atg gaa

!

1293 act tcc tc

!

! .... stop of IX, IX and VIII overlap by four bases

1301 ATG aaa aag tct tta gtc ctc aaa gcc tct gta gcc gtt gct acc ctc

! Start signal sequence of viii.

!

1349 gtt ccg atg ctg tct ttc gct gct gag ggt gac gat ccc gca aaa gcg

! mature VIII --->

1397 acc ttt aac tcc ctg caa gcc tca gcg acc gaa tat atc ggt tat gcg

1445 tgg gcg atg gtt gtt gtt att

1466 gtc ggc gca act atc ggt atc aag ctg ttt aag

1499 aaa ttc acc tcg aaa gca ! 1515

! ........... −35 ..

!

1517 agc tga taaaccgat aoaattaaag gctccttttg

! ..... −10 ...

!

1552 gagccttttt ttttGGAGAt ttt ! S.D. underlined

!

! <------ III signal sequence ---------------------------- ->

! M K K L L F A I P L V (SEQ ID NO: 452)

1575 caac GTG aaa aaa tta tta ttc gca att cct tta gtt ! 1611

!

! V P F Y S H S A Q

1612 gtt cct ttc tat tct cac aGT acA Cag tCT

! ApaLI...

!

1642 GTC GTG ACG CAG CCG CCC TCA GTG TCT GGG GCC CCA GGG CAG

AGG GTC ACC ATC TCC TGC ACT GGG AGC AGC TCC AAC ATC GGG GCA

! BstEII...

1729 GGT TAT GAT GTA CAC TGG TAC CAG CAG CTT CCA GGA ACA GCC CCC AAA

1777 CTC CTC ATC TAT GGT AAC AGC AAT CCC CCC TCA GGG GTC CCT GAC CGA

1825 TTC TCT GGC TCC AAG TCT GGC ACC TCA GCC TCC CTG GCC ATC ACT

1870 GGG CTC CAG GCT GAG GAT GAG GCT GAT TAT

1900 TAC TGC CAG TCC TAT GAC AGC AGC CTG ACT

1930 GGC CTT TAT GTC TTC GGA ACT GGG ACC AAG GTC ACC GTC

! BstEII...

1969 CTA GGT CAG CCC AAG GCC AAC CCC ACT GTC ACT

2002 CTG TTC CCG CCC TCC TCT GAG GAG CTC CAA GCC AAC AAG GCC ACA CTA

2050 GTG TGT CTG ATC ACT CAC TTC TAC CCD GGA GCT GTG ACA GTG GCC TGG

2098 AAG GCA GAT AGC AGC CCC GTC AAG GCG GGA GTG GAG ACC ACC ACA CCC

2146 TCC AAA CAA ACC AAC AAC AAC TAC CCC CCC ACC ACC TAT CTC ACC CTC

2194 ACG CCT GAG CAG TGG AAG TCC CAC AGA AGC TAC AGC TGC CAG GTC ACG

2242 CAT GAA GGG AGC ACC GTG GAG AAG ACA GTG GCC CCT ACA GAA TGT TCA

2290 TAA TAA ACCG CCTCCACCGG GCGCGCCAAT TCTATTTCAA GGAGACAGTC ATA

! AscI.....

!

(SEQ ID NO: 453)

! PelB signal---------------------------------------------->

! M K Y L L P T A A A G L L L L

2343 ATG AAA TAC CTA TTG CCT ACG GCA GCC GCT GGA TTG TTA TTA CTC

!

! 16 17 18 19 20 21 22

! A A Q P A M A

2388 gcG GCC ccg ccG GCC atg gcc

! sfiI..............

! NgoMi...(1/2)

! NcoI

!

! FR1(DP47/V3 23)---------------

! 23 24 25 26 27 28 29 30

! E V Q L L E S G

2409 gaa|gtt|CAA|TTG|tta|gag|tct|ggt|

! | MfeI |

!

! --------------FR1--------------------------------------------

! 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45

! G G L V Q F G G S L R L S C A

2433 |gac|ggt|ctt|gtt|cag|cct|ggt|ggt|tct|tta|cgt|ctt|tct|tgc|gct|

!

! ----FR1---------------->|...CDR1................|---FR2------

! 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

! A S G F T F S S Y A M S W V R

2478 |gct|TCC|GGA|ttc|act|ttc|tct|tCG|TAC|Gct|atg|tct|tgg|gtt|cgC|

!

! -------FRS-------------------------------->|...CDR2.........

! 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75

! Q A P G K G L E W V S A I S G

2523 |CAa|gct|ccT|GGt|aaa|ggt|ttg|gag|tgg|gtt|tct|gct|atc|tct|ggt|

! ...BstXI

!

! .....CDR2............................................|---FR3---

! 76 77 78 79 80 31 82 83 34 35 86 87 88 39 90

! S G G S T Y Y A D S V K G R F

2568 |tct|ggt|ggc|agt|act|tac|tat|gct|gac|tcc|gtt|aaa|ggt|cgc|ttc|

!

! --------FR3--------------------------------------------------

! 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105

! T I S R D N S K N T L Y L Q M

2613 |act|atc|TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|

! | XbaI |

!

! ---FR3----------------------------------------------------->|

! 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120

! N S L R A E D T A V Y Y C A K

2658 |aac|agC|TTA|AGg|gct|gag|gac|aCT|GCA|Gtc|tac|tat|tgc|gct|aaa|

! |AflII | | PstI |

!

! .......CDR3.................|----FR4-------------------------

! 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135

! D Y E G T G Y A F D I W G Q G

2703 |gac|tat|gaa|ggt|act|ggt|tat|gct|ttc|gaC|ATA|TGg|ggt|caa|ggt|

! | NdeI |(1/4)

!

! --------------FR4---------->|

! 136 137 138 139 140 141 142

! T M V T V S S

2748 |act|atG|GTC|ACC|gtc|tct|agt

! | BstEII |

! From BstEII onwards, pV323 is same as pCEB1, except as noted.

! BstEII sites may occur in light chains; not likely to be unique in final

! vector.

!

! 143 144 145 146 147 148 149 150 151 152

! A S T K G P S V F P

2769 gcc tcc acc aaG GGC CCa tcg GTC TTC ccc

! Bsp120I. BbsI...(2/2)

! ApaI....

!

! 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167

! L A P S S K S T S G G T A A L

2799 ctg gca ccC TCC TCc aag agc acc tct ggg ggc aca gcg gcc ctg

! BseRI...(2/2)

!

! 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182

! G C L V K D Y F P E P V T V S

2844 ggc tgc ctg GTC AAG GAC TAC TTC CCc gaA CCG GTg acg gtg tcg

! AgeI....

!

! 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197

! W N S G A L T S G V H T F P A

2889 tgg aac t|a GGC GCC ctg ace ago ggc gto cac ace ttc ccg gct

! KasI...(1/4)

!

! 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212

! V L Q S S G L Y S L S S V V T

2934 gtc cta cag tCt agc GGa ctc tac tcc ctc age ago gta gtg acc

! (Bsu36I...)(knocked out)

!

! 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227

! V P S S S L G T Q T Y I C N V

2979 gtg ccC tct tct agc tTG Ggc acc cag acc tac atc tgc aac gtg

! (BstXI..........)N.B. destruction of BstXI & Bpmi sites.

!

! 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242

! N H K P S N T K V D K K V E P

3024 aat cac aag ccc agc aac acc aag gtg gac aag aaa gtt gag ccc

!

! 243 244 245

! K S C A A A H H H H H H S A

3069 aaa tCt tgt GCG GCC GCt aat cac cac cat cat cac tct gct

! NotI......

!

! E Q K L I S E E D L N G A A

3111 gaa caa aaa ctc atc tca gaa aag gat ctg cat agt gcc gca

!

! D I N D D R M A S G A

3153 GAT ATC aac gat gat cgt atg gct AGC ggc gcc

! rEK cleavage site.......... NheI... KasI...

! EcoRV..

!

! Domain 1 ------------------------------------------------------------

! A E T V E S C L A

3183 gct gaa act gtt gaa agt tat tta gca

!

! K P H T E I S F

3210 aaa ccc cat aca gaa aat tca ttt

!

! T N V W K D D K T

3234 aCT AAC CTC TGG AAA CAC CAC AAA Act

!

! L D R Y A N Y E G C L W N A T G V

3261 tta aat cgt tac gct aac tat gag ggt tgt ctg tgG AAT GCt aca ggc gtt

! BsmI

!

! V V C T G D F T Q C Y G T W V P I

3312 gta gtt tgt act ggt GAC GAA ACT CAG TGT TAC GGT ACA TGG GTT cct att

!

! G L A I P E N

3363 agg ctt gct atc cct aaa aat

!

! LI linker ------------------------------------

! E G G G S E G G G S

3384 gag ggt ggt ggc tct gag ggt ggc ggt tct

!

! E G G G S E G G G T

3414 gag ggt ggc ggt tct gag ggt ggc ggt act

!

! Domain 2

3444 aaa cct cct gag tac aat gat aca cct att ccg ggc tat act tat atc aac

3495 cct ctc gac ggc act tat ccg cct ggt act gag caa aac ccc gct aat cct

3546 aat cct tct ctt GAG GAG tct cag cct ott aat act ttc atg ttt cag aat

! BseRI

3597 act agg ttc cga aat agg cag ggg gca tta act gtt tat acg ggc act

3645 gtt act caa ggc act gac ccc gtt aaa act tat tac cag tac act cct

3693 gta tca tca aaa gcc atg tat gac gct tac tgg aac ggt aaa ttC AGA

! AIwNI

3741 GAC TGc gct ttc cat tct ggc ttt act gaa gat cca ttc gtt tgt gac

! AlwNI

3789 tat caa ggc caa tcg tct gac ctg cct caa cct cct gtc aat gct

!

3634 ggc ggc ggc trt

! start L2--------------------------------------------------------------

3846 ggt ggt ggt tct

3858 ggt ggc ggc tct

3870 gag ggt ggt ggc tct gag ggt ggc ggt tct

3900 gag ggt ggc ggc tct gag gga ggc ggt too

3930 aat ggt ggc tct ggt ! end L2

!

! Domain 3

(SFQ ID NO: 454)

----------------------------------------------------------------

! S G D F D Y F K M A N A N K G A

3945 tcc ggt gat ttt gat tat gaa aag atg gca aac gct aat aag ggg gct

!

! M T E N A D E N A L Q S D A K G

3993 atg act gaa aat gcc gat gaa aac gcg cta cag tct gac gct aaa ggc

!

! K L D S V A T D Y G A A I D G F

4041 aaa ctt gat tct gtc gct act gat tac ggt gct gct atc gat ggt ttc

!

! I G D V S G L A N G N G A T G N

4089 att ggt gaa gtt tcc ggc ctt gct aat ggt cat ggt gct act ggt gat

!

! F A G S N S Q M A Q V G D G D N

4137 ttt gct ggc tct aat tcc caa atg gct caa gtc ggt gac ggt gat aat

!

! S P L M N N F R Q Y I P S L P Q

4185 tca cct tta atg aat aat ttc cgt caa tat tta cct tcc ctc cct caa

!

! S V ECR P F V F SAPKPVE

4233 too gtt gaa tgt ego cot ttt gtc ttt ago get ggt aaa oca tat gaa

!

t FSIDCDKINLF.R.

4281 ttt tot att aat tgt gac aaa ata aac tta tto cgt

! End Domain 3

!

! PVFAFLLYVATFMFVF140

4317 oat pee ttt peg ttt ctt tta tat gtt gee ace ttt atg tat gta ttt

! start transmembrane segment

!

! STFANIL

4365 tot acg ttt got aao ata ctg

t

! ANKES

4386 opt aat aag gag tot TAA ! stop ot iii

! Intracellular anchor.

!

(SEQ ID NO: 455)

! Mi P2VLL5GIP1,1,101,RFLG15

4404 to ATP coa gtt Ott ttg ggt att cog tta tta ttg opt ttc etc ggt

! Start VI

!

4451 tte ott ctg gta act ttg tto ggc tat ctg ott act ttt ott aaa aag

4499 ggc tte ggt aag ata got att got att tea ttg ttt ott pot ott att

4547 att ggg ott aao toa att ott gtg ggt tat etc tot gat att age got

4595 caa tta ccc tot gac ttt gtt cap ggt gtt cap tta att oto cog tot

4643 aat pop ott coo tgt ttt tat gtt att oto tot gta aag got got att

4691 tte att ttt gac gtt aaa caa aaa ate gtt tot tat ttg gat tgg gat

!

(SEQ ID NO: 456)

! Ni A2 V3 F5 LILO G13

4739 aaa TAA t ATP got gtt tat ttt qta act ggc aaa tta ggo tot. gga

! end VI Start gene I

!

! 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

I KTLVSVPKTOCKTVA

4785 aag aog oto att age gtt ggt aag att cap gat aaa att gta got

!

! 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43

! PCKIATNLDLRLQNL

4830 aaa tgc aaa ata gee act net ott gat tta egg ott eaa aac etc

!

! 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58

! PQVGRFAKTPRVLKI

4875 cog caa gtc ggg agg ttc get aaa acg cot ego gtt ott aga ata

!

! 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73

! PDKPSISDLLAIGAG

4920 ccg gat aag cct tct ata tct gat ttg ctt gct att qgg ogc ggt

!

! 74 75 76 77 73 79 80 81 82 83 84 85 86 37 88

! N D S Y D E N K N G L L V L D

4965 aat gat tcc tac gat gaa aat aaa aac ggc ttg ctt gtt ctc gat

!

! 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103

! E C G T W F N T R S W N D K K

5010 aaa tgc ggt act tgg ttt aat acc cgt tct tgg aat gat aaa gaa

!

! 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118

! R Q P I I D W R L H A R R L G

5055 aga cag ccg att att gat tgg ttt cta cat gct cgt aaa tta gga

!

! 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133

! W H I I F L V Q D L S I V D K

5100 tgg gat att att ttt ctt gtt cag gac tta tct att gtt gat aaa

! 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148

! Q A R S A L A E H V V Y Q R R

5145 cag gcg cgt tct gca tta gct gaa cat gtt gtt tat tgt cgt cgt

!

! 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163

! L D R I T L P F V G T L Y S L

5190 ctg sac aga att act tta cct ttt gtc ggt act tta tat tct ctt

!

! 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178

! I T H S R M P L P R L H V G V

5235 att act ggc tcg aaa atg cct ctg cct aaa tta cat gtt ggc gtt

!

! 179 180 181 182 183 184 185 186 137 188 189 190 191 192 193

! V R Y G D S Q L S P T V E R W

5280 gtt aaa tat ggc gat tct caa tta agc cct act gtt gag cgt tgg

!

! 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208

! L Y T H R N L Y N A Y H T R Q

5325 ctt tat act ggt aag aat ttg tat aac gca tat gat act aaa cag

!

! 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223

! A F S S N Y D S H V Y S Y L T

5370 gct ttt tct agt aat tat gat tcc ggt gtt tat tct tat tta acg

!

! 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238

! P Y L S E G R Y F R P L N L G

5415 cct tat tta tca cac ggt cgg tat ttc aaa cca tta aat tta ggt

!

! 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253

! Q R M R L T R I Y L K K F S R

5460 cag aag atg aaa tta act aaa ata tat ttg aaa aag ttt tct cgc

!

! 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268

! V L C L A I G F A S A F T Y S

5505 gtt ctt tgt ctt gcg att gga ttt gca tca gca ttt aca tat apt

!

! 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283

! Y I T Q P K P E V R R V V S Q

5550 tat ata acc caa cct aag ccg gag gtt aaa aag ata gtc tct cag

!

! 224 225 286 227 222 229 290 251 292 293 254 255 296 297 292

! T Y D F D K F T I D S S Q R L

5595 acc tat gat ttt gat aaa ttc act att gac tct tct cag cgt ctt

! 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313

! N L S Y R Y V F K D S K C K I

5640 aat cta agc tat cgc tat gtt ttc aag gat tct aag gga aaa TTA

! PacI

!

314 315 316 317 318 319 320 321 322 323 324 325 326 327 328

I N S D H L Q K Q C Y S L T Y

5685 ATT AAt agc gac gat tta cag aaa caa ggt tat tca ctc aca tat

! PacI

!

! 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343

! i I D L C T V S I K K G N S N E

(SEQ ID NO: 620)

! iv M1 K

5730 att gat tta tgt act gtt tcc att aaa aaa gat aat tca aAT Gaa

! Start IV

!

! 344 345 346 347 348 349

! i I V K C N .End of I

! iv L3 L N5 V I7 N F V10

5775 att gtt aaa tgt aat TAA T TTT GTT

! IV continued

5800 ttc ttg atg ttt gtt tca tca tct tct ttt gct cag gta att gaa atg

5848 aat aat tcg cct ctg cgc gat ttt gta act tgg tat tca aag caa tca

5896 ggc aaa tcc gtt att att tct ccc gat gta aaa ggt act att act gta

5944 tat tca tct gac gtt aaa cct gaa aat cta cgc aat ttc ttt att tct

5992 gtt tta cgt act aat aat ttt gat atg gtt ggt tca att cct tcc ata

6040 att cag aag tat aat cca aat aat cag gat tat att gat gaa ttg cca

6088 tca ttt gat aat cag gaa tat gat gat cat tcc act cct tct ggt ggt

6136 ttc ttt gtt ccg caa aat gat aat gtt act caa act ttt aaa att aat

6184 aac gtt cgg gca aag gat tta ata cga gtt gtc gaa ttg ttt gta aag

6232 tct aat act tct caa tcc tca aat gta tta tct att gac ggc tct aat

6280 cta tta gtt gtt tTT gca cct aaa gat att tta gat aac ctt cct caa

! ApaLI removed

6328 ttc ctt tct act gtt gat ttg cca act gac cag ata ttg att gag ggt

6376 ttg ata ttt gag gtt caa caa ggt gat gct tta gat ttt tca ttt gct

6424 gct ggc tct cag cgt ggc act gtt gca ggc ggt gtt aat act gac cgc

6472 ctc acc tct gtt tta tct tct gct aat ggt tcg ttc ggt att ttt cat

6520 ggc gat gtt tta ggg cta tca gtt cgc gca tta aag act aat agc cat

6568 tca aaa ata ttg tct gtg cca cgt att ctt acg ctt tca ggt ccg aag

6616 ggt tct atc tct gtT GGC CAg aat gtc cct ttt att act ggt cgt gtg

! MscI

6664 act ggt gaa tct gcc aat gta aat act cca ttt cag acg att gag cgt

6712 caa aat gta ggt att tcc atg agc gtt ttt cct gtt gca atg gct ggc

6760 ggt act att gtt ctg gat att acc agc aag gcc gat agt ttg agt tct

6808 tct act cag gca agc gat gtt att act act caa aga agt att gct aca

6856 acg gtt aat ttg cgt gat gga cag act ctt tta ctc ggt ggc ctc act

6904 gat tat aaa aac act tct caa gat tct ggc gta ccg tta ctg tct aaa

6952 atc cct tta atc ggc ctc ctg ttt agc tcc cgc tct gat tcc aac gag

7000 gaa agc acg tta tac gtg ctc gtc aaa gca acc ata gta cgc gcc ctg

7048 TAG cggcgcatt

! End IV

7060 aagcacggcg ggtgtggtaa ttacgcgcag ogtgaccgct acacttgcca gcgccctagc

7120 gcccgctcct ttcgctttct tcccttcctt tctcgccaca ttcGCCGGCt ttccccgtca

! NgoMI_

7180 agctctaaat cgggggctcc ctttagggtt ccgatttagt actttacggc acctoaaccc

7240 caaaaaactt gatttgggtg atggttCACG TAGTGggcca tcgccctgat agacggtttt

! DraIII

7300 tcgccctttG ACGTTGGAGT Ccacgttctt taatagtgga ctcttgttcc aaactggaac

! DrdI

7360 aacactcaac cctatctcgg gctattcttt tgatttataa gggattttgc cgatttcgga

7420 accaccatca aacaggattt tcgcctgctg gggcaaacca gcgtggaccg cttgctgcaa

7480 ctctctcagg gccaggcggt gaagggcaat CAGCTGttgc cCGTCTCact ggtgaaaaga

! PvuII. BsmBI.

7540 aaaaccaccc tGGATCC AAGCTT

! BamHi HindIII (½)

Insert carrying bla gene

7563 gcaggtg gcacttttcg gggaaatgtg ogcggaacee

7600 ctatttgttt atttttctaa atacattcaa atatGTATCC gctcatdaaa caataaccct

! BciVI

7660 gataaatgct tcaataatat tgaaaaAGGA AGAgt

! RBS.?...

! Start bla gene

7695 ATG agt att caa cat ttc cgt gtc gcc ctt att ccc ttt ttt gcg gca ttt

7746 tgc ctt cct gtt ttt gct cac cca gaa acg ctg gtg aaa gta aaa gat gct

7797 gaa gat cag ttg ggC gCA CGA Gtg ggt tac atc gaa ctg gat ctc aac agc

! BssSI...

! ApaLI removed

7848 ggt aag atc ctt gag agt ttt cgc ccc gaa gaa cgt ttt cca atg atg agc

7899 act ttt aaa gtt ctg cta tgt cat aca cta tta tcc cgt att gac gcc ggg

7950 caa aaG CAA CTC GGT CGc cgg acg cag tat tat cag aat gac ttg gtt gAG

! BcgI ScaI

8001 TAC Tca cca gtc aca gaa aag cat ctt acg gat ggc atg aca gta aga gaa

! ScaI_

8052 tta tgc agt gct gcc ata acc atg agt gat aac act gcg gcc aac tta ctt

8103 cta aca aCG ATC Gga gga ccg aag aag cta acc gct ttt ttg cac aac atg

! PvuI

8154 ggg gat cat gta act cgc ctt gat cgt tgg gaa ccg gag ctg aat gaa gcc

8205 ata cca aac gac gag cgt gac acc acg ctg cct gta gca atg cca aca acg

8256 tTG CGC Aaa cta tta act ggc gaa cta ctt act cta gct tcc cgg caa caa

! FspI....

!

8307 tta ata gac tgg atg gag gcg gat aaa gtt gca gga cca ctt ctg cgc tcg

8358 GCC ctt ccG GCt ggc tgg ttt att gct gat aaa tct gga gcc ggt gag cgt

! BglI

8409 gGG TCT Cgc ggt atc att gca gca ctg ggg cca gat ggt aag ccc tcc cgt

! BsaI

8460 atc ata gtt atc tac act ACg ggg aGT Cag gca act atg gat gaa cga aat

! AhdI

8511 aga cag atc gct gag ata ggt gcc tca ctg att aag cat tgg TAA ctgt

! stop

8560 cagaccaagt ttactcatat atactttaga ttgatttaaa acttcatttt taatttaaaa

8620 ggatctaggt gaagatcctt tttgataatc tcatgaccaa aatcccttaa cgtgagtttt

8680 cgttccactg tacgtaagac cccc

8704 AAGCTT GTCGAC tgaa tggcgaa gg cgotttgcct

! HindIII SalI..

! (2/2) HincII

8740 ggtttccggc accagaagcg dtgccggaaa dctggctgga gtgcgatctt

!

8790 CCTGAGG

! Bsu36I_

8797 cogat actgtegtcg tcooctcaaa ctggcagatd

8832 caccidttacg atgcgcccat ctacaccaac dtaacctatc ccattaccidt caatccgccg

8992 t.t.i+32gttr ,ggagaal-r′r′ gF.rgggttgt tartcgr-,-,, atttaatgt tgatgagr..

8952 tdactacagg aaggccagac acgaattatt tttgatggcg ttoctattag ttaaaaaatg

9012 agctgattta acaaaaattt aacgcgaatt ttaacaaaat attaacgttt acaATTTAAA

! Swai...

9072 Tatttgctta tacaatcttc ctgtttttgg gguttttttg attatcaacc GGGGTAcat

! RBS?

9131 ATG att gac atg roe gtt tta cga tta ccg ttc atc gat tct ctt gtt tgc

! Start gene II

9182 tcc aga ctc tca ggc aat gac ctg ata gcc ttt gtA GAT CTc tca aaa ata

! BgiII...

9233 gct ccc ctc tcc ggc atg aat tta tca gct aga acg gtt gaa tat cat ctt

9284 gat ggt gat ttg act gtc tcc ggc ctt tct cac cct ttt gaa tct tta cct

9335 aca cat tac tca ggc att gca ttt aaa ata tat gag ggt tct aaa aat ttt

9386 tat cct tgc gtt gaa ata aag gct tct ccc gca aaa gta tta cag ggt cat

9437 aat gtt ttt ggt aca acc gat tta gct tta tgc tct gag gct tta ttg ctt

9488 aat ttt gct aat tct ttg cct tgc ctg tat gat tta ttg gat gtt ! 9532

! gene II continues

TABLE 21B

Sequence of MALIA3, condensed

LOCUS	MALIA3 9532 CIRCULAR
ORIGIN

(SEQ ID NO: 451)

1	AATGCTACTA CTATTAGTAG AATTGATGCC ACCTTTTCAG CTCGCGCCCC AAATGAAAAT

61	ATAGCTAAAC AGGTTATTGA CCATTTGCGA AATGTATCTA ATGGTCAAAC TAAATCTACT

121	CGTTCGCAGA ATTGGGAATC AACTGTTACA TGGAATGAAA CTTCCAGACA CCGTACTTTA

181	GTTGCATATT TAAAACATGT TGAGCTACAG CACCAGATTC AGCAATTAAG CTCTAAGCCA

241	TCCGCAAAAA TGACCTCTTA TCAAAAGGAG CAATTAAAGG TACTCTCTAA TCCTGACCTG

301	TTGGAGTTTG CTTCCGGTCT GGTTCGCTTT GAAGCTCGAA TTAAAACGCG ATATTTGAAG

361	TCTTTCGGGC TTCCTCTTAA TCTITTTGAT GCAATCCGCT TTGCTTCTGA CTATAATAGT

421	CAGGGTAAAG ACCTGATTTT TGATTTATGG TCATTCTCGT TTTCTGAACT GTTTAAAGCA

481	TTTGAGGGGG ATTCAATGAA TATTTATGAC GATTCCGCAG TATTGGACGC TATCCAGTCT

541	AAACATTTTA CTATTACCCC CTCTGGCAAA ACTTCTTTTG CAAAAGCCTC TCGCTATTTT

601	GGTTTTTATC GTCGTCTGGT AAACGAGGGT TATGATAGTG TTGCTCTTAC TATGCCTCGT

661	AATTCCTTTT GGCGTTATGT ATCTGCATTA GTTGAATGTG GTATTCCTAA ATCTCAACTG

721	ATGAATCTTT CTACCTGTAA TAATGTTGTT CCGTTAGTTC GTTTTATTAA CGTAGATTTT

781	TCTTCCCAAC GTCCTGACTG GTATAATGAG CCAGTTCTTA AAATCGCATA AGGTAATTCA

841	CAATGATTAA AGTTGAAATT AAACCATCTC AAGCCCAATT TACTACTCGT TCTGGTGTTT

901	CTCGTCAGGG CAAGCCTTAT TCACTGAATG AGCAGCTTTG TTACGTTGAT TTGGGTAATG

961	AATATCCGGT TCTTGTCAAG ATTACTCTTG ATGAAGGTCA GCCAGCCTAT GCGCCTGGTC

1021	TGTACACCGT TCATCTGTCC TCTTTCAAAG TTGGTCAGTT CGGTTCCCTT ATGATTGACC

1081	GTCTGCGCCT CGTTCCGGCT AAGTAACATG GAGCAGGTCG CGGATTTCGA CACAATTTAT

1141	CAGGCGATGA TACAAATCTC CGTTGTACTT TGTTTCGCGC TTGGTATAAT CGCTGGGGGT

1201	CAAAGATGAG TGTTTTAGTG TATTCTTTCG CCTCTTTCGT TTTAGGIIGG TGCCTTCGTA

1261	GTGGCATTAC GTATTTTACC CGTTTAATGG AAACTTCCTC ATGAAAAAGT CTTTAGTCCT

1321	CAAAGCCTCT GTAGCCGTTG CTACCCTCGT TCCGATGCTG TCTTTCGCTG CTGAGGGTGA

1381	CGATCCCGCA AAAGCGGCCT TTAACTCCCT GCAAGCCTCA GCGACCGAAT ATATCGGTTA

1441	TGCGTGGGCG ATGGTTGTTG TCATTGTCGG CGCAACTATC GGTATCAAGC TGTTTAAGAA

1501	ATTCACCTCG AAAGCAAGCT GATAAACCGA TACAATTAAA GGCTCCTTTT GGAGCCTTTT

1561	TTTTTGGAGA TTTTCAACGT GAAAAAATTA TTATTCGCAA TTCCTTTAGT TGTTCCTTTC

1621	TATTCTCACA GTGCACAGTC TGTCGTGACG CAGCCGCCCT CAGTGTCTGG GGCCCCAGGG

1681	CAGAGGGTCA CCATCTCCTG CACTGGGAGC AGCTCCAACA TCGGGGCAGG TTATGATGTA

1741	CACTGGTACC AGCAGCTTCC AGGAACAGCC CCCAAACTCC TCATCTATGG TAACAGCAAT

1801	CGGCCCTCAG GGGTCCCTGA CCGATTCTCT GGCTCCAAGT CTGGCACCTC AGCCTCCCTG

1861	GCCATCACTG GGCTCCAGGC TGAGGATGAG GCTGATTATT ACTGCCAGTC CTATGACAGC

1921	AGCCTGAGTG GCCTTTATGT CTTCGGAACT GGGACCAAGG TCACCGTCCT AGGTCAGCCC

1981	AAGGCCAACC CCACTGTCAC TCTGTTCCCG CCCTCCTCTG AGGAGCTCCA AGCCAACAAG

2041	GCCACACTAG TGTGTCTGAT CAGTGACTTC TACCCGGGAG CTGTGACAGT GGCCTGGAAG

2101	GCAGATAGCA GCCCCGTCAA GGCGGGAGTG GAGACCACCA CACCCTCCAA ACAAAGCAAC

2161	AACAAGTACG CGGCCAGCAG CTATCTGAGC CTGACGCCTG AGCAGTGGAA GTCCCACAGA

2221	AGCTACAGCT GCCAGGTCAC GCATGAAGGG AGCACCGTGG AGAAGACAGT GGCCCCTACA

2281	GAATGTTCAT AATAAACCGC CTCCACCGGG CGCGCCAATT CTATTTCAAG GAGACAGTCA

2341	TAATGAAATA CCTATTGCCT ACGGCAGCCG CTGGATTGTT ATTACTCGCG GCCCAGCCGG

2401	CCATGGCCGA AGTTCAATTG TTAGAGTCTG GTGGCGGTCT TGTTCAGCCT GGTGGTTCTT

2461	TACGTCTTTC TTGCGCTGCT TCCGGATTCA CTTTCTCTTC GTACGCTATG TCTTGGGTTC

2521	GCCAAGCTCC TGGTAAAGGT TTGGAGTGGG TTTCTGCTAT CTCTGGTTCT GGTGGCAGTA

2581	CTTACTATGC TGACTCCGTT AAAGGTCGCT TCACTATCTC TAGAGACAAC TCTAAGAATA

2641	CTCTCTACTT GCAGATGAAC AGCTTAAGGG CTGAGGACAC TGCAGTCTAC TATTGCGCTA

2701	AAGACTATGA AGGTACTGGT TATGCTTTCG ACATATGGGG TCAAGGTACT ATGGTCACCG

2761	TCTCTAGTGC CTCCACCAAG GGCCCATCGG TCTTCCOCCT GGCACCCTCC TCCAAGAGCA

2921	CCTCTGGGGG CACAGCGGCC CTGGGCTGCC TGGTCAAGGA CTACTTCCCC GAACCGGTGA

2881	CGGTGTCGTG GAACTCAGGC GCCCTGACCA GCGGCGTCCA CACCTTCCCG GCTGTCCTAC

2941	AGTCTAGCGG ACTCTACTCC CTCAGCAGCG TAGTGACCGT GCCCTCTTCT AGCTTGGGCA

3001	CCCAGACCTA CATCTGCAAC GTGAATCACA AGCCCAGCAA CACCAAGGTG GACAAGAAAG

3061	TTGAGCCCAA ATCTTGTGCG GCCGCTCATC ACCACCATCA TCACTCTGCT GAACAAAAAC

3121	TCATCTCAGA AGAGGATCTG AATGGTGCCG CAGATATCAL CGATGATCGT ATGGCTGGCG

3181	CCGCTGAAAC TGTTGAAAGT TGTITAGCAA AACCCCATAC AGAAAATTCA TTTACTAACG

3241	TCTGGAAAGA CGACAAAACT TTAGATCGTT ACGCTAACTA TGAGGGTTGT CTGTGGAATG

3301	CTACAGGCGT TGTAGTTTGT ACTGGTGACG AAACTCAGTG TTACGGTACA TGGGTTCCTA

3361	TTGGGCTTGC TATCCCTGAA AATGAGGGTG GTGGCTCTGA GGGTGGCGGT TCTGAGGGTG

3421	GCGGTTCTGA GGGTGGCGGT ACTAAACCTC CTGAGTACGG TGATACACCT ATTCCGGGCT

3481	ATACTTATAT CAACCCTCTC GACGGCACTT ATCCGCCTGG TACTGAGCAA AACCCCGCTA

3541	ATCCTAATCC TTCTCTTGAG GAGTCTCAGC CTCTTAATAC TTTCATGTTT CAGAATAATA

3601	GGTTCCGAAA TAGGCAGGGG GCATTAACTG TTTATACGGG CACTGTTACT CAAGGCACTG

3661	ACCCCGTTAA AACTTATTAC CAGTACACTC CTGTATCATC AAAAGCCATG TATGACGCTT

3721	ACTGGAACGG TAAATTCAGA GACTGCGCTT TCCATTCTGG CTTTAATGAA GATCCATTCG

3781	TTTGTGAATA TCAAGGCCAA TCGTCTGACC TGCCTCAACC TCCTGTCAAT GCTGGCGGCG

3841	GCTCTGGTGG TGGTTCTGGT GGCGGCTCTG AGGGTGGTGG CTCTGAGGGT GGCGGTTCTG

3901	AGGGTGGCGG CTCTGAGGGA GGCGGTTCCG GTGGTGGCTC TGGTTCCGGT GATTTTGATT

3961	ATGAAAAGAT GGCAAACGCT AATAAGGGGG CTATGACCGA AAATGCCGAT GAAAACGCGC

4021	TACAGTCTGA CGCTAAAGGC AAACTTGATT CTGTCGCTAC TGATTACGGT GCTGCTATCG

4081	ATGGTTTCAT TGGTGACGTT TCCGGCCTTG CTAATGGTAA TGGTGCTACT GGTGATTTTG

4141	CTGGCTCTAA TTCCCAAATG GCTCAAGTCG GTGACGGTGA TAATTCACCT TTAATGAATA

4201	ATTTCCGTCA ATATTTACCT TCCCTCCCTC AATCGGTTGA ATGTCGCCCT TTTGTCTTTA

4251	GCGCTGGTAA ACCATATGAA TTTTCTATTG ATTGTGACAA AATAAACTTA TTCCGTGGTG

4321	TCTTTGCGTT TCTTTTATAT GTTGCCACCT TTATGTATGT ATTTTCTACG TTTGCTAACA

4381	TACTGCGTAA TAAGGAGTCT TAATCATGCC AGTTCTTTTG GGTATTCCGT TATTATTGCG

4441	TTTCCTCGGT TTCCTTCTGG TAACTTTGTT CGGCTATCTG CTTACTTTTC TTAAAAAGGG

4501	CTTCGGTAAG ATAGCTATTG CTATTTCATT GTTTCTTGCT CTTATTATTG GGCTTAACTC

4561	AATTCTTGTG GGTTATCTCT CTGATATTAG CGCTCAATTA CCCTCTGACT TTGTTCAGGG

4621	TGTTCAGTTA ATTCTCCCGT CTAATGCGCT TCCCTGTTTT TATGTTATTC TCTCTGTAAA

4681	GGCTGCTATT TTCATTTTTG ACGTTAAACA AAAAATCGTT TCTTATTTGG ATTGGGATAA

4741	ATAATATGGC TGTTTATTTT GTAACTGGCA AATTAGGCTC TGGAAAGACG CTCGTTAGCG

4801	TTGGTAAGAT TCAGGATAAA ATTGTAGCTG GGTGCAAAAT AGCAACTAAT CTTGATTTAA

4861	GGCTTCAAAA CCTCCCGCAA GTCGGGAGGT TCGCTAAAAC GCCTCGCGTT CTTAGAATAC

4921	CGGATAAGCC TTCTATATCT GATTTGCTTG CTATTGGGCG CGGTAATGAT TCCTACGATG

4981	AAAATAAAAA CGGCTTGCTT GTTCTCGATG AGTGCGGTAC TTGGTTTAAT ACCCGTTCTT

5041	GGAATGATAA GGAAAGACAG CCGATTATTG ATTGGTTTCT ACATGCTCGT AAATTAGGAT

5101	GGGATATTAT TTTTCTTGTT CAGGACTTAT CTATTGTTGA TAAACAGGCG CGTTCTGCAT

5161	TAGCTGAACA TGTTGTTTAT TGTCGTCGTC TGGACAGAAT TACTTTACCT TTTGTCGGTA

5221	CTTTATATTC TCTTATTACT GGCTCGAALA TGCCTCTGCC TAAATTACAT GTTGGCGTTG

5281	TTAAATATGG CGATTCTCAA TTAAGCCCTA CTGTTGAGCG TTGGCTTTAT ACTGGTAAGA

5341	ATTTGTATAA CGCATATGAT ACTAAACAGG CTTTTTCTAG TAATTATGAT TCCGGTGTTT

5401	ATTCTTATTT AACGCCTTAT TTATCACACG GTCGGTATTT CAAACCATTA AATTTAGGTC

5461	AGAAGATGAA ATTAACTALA ATATATTTGA AAAAGTTTTC TCGCGTTCTT TGTCTTGCGA

5521	TTGGATTTGC ATCAGCATTT ACATATAGTT ATATAACCCA ACCTAAGCCG GAGGTTAAAA

5581	AGGTAGTCTC TCAGACCTAT GATTTTGATA AATTCACTAT TGACTCTTCT CAGCGTCTTA

5641	ATCTAAGCTA TCGCTATGTT TTCAAGGATT CTAAGGGAAA ATTAATTAAT AGCGACGATT

5701	TACAGAAGCA AGGTTATTCA CTCACATATA TTGATTTATG TACTGTTTCC ATTAAAAAAG

5751	GTAATTCAAA TGAAATTGTT AAATGIAATT AATTTTGTTT TCTTGATGTT TGTTTCATCA

5821	TCTTCTTTTG CTCAGGTAAT TGAAATGAAT AATTCGCCTC TGCGCGATTT TGTAACTTGG

5881	TATTCAAAGC AATCAGGCGA ATCCGTTATT GTTTCTCCCG ATGTALLAGG TACTGTTACT

5941	GTATATTCAT CTGACGTTAA ACCTGALLAT CTACGCAATT TCTTTATTTC TGTTTTACGT

6001	GCTAATAATT TTGATATGGT TGGTTCAATT CCTTCCATAA TTCAGAAGTA TAATCCAAAC

6051	AATCAGGATT ATATTGATGA ATTGCCATCA TCTGATAATC AGGAATATGA TGATAATTCC

6121	CCTCCTTCTC CTCCTTTCTT TCTTCCCCAA AATCATAATC TTACTCAAAC TTTTAAAATT

6181	AATAACGTTC GGGCAAAGGA TTTAATACGA GTTGTCGAAT TGTTTGTAAA GTCTAATACT

6241	TCTAAATCCT CAAATGTATT ATCTATTGAC GGCTCTAATC TATTAGTTGT TTCTGCACCT

6301	AAAGATATTT TAGATAACCT TCCTCAATTC CTTTCTACTG TTGATTTGCC AACTGACCAG

6351	ATATTGATTG AGGGTTTGAT ATTTGAGGTT CAGCAAGGTG ATGCTTTAGA TTTTTCATTT

6421	CCTCCTGOCT CTCAGCGTCC CACTOTTGCA CGCOGTOTTA ATACTGACCC CCTCACCTCT

6481	GTTTTATCTT CTGCTGGTGG TTCGTTCGGT ATTTTTAATG GCGATGTTTT AGGGCTATCA

5541	GTTCGCGCAT TAAAGACTAA TAGCCATTCA AAAATATTGT CTGTGCCACG TATTCTTACG

6601	CTTTCAGGTC AGAAGGGTTC TATCTCTGTT GGCCAGAATG TCCCTTTTAT TACTGGTCGT

6661	GTGACTGGTG AATCTGCCAA TGTAAATAAT CCATTTCAGA CGATTGAGCG TCAAAATGTA

5721	CCTATTTCCA TCACCCTTTT TCCTCTTCCA ATCCCTCOCC CTAATATTCT TCTCCATATT

6731	ACCAGCAAGG CCGATAGTTT GAGTTCTTCT ACTCAGGCAA GTGATGTTAT TACTAATCAA

6841	AGAAGTATTG CTACAACGGT TAATTTGCGT GATGGACAGA CTCTTTTACT CGGTGGCCTC

6901	ACTGATTATA AAAACACTTC TCAAGATTCT GGCGTACCGT TCCTGTCTAA AATCCCTTTA

6961	ATCGGCCTCC TGTTTAGCTC CCGCTCTGAT TCCAACGAGG AAAGCACGTT ATACGTGCTC

7021	GTCAAAGCAA CCATAGTACG CGCCCTGTAG CGGCGCATTA AGCGCGGCGG GTGTGGTGGT

7081	TACGCGCAGC GTGACCGCTA CACTTGCCAG CGCCCTAGCG CCCGCTCCTT TCGCTTTCTT

7141	CCCTTCCTTT CTCGCCACGT TCGCCGGCTT TCCCCGTCAA GCTCTAAATC GGGGGCTCCC

7201	TTTAGGGTTC CGATTTAGTG CTTTACGGCA CCTCGACCCC AAAAAACTTG ATTTGGGTGA

7261	TGGTTCACGT AGTGGGCCAT CGCCCTGATA GACGGTTTTT CGCCCTTTGA CGTTGGAGTC

7321	CACGTTCTTT AATAGTGGAC TCTTGTTCCA AACTGGAACA ACACTCAACC CTATCTCGGG

7381	CTATTCTTTT GATTTATAAG GGATTTTGCC GATTTCGGAA CCACCATCAA ACAGGATTTT

7441	CGCCTGCTGG GGCAAACCAG CGTGGACCGC TTGCTGCAAC TCTCTCAGGG CCAGGCGGTG

7501	AAGGGCAATC AGCTGTTGCC CGTCTCACTG GTGAAAAGAA AAACCACCCT GGATCCAAGC

7561	TTGCAGGTGG CACTTTTCGG GGAAATGTGC GCGGAACCCC TATTTGTTTA TTTTTCTAAA

7621	TACATTCAAA TATGTATCCG CTCATGAGAC AATAACCCTG ATAAATGCTT CAATAATATT

7681	GAAAAAGGAA GAGTATGAGT ATTCAACATT TCCGTGTCGC CCTTATTCCC TTTTTTGCGG

I74i	CATTTTGCCT TCCTGTTTTT GCTCACCCAG AAACGCTGGT GAAAGTAAAA GATGCTGAAG

7301	ATCAGTTGGG CGCACGAGTG GGTTACATCG AACTGGATCT CAACAGCGGT AAGATCCTTG

7861	AGAGTTTTCG CCCCGAAGAA CGTTTTCCAA TGATGAGCAC TTTTAAAGTT CTGCTATGTC

7921	ATACACTATT ATCCCGTATT GACGCCGGGC AAGAGCAACT CGGTCGCCGG GCGCGGTATT

7981	CTCAGAATGA CTTGGTTGAG TACTCACCAG TCACAGAAAA GCATCTTACG GATGGCATGA

8041	CAGTAAGAGA ATTATGCAGT GCTGCCATAA CCATGAGTGA TAACACTOCC GCCAACTTAC

8101	TTCTGACAAC GATCGGAGGA CCGAAGGAGC TAACCGCTTT TTTGCACAAC ATGGGGGATC

8161	ATGTAACTCG CCTTGATCGT TGGGAACCGG AGCTGAATGA AGCCATACCA AACGACGAGC

8221	GTGACACCAC GATGCCTGTA GCAATGCCAA CAACGTTGCG CAAACTATTA ACTGGCGAAC

8281	TACTTACTCT AGCTTCCCGG CAACAATTAA TAGACTGGAT GGAGGCGGAT AAAGTTGCAG

8341	GACCACTTCT GCGCTCGGCC CTTCCGGCTG GCTGGTTTAT TGCTGATAAA TCTGGAGCCG

8401	GTGAGCGTGG GTCTCGCGGT ATCATTGCAG CACTGGGGCC AGATGGTAAG CCCTCCCGTA

8461	TCGTAGTTAT CTACACGACG GGGAGTCAGG CAACTATGGA TGAACGAAAT AGACAGATCG

8521	CTGAGATAGG TGCCTCACTG ATTAAGCATT GGTAACTGTC AGACCAAGTT TACTCATATA

8581	TACTTTAGAT TGATTTAAAA CTTCATTTTT AATTTAAAAG GATCTAGGTG AAGATCCTTT

8641	TTGATAATCT CATGACCAAA ATCCCTTAAC GTGAGTTTTC GTTCCACTGT ACGTAAGACC

8701	CCCAAGCTTG TCGACTGAAT GGCGAATGGC GCTTTGCCTG GTTTCCGGCA CCAGAAGCGG

8761	TGCCGGAAAG CTGGCTGGAG TGCGATCTTC CTGAGGCCGA TACTGTCGTC GTCCCCTCAA

8821	ACTGGCAGAT GCACGGTTAC GATGCGCCCA TCTACACCAA CGTAACCTAT CCCATTACGG

8881	TCAATCCGCC GTTTGTTCCC ACGGAGAATC CGACGGGTTG TTACTCGCTC ACATTTAATG

8941	TTGATGAAAG CTGGCTACAG GAAGGCCAGA CGCGAATTAT TTTTGATGGC GTTCCTATTG

9001	GTTAAAAAAT GAGCTGATTT AACAAAAATT TAACGCGAAT TTTAACAAAA TATTAACGTT

9061	TACAATTTAA ATATTTGCTT ATACAATCTT CCTGTTTTTG GGGCTTTTCT GATTATCAAC

9121	CGGGGTACAT ATGATTGACA TGCTAGTTTT ACGATTACCG TTCATCGATT CTCTTGTTTG

9181	CTCCAGACTC TCAGGCAATG ACCTGATAGC CTTTGTAGAT CTCTCAAAAA TAGCTACCCT

9241	CTCCGGCATG AATTTATCAG CTAGAACGGT TGAATATCAT ATTGATGGTG ATTTGACTGT

9301	CTCCGGCCTT TCTCACCCTT TTGAATCTTT ACCTACACAT TACTCAGGCA TTGCATTTAA

9361	AATATATGAG GGTTCTAAAA ATTTTTATCC TTGCGTTGAA ATAAAGGCTT CTCCCGCAAA

9421	AGTATTACAG GGTCATAATG TTTTTGGTAC AACCGATTTA GCTTTATGCT CTGAGGCTTT

9431	ATTGCTTAAT TTTGCTAATT CTTTGCCTTG CCTGTATGAT TTATTGGATG TT

TABLE 22

Primers used in RACE amplification:

Heavy chain
HuCμ-FOR (1^st PCR)	5′-TGG AAG AGG CAC GTT CTT TTC TTT-3′ (SEQ ID NO: 457)
HuCμ-Nested (2^nd PCR)	5′ CTT TTC TTT GTT GCC GTT GGG GTG-3′ (SEQ ID NO: 458)

Kappa light chain
HuCkFor (1^st PCP)	5′-ACA CTC TCC CCT GTT GAA GCT CTT-3′ (SEQ ID NO: 459)
HuCkForAscI (2^nd PCR)	5′-ACC GCC TCC ACC GGG SOC GCC TTA TTA ACA CTC TCC
	CCE GEE GAA OCT CTT-3′
	(SEQ ID NO: 460)

Lambda light chain
HuClambdaFor (1^st PC(K)
HuCL2-FOR	5′-TGA ACA TTC TGT ASS GGC CAC TG-3′ (SEQ ID NO: 461)
HuCL7-FOR	5′-AGA GCA TTC TGC AGG GGC CAC TG-3′ (SEQ ID NO: 462)
HuClambdaForAscI (2^nd PC(K)
HuCL2-FOR-ASC	5′-ACC GCC TCC ACC GGG CGC GCC TTA TTA TGA ACA TTC
	TGT AGG GGC CAC TG-3′ (SEQ ID NO: 463)
HuCL7-FOR-ASC	5′-ACC GCC TCC ACC GGG CGC GCC ETA TTA AGA GCA TTC
	TGC AGG GGC CAC TG-3′ (SEQ ID NO: 464)

GeneRAcer 5′ Primers provided with the kit (invitrogen)

5′A 1^st PCR	(SEQ ID NO: 465) 5′ CGACTGGAGCACGAGGACACTGA 3′
5′NA 2^nd pCR	5′GGACACTGACATGGACTGAAGGAGTA-3′ (SEQ ID NO: 466)

TABLE 23

ONs used in Capture of kappa light chains using CJ method and BsmAI

REdapter (6)
ON_20SK15012	gggAggATggAgAcTcggTc (SEQ ID NO: 467)
ON_20SK15L12	gggAAgATggAgAcTgggTc (SEQ ID NO: 468)
ON_20SK15A17	gggAgAgTggAgAcTcAgTc (SEQ ID NO: 469)
ON_20SK15A27	gggTgccTggAgAcTgcgTc (SEQ ID NO: 470)
ON-20SK15A11	gggTggcTggAgAcTgcgTc (SEQ ID NO: 471)
ON:20SK15B3	gggAgTcTggAgAcTgggTc (residues 1-20 of SEQ ID NO: 477)

Bridges (6)
kapbri1012	gggAggATggAgAcTgggTcATcTggATgTcTTgTgcAcTgTgAcAgAgg (SEQ ID NO: 472)
kapbri1L12	gggAAgATggAgAcTgggTcATcTggATgTcTTgTgcAcTgTgAcAgAgg (SEQ ID NO: 473)
5apbrilA17	gggAgAgTggAgAcTgggTcATcTggATgTcTTgTgcAcTgTgAcAgAgg (SEQ ID NO: 474)
kapbrilA27	gggTgccTggAgAcTgggTcATcTggATgTcTTgTgcAcTgTgAcAgAgg (SEQ ID NO: 475)
kaphrilA11	gggTggcTggAgArTgggTcATcTggATgTcTTgTgcAcTgTgAcAgAgg (SEQ ID NO: 476)
kapbrilB3	gggAgTcTggAgAcTgggTcATcTggATgTcTTgTgoAcTgTgAcAgAgg (SEQ ID NO: 477)

Extender (5′ biotinylated)

kapext1bio	ccTcTgTcAcAgTgcAcAAgAcATccAgATgAcccAgTcTcc (SEQ ID NO: 478)

Primers
kaPCRt1	ccTcTgTcAcAgTgcAcAAgAc (SEQ ID NO: 479)
kapfor	5′-aca ctc tcc cct gtt gaa gct ctt-3′ (SEQ ID NO: 480)

All ONs are written 5′ to 3′.

TABLE 24

PCR program for amplification of
kappa DNA

	95° C.	5 minutes
	95° C.	15 seconds
	65° C.	30 seconds
	72° C.	1 minute
	72° C.	7 minutes
	4° C.	hold

	Reagents (100 ul reaction):
	Template	50 np
	10K turbo PCR buffer	1x
	turbo Pfu	40
	dNTPs	200 uM each
	kaPCRt1	300 nM
	kapfor	300 nM

TABLE 25

h3401-h2 captured Via CJ with BsmAI
(Nucleotide sequence is SEQ ID NO: 481; amino acid sequence is SEQ ID NO: 482)

! 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

! S A Q D I Q M T Q S P A T L S

a GT GCA C aa gac atc cag atg acc cag tct cca gcc acc ctg tct

! ApaLI... a gcc acc ! L25, L6, L20, L2, L16, A11

! Extender..................................Bridge...

! 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

! V S P G E R A T L S C R A S Q

gtg tct cca ggg gaa agg gcc acc ctc tcc tgc agg gcc agt cag

! 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45

! S V S N N L A W Y Q Q K P G Q

agt gtt agt aac aac tta gcc tgg tac cag cag aaa cct ggc cag

! 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

! V P R L 2 I Y G A S T R A T D

gtt ccc agg ctc ctc atc tat ggt gca tcc acc agg gcc act gat

! 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75

! I P A R F S G S G S G T D F T

atc cca gcc agg ttc agt ggc agt ggg tct ggg aca gac ttc act

! 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90

! L T I S R L E P E D F A V Y Y

ctc acc atc agc aga ctg gag cct gaa gat ttt gca gtg tat tac

! 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105

! C C R Y G S S P G W T F G Q G

tat tag cgg tat ggt agc tca ccg ggg tgg acg ttc ggc caa ggg

! 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120

! T K V E I K R T V A A P S V F

acc aag gtg aaa atc aaa cga act gtg gct gca cca tct gtc ttc

! 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135

! I F P P S D E Q L K S G T A S

atc ttc ccg cca tct gat gag cag ttg aaa tct gga act gcc tct

! 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150

! V V C L 2 N N F Y P R E A K V

gtt gtg tgc ctg ctg aat aac ttc tat ccc aga gag gcc aaa gta

! 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165

! Q W K V D N A L Q S G N S Q E

cag tgg aag gtg gat aac gcc ctc caa tcg ggt aac tcc cag gag

! 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180

! S V T E Q D S K D S T Y S L S

agt gtc aca gag cag gac agc aag gac agc acc tac agc ctc agc

! 131 182 183 184 185 186 187 188 189 190 191 192 193 194 195

! S T L T L S K A D Y F K H K V

agc acc ctg acg ctg agc aaa gca gac tac gag aaa cac aaa gtc

! 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210

! Y A C E V T H Q G L S S P V T

tac gcc tgc gaa gtc acc cat cag ggc ctg agc tcg cct gtc aca

! 211 212 213 214 215 216 217 218 219 220 221 222 223

! K S F N K G E C K G S F A

aag agc ttc aac aaa gga gag tgt aag ggc gaa ttc gc.....

TABLE 26

h3401-d8 KAPPA captured with CJ and EsmAI
(Nucleotide sequence is SEQ ID NO: 484; amino acid sequence is SEQ ID NO: 485)

! 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

! S A Q D I Q M T Q S P A T L S

a GT GCA C aa gac atc cag atg acc cag tct cct gcc acc ctg tct

! ApaLI...Extender......................... a gcc acc ! L25, L6, L20, L2, L16, A11

A GCC ACC CTG TCT ! L2 (SEQ ID NO: 483)

! 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

! V S P G E R A T L S C R A S Q

gtg tct cca ggt gas aga gcc acc ctc tcc tgc agg gcc agt cag

! GTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC ! L2

! 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45

! N L L S N L A W Y Q Q K P G Q

aat ctt ctc agc aac tta gcc tgg tac cag cag aaa cct ggc cag

! 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

! A P R L L I F G A S T G A I G

gct ccc agg ctc ctc atc tat act gct tcc acc ggg gcc att ggt

! 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75

! I P A R F S G S G S G T E F T

atc cca acc agg ttc agt ggc cct ggg tct ggg aca gag ttc act

! 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90

! L T I S S L Q S E D F A V F F

ctc acc atc agc agc ctg cag tct gaa gat ttt gca gtg tat ttc

! 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105

! C Q Q Y G T S P P T F G G G T

tgt cag cag tat ggt acc tca ccg ccc act ttc ggc gga ggg acc

! 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120

! K V E I K R T V A A P S V F I

aag gtg gag atc aaa cga act gtg gct gca cca tct gtc ttc atc

! 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135

! F P P S D E Q L K S G T A S V

ttc ccg cca tct gat gag cag ttg aaa tct gga act gcc tct gtt

! 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150

! V C P L N N F Y P R E A K V Q

gtg tgc ccg ctg sat aac ttc tat ccc aga gag gcc aaa gta cag

! 151 152 153 154 155 156 157 153 159 160 161 162 163 164 165

! W K V D N A L Q S G N S Q E S

tgg aag gtg gat aac gcc ctc caa tcg ggt aac tcc cag gag aqt

! 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180

! V T E Q D N K D Q T Y S L S S

gtc aca gag cag gac aac aag gac agc acc tac agc ctc agc agc

! 181 182 133 184 185 186 187 188 189 190 191 192 193 194 195

! T L T L S K V D Y E K H E V Y

acc ctg acg ccg agc aaa gta gac tac gag aaa cac gaa gtc tac

! 196 197 193 199 200 201 202 203 204 205 206 207 200 209 210

! A C E V T H Q G S S S P V T H

gct tgc gaa gtc act cat tag ggc ctt agc tcg ccc gtc acg aag

! 211 212 213 214 215 216 217 218 219 220 221 222 223

! S F N R G F C K K E F V

agc tcc aac agg gga gag tgt aag aaa gaa ttc gtt t

TABLE 27

V3-23 VP framework with variegated rodeos shown

! (Nucleotide sequence is SEQ ID NO: 486; amino acid sequence is SEQ ID NO: 487)

! 17 18 19 20 21 22

! A Q P A M A

5′- ctg tct gaa cG GCC cag ccG GCC atg gcc 29

3′-gac aga ctt gc cgg gtc ggc cgg tac cgg

! Scab.........SfiI............

! NgoMI...

! NcoI....

!

! FR1(DP47/V3-23)---------------

! 23 24 25 26 27 28 29 30

! E V Q L L E S C

gaa|gtt|CAA|TTG|tta|gag|tct|ggt| 53

! ctt|caa|gtt|aac|aat|ctc|aga|cca|

! | MfeI |

!

! --------------FR1--------------------------------------------

! 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45

! G G L V Q P G G S L R L S C A

|ggc|ggt|ctt|gtt| cag | cct | ggt | ggt | tct | tta |cgt|ctt|tct|tgc|gct| 98

! |ccg|cca|gaa|caa|gtc|gga|cca|cca|aga|aat|gca|gaa|aga|acg|cga|

!

! Sites to be varied---> *** *** ***

! ----FR1---------------->|...CDR1----------------|---FR2------

! 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

! A S G F T F S S Y A M S W V R

| gct | TCC | GGA | ttc |a ct | ttc | tct|tCG|TAC|Gct|atg|tct| tgg | gtt | cgC | 143

! |cga|agg|cct|aag|tga|aag|aga|agc|atg|cga|tac|aga|acc|caa|gcg|

!

! Sites to be varies---> *** *** ***

! -------FR2-------------------------------->|...CDR2.........

! 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75

! Q A P G K G L E W V S A I S G

| CAa | gct | ccT | GG t|aaa| ggt | ttg | gag | tgg | gtt | tct |gct|atc|tct|ggt| 188

! |gtt|cga|gga|cca|ttt|cca|aac|ctc|acc|caa|aga|cga|tag|aga|cca|

! ...BstXI |

! *** ***

! .....CDR2............................................|---FR3---

! 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90

! S G G S T Y Y A D S V K G R F

|tct|ggt|ggc|agt|act|tac|ta t | gct | gac | tcc | gtt | aaa | gg t|cgc|ttc| 233

! |aga|cca|ccg|tca|tga|atg|ata|cga|ctg|agg|caa|ttt|cca|gcg|aag|

!

! --------FR3--------------------------------------------------

! 91 92 83 94 95 96 97 88 90 100 101 102 103 104 105

! T I S R D N D K N T L Y L Q M

|act|atc|TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttc|cag|atg| 278

! |tga|tag|aga|tct|ctg|ttg|aga|ttc|tta|tga|gag|atg|aac|gtc|tac|

! | XbaI |

!

! ---FR3----------------------------------------------------->|

! 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120

! N S L R A D D T A V Y Y C A K

|aac|a gC | TTA | AGg | gct | gag | gac | aCT | GCA|Gtc|tac|tat|tgc|gct|aaa| 323

! |ttg|tcg|aat|tcc|cga|ctc|ctg|tga|cgt|cag|atg|ata|acg|aga|ttt|

! |AflII | | PstI |

!

! .......CDR3.................|----FR4-------------------------

! 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135

! D Y E C T G Y A F D I W G Q G

|gac|tat|gaa|ggt|act|ggt|tat| gct | ttc | gaC | ATA | TGg | ggt | c aa|ggt| 368

! |ctc|ata|ctt|cca|tga|cca|ata|cga|aag|ctg|tat|acc|cca|gtt|cca|

! | NdeI |

!

! --------------FR4---------->|

! 136 137 138 139 140 141 142

! T M V T V S S

|act|atG|GTC|ACC|gtc|tct|agt- 339

! |tga|tac|cag|tgg|cag|aga|tca-

! | BstEII |

! 143 144 145 146 147 148 149 150 151 152

! A S T K G P S V F P

gcc tcc acc aaG GGC CCa tcg GTC TTC ccc-3′ 419

! cgg agg t gg ttc ccg ggt agc cag aag ggg -5′

! Bsp120I. BBsI...(2/2)

! ApaI....

(SFPRMET) 5′-ctg tct gaa cG GCC cag ccG-3′ (SEQ ID NO: 488)

(TOPFR1A) 5′-ctg tct gaa cG GCC cag ccG GCC atg gcc-

gaa|gtt|CAA|TTG|tta|gac|tct|ggt|-

|ggc|ggt|ctt|gtt|cag|cct|ggt|ggt|tct|tta-3′ (SEQ ID NO: 489)

(BOTFR1B) 3′-caa|gtc|gga|cca|cca|aga|aat|gca|gaa|aga|acg|cga|-

|cga|agg|cct|aag|tga|aag-5′ ! bottom strand (SEQ ID NO: 490)

(BOTFR2) 3′-acc|caa|gcg|-

|gtt|cga|gga|cca|ttt|cca|aac|ctc|acc|caa|aga|-5′ ! bottom strand

(SEQ ID NO: 491)

(BOTFR3) 3′- a|cga|ctg|agg|caa|ttt|cca|gcg|aag|-

|tga|tag|aga|tct|ctg|ttg|aga|ttc|tta|tga|gag|atg|aac|gtc|tac|-

|ttg|tcg|aat|tcc|cga|ctc|ctg|tga-5′ (SEQ ID NO: 492)

(F06) 5′-gC|TTA|AGg|gct|gag|gac!aCT|GCA|Gtc|tac|tat|tgc|cct|aaa|-

|gac|tat|gaa|ggt|act|ggt|tat|gct|ttc|gaC|ATA|TGg|ggt|c-3′ (SEQ ID NO: 493)

(BOTFR4) 3′-cga|aag|ctg|tat|acc|cca|gtt|cca|-

|tga|tac|cag|tgg|cag|aga|tca-

cgg agg tgg ttc ccg ggt agC cag aag ggg-5′ ! bottom strand

(SEQ ID NO: 494)

(BOTPRCPRIM) 3′-gg ttc ccg ggt agC cag aag ggg-5′ (SEQ ID NO: 495)

!

! CDR1 diversity

!

(ON-vgCl) 5′- |gct|TCC|GGA|ttc|act|ttc|tct|<1>|TAC|<1>|atg|<1>| -

! CDR1...................6859

|tga|gtt|cgC|CAa|gct|ccT|GG-3′ (SEQ ID NO: 496)

!

!<1> stands for an equimolar mix of {ADEFGHIKLMNPQRSTVWY}; no C

! (this is not a sequence)

!

! CDR2 diversity

!

(ON-vgC2) 5′-ggt|ttg|gag|tgg|gtt|tct|<2>|atc|<2>|<3>|-

! CDP2

|tct|ggt|ggc|<1>|act|<1>|tat|gct|gac|tcc|gtt|aaa|gg-3′

(SEQ ID NO: 497)

! CDP2................................................

! <1> is an equimolar mixture of {ADEFGHIKLMKPQRSTVWY}; no C

! <2> is an equimolar mixture of {YRWVGS}; no ACDEFRIKLMNPQT

! <3> is an equimoiar mixture of {PS}; no ACDEFGHIKLMNQRTVWY

TABLE 28

Stutter used in VH (SEQ ID NO: 498)

1 TCCGGAGCTT CAGATCTGTT TGCCTTTTTG TGGGGTGGTG CAGATCGCGT TACGGAGATC

61 GACCGACTGC TTGAGCAAAA GCCACGCTTA ACTGCTGATC AGGCATGGGA TGTTATTCGC

121 CAAACCAGTC GTCAGGATCT TAACCTGAGG CTTTTTTTAC CTACTCTGCA AGCAGCGACA

181 TCTGGTTTGA CACAGAGCGA TCCGCGTCGT CAGTTGGTAG AAACATTAAC ACGTTGGGAT

241 GGCATCAATT TGCTTAATGA TGATGGTAAA ACCTGGCAGC AGCCAGGCTC TGCCATCCTG

301 AACGTTTGGC TGACCAGTAT GTTGAAGCGT ACCGTAGTGG CTGCCGTACC TATGCCATTT

361 GATAAGTGGT ACAGCGCCAG TGGCTACGAA ACAACCCAGG ACGGCCCAAC TGGTTCGCTG

421 AATATAAGTG TTGGAGCAAA AATTTTGTAT GAGGCGGTGC AGGGAGACAA ATCACCAATC

481 CCACAGGCGG TTGATCTGTT TGCTGGGAAA CCACAGCAGG AGGTTGTGTT GGCTGCGCTG

541 GAAGATACCT GGGAGACTCT TTCCAAACGC TATGGCAATA ATGTGAGTAA CTGGAAAACA

601 CCTGCAATGG CCTTAACGTT CCGGGCAAAT AATTTCTTTG GTGTACCGCA GGCCGCAGCG

661 GAAGAAACGC GTCATCAGGC GGAGTATCAA AACCGTGGAA CAGAAAACGA TATGATTGTT

721 TTCTCACCAA CGACAAGCGA TCGTCCTGTG CTTGCCTGGG ATGTGGTCGC ACCCGGTCAG

781 AGTGGGTTTA TTGCTCCCGA TGGAACAGTT GATAAGCACT ATGAAGATCA GCTGAAAATG

841 TACGAAAATT TTGGCCGTAA GTCGCTCTGG TTAACGAAGC AGGATGTGGA GGCGCATAAG

901 GAGTCGTCTA GA

TABLE 29

DNA seguence of bCES5

! pCES5 6680 bases = pC-804 with stuffers in CDR1-2 and CDR3 2000.12.13

!

! Ngene = 6680

! Useful REs (cut MAnoLI fewer than 3 times) 2000.06.05

!

! Non-cutters

!Acc651 Ggtacc AfeI AGCgct AvrII Cctagg

!BsaBI GATNNnnatc BsiWI Cgtacg BsmFI Nnnnnnnnnnnnnnngtccc

(SEQ ID NO: 499) (SEQ ID NO: 500)

!BsrGI Tgtaca BstAPI GCANNNNntgc BstBI TTcgaa

(SEQ ID NO: 501)

!BstZ17I GTAtac BtrI CACgtg Ecl136I GAGctc

!EcoRV GATatc FseI GGCCGGcc KpnI GGTACc

!MscI TGGcca NruI TCGcga NsiI ATGCAt

!PacI TTAATtaa PMeI GTTTaaac PmlI CACgtg

!PpuMI RGgwccy PshAI GACNNnngtc SacI GAGCTc

(SEQ ID NO: 502)

!SacII CCGCgg SbfI CCTGCAgg SexAI Accwggt

!SgfI GCGATcgc SnaBI TACgta SpeI Actagt

!SphI GCATGc Sse8387I CCTGCAgg StuI AGGcct

!SwaI ATTTaaat XmaI Cccggg

!

! cutters

! Enzymes that cut more than 3 times.

!AlwNI CAGNNNctg 5

!BsgI ctgcac 4

!BsrFI Rccggy 5

!EarI CTCTTCNnnn 4

(SEQ ID NO: 625)

!FauI nNNNNNNGCGGG 10

! (SEQ ID NO: 503)

! Enzymes that cut from 1 to 3 times.

!

!EcoO109I RGgnccy 3 7 2636 4208

!BssSI Ctcgtg 1 22

!-″- Cacgag 1 1703

!BspHI Tcatga 3 43 148 1156

!AatII GACGTc 1 65

!BciVI GTATCCNNNNNN 2 140 1667

(SEQ ID NO: 504)

!Eco57I CTGAAG 1 301

!-″- cttcag 2 1349

!AvaI Cycgrg 3 319 2347 6137

!BsiHKAI GWGCWc 3 401 2321 4245

!HgiAI GWGCWc 3 401 2321 4245

!BcgI gcannnnnntcg 1 461

(SEQ. ID NO: 505)

!ScaI AGTact 1 505

!Pvul CGATcy 3 616 3598 5926

!FspI TGCgca 2 763 5946

!BglI GCCNNNNnggc 3 864 2771 5952

(SEQ ID NO: 506)

!BgmI CTGGAG 1 898

!-″- ctccag 1 4413

!BsaI GGTCTCNnnnn 1 916

(SEQ ID NO: 507)

!AhdI GACNNNnngtc 1 983

(SEQ ID NO:: 508)

!Eam1105I GACNNNnngtc 1 983

(SEQ ID NO: 509)

!DrdI GACNNNNnngtc 3 1768 6197 6579

(SEQ ID NO: 510)

!SapI gaagagc 1 1998

!PvuII CAGctg 3 2054 3689 5896

!Pf1MI CCANNNNntgg 3 2233 3943 3991

(SEQ ID NO: 511)

!HindIII Aagctt 1 2235

!ApaLI Gtgcca 1 2321

!BspMI Nnnnnnnnngcaggt 1 2328

(SEQ ID NO: 512)

!-″- ACCTGCNNNNn 2 3460

(SEQ ID NO: 513)

!PStI CTGAg 1 2335

!AccI GTmkac 2 2341 2611

!HincII GTXrac 2 2341 3730

!SalI Gtagac 1 2341

!TliI Ctcgag 1 2347

!XhoI Ctcgag 1 2347

!BbsI gtcttc 2 2383 4219

!B1PI Gctnagc 1 2580

!EspI Gctnagc 1 2580

! SgrAI CRccggyg 1 2648

!AgeI Accggt 2 2649 4302

!AacI GGcgcgcc 1 2689

!BssHII Gcgcgc 1 2690

!SfiI GGCCNNNNnggcc 1 2770

(SEQ ID NO: 514)

!NaeI GCCggc 2 2776 6349

!NgoMIV Gccggc 2 2776 6349

!BtgI Ccrygg 3 2781 3553 5712

!DsaI Ccrygg 3 2781 3553 5712

!NcoI Ccatgg 1 2781

!StyI Ccwwgg 3 2781 4205 4472

!MfeI Caattg 1 2795

!BspEI Tccgga 1 2861

!BglII Agatct 1 2872

!BclI Tgatca 1 2956

!Bsu36I CCtnagg 3 3004 4143 4373

!XcmI CCANNNNNnnnntgg 1 3225

(SEQ ID NO: 515)

!MluI Acgcgt 1 3527

!HpaI GTTaac 1 3730

!XbaI Tctaga 1 3767

!

!AflII Cttaag 1 3811

!BsmI NGcattc 1 3821

!-″- GAATGCN 1 4695

!RsrII CGgwccg 1 3827

!NheI Gctagc 1 4166

!BstEII Ggtnacc 1 4182

!BsmBI CGTCTCNnnnn 2 4188 6625

(SEQ ID NO: 516)

!-″- Nnnnnngagacg 1 6673

(SEQ ID NO: 517)

!ApaI GGGCCc 1 4209

!BanII GGCYc 3 4209 4492 6319

!Bsp120I Gggccc 1 4209

!PspOMI Gggccc 1 4209

!BseRI NNnnnnnnnnctcctc 1 4226

(SEQ ID NO: 518)

!-″- GAGGAGNNNNNNNNNN 1 4957

(SEQ ID NO: 519)

!EcoNI CCTNNnnnagg 1 4278

(SEQ ID NO: 520)

!PflEI GACNnngtc 1 4308

!Tth111I GACNnngtc 1 4308

!KasI Ggcgcc 2 4327 5967

!BstXI CCANNNNNntgg 1 4415

(SEQ ID NO: 521)

!NotI GCggccgc 1 4507

!EagI Cggccg 1 4508

!BamHI Ggatcc 1 5169

!BspDI ATcgat 1 5476

!NdeI CAtatg 1 5672

!EcoRI Gaattc 1 5806

!PsiI TTAtaa 1 6118

!DraIII CACNNNgtg 1 6243

!BsaAI YACgtr 1 6246

!------------------------------------------------------------------------

(Nucleotide sequence is SEQ ID NO: 522; amino acid sequence is SEQ ID NO: 523, respectively)

1 gacqaaaggg aCTCGTGata cgcctatttt tataggttaa tgtcatgata ataatggttt

! BssSI.(1/2)

61 cttaGACGTC aggtggcact tttcggggaa atgtgcgcgg aacccotatt tgtttatttt

1 ASCII.

121 tctaaataca ttcaaatatG TATCCgctca tgagacaata accctgataa atgcttcaat

! BciVI..(1 of 2)

181 aatattgaaa aaggaagagt

! Base # 201 to 1061 = ApR gene from pUC119 with some RE sites removed

!

! 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

! fM S I Q N E R V A L I P E E A

201 atg agt att caa cat ttc opt gtc gcc ctt att ccc ttt Ltt gcg

!

! 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

! A F C L P V F A H P E T L V K

246 gca ttt tgc ctt cct gtt ttt gct cac cca gas acg ctg gtg aaa

!

! 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45

! V K D A E D Q L G A R V G Y I

291 gta aaa gat gct gaa gat cag ttg ggt gcc cga gtg ggt tac atc

!

! 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

! E L D L N S G K I L E S F R P

336 gaa ctg gat ctc aac agc ggt aag atc cct gag agt ttt cgc ccc

!

! 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75

! K E R F P M M S T F K V S S C

381 gaa gaa cgt ttt cca atg atg agc act ttt aaa gtt ctg cta tgt

!

! 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90

! G A V L S K I D A G Q F Q S G

426 ggc gcg gta tta tcc cgt att gac gcc ggg caa gaG CAa ctc ggT

! BcgI.............

!

! 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105

! R R I H Y S Q N D L V E Y S P

471 CGc cgc ata cac tat tat cag cat gac ttg gtt gAG TAC Tca cca

!..BcgI......

!

! 106 107 508 109 110 111 112 113 114 115 116 117 118 119 120

! V T E K H L T D G M T V R E L

516 gtc aca gaa aag cat ctt acg gat ggc atg aca gta aga gaa tta

!

! 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135

! C S A A I T M S D N T A A N L

561 tgc agt gct gcc ata acc atg agt gat aac act gcg gcc aac tta

!

! 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150

! L L T T I G G P K E L T A F L

606 ctt ctg aca aCG ATC Gga gga ccg aag gag cta acc gct ttt ttg

! PvuI.... (1/2)

!

! 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165

! H N M G D H V T R L D R W E P

651 cac aac atg ggg gat cat gta act cgc ctt gat cgt tgg gaa ccg

!

! 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180

! E L N F A I P N D E R D T T M

696 gag ctg aat gaa gcc ata cca aac gac gag cgt gac acc acg atg

!

! 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195

! P V A M A T T L R K L L T G E

741 cct gta GCA ATG gca aca acg tTG CGC Aaa cta tta act ggc gaa

! BsrDI..(1/2) FspI.... (1/2)

!

! 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210

! L L T L A S R Q Q L I D W M E

786 cta ctt act cta gct tcc cgg caa caa tta ata gac tgg atg gag

!

! 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225

! A D K V A G P L L R S A L P A

831 gcg gat aaa gtt gca gga cca ctt ctg cgc tcg gcc ctt ccg gct

!

! 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240

! G W F I A D K S G A G E R G S

876 ggc tgg ttt att gct gat aaa tCT GGA Gcc ggt gag cgt gGG TCT

! BpmI....(1/2) BsaI....

!

241 242 243 244 245 246 247 248 249 250 251 252 253 254 255

! R G I I A A L G P D G K P S R

921 Cgc ggt atC ATT GCa gca ctg gag cca gat ggt aag ccc tcc cat

! BsaI...... BsrDI...(2/2)

!

256 257 258 259 260 261 262 263 264 265 266 267 268 269 270

! I V V I Y T T G S Q A T M D E

966 atc gta gtt atc tac acG ACg ggg aGT Cag gca act atg gat gaa

! AhdT...........

!

! 271 272 272 274 275 276 277 278 279 280 281 282 083 284 285

! R N R Q I A E I G A S L I K H

1011 cga at aga cag atc gct gag ata ggt gcc tca ctg att aag cat

!

! 286 287

! W .

1056 tgg taa

2062 ctgtcagac caagtttact

1081 catatatact ttagattgat ttaaaacttc atttttaatt taaaaggatc taggtgaaga

1141 tcctttttga taatctcatg accaaaatcc cttaacgtga gttttcgttc cactgagcgt

1201 cagaccccgt agaaaagatc aaaggatctt cttgagatcc tttttttctg cgcgtaatct

1261 gctgcttgca aacaaaaaaa ccaccgctac cagaggtggt ttgtttgccg gatcaagagc

1321 taccaactct ttttccgaag gtaactggct tcagcagagc gcagatacca aatactgtcc

1381 ttctagtgta gccgtagtta ggccaccact tcaagaactc tgtagcaccg cctacatacc

1441 tcgctctgct aatcctgtta ccagtggctg ctgccagtgg cgataagtcg tgtcttaccg

1501 ggttggactc aagacgatag ttaccggata aggcgcagcg gtcggggtga acggggggtt

1561 cgtgcataca gcccagcttg gagcgaacga cctacaccga actgagatac ctacagcgtg

1621 agcattgaga aagcgccacg cttcccgaag ggagaaaggc ggacagGTAT CCggtaagcg

! BiVI.. (2 of 2)

1881 gcagggtcgg aacaggagag cgCACGAGgg agcttccagg gggaaacgcc tggtatcttt

! BssSI.(2/2)

1741 atagtcctgt cgggtttcgc cacctctgac ttgagcgtcg atttttgtga tgctcgtcag

1801 gggggcggag cctatggaaa aacgccagca acgcggcctt tttacggttc ctggcctttt

1861 gctggcctct tgctcACATG Ttctttcctg cgttatcccc tgattctgtg gataaccgta

! PciI...

1921 ttaccgcctt tgagtgagct gataccgctc gccgcagccg aacgaccgag cgcagcgagt

1981 cagtgagcga ggaagcgGAA GAGCgcccaa tacgcaaacc gcctctcccc gcgcgttggc

! SapI....

2041 cgattcatta atgCAGCTGg cacgacaggt ttcccgactg gaaagcgggc agtgagcgca

! PvuII.(1/3)

2101 acgcaatTAA TGTgagttag ctcactcatt aggcacccca ggcTTTACAc tttatgcttc

! ..−35.. Plac ..−10.

2161 cggctcgtat gttgtgtgga attgtgagcg gataacaatt tcacaCAGGA AACAGCTATG

! M13Rev_seq_primer

2221 ACcatgatta cgCCAAGCTT TGGagccttt tttttggaga ttttcaac

! PtlMI.......

! Hinda3.

! signal::linker::CLight

!

! 1 2 3 4 5 8 7 8 9 10 11 12 13 14 15

! fM K K L L F A I P L V V P F Y

(Amino acid sequence is SEO ID NO: 524)

2289 gtg aaa aaa tta tta ttc gca att cct tta gtt gtt cct ttc tat

! Linker.............................. End of FR4

! 18 17 18 19 20 21 22 23 24 25 28 27 28 29 30

! S H S A Q V Q L Q V D L E I K

2314 tCt oac aGT GCA Cag gtc caa CTG CAG GTC GAC CTC GAG atc aaa

! ApaLI...... PstI... XhoI...

! BspMI...

! SalI...

! AccI...(1/2)

! HincII.(1/2)

!

! Vlight domains could be cloned in as ApaLI-XhoI fragments.

! VL-CL(kappa) segments can be cloned in as ApaLI-AscI fragments <--------

!

! Ckappa----------------------------------------------------

! 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45

! R G T V A A P S V F I F P P S

2359 cgt gga act gtg gct gca cca tct GTC TTC atc ttc ccg cca tct

! BbsI...(1/2)

!

! 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

! D E Q L K S G T A S V V C L L

2404 gat gag cag ttg aaa tct gga act gcc tct gtt gtg tgc ctg ctg

!

! 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75

! N N F Y P R E A K V Q W K V D

2449 aat aac ttc tat ccc aga gag gcc aaa gta cag tgg aag gtg gat

!

! 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90

! N A L Q S G N S Q E S V T E Q

2494 aac gcc ctc caa tcg ggt aac tcc cag gag agt gtc aca gag cag

!

! 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105

! D S K D S T Y S L S S T L P L

2539 gac agc aag gac agc acc tac agc ctc agc agc acc ctg acG CTG

! EspI...

!

! 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120

! S K A D Y E K H K V Y A C E V

2584 AGC aaa gca gac tac gag aaa cac aaa GTC TAC gcc tgc gaa gtc

! ...EspI.... AccI...(2/2)

!

! 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135

! T H Q G L S S P V T K S F N R

2629 acc cat cag ggc ctg agt tcA CCG GTg aca aag agc ttc aac agg

! AgeI....(1/2)

! 136 137 138 139 140

! G E C . .

2674 gga gag tgt taa taa GG CGCGCCaatt

! AscI.....

! BssHII.

2701 ctatttcaag gagacagtca ta

!

! PelB::3-23(stuffed)::CH1::III fusion gene

!

! 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

! M K Y L L P T A A A G L L L L

(Amino acid sequence is SEQ ID NO: 525)

2723 atg aaa tac cta ttg cct acg gca gcc gct gga ttg tta tta ctc

!

!--------------------------------------------

!

! 16 17 18 19 20 21 22

! A A Q P A M A

2768 gcG GCC cag ccG GCC atg gcc

! SfiI.............

! NgoMIV..(1/2)

! NcoI....

!

! FR1(DP47/V3-23)---------------

! 23 24 25 26 27 28 29 30

! E V Q L L E S G

2789 gaa|gtt|CAA|TTG|tta|gag|tct|ggt|

! | MfeI |

!

! ---------------FR1-------------------------------------------

! 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45

! G G L V Q P G G S L R L S C A

2813 |ggc|ggt|ctt|gtt|cag|cct|ggt|ggt|tct|tta|cgt|ctt|tct|tgc|gct|

!

! ----FR1-----

! 46 47 48

! A S G

2858 |gct|TCC|GGA|

! | BspEI |

!

! Stuffer for CDR1, FR2, and CDR2--------------------------------->

! Thre are no stop codons in this stuffer.

2867 gcttcAGATC Tgtttgcctt

! BglII..

2887 tttgtggggt ggtgcagatc gcgttacgga gatcgaccga ctgcttgagc aaaagccacg

2947 cttaactgcT GATCAggcat gggatgttat tcgccaaacc agtcgtcagg atcttaacct

! BclI..

3007 gaggcttttt ttacctactc tgcaagcagc gacatctggt ttgacacaga gcgatccgcg

3067 tcgtcagttg gtagaaacat taacacgttg ggatggcatc aatttgctta atgatgatgg

3127 taaaacctgg cagcagccag gctctgccat cctgaacgtt tggctgacca gtatgttgaa

3187 gcgtaccgta gtggctgccg tacctatgCC Atttgataag TGGtacagcg ccagtggcta

! XcmI.............

3247 cgaaacaacc caggacggcc caactggttc gctgaatata agtgttggag caaaaatttt

3307 gtatgaggcg gtgcagggag acaaatcacc aatcccacag gcggttgatc tgtttgctgg

3367 gaaaccacag caggaggttg tgttggctgc gctggaagat acctgggaga ctctttccaa

3427 acgctatggc aataatgtga gtaactggaa aacacctgca atggccttaa cgttccgggc

3487 aaataatttc tttggtgtac cgcaggccgc agcggaagaa ACGCGTcatc aggcggacta

! MluI..

3547 tcaaaaccgt ggaacagaaa acgatatgat tgttttctca ccaacgacaa gcgatcgtcc

3607 tgtgcttgcc tgggatgtgg tcgcacccgg tcagagtggg tttattgctc ccgatggaac

3667 agttgataag cactatgaag atcagctgaa aatgtacgaa aattttggcc gtaagtcgct

! PvuII.

3727 ctgGTTAACg aagcaggatg tggaggcgca taaggagtcg

! HpaI..

! HincII(2/2)

!

! --------FR3--------------------------------------------------

! 4 5 6 7 8 9 10 11 12 13 14 15 16

! 93 94 95 96 97 98 99 100 101 102 103 104 105

! S R D N S K N T L Y L Q M (Amino acid SEQ ID NO: 526)

3767 |TCT|AGA|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg|

! | XbaI |

!

! ---FR3----------------------------------------------------->|

! 17 18 19 20

!

! 106 107 108 109

! N S L s l s i r s g

3806 |acc|agC|TTA|AG t ctg agc att CGG TCC G

! |aflII |

!

! q h s p t .

3834 gg caa cat tct cca aac tga ccagacga cacaaacggc

3872 ttacgctaaa tcccgcgcat gggatggtaa agaggtggcg tctttgctgg cctggactca

3932 tcagatgaag gccaaaaatt ggcaggagtg gacacagcag gcagcgaaac aagcactgac

3992 catcaactgg tactatgctg atgtaaacgg caatattggt tatgttcata ctggtgctta

4052 tccagatcgt caatcaggcc atgatccgcg attacccgtt cctggtacgg gaaaatggga

4112 ctggaaaggg ctattgcctt ttgaaatgaa ccctaaggtg tataaccccc ag

4164 aa GCTAGC ctgcggcttc

! NheI..

!

4182 G|GTC|ACC| gtc tca agc

! | BstEII |

!

(Amino acid sequence is SEQ ID NO: 527)

! 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150

! A S T K G P S V F P L A P S S

4198 gcc tcc acc aag ggc cca tcg gtc ttc ccc ctg gca ccc tcc tcc

!

! 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165

! K S T S G G T A A L G C S V K

4243 aag agc acc tct ggg ggc aca gcg gcc ctg ggc tgc ctg gtc aag

!

! 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180

! D Y F P E P V T V S W N S G A

4288 gac tac ttc ccc gaa ccg gtg acg gtg tcg tgg aac tca ggc gcc

!

! 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195

! L T S G V H T F P A V L Q S S

4333 ctg acc agc ggc gtc cac acc ttc ccg gct gtc cta cag tcc tca

!

! 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210

! G L Y S L S S V V T V P S S S

4378 gga ctc tac tcc ctc agc agc gta gtg acc gtg ccc tcc agc agc

!

! 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225

! L G T Q T Y I C N V N H K P S

4423 ttg ggc acc cag acc tac atc tgc aac gtg aat cac aag ccc agc

!

! 226 227 228 229 230 231 232 233 234 235 236 237 238

! N T K V D K K V E P K S C

4468 aac acc aag gtg gac aaG AAA GTT GAG CCC AAA TCT TGT

! ON-TQHCforw......................

!

! Poly His linker

! 139 140 141 142 143 144 145 146 147 148 149 150

! A A A H H H H H H G A A

4507 GCG GCC GCa cat cat cat cac cat cac ggg gcc gca

! NotI......

! EagI....

!

! 151 152 153 154 155 156 157 158 159 160 161 162 163 264 165

! E Q K L I S E E D L N G A A .

4543 gaa caa aaa ctc atc tca gaa gag gat ctg aat ggg gcc gca tag

!

! Mature III------------------------------------------------>...

! 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180

! T V E S C L A K P H T E N S F

4588 act gtt gaa agt tgt tta gca aaa cct cat aca gaa aat tca ttt

!

! 181 182 183 184 185 186 137 188 189 190 191 192 193 194 195

! T N V W K D D K T L D R Y A N

4633 act aac gtc tgg aaa gac gac aaa act tta gat cgt tac gct aac

!

! 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210

! Y E G C L W N A T G V V V C T

4678 tat gag ggc tgt ctg tgG AAT GCt aca ggc gtt gtg gtt tgt act

! BsmI....

!

! 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225

! G D E T Q C Y G T W V P I G L

4723 ggt qac gaa act cag tgt tac ggt aca tgq qtt cct att ggg ctt

!

! 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240

! A I P E N E G G G S E C G G S

4768 gct atc cct gaa cat gag ggt ggt ggc tct gag ggt ggc ggt tct

!

! 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255

! E G G G S E G G G T A P P E Y

4813 gag ggt ggc ggt tct gag ggt ggc ggt act aaa cct cct gag tac

!

! 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270

! G D T P I P G Y T Y I N P L D

4858 ggt gat aca cct att ccg ggc tat act tat atc aac cct ctc gac

!

! 271 272 273 274 275 276 277 278 279 280 291 282 283 284 285

! G T Y P P G T E Q N P A N P N

4903 ggc act tat ccg cct ggt act gag caa aac ccc gct aat cct aat

!

! 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300

! P S L E E S Q P L N T F M F Q

4948 cct tct ctt GAG GAG tct cag cct ctt act act ttc atg ttt cag

! EseRI..(2/2)

!

! 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315

! N N R F R N R Q G A L T V Y T

4993 aat aat agg ttc cga aat agg cag ggt gca tta act gtt tat acg

!

! 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330

! G T V T Q G T D P V K T Y Y Q

5038 ggc act gtt act caa ggc act gac ccc gtt aaa act tat tac cag

!

! 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345

! Y T P V S S K A M Y D A Y W N

5083 tac act cct gta tca tca aaa gcc atg tat gac gct tac tgg aac

! 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360

! G K F R D C A F H S G F N E D

5128 ggt aaa ttc aga gac tgc gct ttc cat tct ggc ttt aat gaG GAT

! BamHT...

! 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375

! P F V C E Y Q G Q S S D L P Q

5173 CCa ttc gtt tgt gaa tat caa ggc caa tcg tct gAC CTG Cct caa

! BamHI... BspMI...(2/2)

!

! 376 377 378 379 380 381 382 383 384 385 386 387 389 289 390

! P P V N A G G G S G G G S G G

5218 cct cct gtc aat gct ggc ggc ggc tct ggt ggt ggt tct ggt ggc

!

! 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405

! G S E G G G S E G G G S E G G

5263 ggc tct gag ggt ggc ggc tct gag ggt ggc ggt tct gag ggt ggc

!

! 406 407 408 409 410 411 412 423 414 415 416 417 418 419 420

! G S E G G G S G G G S G S G D

5308 ggc tct gag ggt ggc ggt tcc ggt ggc ggc tcc ggt tcc ggt gat

!

! 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435

! F D Y E K M A N A N K G A M T

5353 ttt gat tat gaa aaa atg gca aac gct aat aag ggg gct atg acc

!

! 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450

! E N A D E N A L Q S D A K G K

5398 gaa aat gcc gat gaa aac gcg cta cag tct gac gct aaa ggc aaa

!

! 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465

! L D S V A T D Y G A A I D G F

5443 ctt gat tcc gtc gct act gat tac ggt gct gct ATC GAT ggt ttc

! BspDi..

!

! 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480

! I G D V S G L A N G N G A T G

5488 att ggt gac gtt tcc ggc ctt gct aat ggt aat ggt gct act ggt

!

! 481 482 483 484 485 486 487 488 489 490 492 492 403 494 495

! D F A G S N S N M A Q V G D G

5533 gat ttt gct ggc tct aat tcc caa atg gct caa gtc ggt gac ggt

!

! 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510

! D N S P L M N N F R Q Y L P S

5578 gat aat tca cct tta atg aat aat ttc cgt caa tat tta cct tct

!

! 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525

! L P Q S V E C R P Y V F G A G

5623 ttg cct cag tcg gtt gaa tgt cgc cct tat gtc ttt ggc gct ggt

!

! 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540

! K P Y E F S I D C D K T N L F

5668 aaa cCA TAT Gaa ttt tct att gat tgt gac aaa ata aac tta ttc

! NdeI....

!

! 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555

! R G V F A F L L Y V A T F M Y

5713 cgt ggt gtc ttt gcg ttt ctt tta tat gtt gcc acc ttt atg tat

!

! 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570

! V F S T F A N I L R N K E S .

5758 gta ttt tcg acg ttt gct aac ata ctg cgt aat aag gag tct taa

!

! 571

! .

5803 taa GAATTC

! EcoRI.

5812 actggccgt cgttttacaa cgtcgtgact gggaaaaccc tggcgttacc caacttaatc

5871 gccttgcagc acatccccct ttcgccagct ggcgtaatag cgaagaggcc cgcacCGATC

! PvuI..

5931 Gcccttccca acagtTGCGC Agcctgaatg gcgaatGGCG CCtgatgcgg tattttctcc

! ...PvuI... (3/3) FspI... (2/2) KasI...(2/2)

5991 ttacgcatct gtgcggtatt tcacaccgca tataaattgt aaacgttaat attttgttaa

6051 aattcgcgtt aaatttttgt taaatcagct cattttttaa ccaataggcc gaaatcggca

6111 aaatcccTTA TAAatcaaaa gaatagcccg agatagggtt gagtgttgtt ccagtttgga

! PsiI...

6171 acaagagtcc actattaaag aacgtggact ccaacgtcaa agggcgaaaa accgtctatc

6231 agggcgatgg ccCACtacGT Gaaccatcac ccaaatcaag ttttttgggg tcgaggtgcc

! DraIII....

6291 gtaaagcact aaatcggaac cctaaaggga gcccccgatt tagagcttga cggggaaaGC

! NgoMIV..

6351 CGGCgaacgt ggcgagaaag gaagggaaga aagcgaaagg agcgggcgct agggcgctgg

! ..NgoMIV.(2/2)

6411 caagtgtagc ggtcacgctg cgcgtaacca ccacacccgc cgcgcttaat gcgccgctac

6471 agggcgcgta ctatggttgc tttgacgggt gcagtctcag tacaatctgc tctgatgccg

6531 catagttaag ccagccccga cacccgccaa cacccgctga cgcgccctga cgggcttgtc

6591 tgctcccggc atccgcttac agacaagctg tgaccgtctc cgggagctgc atgtgtcaga

6651 ggttttcacc gtcatcaccg aaacgcgcga

TABLE 30

Oliaonucleotides used to clone CDR1/2 diversity
All sequences are 5′ to 3′.

1) oN_cD1Bsp, 30 bases (SEQ ID NO: 558)
A c c T c A c T g g c T T c c a g A
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
T T c A c T T T c T c T
19 20 21 22 23 24 25 26 27 28 29 30

2) ON_Br12, 42 bases (SEQ ID NO: 529)
A g A A A c c c A c T c c A A A c c
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
T T T A c c A g g A g c T T g g c g
19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
A A c c c A
37 38 39 40 41 42

3) ON_CD2Xba, 51 bases (SEQ ID NO: 53))
g g A A g g c A a T g A T c T A g A
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
g A T A g T g A A g c g A c c T T T
19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
A A c g g A a T c A g c A T A
37 38 39 40 41 42 43 44 45 46 47 48 49 50 51

4) ON_BotXba, 23 bases (SEQ ID NO: 531)
g g A A g g c A g T g A T c T A g A
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
g A T A a
19 20 2 22 23

TABLE 31

Bridge/Extender Oligonucleotides
(SEQ ID NOs: 532-548, respectively in order of appearance)

ON_Lam1aB7(rc) .........................GTGCTGACTCAGCCACCCTC. 20

ON_Lam2aB7(rc) ........................GCCCTGACTCAGCCTGCCTC. 20

ON_Lam31B7(rc) .......................GAGCTGACTCAGG.ACCCTGC 20

ON_Lam3rB7(rc) ........................GAGCTGACTCAGCCACCCTC. 70

ON_LamHf1cBrg(rc) CCTCGACAGCGAAGTGCACAGAGCGTCTTGACTCAGCC....... 38

ON_LamHf1cExt CCTCGACAGCGAAGTGCACAGAGCGTCTTG............... 30

ON_LamHf2b2Brg(rc) CCTCGACAGCGAAGTGCACAGAGCGCTTTGACTCAGCC....... 30

ON_LamHf2b2Ext CCTCGACAGCGAAGTGCACAGAGCGCTTTG............... 30

ON_LamHf2dBrg(rc) CCTCGACAGCTAAGTGCACAGAGCGCTTTGACTCAGCC....... 38

ON_LamHf2dExt CCTCGACAGCGAAGTGCACAGAGCGCTTTG............... 30

ON_LamHf31Brg(rc) CCTCGACAGCGAAGTGCACAGAGCGAATTGACTCAGCC....... 30

ON_LamHf31Ext CCTCGACAGCGAAGTGCACAGAGCGAATTG............... 30

ON_LamHf3rBrg(rc) CCTCGACAGCGAAGTGCACAGTACGAATTGACTCAGCC....... 30

ON_LamHf3rExt CCTCGACAGCGAAGTGCACAGTACGAATTG............... 30

ON_lamPlePCR CCTCGACAGCGAAGTGCACAG........................ 21

ConSensus

TABLE 32

Oligonucleotides used to make SSDNA locally
double-stranded
(SEQ ID NOs: 548-552, respectively in
order of appearance)

Adapters (8)

H43HF3.1?02#1 5′-cc gtg tat tac tgt gcg aga g-3′

H43.77.97.1-03#2 5′-ct gtg tat tac tgt gcg aga g-3′

H43.77.97.323#22 5′-cc gta tat tac tgt gcg aaa g-3′

H43.77.97.230#23 5′-ct gtg tgt gcg aaa g-3′

H43.77.97.439#44 5′-ct tat tac tgt gcg aga c-3′

H43.77.97.551#48 5′-cc atg tat tac tgt gcg aga c-3

TABLE 33

Bridge/extender pairs

Bridges (2)

H43.XABr1

5′ggtgtagtgaTCTAGtgacaactctaagaatactctctacttgcagat

gaacagCTTtAGggctgaggacaCTGCAGtctactattgtgcgaga-3′

(SEQ ID NO: 553)

H43.XABr2

5′ggtgtagtgaTCTAGtgacaactctaagaatactctctacttgcagat

gaacagCTTtAGagctgaggacaCTGCAGtctactattgtgcgaaa-3′

(SEQ ID NO: 554)

Extender

H43.XAExt

5′ATAgTAgAcTqcAgTgTccTcAgcccTTAAgcTqTTcATcTgcAAgTA

cTAcTAgTATTcTTAqAgTTgTcTcTAcTATcAcTAcAcc-3′

(SEQ ID NO: 555)

TABLE 34

PCR primers

Primers

H43.XAPCR2 gactgggTgTAgTgATcTAg (SEQ ID NO: 556)

Hucmnest cttttctttgttgccgttagggtg (SEQ ID NO: 557)

TABLE 35

PCR program for amplification of
heavy chain CDR3 DNA

	95 degrees C. 5 minutes
	95 degrees C. 20 seconds
	60 degrees C. 30 seconds repeat 20x
	72 degrees C. 1 minute
	72 degrees C. 7 minutes
	4 degrees C. hold

	Reagents (100 ul reaction):
	Template 5 ul ligation mix
	10x PCR buffer 1x
	Taq 5 U
	dNTPs 200 uM each
	MyCl2 2 mM
	H43.XAPCR2-biotin 400 nM
	Hucmnest 200 nM

TABLE 36

Annotated sequence of CJR DY3F7(CJR-A05) 10251 bases

!

! Non-cutters

!

!BclI Tgatca BsiWI Cgtacg BssSI Cacgag

!BstZ17I GTAtac BtrI CACgtg EcoRV GATatc

!FseI GGCCGGcc HPaI GTTaac MluI Acgcgt

!PmeI GTTTaaac PmlI CACgtg PpuMI RGgwccv

!RsrII CGgwccg SapI GCTCTTC SexAI Accwqgt

!SgfI GCGATcgc SgrAI CRccggyg SphI GOATGc

!StuI AGGcct XmaI Cccggg

!

! cutters

!

! Enzvmes that cut from 1 to 4 times and other features

!

!End at genes II and X 829

!Start gene V 843

!EsrGI Tgtaca 1 1021

!BspMI Nnnnnnnnngcaggt 3 1104 5997 9183

(SEQ ID NO: 558)

!-″- ACCTGCNNNNn 1 2281

(SEQ ID NO: 559)

!End of gene V 1106

!Start gene VII 1108

!BsaBI GATNNnnatc 2 1149 3967

(SEQ ID NO: 560)

!Start gene IX 1208

!End gene VII 1211

!SnaBI TACgta 2 1268 7133

!BspHI Tcatga 3 1299 6085 7093

!Start gene VIII 1301

!End gene IX 1304

!End gene VIII 1522

!Start gene III 1578

!EagI Cggccg 2 1530 8905

!XbaI Tctaga 2 1643 8436

!KasI Ggcgcc 4 1650 8724 9039 9120

!BsmI GAATGCN 2 1769 9065

!BseRI GAGGAGNNNNNNNNNN 2 2031 8516

(SEQ ID NO: 561)

!-″- NNnnnnnnnnctcctc 2 7603 8623

(SEQ ID NO: 562)

!AlWNI CAGNNNctg 3 2210 8072 8182

!BspDI ATcgat 2 2520 9883

!NdeI CAtatg 3 2716 3796 9847

!End gene III 2846

!Start gene VI 2848

!AfeI AGCgct 1 3032

!End gene VI 3187

!Start gene I 3189

!EarI CTCTTCNnnn 2 1067 9271

(SEQ ID NO: 563)

!-″- Nnnnnqaagag 2 6126 8953

(SEQ ID NO: 564)

!PacI TTAATtaa 1 4125

!Start gene IV 4213

!End gene I 4235

!BsmFI Nnnnnnnnnnnnnnngtccc 2 5068 9515

(SEQ ID NO: 565)

!MscI TGGcca 3 5073 7597 9160

!PsiI TTAtaa 2 5349 5837

!End gene IV 5493

!Start ori 5494

!NgoMIV Gccggc 3 5606 8213 9315

!BanII GRGCYc 4 5636 8080 8606 8889

!DraIII CACNNNgtg 1 5709

!DrdI GACNNNNnngtc 1 5752

(SEQ ID NO: 566)

!AvaI Cycgrg 2 5818 7240

!PvuII CAGctg 1 5953

!BsmBI CGTCTCNnnnn 3 5964 8585 9271

(SEQ ID NO: 567)

!End ori region 5993

!BamHI Cgatcc 1 5994

!HindIII Aagctt 3 6000 7147 7384

!BciVI GTATCCNNNNNN 1 6077

(SEQ ID NO: 568)

!Start bla 6132

!Eco57I CTGAAG 2 6238 7716

!SpeI Actagt 1 6257

!BcgI gcannnnnntcg 1 6398

(SEQ ID NO: 569)

!ScaI AGTact 1 6442

!PvuI CGATcg 1 6553

!FspI TGCgca 1 6700

!BglI GCCNNNNnggc 3 6801 8208 8976

(SEQ ID NO: 570)

!BsaT GGTCTCGgggg 1 6853

(SEQ ID NO: 571)

!AhdI GACNNNnngtc 1 6920

(SEQ ID NO: 572)

!Eam1105I GACNNNnngtc 1 6920

(SEQ ID NO: 573)

!End bla 6998

!AccI GTmkac 2 7153 8048

!HincII GTYrac 1 7153

!SalI Gtcqac 1 7153

!XhoI Ctcgag 1 7240

!Start PlacZ region 7246

!End PlacZ region 7381

!PflMI CCANNNNntgg 1 7382

(SEQ ID NO: 574)

!RBS1 7405

!Start M13-iii signal scq for LC 7418

!APaLI Gtgcac 1 7470

!end M13-iii signal seq 7471

!Start light chain kappa L20:JK 1 7472

!Pf1FI GACNnngtc 3 7489 8705 9099

!SbfI CCTGCAgg 1 7542

!PstI CTGCAg 1 7543

!KpnI GGTACc 1 7581

!XcmI CCANNNNNnnnntgg 2 7585 9215

(SEQ ID NO: 575)

!NsiI ATGCAt 2 7626 9503

!BsgI ctgcac 1 7809

!BbsI gtcttc 2 7820 8616

!BlpI GCtnaac 1 8017

!EspI GCtnagc 1 8017

!EcoO109I RGgnccy 2 8073 8605

!Ecl136I GAGctc 1 8080

!SacI GAGCTc 1 8080

!End light chain 8122

!AscI GGcgcgcc 1 8126

!BssHII Gcgcgc 1 8127

IRBS2 8147

!SfiI GGCCNNNNnggcc 1 8207

(SEQ ID NO: 576)

!NcoI Ccatgg 1 8218

!Start 3-23, FR1 8226

!MfeI Caattg 1 8232

!BspEI Tccgga 1 8298

!Start CDR1 8316

!Statt FR2 8331

!BstXI CCANNNNNntgg 2 8339 8812

(SEQ ID NO: 577)

!EcoNI CCTNNnnnagg 2 8346 8675

(SEQ ID NO: 578)

!Start FR3 8373

!XbaI Tctac 2 8436 1643

!AflII Cttaag 1 8480

!Start CDR3 8520

!AatII GACGTc 1 8556

!Start FR4 8562

!PshAI GACNNnngtc 2 8573 9231

(SEQ ID NO: 579)

!BstEII Ggtnacc 1 8579

!Start CH1 8595

!ApaI GGGCc 1 8606

!Bspl20I Gggccc 1 8606

!PspOMI Gggccc 1 8606

!AgeI Accggt 1 8699

!Bsu361 CCtnagg 2 8770 9509

!End of CH1 8903

!NOtI GCggccgc 1 8904

!Start His6 tag 8913

(SEQ ID NO: 12)

!Start cMyc tag 8931

!Amber codon 8982

!NheI Gctagc 1 8985

!Start M13 III Domain 3 8997

!NruI TCGcga 1 9106

!BstBI TTcgaa 1 9197

!EcoRI Gaattc 1 9200

!XcmI CCANNNNNnnnntgg 1 9215

(SEQ ID NO: 580)

!BstAPI GCANNNNntgc 1 9337

(SEQ ID NO: 581)

!SacII CCGCgg 1 9365

!End IIIstump anchor 9455

!AvrII Cctagg 1 9462

!trp terminator 9470

!SwaI ATTTaaat 1 9784

!Start gene II 9850

!BglII Agatct 1 9936

!----------------------------------------------------------------------

(SEQ ID NO: 582)

1 aat gct cct act att agt aga att gat gcc acc ttt tca gct cgc gcc

! gene ii continued

49 cca aat gaa aat ata gct aaa cag gtt att gac cat ttg cga act gta

97 tct cat ggt caa act aaa tct act cgt tcg cag act tgg gcc tcc act

145 gtt aTa tgg cat gaa act tcc aga cac cgt act tta gtt gca tat tta

193 aaa cat gtt gag cta cap caT Tat att cag caa tta agc tct aag cca

241 tcc gca aaa atg acc tct tat caa aag gag caa tta aag gta ctc tct

289 aat cct gac ctg ttg gag ttt gct tcc ggt ctg gtt cgc ttt gaa gct

337 cga att aaa acg cga tat ttg aag tct ttc ggg ctt cct ctt aat ctt

385 ttt gat gca atc cgc ttt gct tct gac tat aat agt cag ggt aaa gac

433 ctg att ttt gat tta tgg tca ttc tcg ttt tct aaa ctg ttt aaa gca

481 ttt gag ggg gat tca ATG cat att tat gac gat tcc gca gta ttg gac

! Start gene x, ii continues

529 gct atc cag tct aaa cat ttt act att acc ccc tct ggc aaa act tct

577 ttt gca aaa gcc tct cgc tat ttt ggt ttt tat cgt cgt ctg gta aac

625 gag ggt tat gat agt gtt gct ctt act atg cct cgt aat tcc ttt tgg

673 cgt tat gta tct gca tta gtt gaa tgt ggt att cct aaa tct caa ctg

721 atg aat ctt tct acc tgt act aat gtt gtt ccg tta gtt cgt ttt att

769 aac gta gat ttt tct tcc caa cgt cct gac tgg tat aat gag cca gtt

817 ctt aaa atc gca TAA

! End X & II

832 ggtaattca ca

! (SEQ ID NO: 626)

! M1 E5 Q10 T15

843 ATG att aaa gtt gaa att aaa cca tct caa gcc caa ttt act act cgt

Start gene V

!

! S17 S20 P25 E30

891 tct ggt gtt tct cgt ccg ggc cap cct tat tca ctg act gag cag ctt

!

! V35 E40 V45

939 tgt tac gtt gat ttg ggt aat gaa tat cog gtt ctt gtc aag att act

!

! D50 A55 L60

987 ctt gat gaa ggt cag cca gcc tat gcg cct ggt cTG TAC Acc gtt cat

! BsrGI...

! L65 V70 S75 R80

1035 ctg tcc tct ttc aaa gtt ggt cag ttc ggt tcc ctt atg att gac cgt

!

! P85 K87 end of V

1083 ctg cgc ctc gtt ccg gct aag TAA C

!

1108 ATG gag cag gtc gcg gat ttc gat aca att tat cag gcg atg

! Start gene VII

!

1150 ata caa atc tcc gtt gta ctt tgt ttc gcg ctt ggt ata atc

!

! VII and IX overlap.

..... S2 V3 L4 V5 (SEQ ID NO: 621) S10

1192 gct ggg ggt caa agA TGA gt gtt tta gtg tat tot ttT gcc tct ttc gtt

! End VII

! |start IX

! L13 W15 G20 T25 E29

1242 tta ggt tgg tgc ctt cgt apt ggc att acg tat ttt acc cgt tta atg gaa

!

1293 act tcc tc

! .... stop of IX, IX and VIII overlap by four bases

1301 ATP aaa aag tct tta gtc ctc aaa gcc tct gta gcc gtt act acc ctc

! Start signal seauence of viii.

!

1349 gtt ccg atg ctg tct ttc gct gct gag ggt gac gat ccc gca aaa gcg

! mature VIII --->

1397 gcc ttt aac tcc ctg caa gcc tca gcg acc gaa tat atc ggt tat gcg

1445 tgg gcg atg gtt gtt gtc att

1466 gtc ggc gca act atc ggt atc aag ctg ttt aag

!

! bases 1499-1539 are probable promoter for iii

1499 aaa ttc acc tcg aaa gca ! 1515

! ........... −35 ..

!

1517 agc tga taaaccgat acaattaaag gctccttttg

! ..... −10 ...

!

1552 gagccttttt ttt GGAGAt ttt ! S.D. uppercase, there may be 9 Ts

!

! <------ III signal sequence ----------------------------->

(SEQ ID NO: 583)

! M K K L L F A I P L V V P F

1574 caac GTG aaa aaa tta tta ttc gca att cct tta gtt gtt cct ttc ! 1620

!

! Y S G A A E S H L D G A

1620 tat tct ggc gCG GCC Gas tca caT CTA GAc ggc gcc

! EagI.... XbaI....

!

! Domain 1 ------------------------------------------------------------

A E T V E S C L A

1656 gct gaa act gtt gaa agt tgt tta gca

!

! K S H T E I S F T N V W K D D K T

1683 aaA Tcc cat aca gaa aat tca ttt aCT AAC GTC TGG AAA GAC GAC AAA ACt

!

! L D R Y A N Y E G S L W N A T G V

1734 tta gat cgt tac gct sac tat gag ggC tgt ctg tgG AAT GCt aca ggc gtt

! Bsmi....

! V V C T G D E T Q C Y G T W V P I

1785 gta gtt tgt act ggt GAC GAA ACT CAG TGT TAC GGT ACA TGG GTT cct att

!

! G L A I P E N

1336 ggg ctt gct atc cct gaa aat

!

! L1 linker ----------------------------------

! E G G G S E G G G S

1857 gag ggt ggt ggc tct gag ggt ggc ggt tct

!

! E G G G S E G G G T

1887 gag ggt ggc ggt tct gag ggt ggc ggt act

!

! Domain 2 -----------------------------------

1917 aaa cct cct gag tac ggt gat aca cct att ccg ggc tat act tat atc aac

1968 cct ctc gac ggc act tat ccg cct ggt act gag caa aac ccc gct aat cct

2019 aat cct tct ctt GAG GAG tct cag cct ctt aat act ttc atg ttt cag aat

! BseRI..

2070 aat agg ttc cga aat agg cag ggg gca tta act gtt tat acg ggc act

2118 gtt act caa ggc act gac ccc gtt aaa act tat tac cag tac act cct

2166 gta tca tca aaa gcc atg tat gac gct tac tgg aac ggt aaa ttC AGA

! AlwNI

2214 GAC TGc gct ttc cat tct ggc ttt aat gaG gat TTa ttT gtt tgt gas

! AlwNI

2262 tat caa ggc caa tcg tct gac ctg cct caa cct cct gtc sat gct

2307 ggc ggc ggc tct

! start L2

2319 ggt ggt ggt tct

2331 ggt ggc ggc tct

2343 gag ggt ggt ggc tct gag gga ggc ggt tcc

2373 ggt ggt ggc tct ggt ! end L2

!

! Many published sequence of M13-derived phage have a longer linker

! than shown here by repeats of the EGGGS motif two more Limes.

! Domain 3

(SEQ ID NO: 584)

------------------------------------------------------------

! S G D F D Y E K M A N A N K G A

2388 tcc ggt gat ttt gat tat gaa aag atg gca aac act aat aag ggg gct

!

! M T E N A D E N A L Q S D A K G

2436 atg acc gaa aat gcc gat gaa aac gcg cta cag tct gac gct aaa ggc

!

! K L D S V A T N Y G A A M D G F

2484 aaa ctt gat tct gtc gct act gat tac ggt gct gct atc gat ggt ttc

!

! I G D V S G L A N G N G A T G D

2532 att ggt gac gtt tcc ggc ctt gct aat ggt aat ggt gct act ggt gat

!

! F A G S N S Q M A Q V G D G D N

2580 ttt gct ggc tct aat tcc caa atg gct caa gtc ggt gac ggt gat aat

!

! S P L M N N F R Q Y L P S L P Q

2629 tca cct tta atg aat act ttc cgt cca tat tta cct tcc ctc cct caa

!

! S V E C R P F V F N A G K P Y E

2676 tcg gtt gaa tat cgc cct ttt gtc ttt Ggc gct ggt aaa cca tat gaa

!

! F S I D C D K I N L F R

2724 ttt tct att gat tgt gac aaa ata aac tta ttc cgt

! End Domain 3

!

! G V F A F L L Y V A F F N Y V F140

2760 ggt gtc ttt gct ttt ctt tta tat gtt gcc acc ttt atg tat gta ttt

! start transmembrane segment

!

! S T F A N I L

2808 tct ccg ttt gct aac ata ctg

!

! R N K E S

2629 cgt aat aag gag tct TAA ! stop of iii

! Intracellular anchor.

! (SEQ ID NO: 585)

! M1 P2 V L L5 G I P L L10 L R F L G15

2847 tc ATG cca gtt ctt ttg ggt att ccg tta tta ttg cgt ttc ctc ggt

! Start VI

!

2894 ttc ctt ctg gta act ttg ttc ggc tat ctg ctt act ttt ctt aaa aag

2942 ggc ttc ggt act ata gct att gct att tca ttg ttt ctt gct ctt att

2990 att ggg ctt aac tca att ctt gtg ggt tat ctc tct gat att agc gct

3038 caa tta ccc tct gac ttt gtt cag ggt gtt cag tta att ctc ccg tct

3086 aat acg ctt ccc tgt ttt tat gtt att ctc tct gta aag act gct att

3134 ttc att ttt gac gtt aaa caa aaa atc gtt tct tat ttg gat tgg gat

!

! M1 A2 V3 F5 L10 G13

3182 aaa TAA t ATG gct gtt tat ttt gta act ggc aaa tta ggc tct gga

! end VI Start gene 1

!

(SEQ ID NO: 586)

! K T L V S V G K I Q D K I V A

3228 aag acg ctc gtt agc gtt ggt aag att tag gat aaa att gta gct

!

! G C K I A T N L D L R L Q N L

3273 ggg tgc aaa ata gca act aat ctt gat tta agg ctt caa aac ctc

!

! P Q V G R F A K T P R V L R I

3318 ccg caa gtc ggg agg ttc gct aaa ccg cct cgc gtt ctt aga ata

!

P D K P S I S D L L A I G R G

3363 ccg aat aag cct tct ata tct gat ttg ctt gct att ggg cgc ggt

!

! N D S Y D E N K N G L L V L D

3408 aat gat tcc tac gat gaa aat aaa aac ggc ttg ctt gtt ctc gat

!

! E C G T W F N T R S W N D K E

3453 gag tgc ggt act tgg ttt aat act cgt tct tgg aat gat aag gaa

!

! R Q P I I D W F L H A R K L G

3498 aga tag ccg att att gat tgg ttt cta cat gct cgt aaa tta gga

!

! W D I I F L V Q D L S I V D K

3543 tgg gat att att ttt ctt gtt tag gac tta tct att gtt gat aaa

!

! Q A R S A L A E H V V Y C R R

3588 tag gcg cgt tct gca tta gct gaa cat gtt gtt tat tgt cgt cgt

!

! L D R I T F P F V G T L Y S L

3633 ctg gac aga att act tta cct ttt gtc ggt act tta tat tct ctt

!

! I T G S K M P L P K L H V G V

3678 att act ggc tcg aaa atg cct ctg cct aaa tta cat gtt ggc gtt

!

! V K Y G D S Q L S P T V E R W

3723 gtt aaa tat ggc gat tct caa tta ago cct act gtt gag cgt tgg

!

! L Y T G K N L Y N A Y P T K Q

3768 ctt tat act ggt aag aat ttg tat act gca tat gat act aaa cag

!

! A F S S N Y D S G V Y S Y L T

3813 gct ttt tct agt aat tat gat tcc ggt gtt tat tct tat tta ccg

!

! P Y L S H G R Y F K D L N L G

3858 cct tat tta tca cac ggt cgg tat ttc aaa cca tta aat tta ggt

!

! Q K N K L T K I Y L K K F S R

3903 cag aag atg aaa tta act aaa ata tat ttg aaa aag ttt tct cgc

!

! V L C L A I G F A S A F T Y S

3948 gtt ctt tgt ctt gcg att gga ttt gca tca gca ttt aca tat agt

!

! Y I T Q P K P E V K K V V S Q

3993 tat ata acc caa cct aag ccg gag gtt aaa aag gta gtc tct tag

!

! T Y D F D K F T I D S S Q R L

4082 acc tat gat ttt gat aaa ttc act att gac tct tct cag cgt ctt

!

4083 aat cta agc tat cgc tat gtt ttc aag gat tct aag gga aaa TTA

! PacI

!

! I N S D D L Q K Q G Y S L T Y

4128 ATT AAt agc gac gat tta cag aag caa ggt tat tca ctc aca tat

! PacI

!

! i I D L C T V S I K K G N S N E

! iv M1 K

4173 att gat tta tgt act gtt tcc att aaa aaa ggt aat tca aAT Gaa

! Start IV

! (SEQ ID NO: 527)

! i I V K C N .End of I

! iv L3 L N5 V I7 N F V10

4218 att gtt aaa tgt aat TAA T TTT GTT

! IV continued.....

4243 ttc ttg atg ttt gtt tca tca tct tct ttt gct cag gta att gaa atg

4291 aat aat tcg cct ctg cgc gat ttt gta act tgg tat tca aag caa tca

4339 ggc gaa tcc gtt att gtt tct ccc gat gta aaa ggt act gtt act gta

4387 tat tca tct gac gtt aaa cct gaa aat cta cgc aat ttc ttt att tct

4435 gtt tta cgt gcA aat aat ttt gat atg gtA ggt tcT aAC cct tcc atT

4483 att cag aag tat aat cca aac aat cag gat tat att gat gaa ttg cca

4531 tca tct gat aat cag gaa tat gat gat aat tcc gct cct tct ggt ggt

4579 ttc ttt gtt ccg caa aat gat aat gtt act caa act ttt aaa att aat

4627 aac gtt cgg gca aag gat tta ata cga gtt gtc gaa ttg ttt gta aag

4675 tct aat act tct aaa tcc tca aat gta tta tct att gac ggc tct aat

4723 cta tta gtt gtt agt gcT cct aaa gat att tta gat aac ctt cct caa

4771 ttc ctt tcA act gtt gat ttg cca act gac cag ata ttg att gag ggt

4819 ttg ata ttt gag gtt cag caa ggt gat gct tta gat ttt tca ttt gct

4867 gct ggc tct cag cgt ggc act gtt gca ggc ggt gtt aat act gac cgc

4915 ctc acc tct gtt tta tct tct gct ggt ggt tcg ttc ggt att ttt aat

4963 ggc gat gtt tta ggg cta tca gtt cgc gca tta aag act aat agc cat

5011 tca aaa ata ttg tct gtg cca cgt att ctt acg ctt tca ggt cag aag

5059 ggt tct atc tct gtT GGC CAg aat gtc cct ttt att act ggt cgt gtg

! MscI....

5107 act ggt gaa tct gcc aat gta aat aat cca ttt cag acg att gag cgt

5155 caa aat gta ggt att tcc atg agc gtt ttt cct gtt gca atg gct ggc

5203 ggt aat att gtt ctg gat att acc agc aag gcc gat agt ttg agt tct

5251 tct act cag gca agt gat gtt att act aat caa aga agt att gct aca

5299 acg gtt aat ttg cgt gat gga cag act ctt tta ctc ggt ggc ctc act

5347 gat tat aaa aac act tct caG gat tct ggc gta ccg ttc ctg tct aaa

5395 atc cct tta atc ggc ctc ctg ttt agc tcc cgc tct gat tcT aac gag

5443 gaa agc acg tta tac gtg ctc gtc aaa gca acc ata gta cgc gcc ctg

5491 TAG cggcgcatt

! End IV

5503 aagcgcggcg ggtgtggtgg ttacgcgcag cgtgaccgct acacttgcca gcgccctagc

5563 gcccgctcct ttcgctttct tcccttcctt tctcgccacg ttcGCCGGCt ttccccgtca

!

5623 agctctaaat cgggggctcc ctttagggtt ccgatttagt gctttacggc acctcgaccc

5683 caaaaaactt gatttgggtg atggttCACG TAGTGggcca tcgccctgat agacggtttt

!

5743 tcgccctttG ACGTTGGAGT Ccacgttctt taatagtgga ctcttgttcc aaactggaac

!

5803 aacactcaac cctatctcgg gctattcttt tgatttataa gggattttgc cgatttcgga

5863 accaccatca aacaggattt tcgcctgctg gggcaaacca gcgtggaccg cttgctgcaa

5923 ctctctcagg gccaggcggt gaagggcaat CAGCTGttgc cCGTCTCact ggtgaaaaga

!

5983 aaaaccaccc tGGATCC AAGCTT

! BamHI HindIII (1/2)

! Insert carrying bla gene

6006 gcaggtg gcacttttcg gggaaatgtg cgcggaaccc

6043 ctatttgttt atttttctaa atacattcaa atatGTATCC gctcatgaga caataaccct

! BciVI

6103 gataaatgct tcaataatat tgaaaaAGGA AGAgt

! RBS.?...

! Start bla gene

6138 ATG agt att caa cat ttc cgt gtc gcc ctt att ccc ttt ttt gcg gca ttt

6189 tgc ctt cct gtt ttt gct cac cca gaa acg ctg gtg aaa gta aaa gat gct

6240 gaa gat cag ttg ggC gcA CTA GTg ggt tac atc gaa ctg gat ctc aac agc

! SpeI....

! ApaLI & BssSI Removed

6291 ggt aag atc ctt gag agt ttt cgc ccc gaa gaa cgt ttt cca atg atg agc

6342 att ttt aaa gtt ctg cta tgt GGC GcG Gta tta tcc cgt att gac gcc ggg

6393 caa gaG CAA CTC GGT CGc cgC ATA cAC tat tct cag aat gac ttg gtt gAG

! BcgI............ ScaI

6444 TAC Tca cca gtc aca gaa aag cat ctt acg gat ggc atg aca gta aga gaa

! ScaI.

6495 tta tgc agt gct gcc ata acc atg agt gat aac act gcg gcc aac tta ctt

6546 ctg aca aCG ATC Gga gga cog aag gag cta acc gct ttt ttg cac aac atg

! Pvul....

6597 ggg gat cat gta act cgc ctt gat cgt tgg gaa ccg gag ctg aat gaa gcc

6648 ata cca aac gac gag cgt gac acc acg atg cct gta gca atg Gca aca acg

6699 tTG CCC Aaa cta tta act ggc gaa cta ctt act cta gct tcc cgg caa caa

! FspI....

!

6750 tta ata gac tgg atg gag gcg gat aaa gtt gca gga cca ctt ctg cac tcg

6801 GCC ctt ccG GCt ggc tgg ttt att gct gat aaa tct gga gcc ggt gag cgt

! BglI..........

6852 gGG TCT Cgc ggt atc att gca gca ctg ggg cca gat ggt aag ccc tcc cgt

! BsaI....

6903 atc gta gtt atc tac acG ACg ggg aGT Cag gca act atg gat gaa cga aat

! AndI...........

6954 aga cag atc gct gag ata ggt gcc tca ctg att aag cat tgg TAA ctgt

! stop

7003 caqaccaaqt ttactcatat atactttaaa ttqatttaaa acttcatttt taatttaaaa

7063 ggatctaggt gaagatcctt tttgataatc tcatgaccaa aatcccttaa cgtgagtttt

7123 cgttccactg tacgtaagac cccc

7147 AAGCTT GTCGAC tgaa tggcgaatgg cgctttgcct

! HindIII SalI..

! (2/2) HincII

7183 ggtttccggc accagaagog gtgccggaaa gctggctgga gtgcgatctt

!

! Start of Fab-display cassette, the Fab DSR-A05, selected for

! binding to a protein antigen.

!

7233 CCTGAcG CTCGAG

! xBsu36I XhoI..

!

! PlatZ promoter is in the following block

!

7246 cgcaacgc aattaatgtg agttagctca

7274 ctcattaggc accccaggct ttacacttta tgcttccggc tcgtatqttg

7324 tgtggaattg tgagcggata acaatttcac acaggaaaca gctatgacca

7374 tgattacgCC AagcttTGGa gccttttttt tggagatttt caac

! PflMI.......

! Hind3. (there are 3)

! Gene iii signal sequence: (Amino acid sequence is SEQ ID NO: 587)

! 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

! M K K L B F A I P L V V P F Y

7418 gtg aaa aaa tta tta ttc gca att cct tta gtt gtt cct ttc tat

!

16 17 18 Start light chain (L20:JK1)

! S H S A Q D I Q M T Q S P A

7463 tct cac aGT GCA Caa gac atc cag atg acc cag tct cca gcc

! ApaLI...

! Sequence supplied bv extender

! T L S L

7505 act ctg tct ttg

!

! S P G E R A T L S C R A S Q G

7517 tct cca ggg gaa aga gcc acc ctc tcc tgc agg gcc agt cag Ggt

!

! V S S Y L A W Y Q Q K P G Q A

7562 gtt agc agc tac tta gcc tgg tac cag cag aaa cct ggc cag gct

!

! P R L L I Y D A S S R A T G I

7607 ccc agg ctc ctc atc tat gAt gca tcc aAc agg gcc act ggc atc

!

! P A R F S G S G P G T D F T L

7652 cca gCc agg ttc agt ggc agt ggg Cct ggg aca gac ttc act ctc

!

! T I S S L E P E D F A V Y Y C

7697 acc atc agc agC ctA gag cct gaa gat ttt gca gtT tat tac tgt

!

! Q Q R S W H P W T F G Q G T R

7742 cag cag CGt aAc tgg cat ccg tgg ACG TTC GGC CAA GGG ACC AAG

!

! V E I K R T V A A P S V F I F

7787 gtg gaa atc aaa cga act gtg gCT GCA Cca tct gtc ttc atc ttc

! BsgI....

!

! P P S D E Q L K S G T A S V V

7832 ccg cca tct gat gag cag ttg aaa tct gga act gcc tct gtt gtg

!

! C L L N N F Y P R E A K V Q W

7877 tgc ctg ctg aat aac ttc tat ccc aga gag gcc aaa gta cag ttg

!

! K V D N A L Q S G N S Q E S V

7922 aag gtg gat aac gcc ctc caa tcg ggt aac tcc cag gag agt gtc

!

! T E R D S K D S T Y S L S S T

7967 aca gag cgg gac agc aag gac agc acc tac agc ctc agc agc acc

!

! L T L S K A D Y E K H K V Y A

8012 ctg acG CTG AGC aaa gca gac tac gag aaa cac aaa gtc tac gcc

! EspI.....

!

! C E V T H Q G L S S P V T K S

8057 tgc gaa gtc acc cat cag ggc ctG AGC TCg ccc gtc aca aag agc

! SacI....

!

! F N R G E C . .

8102 ttc aac agg gga gag tgt taa taa

!

8126 GGCGCG CCaattctat ttcaaGGAGA cagtcata

! AscI..... RBS2.

! (Amino acid sequence is SEQ ID NO: 558)

! PelB signal sequence------(22 codons)----->

! 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

! M K Y L L P T A A A G L L L L

8160 atg aaa tac cta ttg cct acg gca gcc gct gga ttg tta tta ctc

!

! ...PelB signal------------> Start VH, FR1----------------->

! 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

! A A Q P A M A E V Q L L E S G

8205 gcG GCC cag ccG GCC atg gcc gaa gtt CAA TTG tta gag tct ggt

! SfiI............. MfeI...

! NcoI....

!

! 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45

! G G L V Q P G G S L R L S C A

8250 ggc ggt ctt gtt cag cct ggt ggt tct tta cgt ctt tct tgc gct

!

! ...FR1--------------------> CDR1--------------> FR2-------->

! 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

! A S G F T F S T Y E M R W V R

8295 gct TCC GGA ttc act ttc tct act tac gag atg cgt tgg gtt cgC

! BspEI.. BstXI...

!

! FR2--------------------------------------> CDR2 ---------->

! 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75

! Q A P G K G L E W V S Y I A P

8340 CAa gct ccT GGt aaa ggt ttg gag tgg gtt tct tat atc gct cct

! BstXI.............

!

! ...CDR2------------------------------------------> FR3---->

! 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90

! S G G D T A Y A D S V K G R F

8385 tct ggt ggc gat act gct tat gct gac tcc gtt aaa ggt cgc ttc

!

! 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105

! T I S R D N S K N T L Y L Q M

8430 act atc TCT AGA gac aac tct aag aat act ctc tac ttg cag atg

! XbaI...

! Supplied by extender-------------------------------

!

! -----------------------------------------FR3-------------->

! 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120

! N S L R A E D T A V Y Y C A R

8475 aac agC TTA AGg gct gag gac act gca gtc tac tat tgt gcg agg

! AflII...

! from extender--------------------------------->

!

! CDR3--------------------------------------------------> FR4-->

! 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135

! R L D G Y I S Y Y Y G M D V W

8520 agg ctc gat ggc tat att tcc tac tac tac ggt atg GAC GTC tgg

!

! 136 137 138 139 140 141 142 143 144 145

! G Q G T T V T V S S

8565 ggc caa ggg acc acG GTC ACC gtc tca agc

! BstEII...

!

! CH1 of IgG1---------->

! A S T K G P S V F P L A P S S

8595 gcc tcc acc aag ggc cca tcg gtc ttc ccc ctg gca ccc tcc tcc

!

! K S T S G G T A A L G C L V K

8640 aag agc acc tct ggg ggc aca gcg gcc ctg ggc tgc ctg gtc aag

!

! D Y F P E P V T V S W N S G A

8685 gac tac ttc ccc gaa ccg gtg acg gtg tcg tgg aac tca ggc gcc

!

! L T S G V H T F P A V L Q S S

8730 ctg acc agc ggc gtc cac acc ttc ccg gct gtc cta cag tCC TCA

! Bsu36I....

!

! G L Y S L S S V V T V P S S S

8775 GGa ctc tac tcc ctc agc agc gta gtg acc gtg ccc tcc agc agc

! Bsu36I....

!

! L G T Q T Y I C N V N H K P S

8820 ttg ggc acc cag acc tac atc tgc aac gtg aat cac aag ccc agc

!

! N T K V D K K V E P K S C A A

8865 aac acc aag gtg gac aag aaa gtt gag ccc aaa tct tgt GCG GCC

! NotI......

!

! A H H H H H H G A A E Q K L I

8910 GCa cat cat cat cac cat cac ggg gcc gca gaa caa aaa ctc atc

! ..NotI.... H6 tag................. Myc-Tag........................

!

! S E E D L N G A A q A S S A

8955 tca gaa gag gat ctg aat ggg gcc gca tag GCT AGC tct gct

! Myc-Tag.................... ... NheI...

! Amber

!

! III′stump

!

! Domain 3 of III -------------------------------------------------------

! S G D F D Y E K M A N A N K G A

8997 agt ggc gac ttc gac tac gag aaa atg gct aat gcc aac aaa GGC GCC

! tcc t t t t t a g a c t t g g t !W.T.

! KasI...(2/4)

!

! M T E N A D E N A L Q S D A K G

9045 atG ACT GAG AAC GCT GAC GAG aat gct ttg caa agc gat gcc aag ggt

! c a t c t a c g c a g tct c t a c !W.T.

!

! K L D S V A T D Y G A A I D G F

9093 aag tta gac agc gTC GCG Acc gac tat GGC GCC gcc ATC GAc ggc ttt

! a c t t tct t t t c t t t t t c !W.T.

! NruI.... KasI...(3/4)

!

! I G D V S G L A N G N G A T G D

9141 atc ggc gat gtc agt ggt tTG GCC Aac ggc aac gga gcc acc gga gac

! t t c t tcc c c t t t t t t t t t t !W.T.

! MscI...(3/3)

!

! F A G S N S Q M A Q V G D G D N

9189 ttc GCA GGT tcG AAT TCt cag atg gcC CAG GTT GGA GAT GGg gac aac

! t t c t c a t a c t c t t t !W.T.

! BspMI.. (2/2) XcmI................

! EcoRI...

!

! S P L M N N F R Q Y L P S L P Q

9237 agt ccg ctt atg aac aac ttt aga cag tac ctt ccg tct ctt ccg cag

! tca t t a t t c c t a t t a t c c t a !W.T.

!

! S V E C R P F V F S A G K P Y E

9285 agt gtc gag tgc cgt cca ttc gtt ttc tct gcc ggc aag cct tac gag

! tcg t a t c t t c t agc t t a a t a !W.T.

!

9333 ttc aGC Atc gac TGC gat aag atc aat ctt ttC CGC

! t tct t t t c a a c t a c t !W.T.

! BstAPI........ SacII...

! End Domain 3

!

9369 GGc gtt ttc gct ttc ttg cta tac gtc gct act ttc atg tac gtt ttc

! t c t g t c t t a t t c c t t a t !W.T.

! start transmembrane segment

!

! S T F A N I L R N K E S

9417 aGC ACT TTC GCC AAT ATT TTA Cgc aac aaa gaa agc

! tct g t t c a c g t t g g tct !W.T.

! Intracellular anchor.

!

! . .

9453 tag tga tct CCT AGG

! AvrII..

!

9468 aag ccc gcc taa tga gcg ggc ttt ttt ttt ct ggt

! | Trp terminator |

!

! End Feb cassette

!

9503 ATGCAT CCTGAGG ccgat actgtcgtcg tcccctcaaa ctggcaaatg

! NsiI.. Bsu36I.(3/3)

9551 cacggttacg atgcgcccat ctacaccaac gtgacctatc ccattacggt caatccaccg

9611 tttgttccca cggagaatcc gacgggttgt tactcgctca catttaatgt tgatgaaagc

9671 tggctacagg aaggccagac gcgaattatt tttgatggcg ttcctattgg ttaaaaaatg

9731 agctgattta acaaaaattt aaTgcgaatt ttaacaaaat attaacgttt acaATTTAAA

! SwaI...

9791 Tatttgctta tacaatcttc ctatttttgg ggcttttctg attatcaacc GGGGTAcat

9850 ATG att gac atg cta gtt tta cga tta cog ttc atc gat tc t ctt gtt tgc

! Start gene II

9901 tcc aga ctc tca ggc aat gac ctg ata gcc ttt gtA GAT CTc tca aaa ata

! BglII...

9952 gct acc ctc tcc ggc atT aat tta tca act aga acg gtt gaa tat cat att

10003 gat ggt gat ttg act gtc tcc ggc ctt tct cac cct ttt gaa tct tta cct

10054 aca cat tac tca ggc att gca ttt aaa ata tat gag ggt tct aaa aat ttt

10105 tat cct tgc att gaa ata aag gct tct ccc gca aaa gta tta cag ggt cat

10156 aat gtt ttt ggt aca acc gat tta gct tta tgc tct gag gct tta ttg ctt

10207 aat ttt gct aat tct tta cct tgc ctg tat gat tta ttg aat gtt !

! gene II continues

!

!----------------------

TABLE 37

! DNA seq of w.t. M3 gene iii
!
(Nucleotide sequence is SEQ ID NO: 590; Amino acid sequene is SEQ ID NO: 591)
! 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
! fm K K L L F A I P L V V P F Y
1579 gtg aaa aaa tta tta ttc gca att cct tta gtt gtt cot ttc tat
! Signal sequence............................................
! 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
! S E S A K T V E S C L A K P H
1624 tct cac tcc gct gaa act gtt gaa agt tgt tta gca aaa ccc cat
! Signal sequence> Domain 1---------------------------------------
!
! 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
! T E N S F T N V W K D D K T L
1669 aca gaa act tca ttt act aac gtc tgg aaa gac gac aaa act tta
! Domain 1---------------------------------------------------
! 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
! D R V A N Y E G C L W N A T G
1714 gat cgt tac gct aac tat gag ggt tgt ctg tgG AAT GCt aca ggc
! BsmI....
! Domain 1---------------------------------------------------
! 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75
! V V V C T G D E T Q C Y G T W
1759 gtt ata gtt tgt act ggt gac gas act cag tgt tac ggt aca tgg
! Domain 1
!
! 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
! V P I G L A I P E N E G G G S
1804 gtt cct att ggg ctt gct atc cct gaa aat gag ggt ggt ggc tct
! Domain 1------------------------------> Linker 1-----------
!
! 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105
! E G G G S E G G G S E G G G T
1849 gag ggt ggc ggt tot gag ggt ggc ggt tct gag ggt ggc ggt act
! Linker 1-------------------------------------------------->
!
! 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
! K P P E Y G D T P I P G Y T Y
1894 aaa cct cct gag tac ggt gat aca cot att ccg ggc tat act tat
! Domain 2---------------------------------------------------
! 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135
! I N P L D G T Y P P G T E Q N
1939 atc aac cct ctc gac ggc act taT CCG CCt ggt act gag caa aac
! Domain 2---------------------------------------------------
! 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150
! P A N P N P S L E E S Q P L N
1984 ccc gct act cct act cct tct ctt GAG GAG tct cag cct ctt act
! BseRI..
! Domain 2
! 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165
! T F M F Q N N R F R N R Q C A
2029 act ttc atg ttt cag act act agg tcc oga aat agg cag ggg gca
! Domain 2---------------------------------------------------
!
! 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180
! L T V Y T G T V T Q G T D P V
2074 tta act gtt tat acg ggc act gtt act caa ggc act gac ccc gtt
! Domain 2---------------------------------------------------
!
! 181 132 183 184 185 186 137 188 189 190 191 192 193 194 195
! K T Y Y Q Y T P V S S K A M Y
2119 aaa act tat tac cag tac act cot gta tca toa aaa gcc atg tat
! Domain 2-----------------------------------------------------
!
! 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210
! D A Y W N G K E R D C A F H S
2164 gac gct tac tgg aac ggt aaa ttC AGa gaC TGc gct ttc cat tct
! AlwNI.......
! Domain 2---------------------------------------------------
!
! 211 212 213 214 215 216 217 214 219 220 221 222 223 224 225
! G E N E D P F V C E Y Q G Q S
2209 ggc ttt aat gaG GAT CCa ttc gtt tgt gaa tat caa ggc caa tcg
! BamHI...
! Domain 2---------------------------------------------------
!
! 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240
! S D L P Q P P V N A G G G S G
2254 tct gac ctg cct caa cct cct gtc aat gct ggc ggc ggc tct ggt
! Domain 2------------------------------> Linker 2-----------
!
! 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255
! G G S G G G S E G G G S E G G
2299 ggt ggt tot ggt ggc ggc tot gag ggt ggt ggc tct gag ggt ggc
Linker 2---------------------------------------------------
!
! 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270
! G S E G G G S E G G G S G G G
2344 ggt tct gag ggt ggc ggc tct gag gga ggc ggt tcc ggt ggt ggc
! Linker 2---------------------------------------------------
!
! 271 272 273 274 275 276 277 273 279 280 231 282 283 284 285
! S G S G D F D Y E K M A N A N
2389 tct ggt tcc ggt gat ttt gat tat gaa aag atg gca aac gct aat
!Linker 2> Domain 3-------------------------------------------
!
286 287 288 289 290 291 292 293 294 295 296 297 298 299 300
! K G A M T E N A D E N A L Q S
2434 aag ggg got atg acc gaa aat gcc gat gaa aac gog cta cag tCt
! Domain 3---------------------------------------------------
!
! 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315
! D A K G K L D S V A T D Y G A
2479 gac gct aaa ggc aaa ctt gat tct gtc gct act gat tac ggt gct
! Domain 3---------------------------------------------------
!
! 316 317 319 319 320 321 322 323 324 325 326 327 328 329 330
! A I D G F I G D V S G L A N G
2524 gct atc gat ggt ttc att ggt gac gtt tcc ggc ctt gct aat ggt
! Domain 3---------------------------------------------------
!
! 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345
! N C A T G D F A C S N S Q M A
2569 aat ggt gct act ggt gat ttt got ggc tct aat tcc caa atg gct
! Domain 3---------------------------------------------------
! 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360
! Q V G D G D N S P L M N N E R
2614 caa gtc ggt gac ggt gat aat tca cct tta atg aat aat ttc cgt
! Domain 3---------------------------------------------------
!
! 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375
! Q Y L P S L P Q S V E C R P F
2659 caa tat tta cct tcc ctc cct caa tcg gtt gaa tgt cgc cct ttt
! Domain 3---------------------------------------------------
!
! 376 377 378 379 330 381 382 383 384 385 386 387 338 389 390
! V E S A G K P Y E F S I D C D
2704 gtc ttt agc gct ggt aaa cca tat gaa ttt tct att gat tat gac
! Domain 3---------------------------------------------------
! 391 392 393 394 395 396 391 398 399 400 401 482 493 494 405
! K I N L F R G V F A F L L Y V
2749 aaa ata aac tta ttc cgt ggt gtc ttt gcg ttt ctt tta tat gtt
! Domain 3--------------> Transmembrane segment
!
! 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420
! A T E M Y V E S T F A N I L R
2794 gcc acc ttt ata tat gta ttt tct acg ttt gct aac ata ctg cgt
! Transmembrane segment---------------------------------> ICA--
! 421 422 423 424 425
! N K E S .
2339 aat aag gag tct taa ! 2853
! ICA-----------> ICA = intracellular anchor
!------------------ End of Table -----------------------------------------

TABLE 36

Whole mature III anchor M13-III
derived anchor with recoded DNA

!

! 1 2 3

! A A A (SEQ ID NO: 594)

1 GCG gcc gca (SEQ ID NO: 593)

! NotI......

!

! 4 5 6 7 8 9 10 11 12 13 14 15 16 17

! H H H H H H G A A E Q K L I

10 cat cat cat cac cat cac ggg gcc gca gaa caa aaa ctc atc

!

! 18 19 20 21 22 23 24 25 26 27 28 29

! S E E D L N G A A . A S

52 tca gaa gag gat ctg act ggg gcc gca Tag GCT AGC

! NheI...

!

! 30 31 32 33 34 35 36 37 38 39

! D I N D D R M A S T

88 GAT ATC aac gat gat cgt atg gct tct act

! (ON_C37bot) [RC] 5′-c aac gat gat cgt atg gcG CAt Gct gcc gag aca g-3′

! EcoRV.. (SEQ ID NO: 592)

! Enterokinase cleavage site.

! Start mature III (recoded) Domain 1 ---->

! 40 41 42 43

! A E T V

118 |gcC|gaG|acA|gtC|

! t a t t ! W.T.

! 44 45 46 47 48 49 50 51 52 53 54 55 56 57 53

! E S C L A K P H T E N S F I N

130 |gaa|TCC|tgC|CTG|GCC|AaG|ccT|caC|acT|gaG|aat|AGT|ttC|aCA|Aat|

! agt t t a a a c t a a tce t t c ! W.T.

! MscI....

!

! 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73

! V W K D D K I L D R Y A N Y E

175 |gtg|TGG|aaG|gaT|gaT|aaG|acC|CtT|gAT|CGA|TaT|gcC|aaT|taC|gaA|

! c a c c a t t a t c t c t g ! W.T.

! BspDI...

! 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88

! G C L W N A T G V V V C T G D

220 |ggC|tqC|TtA|tgg|aat|gcC|ACC|GGC|GtC|gtT|gtC|TGC|ACG|ggC|gaT|

t t c g t a t a t t t t c ! W.T.

! SgrAT...... BsgI....

!

! 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103

! E T Q C Y G T W V P I G L A I

265 |gaG|acA|caA|tgC|taT|ggC|ACG|TGg|atG|ccG|atA|gGC|TTA|GCC|atA|

! a t a t c t a t t t g c t t c ! W.T.

! PmlI.... BlpT.....

!

! Domain 1-----> Linker 1---------------->

! 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118

! P E N E G G G S E G G G S E G

310 |ccG|gaG|aaC|gaA|ggC|ggT|ggT|AGC|gaA|ggC|ggT|ggC|AGC|gaA|ggC|

! t a t g t t c tct g t c t tct g t ! W.T.

!

! Linker 1----------------------> Domain 2--------------->

! 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133

! G G S E G G G T H P P E Y G D

355 |ggT|GGA|TCC|gaA|ggA|ggT|ggA|acC|aaG|ccG|ccG|gaA|taT|ggC|gaC|

! c t t g t c t t a t t g c t t ! W.T.

! BamHI..(2/2)

!

134 135 136 137 138 139 140 141 142 143 144 145 146 147 148

! T P I P G Y T Y I N P L D G T

400 |acT|ccG|aCA|CCT|GGT|CaC|acC|CaC|aCT|aaT|ccG|TCA|gaT|ggA|acC|

! a t t g a t t t c c t c c c c t ! W.T.

! SexAI....

!

! 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163

! Y P P G T E Q N P A N P N P S

445 |taC|ccT|ccG|ggC|acC|gaA|caG|aaT|ccT|gcC|aaC|ccG|aaC|ccA|AGC|

! T G t t t g a c c t t t t t tct ! W.T.

! Hindiii...

!

! 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178

! L E E S Q P L N T F M F Q N N

490 |TTA|gaA|gaA|AGC|caA|ccG|TtA|aaC|acC|ttT|atg|ttC|caA|aaC|aaC|

! c t G G tct g t c t t t c t g t t ! W.T.

! HindIII.

!

! 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193

! R F R N R Q G A L T V Y T G T

535 |CgT|ttT|AgG|aaC|CgT|caA|gGT|GCT|CtT|acC|gTG|TAC|AcT|ggA|acC|

! a g c c a t a g g g a t a t t t g c t ! W.T.

! HgiAI... BsrGI...

194 195 196 197 198 199 200 201 202 203 204 205 206 207 208

! V T Q G T D P V K T F Y Q Y T

580 |gtC|acC|caG|GGT|ACC|gaT|ccT|gtC|aaG|acC|taC|taT|caA|taT|acC|

! t t a c t c c t a t t c g c t ! W.T.

! KpnI...

!

! 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223

! P V S S K A N Y D A Y W N G K

625 |ccG|gtC|TCG|AGt|aaG|gcT|atg|taC|gaT|gcC|taT|tgg|aaT|ggC|aaG|

! t a a tca a c t c t c c t a ! W.T.

! BaaI....

! XhoI....

!

! 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238

! F R D C A F H S G F N E D P F

670 |ttT|CgT|gaT|tgT|gcC|ttT|caC|AGC|ggT|ttC|aaC|gaa|gac|CCt|ttT|

! C A a C c t c t tct c t t G T a c ! W.T.

!

! 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253

! V C E Y Q G Q 3 S D L P Q P P

715 |gtC|tgC|gaG|taC|caG|ggT|caG|AGT|AGC|gaT|TtA|ccG|caG|ccA|CCG|

! t t a t a c a tcg tct c c g t a t t ! W.T.

! DrdI..... AgeI.....

!

! Domain 2--------> Linker 2--------------------->

! 254 255 256 257 258 259 260 251 262 263 264 255 266 267 268

! V N A C C C S C C C S C C C S

760 |GTT|AAC|gcG|ggT|ggT|ggT|AGC|ggC|ggA|ggC|AGC|ggC|ggT|ggT|AGC|

! c t t c c c tct t t t tct t c c tct ! W.T.

! ApeI.....

! HpaI...

! HincII.

!

! Linker 2----------------------------------------------> Domain 3-->

! 269 270 271 272 273 274 275 276 277 278 279 200 281 282 283

! E G G G S E G G G S G G G S G

805 |gaA|ggC|ggA|ggT|AGC|gaA|ggA|ggT|ggC|AGC|ggA|ggC|ggT|AGC|ggC|

! g t t c tct g t c t tct g t c tct t ! W.T.

!

! ------------Domain 3------------------->

! 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298

! S G D F D Y E K M A N A N K G

850 |AGT|ggC|gac|ttc|gac|tac|gag|aaa|atg|gct|aat|gcc|aac|aaa|GGC|

! tcc t t t t t a g a c t t g g ! W.T.

! KasI....

!

! 299 300 301 302 302 304 305 306 307 308 309 310 311 312 313

! A M T E N A D E N A L Q S D A

895 |GCC|atg|act|gag|aac|gct|gac|gaG|AAT|GCA|ctg|caa|agt|gat|gCC|

! t c a t c t a c g a g tct c t ! W.T.

! KasI.... BsmI.... StyI...

!

! 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328

! K G K L D S V A T D Y G A A I

940 |AAG|GGt|aag|tta|gac|agc|gTC|GCc|Aca|gac|tat|ggT|GCt|gcc|atc|

! a c a c t t tct t t t c t ! W.T.

! StyI...... PflFT......

!

! 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343

! D G F I G D V S G L A N G N G

985 |gac|ggc|ttt|atc|ggc|gat|gtc|aat|ggt|ctg|act|aac|ggc|aac|gga|

! t t c t t c t tcc c c t t t t t ! W.T.

!

! 344 345 346 347 348 349 350 351 352 353

! A T G D F A G S N S

1030 |gcc|acc|gga|gac|ttc|GCA|GGT|tcG|AAT|TCt|

! t t t t t t c t c ! W.T.

! BstBI...

! EcoRI...

! BspMI..

!

! 354 355 356 357 358 359 360 361 362 363

! Q M A Q V G D G D N

1060 cag atg gcC CAG GTT GGA GAT GGa gac aac

! a t a c t c t t t ! W.T.

! XcmI................

!

! 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379

! S P L M N N F R Q Y L P S L P Q

1090 agt ccg ctt atg aac aac ttt aga tag tac ctt ccg tct ctt ccg cag

! tca t t a t t c c t a t t a t c c t a ! W.T.

!

! 380 381 392 333 384 385 386 397 328 389 390 391 392 393 394 395

! S V E C R P F V F S A G K P Y E

1138 agt gtc gag tgc cgt cca ttc gtt ttc tct gcc ggc aag cct tac gaa

! tcg t a t c t t c t agc t t a a t a ! W.T.

!

! Domain 3-------------------------------------->

! 396 397 398 399 400 401 402 403 404 405 406 407

! F S I D C D K I N L F R

1186 ttc aGC Atc gac TGC gat aag atc aat ctt ttC CGC

! t tct t t t c a a c t a t

! BRtAPI........ SacII...

!

! transmembrane segment------------->

! 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423

! G V F A F L L Y V A T F M F V F

1222 GGc gtt ttc gct ttc ttg cta tac gtc gct act ttc atg tac gtt ttc

! t c t g t c t t a t t c c t t a t ! W.T.

!

! 424 425 426 427 428 429 430 431 432 433 434 435

! S T F A N I L R N K E S

1270 aGC ACT TTC GCC AAT ATT TTA Cgc aac aaa gaa agc

! tct g t t c a c g t t g g tct ! W.T.

! Intracellular anchor.

! . .

1306 tag tga tct CCT AGG

! AvrII..

!

1321 aag ccc gcc taa tga gcg ggc ttt ttt ttt ct ggt

! | Trp terminator |

! End Fab cassette

!------------------------------End of Table ------------------------

TABLE 39

ONs to make deletions in III

! ONs for use with NheI

! N

(SEQ ID NO: 595)

(ON_G29bot) 5′-c aTT gAT ATc gct Agc cTA Tgc-3′ !

22

! this is the reverse complement of 5′-aca tag gct agc gat atc aac g-3′

! NheI... scab.........

(ON_G104top) 5′-g|ata|ggc|tta|gcT|aGC|ccg|gag|aac|gaa|gg-3′ ! 30

(SEQ ID NO: 596)

! Scab.............NheI... 104 105 106 107 108

(ON_G236top) 5′-c|ttt|cac|agc|ggt|ttc|GCT|AGC|gac|cct|ttt|gtc|tgc-3′ ! 37

(SEQ ID NO: 597)

! NheI... 236 237 238 239 240

(ON_G236tCS) 5′-c|ttt|cac|agc|agt|ttc|GCT|AGC|gac|cct|ttt|gtc|Agc-

! NheI... 236 237 238 239 240

gag|tac|cag|ggt|c-3′ (SEQ ID NO: 598)

! 50

! ONs for use with Sph1 G CAT Gc

(ON_X37bot) 5′-gAc TgT cTc ggc Agc ATg cgc cAT Acg ATc ATc gTT g-3′! 37

(SEQ ID NO: 599)

! N D D R M A H A (SEQ ID NO: 601)

!(ON_X37bot)=[RC] 5′-c aac gat gat cgt atg gcG CAt Gct gcc gag aca gtc-3′

(SEQ ID NO: 600)

! SphI....Scab.............

(ON_X104top) 5′-g|gtG ccg|ata|ggc|ttG|CAT|GCa|ccg|gag|aac|gaa|gg-3′ ! 36

(SEQ ID NO: 617)

! Scab...............SphI.... 104 105 106 107 108

(ON_X-236top) 5′-c|ttt|cac|agc|ggt|ttG|CaT|gCa|gac|cct|ttt|gtc|tgc-3′ ! 37

(SEQ ID NO: 602)

! SphI.... 236 237 238 239 240

(ON_X236tCS) 5′-c|ttt|cac|agc|ggt|ttG|CaT|aCa|gac|cct|ttt|atc|Agc-

! NheI... 236 237 238 239 240

gag|tac|cag|ggt|c-3′ (SEQ ID NO: 603)

! 50

TABLE 40

Phage titers and enrichments of a selections
with a DY3F31-based human Fab library

Input	Output	Output/input
(total cfu)	(total cfu)	ratio

R1-ox	4.5 × 10¹²	3.4 × 10⁵	7.5 × 10⁻⁸
selected on
phOx-BSA
R2-Strep	9.2 × 10¹²	3 × 10⁸	3.3 × 10⁻⁵
selected on
Strep-beads

TABLE 41

Frequency of ELISA positives in DY3F31-based Fab libraries

Anti-	9E10/	Anti-
M13	RAM-	CK/CL
HRP	HRP	Gar-HRP

R2-ox (with IPTG induction)	18/44	10/44	10/44
R2-ox (without IPTG)	13/44	ND	ND
R3-strep (with IPTG)	39/44	38/44	36/44
R3-strep (without IPTG)	33/44	ND	ND

Claims

1.-116. (canceled)

117. A method for preparing single-stranded nucleic acids, the method comprising the steps of:

(i) contacting a single-stranded nucleic acid sequence that has been cleaved with a restriction endonuclease with a partially double-stranded oligonucleotide, the single-stranded region of the oligonucleotide being functionally complementary to the nucleic acids in the region that remains after cleavage, the double-stranded region of the oligonucleotide including any sequences necessary to return the sequences that remain after cleavage into proper and original reading frame for expression and containing a restriction endonuclease recognition site 5′ of those sequences; and

(ii) cleaving the partially double-stranded oligonucleotide sequence solely at the restriction endonuclease recognition site contained within the double-stranded region of the partially double-stranded oligonucleotide,

the contacting and the cleaving steps being performed at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur at the chosen temperature and at the desired location, and the cleavage being carried out using a restriction endonuclease that is active at the chosen temperature.

118. The method according to claim 117, wherein the length of the single-stranded portion of the partially double-stranded oligonucleotide is between 2 and 15 bases.

119. The method according to claim 118, wherein the length of the single-stranded portion of the partially double-stranded oligonucleotide is between 7 and 10 bases.

120. The method according to claim 117, wherein the length of the double-stranded portion of the partially double-stranded oligonucleotide is between 12 and 100 base pairs.

121. The method according to claim 120, wherein the length of the double-stranded portion of the partially double-stranded oligonucleotide is between 20 and 100 base pairs.

122. A method for preparing a library comprising a collection of genetic packages that display a member of a diverse family of peptides, polypeptides or proteins and that collectively display at least a portion of the family comprising the steps:

(i) preparing a collection of nucleic acids that code at least in part for members of the diverse family;

(ii) rendering the nucleic acids single-stranded;

(iii) cleaving the single-stranded nucleic acids at a desired location by a method comprising the steps of:

(a) contacting the nucleic acid with a single-stranded oligonucleotide, the oligonucleotide being functionally complementary to the nucleic acid in the region in which cleavage is desired and including a sequence that with its complement in, the nucleic acid forms a restriction endonuclease recognition site that on restriction results in cleavage of the nucleic acid at the desired location; and

(b) cleaving the nucleic acid solely at the recognition site formed by the complementation of the nucleic acid and the oligonucleotide;

the contacting and the cleaving steps being performed at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur at the chosen temperature and at the desired location, and the cleavage being carried out using a restriction endonuclease that is active at the chosen temperature;

(iv) contacting the nucleic acid with a partially double-stranded oligonucleotide, the singles stranded region of the oligonucleotide being functionally complementary to the nucleic acids in the region that remains after the cleavage in step (iii) has been effected, and the double-stranded region of the oligonucleotide including any sequences necessary to return the sequences that remain after cleavage into proper and original reading frame for display and containing a restriction endonuclease recognition site 1 of those sequences that is different from the restriction site used in step (iii); and

(v) cleaving the nucleic acid solely at the restriction endonuclease recognition cleavage site contained within the, double-stranded region of the partially double-stranded oligonucleotide;

the contacting and the cleaving steps being performed at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur at the chosen temperature and at the desired location, and the restriction being carried out using a cleavage endonuclease that is active at the chosen temperature; and

(vi) displaying a member of the family of peptides, polypeptides or proteins coded, at least in part, by the cleaved nucleic acids on the surface of the genetic package and collectively displaying at least a portion of the diversity of the family.

123. A method for preparing a library comprising a collection of members of a diverse family of peptides, polypeptides or proteins and collectively comprising at least a portion of the family comprising the steps:

(ii) rendering the nucleic acids single-stranded;

(a) contacting the nucleic acid with a single-stranded oligonucleotide, the oligonucleotide being functionally complementary to the nucleic acid in the region in which cleavage is desired and including a sequence that with its complement in the nucleic acid forms a restriction endonuclease recognition site that on restriction results in cleavage of the nucleic acid at the desired location; and

(iv) contacting the nucleic acid with a partially double-stranded oligonucleotide, the single-stranded region of the oligonucleotide being functionally complementary to the nucleic acids in the region that remains after the cleavage in step (iii) has been effected, and the double-stranded region of the oligonucleotide including any sequence necessary to return the sequences that remain after cleavage into proper and original reading frame for expression and containing a restriction endonuclease recognition site 5′ of those sequences that is different from the restriction site used in step (iii); and

(v) cleaving the nucleic acid solely at the restriction endonuclease recognition cleavage site contained within the double-stranded region of the partially double-stranded oligonucleotide;

(vi) expressing a member of the family of peptides, polypeptides or proteins coded, at least in part, by the cleaved nucleic acids and collectively expressing at least a portion of the diversity of the family.

124. The method according to claim 122, further comprising at least one nucleic acid amplification step between one or more of steps (i) and (iii) steps (ii) and (iii), steps (iii) and (iv) and steps (iv) and (v).

125. A library comprising a collection of genetic packages that display a member of a diverse family of peptides, polypeptides or proteins and collectively display at least a portion of the diversity of the family, the library being produced using the method of claim 122.

126. A library comprising a collection of members of a diverse family of peptides, polypeptides or proteins and collectively comprise at least a portion of the diversity of the family, the library being produced using the method of claim 123.

127. The method or library according to claim 122, wherein the members of the library encode an immunoglobulin.

128. The method or library according to claim 127, wherein the double-stranded region of the oligonucleotide encodes at least a part of a framework sequence of an immunoglobulin.

129. The method or library according to claim 128, wherein the framework sequence comprises framework 1 of an antibody.

130. The method or library according to claim 129, wherein the framework sequence comprises framework 1 of a variable domain of a light chain.

131. The method or library according to claim 129, wherein the framework sequence comprises framework 1 of a variable domain of a heavy chain.

132. A method for displaying a member of a diverse family of peptides, polypeptides or proteins on the surface of a genetic package and collectively displaying at least a portion of the diversity of the family, the method comprising the steps of:

(i) preparing a collection of nucleic acids that code, at least in part, for members of the diverse family;

(ii) rendering the nucleic acids single-stranded;

(a) contacting the nucleic acid with a partially double-stranded oligonucleotide, the single-stranded region of the oligonucleotide being functionally complementary to the nucleic acid at its 5′ terminal region; and

(b) cleaving the nucleic acid solely at a restriction endonuclease cleavage site located in the double-stranded region of the oligonucleotide or amplifying the nucleic acid using a primer at least in part functionally complementary to at least a part of the double-stranded region of the oligonucleotide, the primer also introducing on amplification an endonuclease cleavage site and cleaving the amplified nucleic acid sequence solely at that site;

(iv) displaying a member of the family of peptides, polypeptides or proteins coded, at least in part, by the cleaved nucleic acids on the surface of the genetic package and collectively displaying at least a portion of the diversity of the family.

133. A method for expressing a member of a diverse family of peptides, polypeptides or proteins and collectively expressing at least a portion of the diversity of the family, the method comprising the steps of:

(ii) rendering the nucleic acids single-stranded;

(b) cleaving the nucleic acid solely at a restriction endonuclease cleavage site located in the double-stranded region of the nucleotide; or amplifying the nucleic acid using a primer at least in part functionally complementary to at least a part of the double-stranded region of the oligonucleotide, the primer also introducing on amplification an endonuclease cleavage site and cleaving the amplified nucleic acid sequence solely at that site;

the contacting and the cleaving steps being performed at a temperature sufficient to maintain the nucleic acid in substantially single-stranded form, the oligonucleotide being functionally complementary to the nucleic acid over a large enough region to allow the two strands to associate such that cleavage may occur at the chosen temperature and at the desired location, and the restriction being carried out using a cleavage endonuclease that is active at the chosen temperature; and (iv) expressing a member of the family of peptides, polypeptides or proteins coded, at least in part, by the cleaved nucleic acids and collectively expressing at least a portion of the diversity of the family.

134. The method according to claim 132, further comprising at least one nucleic acid amplification step between one or more of steps (i) and (ii), steps (ii) and (iii), and steps (iii) and (iv).

135. A library comprising a collection of genetic packages that display a member of a diverse family of peptides, polypeptides or proteins and collectively display at least a portion of the diversity of the family, the library being produced using the method of claim 132.

136. A library comprising a collection of members of a diverse family of peptides, polypeptides or proteins and collectively comprise at least a portion of the diversity of the family, the library being produced using the method of claim 133.

137. The method according to claim 132, wherein the members of the library encode immunoglobulins.

138. A method for cleaving a nucleic acid sequence at a desired location, the method comprising the steps of:

(i) contacting a single-stranded nucleic acid sequence with a partially double-stranded oligonucleotide, the single-stranded region of the oligonucleotide being functionally complementary to the 5′ terminal region of the nucleic acid sequence, the double-stranded region of the oligonucleotide including any sequences necessary to return the sequence in the single-stranded nucleic acid sequence into proper and original reading frame for expression; and

(ii) cleaving the partially double-stranded oligonucleotide-single-stranded nucleic acid combination solely at a restriction endonuclease cleavage site contained within the double-stranded oligonucleotide or amplifying the combination using a primer at least in part functionally complementary to at least part of the double-stranded region of the oligonucleotide, the primer introducing during amplification an endonuclease cleavage site and cleaving the amplified sequence solely at the site.

139. The method according to claim 138, wherein the length of the single-stranded portion of the partially double-stranded oligonucleotide is between 2 and 15 bases.

140. The method according to claim 139, wherein the length of the single-stranded portion of the partially double-stranded oligonucleotide is between 7 and 10 bases.

141. The method according to claim 138, wherein the length of the double-stranded portion of the partially double-stranded oligonucleotide is between 12 and 100 base pairs.

142. The method according to claim 141, wherein the length of the double-stranded portion of the partially double-stranded oligonucleotide is between 20 and 100 base pairs.

143. The method according to claim 138, further comprising at least one nucleic acid amplification step between steps (i) and (ii).